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ABSTRACT  
Cutaneous and genital human papillomavirus (HPV) infection in HIV patients, 
on suppressive anti-retroviral therapy (ART), poses under-investigated clinical 
challenges.  HPV in HIV may represent a form of immune reconstitution 
associated disease (IRAD).  HPV disease and IRADs have been separately 
correlated with human leucocyte antigen (HLA) genotype.  HLA might 
also influence HPV in HIV. 
 
 Comprehensive HPV typing of persistent warts obtained from HIV infected and 
healthy subjects was performed.  Cutaneous HPV types were detected using 
nested PCR/sequencing and newly developed (Luminex based) HSL-
PCR/MPG; genital and beta HPV types were identified using a reverse 
hybridisation line probe assay.  Real time PCR was employed to determine 
HPV DNA viral loads.  HLA alleles were defined in HIV infected and healthy 
patients by Luminex-based molecular typing using DNA derived from blood. 
 
 The HPV profile of cutaneous and genital HIV warts differs significantly from 
warts from healthy individuals. In HIV, HPV 7 has been confirmed to be an 
important HPV type in cutaneous warts (p=0.001).  In genital warts in HIV, HPV 
11 is the predominant HPV type (p=0.15) and HPV 6 is less common (p=0.002), 
contrasting with the usual finding that HPV 6 is the principal type in the general 
population.  Cross-over of HPV types between cutaneous and genital sites 
suggests that HPV tropism is less important than previously thought.  An excess 
of beta HPV types, predominantly as mixed infections, is seen in cutaneous 
warts in HIV (p<0.0005).  
 
The HLA class I allele group HLA-B*44 (as the allele HLA-B*44:02 and the 
haplotype HLA-B*44, -C*05) has been identified more frequently in HIV than in 
controls (p=0.004, allele group; p=0.0006, allele; p=0.001, haplotype).  The 
class II allele HLA-DQB1*06 may also be of interest (p=0.03).  However, the 
differences are reduced after correction for multiple testing.  
  
Further work is required to ascertain if these HPV types and alleles are of 
importance.
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CHAPTER 1:  
INTRODUCTION 
	  CHAPTER 1: INTRODUCTION 
 
   
Dermatological involvement in HIV infection and AIDS has been appreciated 
since the disease was first recognised.  A wide spectrum of skin disease is seen 
in HIV infection (Bunker & Gotch, 2010).  In 1996 anti-retroviral therapies (ART) 
began to be used in combinations that had the potential to suppress HIV 
replication and the concept of highly active ART (HAART) was born (Gulick et 
al., 1997).  The introduction of assays to measure viral load and resistance 
testing based on genetic mutation analysis of HIV has led to the notion of ‘fully 
suppressive’ ART and this has become the benchmark for HIV treatment.  Fully 
suppressive ART has been beneficial to patients with skin disease, for example 
eosinophilic folliculitis (EF) and psoriasis.  However some problems can be 
persistent, for example anal intra-epithelial neoplasia (AIN) and muco-
cutaneous warts related to HPV (Bunker & Gotch, 2010).  It is not known why 
some people with HIV get complications and not others.  The pattern and 
severity of skin disease in HIV infected patients may be determined by factors 
that transcend their level of immunosuppression.  A patient’s specific, perhaps 
unique, immunodysfunction may reflect, amongst other parameters, their 
immunogenotype (for example, human leucocyte antigen or HLA type), the 
course of their disease (for example, the CD4 T-cell nadir) and the virulence of 
the HIV itself (Seoane Reula et al., 2005). 
 
Persistent and florid cutaneous and anogenital human papillomavirus (HPV) 
infection still poses a significant clinical problem in HIV infected patients despite 
suppressive ART and apparently adequate immune reconstitution.  HPV related 
disease in HIV infected patients is common and can be a disabling and 
stigmatising dermatosis. In HIV infection persistent HPV genital disease can 
lead to the development of pre-cancerous lesions and the risk of progression to 
actual cancer. This transition is likely to be augmented by chronic HIV infection 
(Hagensee et al., 2004; Bernard et al., 2008).   
 
 
	  1.1 THE HUMAN PAPILLOMAVIRUS (HPV) 
 
HPV is a significant problem in HIV infection but it is also a pervasive human 
pathogen.  HPV has become well adapted to man and is able to persist and 
propagate efficiently in human epithelial cells (Munoz et al., 2006). It is a non-
enveloped DNA virus that is resistant to environmental desiccation.  The HPV 
genome is circular and double stranded comprising of 8000 nucleotide base 
pairs (bp).  It contains two genes that are expressed late (L) in viral reproduction 
encoding viral capsid proteins (L1, L2), and six early (E) genes E1, E2, E4, E5, 
E6, E7, and an (upstream) regulatory region (URR) that enables viral 
replication.  The E1 and L1 genes are highly conserved across the 100 different 
HPV types; HPV type is based on genetic homology of the L1 gene (de Villiers 
et al., 2004).   
 
Over 100 types of HPV have been identified to date and they are distinct in 
terms of both site specificity and specific host immunity (Bernard, 2005; Wiley & 
Masongsong, 2006).  Carriage of cutaneous and genital HPVs in the general 
population is exceedingly common; the lifetime cumulative risk of genital HPV 
infection has been estimated at over 50% for both females and males 
(Baseman & Koutsky, 2005) and others have estimated that it may be as high 
as around 80% (Koutsky, 1997).  One must also add to this the burden of 
disease caused by cutaneous wart associated HPV types; the prevalence of 
cutaneous warts in school age children has been estimated to be between 2-
20% (Kilkenny & Marks, 1996; Sterling, 2010). Beta HPV (as opposed to alpha 
and gamma) types also cause disease, but probably only in certain situations 
(such as in immunosuppressed patients).   Therefore, the vast majority of 
individuals will contract HPV at some point in their lives; most infections are 
asymptomatic.  
 
1.1 .1 HPV classification  
 
HPVs can be divided phylogenetically into a number of genera and “types” 
based on sequence homology.  Those that are clinically relevant in humans are 
	  displayed in Figure 1.1 and Table 1.1.  Three groupings of clinical importance 
can be delineated; (i) cutaneous, (ii) beta and (iii) genital HPV types. 
 
(i) The primary HPV types found in cutaneous warts (herein referred to as 
cutaneous wart associated HPV types or cutaneous HPV types) are 2, 3, 10, 27 
and 57.  Phylogenetically cutaneous warts associated types are largely 
classified in the alpha genus but some types are also found in the gamma (HPV 
4), mu (HPV 1, 63) and the nu (HPV 41) genera; Figure 1.1, red circles.  
Cutaneous types predominantly have low carcinogenic potential. 
 
 
 
Figure 1.1 Papillomavirus phylogenetic tree.  Classification of PV is based on the genetic 
sequence of the late (L)1 open reading frame.  The outermost semicircles identify HPV genera; 
the numbers in bold type at the inner semicircles indicate HPV species.  Each HPV type is 
identified by a number at the end of each of the branch: for example, HPV type 7 is classified in 
species 8 from the alpha HPV genus.  Clinically important cutaneous wart associated types are 
highlighted with the red circles, the beta types with the blue circle and the genital types are 
highlighted with the green circles.  The original figure has been taken from de Villiers et al., 
(2004).  Abbreviations: c - candidate HPV types (at the time of original figure publication).  
Other abbreviations refer to animal HPV types – see original publication for further information. 
 
	  Table 1.1 HPV types by genus and clinical disease association. The HPV types of 
greatest clinical significance are shown in bold.  Table has been drawn from the following 
references:  de Villiers et al., (2004), Harper et al., (2004), Majewski & Jablonska (2004), 
Bernard (2005), Munoz et al., (2006), IARC (2007), Madkan et al., (2007), Bouwes Bavinck 
et al., (2008), Sterling (2010) and Atkinson et al., (2011). 
 
(Atkinson et al., 2011) 
(de Villiers et al., 2004; Harper et al., 2004; Majewski & Jablonska, 2004; Bernard, 2005; 
Bouwes Bavinck et al., 2008) (Madkan et al., 2007) (Kilkenny & Marks, 1996; Munoz et al., 
2006) 
(ii) The beta HPV types have been considered to be largely non-pathogenic.  
However, beta HPV are associated with cutaneous disease in the rare genetic 
disease epidermodysplasia verruciformis (EV) and perhaps also in 
immunosuppression.  HPV 5 and 8 have oncogenic potential (at least in EV 
patients) and are probably the most important.  A number of other types are still 
under investigation.  
 
(iii) HPVs causing genital lesions (herein referred to as the genital HPV types) 
are classified as of low, high and undetermined carcinogenicity and belong to 
the alpha genus.  The most important high risk (HR) HPV types for anogenital 
cancers are HPV 16 and 18.  Types 6 and 11 are low risk (LR) in the cervix.  
However, uncommonly, they can cause cancers at other sites for example oro-
pharyngeal, laryngeal and (non-cervical) genital verrucous (Buschke-
Lowenstein) carcinomas and HPV 6/11 also cause recurrent respiratory 
papillomatosis - RRP (Sterling, 2010).  
 
	   
 
 
 
 
 
	  1.1.2 HPV life cycle 
 
HPV is thought to enter epithelia through abrasions, allowing the virus to infect 
epithelial cells of the basal layer.  Once infection is initiated it can persist 
episomally in low copy numbers (10-200 copies/cell), expressing E1, E2 
proteins that are important for viral maintenance at this stage and E6, E7 that 
allow viral replication (De Geest et al., 1993 and Stanley et al., 1993, both as 
cited by Doorbar, 2005).  A proliferative phase of viral infection is also seen; 
basal cells stop replicating and move upwards in the epithelium.  HPV genome 
replication occurs in these cells with increasing production of E4, E5 proteins 
and later L1 and L2 before intracellular virions are formed and then released 
into the environment during shedding of the epithelial cell (Doorbar, 2005; 
Munoz et al., 2006).  A latent phase may follow (Doorbar, 2005) 
 
Infection of stem cells may be an important mechanism behind HPV 
persistence and latency (Schmitt et al., 1996; Egawa, 2003). Different HPV 
types have been shown to be maintained in different parts of the same lesion, 
suggesting that the origin of a wart is polyclonal and related to the original HPV 
type infecting founder cells (Harwood et al., 1999).  
 
1.1.3 Identification of HPV  
 
The distinction between genera and types is important when considering HPV 
DNA detection.  Each HPV type is defined by an L1 gene DNA sequence 
variation of more than 10% from its nearest genetically related neighbour (de 
Villiers et al., 2004).  Although HPV DNA may be detected in tissue by in situ 
techniques, sensitivity can be greatly increased by utilising amplification by 
polymerase chain reaction (PCR).  HPV PCR techniques can be broadly 
categorised into type specific or group specific.   
 
HPV type specific PCR 
Primers that are HPV type specific may be used to amplify viral nucleic acid.  
However, it is time and labour intensive because a separate reaction is required 
for each HPV type.  This methodology can be useful if a limited number of types 
	  are investigated, such as when the viral load of a specific type is investigated, 
or to quantify the prevalence of a specific type. 
 
Group specific PCR 
The group specific approach is useful as it casts a wide net.  The primers that 
have been used are mostly degenerate: they contain a mixture of 
oligonucleotides that vary at certain bases to allow binding to an increased 
number of HPV types (Molijn et al., 2005).  Predominantly, they have been 
directed at relatively conserved regions of the HPV genome, such as the L1 
open reading frame. Nested group specific PCR (where two sets of primers are 
used sequentially in two rounds of PCR, the second amplicon nested within the 
first) or semi-nested PCR (two rounds of PCR where one of the second round 
primers is nested and the other is the same as was used in the first round) have 
been used to increase assay sensitivity (Harwood et al., 1999).  These have the 
potential drawback of false positive results; stringent anti-contamination 
procedures and careful use of negative controls are necessary.  
 
Downstream amplicon detection 
It is not sufficient for most purposes to determine the presence/absence of HPV 
DNA; it is also clinically imperative to identify the HPV type (for example LR or 
HR).  A variety of post PCR amplicon detection systems are available.   
 
HPV types can be identified by direct sequencing.  Detected sequences can be 
compared with published sequences from all known HPV types. Usually this 
only identifies the ‘dominant’ type in a PCR sample. The efficiency of PCR 
replication is not constant for each HPV type; it is dependent on primer binding 
and competition between DNA from different HPV types.  Therefore, the HPV 
type detected through sequencing may not necessarily be the predominant type 
in a lesion. Mixed infections with more than one infecting HPV type may be 
important in immunosuppressed patients (Harwood et al., 1999).  One approach 
to overcome this is to use cloning.  Amplicons can be inserted into a plasmid 
that is then replicated in bacteria.  DNA from a number of different bacterial 
colonies (clones) are then sequenced.  This will, for example, detect a non-
	  dominant HPV type whose amplicons make up a minor proportion of the post 
PCR DNA.  
 
Amplicons can also be detected by more efficient, modern techniques.  Enzyme 
linked immunosorbant assays (ELISAs) have become available that detect a 
broad spectrum of HPV types simultaneously.  The PCR product is mixed with 
large number of type/group specific DNA probes and allowed to hybridise; 
washing removes unbound DNA.  Probes bound to DNA are detected using a 
chemical reaction that produces a quantifiable colour change.  This is useful to 
detect the presence or absence (positive/negative result) of HR genital HPV 
(Molijn et al., 2005) but the identification of specific HPV types requires multiple 
reactions.  Assays to detect amplicons can be utilised in other ways to identify a 
large number of HPV types simultaneously. Reverse hybridisation assays 
(RHAs) operate by allowing PCR products (in liquid phase) to hybridise to 
probes immobilised on plastic strips (solid phase).  RHAs are also known as line 
probe assays (LiPA), line blot assay (LBA) or linear array (LA).   This technique 
is particularly helpful in identifying mixed HPV infections (Molijn et al., 2005).  
 
Identifying important HPV types 
The HPV viral load (copies per cell), calculated from quantitative PCRs, can be 
useful in determining which type is likely to be important in generating a lesion.  
Other methods involve directly localising DNA/RNA/protein in infected cells 
(such as in situ hybridisation - ISH) or dissecting virally infected cells from tissue 
(for example, by using laser capture microdissection). 
 
HPV RNA can also be detected in tissues by a reverse transcriptase step.  This 
can be useful in tissues harbouring HR types that have become fragmented and 
where the (oncogenic) E6 and E7 genes have become integrated into the host 
genome (Molijn et al., 2005).  It can also provide information about which of 
several  types might be most transciptionally active. 
 
 
 
 
	  1.1.4 Clinical aspects:  cutaneous  wart  associated HPVs and cutaneous 
disease 
 
Cutaneous warts are exceedingly common, especially in the young; between 
2% and 20% of school age children are estimated to be affected (Sterling, 
2001).  In adults, one estimate suggests a prevalence of around 3% (Rea et al., 
1976) but in another study of the general population a range of 1-13% was 
reported (Gibbs & Harvey, 2006).  The average duration of cutaneous warts has 
been reported to be around 18 months to 2 years (Rulison, 1942 as cited by 
Sterling, 2001; Rubben et al., 1997).  Infection with cutaneous HPV types 
usually results in benign tumours (cutaneous warts) that are self limiting and 
undergo spontaneous resolution (Moore & Tyring, 2001).  HPV types 
demonstrate site specificity and appear to have evolved to fill ecological niches.  
Certain HPV types may be site restricted (for example HPV 1 in plantar warts).  
Others have morphological tendencies (for example HPV 3 and 10 in plane, thin 
flat topped, warts) or are prevalent in certain patient groups, such as HPV 7 
causing so-called butcher’s warts on the hands of those with extensive contact 
with moisture (Rubben et al., 1993; Moore & Tyring, 2001).  Current dogma is 
that genital HPV types are not commonly found in cutaneous warts in the 
absence of immunosuppression. 
 
1.1.5 Clinical aspects: beta HPV types, epidermodysplasia verruciformis 
(EV) and skin cancer 
 
Recently there has been renewed interest in cutaneous and beta HPVs in the 
era of high resolution molecular biology. This revival is for a number of reasons, 
including:  the exploration of EV as a genetic disease, investigation of HPV as 
an etiological agent in skin cancer, and recognition of the importance of HPV in 
immunosuppressed patients (whether iatrogenically or HIV related).   
 
EV is a genodermatosis that is characterised by an inherited immunotolerance 
to beta HPV types in individuals who are otherwise healthy (Orth, 2008).   Two 
genes (EVER1/TMC6 and EVER2/TMC8) have been identified that confer 
susceptibility in many cases (Ramoz et al., 2002).  EV patients have absent 
	  cutaneous responses to sensitisers (eg dinitrochlorobenzene) and may have 
defective antigen presentation; disturbances in T helper cell numbers and 
function have been noted (Majewski & Jablonska, 2001; Sterling, 2010).  
Characteristic lesions develop on sun exposed sites: hypo or hyper-pigmented 
slightly scaling pityriasis versicolor-like macules and warty plaques having the 
appearance of seborrhoeic keratoses and/or plane (flat) warts (Sterling, 2010).  
Pre-cancers such as cutaneous Bowen’s disease and actinic keratoses (AK) 
also develop.  Around half of affected individuals develop HPV associated 
cutaneous squamous cell carcinomas (SCCs) on UV-exposed sites later in life 
(Majewski & Jablonska, 2001).  Patients with EV are afflicted with specific types 
of HPV (largely from the beta genus of around 20 types) that are not thought to 
cause warts in immunocompetent individuals (Majewski & Jablonska, 2001) .  
 
Skin cancer and beta types 
The exact role of beta HPV types in non-melanoma skin cancer (NMSC) 
remains controversial (Bouwes Bavinck et al., 2008).  In immunocompetent 
individuals beta types are prevalent in SCCs, basal cell carcinomas (BCCs) and 
cutaneous pre-cancers.  But this is also the case for normal skin and beta HPVs 
are highly prevalent in plucked hairs; they have been detected in up to 93% of 
hairs from healthy individuals (Sterling, 2005; de Koning et al., 2007).  Beta 
HPVs have also been identified in swabs taken from pre-cancerous genital 
(penile) and anal lesions, although the significance of this is not known 
(Wieland et al., 2000; Kreuter et al., 2008).   The proportion of lesions in which 
beta types can be detected is increased in organ transplant recipients (OTRs), 
who also have a much higher risk of NMSC: 50-100 times the general 
population (Harwood & Proby, 2001; Sterling, 2005).  HPV 5 and 8 are 
carcinogenic in EV patients but they are probably less so than the mucosotropic 
HR types as they may require the additional effect of UV and a long period of 
persistence to induce pre-cancers and NMSC (Bouwes Bavinck et al., 2008).  
HPV 15, 20, 24, 36 and 38 have also been associated with SCC (Bouwes 
Bavinck et al., 2008).     
 
Skin cancer and genital types 
HR genital types have been frequently (18-35%) isolated from extra-genital pre- 
	  cancers, BCCs and SCCs from immunosuppressed and immunocompetent 
individuals (Iftner et al., 2003).  An increased relative risk of NMSC in 
immunocompetent individuals has been associated with the presence of genital 
types (Iftner et al., 2003) and to a lesser extent beta types (Harwood et al., 
2004).  Genital types have been frequently isolated from verrucous carcinoma 
and peri-ungual SCC (Sterling, 2005).  
 
1.1.6 Clinical aspects: genital HPV, genital pre-cancer and genital cancer  
 
Genital warts and (molecularly detectable) genital HPVs are common in the 
general population.  The prevalence of genital warts in otherwise healthy men 
and women genital warts has been estimated to be between 0.24 and 13% 
(IARC, 2007).  HPV 6 or 11 are associated with around 95% of external genital 
wart lesions (IARC, 2007).   The number of subclinical infections has been 
estimated at around two to ten times that of clinically evident disease (Koutsky, 
1997; IARC, 2007).  Genital HPVs have been detected by molecular methods in 
between 2 and 39% of women with cytologically normal cervical smears (IARC, 
2007). This wide range is dependent on the variety of techniques used and the 
population sampled including the age: the highest prevalence is in young 
adults.  
 
HPV is clearly associated with anogenital pre-cancer and cancer.  This 
relationship appears to be limited to certain types of HPV that have been 
classified as HR.  HPV infection leads to pre-cancerous changes in susceptible 
individuals.  In addition to the presence of HR HPV (primarily HPV 16) there are 
two main factors associated with the development of pre-cancerous anogenital 
lesions.  Firstly, the site of infection (principally anus and cervix) is important 
and secondly HPV persistence (molecularly and/or clinically) may lead to pre-
cancer.   
 
Anal and cervical epithelia have distinct transformation zones where mucosal 
columnar epithelium gives way to squamous epithelium, with the resultant 
potential for squamous metaplasia (Moscicki et al., 2006).  These 
transformation zones appear to be highly susceptible to HPV-mediated 
	  dysplasia, perhaps because HPV cannot complete its lifecycle in cells of 
columnar epithelia, leading to so-called abortive infections (Doorbar, 2005).   
 
It is thought that HPV infections that persist for longer than 1-2 years are more 
likely to progress to high-grade cervical intra-epithelial carcinoma (CIN) or 
cervical cancer.  However this has only been shown to occur in a small 
proportion of cases (Schiffman et al., 2007).  Cervical cancer in women and 
anal cancer in men who have sex with men (MSM) has been strongly linked to 
HR HPV (Steenbergen et al., 2005; Partridge & Koutsky, 2006).  Penile, vaginal 
and vulval epithelia may be more resistant to HPV as there is no transformation 
zone as in the cervix and anus; Table 1.2.  
 
 
 
 
 
 
 
Table 1.2 Summary of the molecular prevalence of HPV.  The percentage of HPV 
positive lesions are shown. Abbreviation: CIN III – high grade CIN.   References:  a – 
Sterling, 2001; Parkin & Bray, 2006; Partridge & Koutsky, 2006; b -  Munoz et al., 2006; 
c - Munger & Howley, 2002; Bosch & de Sanjose, 2003; d - Bernard et al., 2008; Gohy 
et al., 2008;  e - Dillner et al., 2000, f - Munoz et al., 2006. 
 
 
:  a - (Sterling, 2001; Parkin & Bray, 2006; Partridge & Koutsky, 2006); b -  (Munoz et al., 
2006); c - (Munger & Howley, 2002; Bosch & de Sanjose, 2003); d - (Bernard et al., 
2008; Gohy et al., 2008);  e - (Dillner et al., 2000), f - (Munoz et al., 2006). 
 
	  1.1.7 HPV mediated carcinogenesis  
 
HPV E6 and E7 proteins derived from HR types (particularly HPV 16) have 
been shown to inhibit host cellular maturation.  They allow unchecked cell 
division in the basal layers of epithelia leading to an accumulation of genetic 
mutations and subsequent carcinogenesis (von Knebel Doeberitz, 2002).  E6 
and E7 have complementary actions. E7 has been shown to block the inhibitory 
effect of pocket protein pRb (the protein product of the tumour suppressor 
retinoblastoma gene) on cell replication by disrupting the complex formed by 
pRb and E2F transcription factors.  Inactivation of pRb in HPV transformed 
tissues can be monitored by elevated levels of its upstream regulator, p16INK4A, 
that is increased through a feedback mechanism (Steenbergen et al., 2005).  
E7 also promotes ongoing cellular DNA replication by interactions with other cell 
cycle modulators such as histone deacetylases, activating protein 1 (AP-1) 
transcription factors, and cyclin-dependent p21, p27, p107 and p130 (Doorbar, 
2005).  E6 may impair apoptosis through interaction with p53 mediated tumour 
suppressor effects and perhaps also the inhibition of other pro-apoptotic 
proteins Bak and Bax (Doorbar, 2005).  
 
In the progression from pre-cancer to cancer, HPV viral genes can become 
integrated into the host genome, often resulting in over-expression of E6/E7 
through loss of regulatory by E2 (Doorbar, 2005).  Although the site of HPV 
integration appears to be a random process, host gene disruption may also 
occur (Steenbergen et al., 2005).  Integration also occurs in LR types, but 
protein expression is thought to be less and its effect less pronounced 
(Longworth & Laimins, 2004; Munoz et al., 2006; Madkan et al., 2007).  HPV 
has been shown to modulate telomerase activity in host cells; cell division is 
normally limited by telomere shortening, marking the number of divisions a cell 
undergoes.  Telomerase is a ribonucleoprotein complex that can lengthen 
telomeres and increase the number of cell divisions, leading to cell 
immortalisation (Klingelhutz et al., 1996; Steenbergen et al., 2005).  
Chromosomal aberrations have also been associated with HPV infected 
keratinocytes (some of which have been substantiated in CIN/cervical 
carcinoma) and include deletions at 3p, 6q, 10p, 11p, 11q, 13q, 18q, perhaps 
	  indicating the loss of putative tumour suppressor genes (Steenbergen et al., 
2005).  
 
In contrast to genital HPV medicated oncogenesis, beta HPVs do not require 
viral genome integration into the host cell to initiate carcinogenesis in EV 
(Harwood et al., 2004).  Beta HPV derived E6 does not appear to interact with 
p53 and E7 has been shown to have a low transforming ability compared with 
the genital types (Majewski & Jablonska, 2004).  In contrast to the genital HPV 
types, UV-induced oncogenesis may be more important for beta types.  
Certainly HPV 5 E6 oncoprotein can inhibit UVB induced apoptosis and DNA 
repair through p53/Bak protein, suggesting a pathway to the induction of skin 
cancers (Sterling, 2005; de Koning et al., 2007).  
 
Therefore, under the influence of oncogenic HPV E6/E7 host cell replication can 
be enhanced and apoptosis impaired.  This leads to the accumulation of genetic 
mutations and the eventual generation of invasive cancer over a number of 
decades. 
 
 
1.2 HPV DISEASE IN HIV INFECTION 
 
HIV infected individuals are likely to have an increased exposure to HPV both in 
terms of the number of inoculations and exposure to a greater number of types, 
particularly HR genital types (Koutsky, 1997; Petter et al., 2000).  They more 
frequently have warts or harbour HPV; 5-30% of all HIV patients may be 
afflicted with warts (Sun et al., 1997; Bunker & Gotch, 2010).  However, the 
greatest burden of HPV related disease in HIV infection is probably anogenital 
cancers and pre-cancerous disease.  NMSC has also been shown to be 
increased in HIV; around three to five times the incidence of the general 
population (Pantanowitz et al., 2006; Bunker & Gotch, 2010).  Cutaneous warts 
in HIV are a clinical challenge from three perspectives; firstly the paucity of 
effective treatments, secondly the high cost of treatment and thirdly because of 
patient stigmatisation.   Persistent genital disease is also a significant problem 
and leads to morbidity in the form of genital and sexual dysfunction and 
	  mortality as seen in the increased incidence of HPV related cancers in HIV, 
particularly of the anus, cervix and penis (Frisch et al., 2000).  
 
1.2.1 Cutaneous HPV disease in HIV infection 
 
HIV infected individuals manifest a high prevalence of cutaneous warts, 
compared with the general population, that may not recede after suppressive 
ART (Zancanaro et al., 2006; Kyriakis et al., 2007; Bunker & Gotch, 2010).  
Different patterns of disease may also occur, although variation in HPV 
detection techniques makes evaluation of HPV in this group difficult.    
 
Different HPV types may flourish in HIV infected individuals compared with the 
general population; Table 1.3 and Appendix Table A1.1-1.2.  However, there is 
only one case-control study that has HPV typed cutaneous warts from HIV 
infected individuals (Porro et al., 2003) and limited HPV typing data exist for 
oral warts; Table 1.3 and Appendix Table A1.3. 
 
The common cutaneous wart types, such as HPV 1, 2, 3, 4, 10, 27 and 57, that 
are found in the general population (Chen et al., 1993; Rubben et al., 1997; 
Doorbar & Sterling, 2001; Iftner et al., 2003; Hagiwara et al., 2005; Lei et al., 
2009) have also been found in HIV infected patients (Porro et al., 2003).  
However, HPV 6, that commonly causes genital warts in immunocompetent 
individuals and HPV 7, causing butcher’s warts, have also been identified in 
cutaneous warts from HIV infected patients (de Villiers, 1989; Porro et al., 
2003).  Other genital types, including HR genital types (HPV 16, 31, 33, 35) 
have also been found (Cavalcanti et al., 1998; Nunes et al., 2008).  This 
phenomenon of genital HPV types appearing in cutaneous warts has also been 
described in healthy individuals and may be not uncommon: genital HPVs were 
seen in 3-15% of cutaneous warts from the general population; Appendix Table 
A.1.1-1.2 (Chen et al., 1993; Iftner et al., 2003; Hagiwara et al., 2005; Payal et 
al., 2006).  HPV 26 (a genital type of uncertain malignant potential) has been 
isolated from digital   SCCs, from  a  HIV   infected  individual  (Handisurya et 
al., 2007).   Beta HPVs may be common in the warts  of HIV infected individuals  
 
	   
 
 
 
 
 
Table 1.3 HPV typing of cutaneous warts from HIV infected individuals published to 
date.  The one available case-control study in HIV and selected case reports have been 
included in this table.  Percentages do not total 100%; multiple types were identified in some 
lesions.  Bold type indicates genital HPV prevalence in cutaneous warts. Abbreviations: b - 
beta HPV type, c – cutaneous wart associated type, FFPE – formalin fixed paraffin 
embedded; g – genital HPV type; ISH – in situ hybridisation probe; m – mucocutaneous HPV 
type; RFLP – restriction fragment length polymorphism; unident – unidentified HPV type.  
	  but then they are also commonly found in healthy people (Harwood & Proby, 
2001; de Koning et al., 2007). 
 
Some extrapolation has been made from organ transplant recipients (OTRs), 
who have been more extensively studied, although it remains to be seen if such 
extrapolation is appropriate; Appendix Table A1.4.  In OTRs the cutaneous wart 
associated HPV types have also been commonly found (HPV 1, 2, 3, 4, 10, 27, 
57). However, beta types (HPV 5, 8) and a high prevalence of beta HPV 
variants have been seen; genital types have also been detected in cutaneous 
warts Appendix Table A1.4 (Berghout et al., 2000 Bouwes Bavinck et al., 2001; 
Harwood & Proby, 2001; Meyer et al., 2003, Kohler et al., 2009). 
  
Mixed HPV types in the same lesion and novel types may be common in OTRs 
(Bouwes Bavinck et al., 2001).  This may also be true of HIV-positive 
individuals, although the data are scanty.  OTRs and HIV infected patients, 
however, may differ in a number of respects including the mechanism, intensity 
and duration of immunosuppression and the host interactions with HPV 
(Harwood & Proby, 2001; Palefsky & Holly, 2003).  The clinical picture of 
cutaneous warts that is seen in OTRs may be influenced to a large degree by 
persistence/reactivation of HPV.  In HIV-infected patients both 
immunosuppression (leading to persistence/reactivation) and increased 
exposure to a greater number of HPV types may be important. 
 
Unusual presentations of plane/flat warts in an EV-like pattern have been 
described in HIV infection harbouring beta HPV types particularly HPV 5 and 8 
(Berger et al., 1991; Barzegar et al., 1998; Davison et al., 2004; Jacobelli et al., 
2011).  
 
HIV infected patients have been shown to have a higher incidence of non-AIDS 
defining malignancies including NMSC (Burgi et al., 2005; Pantanowitz et al., 
2006).  This is of interest given that beta and genital HPVs have been 
implicated in NMSC.  The ratio of BCCs to SCCs in HIV infected individuals has 
been shown to be in the range of 7:1 to 3:1 and this may be higher than the 
ratio seen in the general population (around 4:1) and in OTRs, that is in the 
	  region of 1:1.8 (Harwood & Proby, 2001; Burgi et al., 2005; Clifford et al., 2005; 
Nindl et al., 2007; Bunker & Gotch, 2010).  In HIV infected individuals this 
increased incidence may be due to HPV or UV or both; indeed sun exposure 
may be more important than immunosuppression (de Boer & Danner, 1990).  
The effect of suppressive ART on NMSC in HIV is not known.   
 
1.2.2 Anogenital HPV disease in HIV infection 
 
Genital warts and molecularly detected genital HPV infections have been found 
more frequently in HIV positive individuals (Sun et al., 1997; de Sanjose & 
Palefsky, 2002).  Genital warts in HIV infected individuals may carry a higher 
proportion of HR HPV types than in healthy subjects, but warts have been much 
less rigorously studied than cervical or anal disease (Brown et al., 1999); Table 
1.4 and Appendix Tables A1.5-1.6.  HIV positive women are more likely to carry 
and acquire cervical HPV infection;  they have been shown to carry HR types 
and more persistent infections; Table 1.4.  Therefore, these women may be less 
likely to clear HPV infections (de Sanjose & Palefsky, 2002).  Anal HPV 
infection has been shown to be increased in HIV infected MSM; HPV DNA has 
been found in 93% of individuals compared with 61% of HIV negative MSM 
(Palefsky et al., 1998).  Mixed HPV infections are more common in the female 
cervix and in the anal canal in MSM (Chin-Hong & Palefsky, 2002; de Sanjose 
& Palefsky, 2002).  There is evidence to suggest that reactivation may be an 
important part of the increased detection of HPV in HIV infected individuals 
(Palefsky et al., 2006). 
 
Pre-cancerous anogenital HPV related disease is also increased in HIV.  CIN, 
vulval/vaginal intra-epithelial neoplasia (VIN/VaIN) and penis carcinoma in situ 
(PCIS) have been shown to be more prevalent in HIV.  The occurrence of AIN 
in HIV positive men and women is high; up to 81% of HIV positive MSM may 
have AIN (de Sanjose & Palefsky, 2002; Palefsky et al., 2005; Kreuter et al., 
2008).  A higher incidence of high grade lesions has been noted in HIV infected 
patients, in addition to increased rates of progression (from HPV infection to 
CIN/AIN) and a reduction in regression of CIN/AIN (de Sanjose & Palefsky, 
2002; Kreuter et al., 2008).  
	   
Table 1.4 Studies of HPV typing of genital warts and cervical smears/lavage from HIV 
infected individuals. Studies that are included are those with the greatest patient numbers 
and those that have used broad spectrum HPV identification techniques.  Percentages do not 
total 100% as multiple types have been identified in some lesions.  Bold type indicates HR 
genital HPV prevalence. Abbreviations: ASCUS/LSIL – atypical squamous cells of 
undetermined significance/low grade intra-epithelial lesion; FFPE – formalin fixed paraffin 
embedded; HSIL – high grade intra-epithelial lesion; n/a – data not available; n/s – not 
specified.  Superscript symbols/abbreviations: ‡ - genital SPF 10 primers and line probe 
assay primers/detection system (similar to that used in this thesis); Ω – methodology almost 
identical to that used in thesis.   * - two-sided Fisher’s exact test of significance p=0.0002. 
 
 
 
 
 
 
	  Cervical cancer is an AIDS defining diagnosis and has been shown to have an 
increased relative risk in HIV infection of five times that of the general 
population (Frisch et al., 2000).  Anal cancer has an even stronger association 
with HIV infection.  A 37-fold increased risk has been observed in  HIV  infected 
men and a seven-fold risk in HIV infected women; the risk was even higher, at 
60-fold, in HIV infected MSM (Frisch et al., 2000).  This probably reflects higher 
exposure to anal HPV infection in this group in the absence of a screening 
program for pre-invasive anal disease, such as exists for cervical disease.  
Penile, vulval and vaginal cancers are also increased in HIV but probably to a 
lesser extent. 
 
1.2.3 HPV in the post ART era  
 
It was expected that HAART/fully suppressive ART would bring about a 
reduction in HIV related skin diseases.  This is true for some (seborrhoeic 
dermatitis, EF, psoriasis) but not others such as HPV related disease (Bunker & 
Gotch, 2010).  Although regression of HPV-associated warts with ART has 
been shown in some patients (Costner & Cockerell, 1998; Spach & Colven, 
1999), there is evidence to suggest that cutaneous (including plantar), oral and 
genital warts may not decrease after ART.  This may also be true of HPV 
related pre-cancer and cancer. 
 
Cutaneous and oral warts: ART  
The Women’s Interagency HIV Study (WIHS), USA, examined the effect of ART 
on dermatological diseases.  In 1999, early in the post HAART era, the WIHS 
showed no effect of suppressive ART on cutaneous warts; an odds ratio (OR) of 
warts with/without suppressive ART of 1.17 was reported, 95% confidence 
interval: 0.61-2.67 (Maurer et al., 2004).  A more recent analysis of the same 
cohort (in 2004) revealed no significant effect of suppressive ART on cutaneous 
warts in 1790 HIV infected women; the unadjusted cumulative incidence of 
cutaneous warts was 6.7% in patients taking suppressive ART compared with 
8.4% for those not on suppressive ART (Dolev et al., 2008).  
 
	  Persistent cutaneous HPV disease despite suppressive ART has been 
described (Price et al., 2001a).  This is in the form of widespread persistent 
cutaneous warts occurring late in the course of immune reconstitution, often 
more than three years after ART initiation.  Others have also reported that a 
proportion of HIV positive individuals on suppressive ART display persistent 
cutaneous HPV disease, noticing that the CD4 T-cell count nadirs were lower in 
the subset of patients whose warts did not regress; median of 50 compared with 
258 cells/µl (Rodrigues et al., 2001).  Although this effect may be partially 
explicable by CD4 T-cell nadirs, acting as an ‘evolutionary bottleneck’, 
constitutive immunity (immunogenetics) may also have an influence.  Our 
clinical observations concur with those of Price et al., (2001a) and Rodrigues et 
al., (2001) and colleagues; that cutaneous warts may persist or occur late after 
suppressive ART initiation in a subset of patients.     
 
The consensus appears to be that oral warts increase with suppressive ART 
and this has been proposed to represent immune reconstitution associated 
disease (IRAD) by our group and others (Greenspan et al., 2001; King et al., 
2002; Lehloenya & Meintjes, 2006).  Other workers (Patton et al., 2000; 
Schmidt-Westhausen et al., 2000; Greenwood et al., 2002; Cameron et al., 
2005) have also noted the increase in oral warts or HPV DNA prevalence in 
patients on suppressive ART; another analysis of the WIHS showed no change 
in the cumulative incidence of oral warts with suppressive ART (Greenspan et 
al., 2004).   
 
Anogenital warts: ART 
The effect of suppressive ART on anogenital warts and pre-cancer is not 
entirely consistent.   However, overall there is probably no reduction in the 
prevalence of anogenital HPV infection or pre-cancer with suppressive ART.  
Not all studies have taken absolute CD4 T-cell counts and CD4 T-cell count 
nadirs into account, yet such parameters are probably important.   
 
A small decrease in genital wart incidence with suppressive ART has been 
observed by WIHS that became non-significant when CD4 T-cell count was 
taken into consideration (Massad et al., 2004).  However, a later publication 
	  arising from the WIHS showed that there was no change in the cumulative 
incidence of genital warts in HIV positive women on suppressive ART versus 
ART naïve subjects; 28.4% compared with 25.1% respectively (Dolev et al., 
2008).  Unfortunately however, it is not known how the prevalence changed 
under the influence of suppressive ART.  Others have suggested a decrease in 
relapse rates of genital warts with suppressive ART, but there were 
methodological problems; 6 month follow-up and small numbers (Orlando et al., 
1999). 
 
HPV related pre-cancer and cancer: ART 
A reduction in the relative risk of VIN with suppressive ART has been observed 
after controlling for CD4 T-cell count; WIHS (Massad et al., 2004).  Studies 
looking at CIN have either shown no change in its natural history or a modest 
positive effect on incidence, progression and regression with suppressive ART 
(Lillo et al., 2001; IARC, 2007).  However, CIN may be different from the other 
anogenital cancers because a widespread effective screening program exists.  
There is no such screening program for pre-invasive lesions for AIN, VIN or 
PCIS.   Little or no beneficial effect of suppressive ART on anal HPV infection/ 
AIN (IARC, 2007) has been shown and the incidence of both appears to be 
rising rapidly in HIV positive MSM in the period after suppressive ART has 
become available (Palefsky et al., 2005).  High grade CIN and AIN do not 
regress more frequently with suppressive ART (de Sanjose & Palefsky, 2002).  
Therefore, HIV infection itself increases the prevalence of anogenital pre-cancer 
but present evidence suggests that suppressive ART does not confer a 
substantial beneficial effect on anogenital pre-cancers.    
 
Anogenital cancers: ART 
In the UK the incidence of anal cancer in HIV positive men has increased from 
35 to 92 per 100,000 in the period since the introduction of suppressive ART 
(Frisch et al., 2000; Fox, 2006.  There has been no evidence that cervical 
cancer has declined in the post HAART era (Heard et al., 2004).  Therefore, 
there does not appear to a beneficial effect of suppressive ART on cervical or 
anal cancer (Palefsky et al., 2006; IARC, 2007).  The impact of suppressive 
ART on penile, vulval and vaginal cancers has been incompletely investigated, 
	  but suppressive ART does not appear to be beneficial (IARC, 2007).  Therefore, 
decreased or no change in the regression of anogenital pre-cancers (which take 
years to decades to progress to invasive cancer) with suppressive ART, 
combined with increased longevity of HIV patients may lead to further rises in 
anal cancer and to an increase in cervical cancer in the post HAART era (de 
Sanjose & Palefsky, 2002).   
 
A model of carcinogenesis in HIV has been proposed (de Sanjose & Palefsky, 
2002).  Being infected with HIV even under the influence of suppressive ART 
might allow persistence of HPV with a greater number of types, particularly HR 
types, for a longer period than in non-immunosuppressed individuals.  This 
subsequently leads to the accumulation of genetic changes and dysplasia.  
Once pre-cancer develops, improved immunity with suppressive ART may be of 
little value in preventing progression to invasive disease.  Therefore, the 
persistence of HPV disease in HIV positive individuals may be the reason why a 
higher incidence of anogenital cancers is observed compared with the general 
population.  Persistence may be the key to understanding why the incidence of 
some of these problems still appear to be increased despite the influence of 
suppressive ART (de Sanjose & Palefsky, 2002).  
 
In summary, therefore, suppressive ART has had either a modest positive 
(VIN), negligible (cutaneous warts, genital warts, CIN, anogenital cancer) or 
negative effect (oral warts, AIN) on HPV related diseases in HIV infected 
patients.  However, in a subset of individuals HPV-related cutaneous disease 
has been shown to become persistent or emerge despite suppressive ART 
(Price et al., 2001a; Rodrigues et al., 2001; French et al., 2004).  Wart disease 
appearing in the post HAART era has been viewed as a form of IRAD (French 
et al., 2004).  In considering this, a discussion of the immunopathogenesis of 
HPV is warranted. 
 
 
 
 
 
	  1.3 IMMUNOPATHOGENESIS OF HPV IN HIV 
 
1.3.1 HPV immunology  
 
HPV utilises a number of biological mechanisms that enable it to evade 
detection by the healthy immune system.  It has long latency periods with its 
DNA existing episomally in low copy numbers but it can also integrate into the 
host genome.  It replicates intracellularly and is non-lytic; virions are shed within 
intact mature epithelial cells, limiting the exposure of the immune system to 
HPV antigens (Doorbar, 2005; Munoz et al., 2006).  
 
Humoral immunity is important in HPV clearance and is of potential importance 
prophylactically and therapeutically.  Serological responses to HPV have been 
extensively studied in recent years in parallel with the development of the two 
prophylactic L1 vaccines for genital HPV 16/18 and for HPV 6/11/16/18 that are 
now available.  The vaccination target group is teenagers/young adults prior to 
(or soon after) first sexual activity.  HPV antibodies have been shown to be HPV 
type-specific and do not appear to be protective against other HPV types 
(Frazer, 2002).  However, one review concluded that although there was 
conflicting evidence that HPV-type cross-protection might occur secondary to 
naturally occurring genital HPV infections, trials indicate that vaccination may 
also be protective against disease related to HPV types that are not included in 
the vaccine (Ault, 2007; Stanley, 2009).  Vaccines for cutaneous wart 
associated types are under development in mice (Senger et al., 2010). 
 
Genital HPV antibodies have been shown to appear after puberty, relating to 
sexual debut (Michael et al., 2008).  There was usually a delay of several 
months after HPV infection before antibody production occurred, due to the 
ability of HPV to evade initial detection (Moscicki et al., 2006).  Although the 
production of antibodies has been related to HPV clearance, not all individuals 
seroconverted to HPV after exposure.  Less than 70% of individuals that had an 
incident HPV infection seroconverted to the same HPV type and HPV type 
specific antibodies have been identified in only 33-69% of those individuals with 
anogenital cancer relating to the same HPV (Carter et al., 2000; Carter et al., 
	  2001).  Therefore, although HPV antibodies have been associated with 
detection of DNA of the corresponding HPV type, antibodies to a particular HPV 
type are not a reliable marker of current or past genital infection.  This is 
probably also the case for beta and cutaneous HPVs. 
 
Beta HPVs are acquired throughout life, commencing from early in infancy and 
becoming ubiquitous, often persisting for years on the skin and in hair follicules 
(Antonsson et al., 2000; Antonsson et al., 2003; de Koning et al., 2007).  
Seroprevalence of beta HPVs have been shown to increase  steadily until the 
6th decade, when it plateaus (Michael et al., 2008; Waterboer et al., 2009).  In 
adults the prevalence of beta HPV antibodies was >50% (Waterboer et al., 
2009).  As is the case for genital HPVs, this does not reflect the prevalence of 
beta HPVs, that is probably close to 100% (de Koning et al., 2007).  
 
Cutaneous wart associated HPV antibodies are acquired from early in life.  
They are also probably under-detected.  Gamma HPVs antibodies (for HPVs 
4/48/65/95) have been reported in 26-48% of the general population.  
Antibodies to other groups of cutaneous HPVs have been detected with a 
similar prevalence: antibodies to each of HPVs 1, 2, 3, 10, 57, 41, 63 or 77 
were found in 5-30% of individuals (Michael et al., 2008; Waterboer et al., 
2009).  In terms of possible targets for a genital HPV therapeutic vaccine the 
oncogenic protein products of HPV E2, E6 and E7 are of interest (Moscicki et 
al., 2006).  HPV L1 humoral responses induced by existing prophylactic 
vaccines are unlikely to be of benefit as a therapeutic option; once HPV 
infection is established in pre-cancerous/cancerous lesions viral genes 
(particularly E6, E7) are often integrated into the host genome and viral L1 may 
be lost (Moscicki et al., 2006).  
 
Individuals with persistent HPV infection appear to develop a related cell-
mediated immune response, suggesting that in those individuals who can clear 
HPV infections effectively, early activation of the innate immune system may be 
an important initial defense (Carter et al., 2000; Konya & Dillner, 2001).   The 
adaptive immune system is integral to HPV immune defense.  A T-cell helper 
type 1 (Th1) response involving inflammatory cytokines, such as interferon (IF)- 
	  gamma and recruitment of cytotoxic T-cells (CD8+), antigen presenting 
Langerhans cells (LC) in the epidermis and dendritic cells (DCs) in the dermis 
form an important defence against HPV.  Histologically, resolving warts have a 
prominent CD4 T-cell infiltrate (Coleman et al., 1994).  Natural Killer (NK) cells 
may be important in HPV immunity (Majewski et al., 1986).   
 
HPV can evade detection by the immune system.  It has also been shown to 
influence the local cytokine and chemokine environments resulting in a 
disordered anti-HPV immune response, even in healthy individuals (Stern, 
2005).  LCs have been shown to be reduced in number in HPV infection and in 
dysplastic lesions (Connor et al., 1999).  Downregulation of E-cadherin 
expression on epithelial cells has also been shown, perhaps resulting in poor 
antigen presentation and LC activation (Matthews et al., 2003).  T-cell helper 
type 2  (Th2) responses, that encourage allergic/antibody driven inflammation, 
may be propagated in CIN compared to normal cervices by the downregulation 
of tumour necrosis factor (TNF)-α, a Th1 cytokine, and the upregulation of 
interleukin (IL)-10, a Th2 cytokine (Mota et al., 1999).  Increased regulatory T-
cells (T-regs) have also been observed in invasive cancer and this may be at 
the expense of an effective anti-viral Th1 response (Sheu et al., 2001).  
 
1.3.2 HPV Immunology and HIV 
 
In HIV infected patients taking suppressive ART with disseminated warts, 
dysregulated T-cell responses have been observed (by French et al, from 
unpublished data); they had an absent cutaneous delayed-type hypersensitivity 
(DTH) reaction despite substantial increases in CD4 T-cell counts (as cited in 
Price et al., 2001a).  After an individual with HIV infection regains a given CD4 
T-cell count with suppressive ART following a low CD4 T-cell nadir immunity 
may continue to be impaired.  For example, a CD4 T-cell count of 400 cells/µl 
after a low nadir (<25 cells/µl) may not provide the same level of protective 
immunity to that individual, than had the CD4 T-cell nadir been higher, for 
example >300 cells/µl (Cooney, 2002).   Some pathogen specific CD4 T-cell 
clones may be deleted in HIV infection prior to suppressive ART, therefore, 
eliminating specific immunity to certain pathogens (Cooney, 2002).  HPV is 
	  compartmentalised in the skin and less ‘visible’ to the immune system 
especially when latent in basal epithelial cells where there is both a low copy 
number and low virus turnover (Doorbar, 2005).  Therefore the destruction of 
specific memory T-cells may contribute to the subsequent appearance of HPV 
in HIV infected individuals (Doorbar, 2005; Munoz et al., 2006).   
 
The seroprevalence of genital HPVs is probably higher in HIV infected women 
than in HIV negative women, as reviewed in Egelkrout & Galloway, (2007).  The 
presence of HPV antibodies in HIV infection does not appear to translate into 
decreased risk of subsequent infection with the homologous HPV type, 
compared with HPV seropositive HIV uninfected women (Viscidi et al., 2005).  
However, seroprevalence of HPV 6/16 is similar in HIV infected and uninfected 
MSM (Hagensee et al., 1997), reflecting that sexual activity (for example, the 
number of previous partners) may lead to increased HPV seroprevalance, 
rather than HIV infection status per se. 
 
HIV positive women are still able to generate antibodies against HPV, even 
when CD4 T-cell counts are low (Palefsky et al., 2006).  Anti-HPV vaccination 
may be effective although such studies have not yet been conducted in HIV 
positive individuals (Palefsky et al., 2006).  However, there are limiting factors to 
consider including different HPV types in HIV, timing of vaccination with CD4 T-
cell count and dosing schedule (Palefsky et al., 2006).  The currently available 
prophylactic L1 vaccines may have little effect in individuals already exposed to 
HPV; however, HIV infected individuals might become a target group if 
therapeutic vaccination becomes possible.  Therefore, in summary, HPV in HIV 
may be due to persistent immunodeficiency/dysregulation despite suppressive 
ART.  The concept of HPV as an immune reconstitution associated disease is 
now considered. 
 
 
1.4 IMMUNE RECONSTITUTION ASSOCIATED DISEASE (IRAD) 
 
In the early days  of  active HIV  treatment  a subset  of patients deteriorated or 
developed  paradoxical  manifestations of Mycobaterium avium-intracellularae 
	  (MAI) under the influence of zidovudine (AZT) monotherapy.  This was thought 
to occur as the immune system recovered from the burden of HIV infection 
(French et al., 1992).  Descriptions of MAI reactions after AZT treatment are 
analogous to, for example, lepromatous reversal reactions or to the paradoxical 
worsening of M. tuberculosis infection that may occur after restoration of cell 
mediated immunity (CMI) with anti-tuberculous treatment.  Both of these clinical 
manifestations are related to the return of immune function and were well 
characterised prior to the advent of HIV (Choremis et al., 1955; Shelburne et al., 
2006).  Many other infections such as tuberculosis, Cryptococcus, 
cytomegalovirus (CMV), herpes viruses and hepatitis B/C in addition to 
systemic diseases like sarcoid, inflammatory diseases such as progressive 
multifocal leukoencephalopathy and autoimmune disease have since been 
reported as immune reconstitution events after treatment for HIV (French et al., 
2004).  Since AZT, the first specific anti-HIV treatment, was introduced in 1987, 
and increasingly since the introduction of powerful, fully suppressive ART in 
1996, it has become recognised that immune reconstitution events are common 
(Murdoch et al., 2007).  IRAD has been reported in 15–25% of individuals 
commencing suppressive ART, but is probably higher (around 30–45%) in 
those with a pre-existing opportunistic infection (Lehloenya & Meintjes, 2006; 
Lipman & Breen, 2006; Shelburne et al., 2006; French & Colebunders, 2008; 
French, 2009). 
 
Various attempts have previously been made to define and to characterise 
IRAD (French et al., 2000; French et al., 2004; Lehloenya & Meintjes, 2006; 
Shelburne et al., 2006; Manabe et al., 2007); Table 1.5.  It has been stipulated 
that IRAD should occur within three months of suppressive ART initiation 
(French et al., 2000; Manabe et al., 2007).  While this time constraint may be 
suitable for a definition of inflammatory IRAD, many disorders develop later in 
the setting of suppressive ART-treated chronic HIV disease, such as 
presentations  of  autoimmune  disease  that  may  occur  up  to  two years after 
suppressive ART (Manabe et al., 2007). 
 
Immune reconstitution/restoration disease (IRD) and immune 
reconstitution/restoration  inflammatory  syndrome  (IRIS)   are  also  terms  that  
	   
have been used to describe immune reconstitution events with suppressive 
ART.  Historically, they have often been used loosely and interchangeably.  
However, diseases presenting as immune reconstitution events are 
heterogenous; describing them is difficult.  Not all infections/disease are 
‘inflammatory’ as is implied by the term ‘IRIS’ and not all of the diseases 
described are atypical presentations (that is, deviate from the expected course 
of infection); for example IRAD due to herpes simplex virus (HSV) or diseases 
such as sarcoid (French, 2009; Price et al., 2009). 
 
French, credited with first describing a syndrome associated with immune 
reconstitution (French et al., 1992), writing recently, has been careful in his 
approach to ‘reappraising’ terminology (French, 2009).    He reserves ‘IRIS’ for 
entities with a large inflammatory component, such as tuberculosis, central 
nervous system cryptococcosis, pneumocystis, CMV related immune recovery 
uveitis and JC (John Cunningham) virus causing multifocal 
leucoencephalopathy.   Certainly, IRIS implies that inflammation must be 
present.  Some authors (Lehloenya & Meintjes, 2006; Dhasmana et al., 2008) 
have overlooked this, as they include the common form of HSV and varicella 
zoster virus (VZV) presentations as ‘IRIS’.  However, both herpes virus 
diseases can be manifest by an increase in the number of attacks (orogenital 
Table 1.5  Consensus definition of inflammatory IRAD (IRIS).   The main clinical and 
laboratory features are summarised as points 1-3.  Table from Meys et al., (2010) after the 
International Network for the Study of HIV-associated IRIS (INSHI) www.inshi.umn.edu [last 
accessed 25th September, 2010] and Shelburne et al., (2006). 
 
	  HSV or shingles in patients after the commencement of suppressive ART) that 
are clinically indistinguishable from episodes occurring outside the context of 
immune reconstitution, so they are not strictly hyperinflammatory or atypical 
(Robertson et al., 2006).  
Most authors recognise two main types of IRIS; a paradoxical type presenting 
with paradoxical worsening of an opportunistic infection under antimicrobial 
treatment and an unmasking type, where the first presentation of a disease is 
unveiled by ART (Lehloenya & Meintjes, 2006).  French uses ‘IRD’ strictly for 
diseases characterised by a restoration of pathogen-specific immunity (French, 
2009) and ‘IRIS’ as a broader term.  
 
French has also introduced another term: ‘immune reconstitution-associated 
autoimmune disease’ to describe entities such as Graves disease and diseases 
of unknown aetiology, such as sarcoidosis, that are unveiled by ART (French, 
2009).  However, given that IRIS is restricted by definition to inflammatory 
diseases, and that IRD is widely regarded as being synonymous with IRIS 
(Price et al., 2009) it seems useful to appropriate but modify French’s 
terminology to define IRAD broadly to include four subtypes:  
• inflammatory disorders (such as cryptococcosis, tuberculosis ‘IRIS’);  
• disorders associated with immune reconstitution having a pathogenesis 
other than inflammation, such as Kaposi’s sarcoma (KS) IRAD, which may 
be proliferative in nature (French, 2009);  
• immune reconstitution-associated autoimmune diseases (such as Graves 
disease, systemic lupus erythematosus) and those of unknown aetiology 
(such as sarcoidosis) that are not associated with a return of pathogen- 
specific immunity; and 
• those diseases that have been reported in greater frequencies in 
suppressive ART-treated patients (such as HSV, shingles, molluscum and 
HPV).  
 
IRAD, therefore, embraces all abnormal patterns and/or emergent/persistent 
disease in suppressive ART-treated HIV infection and is considered by the 
author to be preferable to other such terms.  Hereafter, IRAD is used in this 
broad capacity.  
	  
Table 1.6 Main dermatological immune reconstitution associated diseases (IRADs). 
Table from Meys et al., (2010) after Lehloenya & Meintjes (2006), Shelbourne et al., (2006), 
Huiras et al., (2008) and Bunker & Gotch (2010). 
 
(after (Lehloenya & Meintjes, 2006; Shelburne et al., 2006; Huiras et al., 2008; Bunker & 
Gotch, 2010).   
 
1.4.1 Cutaneous IRAD  
 
Cutaneous IRAD is surprisingly common yet can be diagnostically challenging 
for dermatologists; studies that have included dermatologic manifestations of 
IRAD have suggested that half to three quarters of IRAD presentations are 
dermatological (Lehloenya & Meintjes, 2006).  The most common 
dermatological presentations are due to the herpes viruses: HSV and VZV 
(HSV orogenital recurrences and VZV presenting as shingles), occurring  in 
between 0.5 to 12% of individuals. A much rarer form of inflammatory HSV 
IRAD has also been described that is characterised by chronic anogenital 
ulceration and a low pathogen load (Fox et al., 1999).  Lehloenya and Meintjes 
(2006) have recently reviewed the cutaneous forms of IRAD in some detail; 
Table 1.6. 
 	   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	  1.4.2 HPV as an IRAD 
 
Studies of dermatological IRAD have recognised that HPV IRAD is both a 
common and a distinct entity.  In 199 individuals commencing suppressive ART 
in the UK, 44 patients developed an IRAD within six months.  Fifty percent 
(22/44) developed HSV IRAD and 23% (10/44) developed HPV related IRAD - 
genital warts (Ratnam et al., 2006).  Others have found that 51% of 59 patients 
starting suppressive ART developed IRAD within six months of treatment 
initiation; HPV related disease (genital warts, plane/flat warts) was ranked fifth 
and occurred in 10% of subjects or 3/30 (Osei-Sekyere & Karstaedt, 2010).  
 
The increase in oral warts with suppressive ART has already been remarked 
upon; section 1.2.3.  Greenspan et al., (2001) showed treatment with HAART 
regimens that included protease inhibitors (PI) significantly increased the risk of 
developing oral warts; 23% of patients on ART including a PI were affected, 
compared with 15% of patients receiving non-PI therapy and 5% on no 
treatment (Greenspan et al., 2001).  King et al., (2002) showed that in HIV 
infected patients, the incidence of oral warts has been rising rapidly since the 
introduction of suppressive ART and that this trend was statistically significant 
(King et al., 2002).  Other workers have also remarked on the increase in oral 
warts and increased oral HPV DNA prevalence in patients on suppressive ART 
regimes (Patton et al., 2000; Schmidt-Westhausen et al., 2000; Greenwood et 
al., 2002; Cameron et al., 2005).  Some have proposed that it may be 
associated with immune reconstitution (Greenspan et al., 2001; King et al., 
2002), or identified it as ‘IRIS’ (Hodgson et al., 2006; Tsang & Samaranayake, 
2010). 
 
Comparable to the ‘acute’ and ‘chronic forms’ of HSV IRAD (and mollusca in 
suppressive ART treated HIV), we suggest that these two main forms may also 
be applied to HPV IRAD.  Firstly, an acute form of HPV IRAD may manifest as 
atypical inflammation of pre-existing warts/mollusca; such as that exemplified by 
the case in Appendix A2.2.1 (Meys et al., 2011).  In some cases massive 
enlargement has been reported (Moussa et al., 2004).  An ‘effluorescence’ of 
facial warts and the sudden eruption of plane/flat cutaneous warts have also 
	  been described previously (Kerob et al., 2007; Iarikov et al., 2008).  Such acute 
presentations usually occur within months of suppressive ART initiation.   
 
Secondly, a chronic form of HPV IRAD may be represented by a subset of 
patients who develop persistent cutaneous HPV disease despite suppressive 
ART.  This has been reported by others and is supported by our clinical 
experience  (Price et al., 2001a; Rodrigues et al., 2001; Meys et al., 2011).  
Recapitulating, (a) that acute IRAD events are relatively common in patients 
commencing suppressive ART and that HPV is a frequent presentation of IRAD 
(Ratnam et al., 2006; Osei-Sekyere & Karstaedt, 2010) and (b) that chronic 
persistent/emergent warts and HPV carriage are also commonplace; HPV is an 
indubitably important disease in suppressive ART treated HIV that merits further 
attention.  The immunopathogenesis of IRAD will now be discussed. 
 
1.4.3 Immunopathogenesis of IRAD 
 
The pathogenesis of IRAD is incompletely understood.  Current dogma is that 
(at least for inflammatory IRAD) latent antigen becomes recognised by the 
recovering immune system under the influence of fully suppressive ART, 
resulting in antigen-directed pathological inflammation (Price et al., 2001a; 
French et al., 2004; Lehloenya & Meintjes, 2006; Lipman & Breen, 2006).  
However, this does not adequately explain why such unusual patterns of 
disease are observed.  IRADs have been described as being ‘protean’, 
consisting of a variety of presentations due to many opportunistic infections and 
inflammatory disorders with diverse aetiologies (French & Colebunders, 2008).  
They are often organ specific. Immune reconstitution may be 
compartmentalised; consequently measuring systemic changes may be 
irrelevant.  For example, in CMV IRD there appears to be little correlation 
between disease severity and increase of CD4 T-cells in peripheral blood 
(Lipman & Breen, 2006).  This means that there may be no one unifying 
pathological process.  The literature on the pathogenesis of IRAD is also difficult 
to assimilate because of disparate definitions and the difficulty in correlating 
immunological parameters with immunological function or dysfunction 
(Dhasmana et al., 2008). 
	   
A number of mechanisms (or a combination of mechanisms) have been 
proposed to explain the immunopathogenesis of IRAD.  Restoration of CD4 T-
cells in response to fully suppressive ART occurs in two phases.  The first is 
rapid and related to redistribution of circulating memory CD4 (CD45RO+) T-
cells from the gut/lymphoid tissue and reduction in HIV mediated CD4 T-cell 
killing (Janeway et al., 2005).  The second is more gradual over months to 
years and involves the production of naïve (CD45RA+) T-cells from the thymus 
(Lipman & Breen, 2006). Therefore memory T-cells which exist in smaller 
numbers (for example those T-cell clones responsible for tetanus-specific 
immune responses) may be more susceptible to HIV-induced deletion than 
those T-cells that are circulating in higher numbers due to repeated antigen 
exposure/reactivation, for example CMV-specific clones (Cooney, 2002). 
 
A shift from a HIV CD4 T-cell depleted Th2 phenotype to a pro-inflammatory 
Th1 phenotype during dysregulated immune restoration under the influence of 
suppressive ART may contribute to inflammatory IRAD (Lehloenya & Meintjes, 
2006).  The Th1 phenotype is pro-inflammatory, characterised by the secretion 
of IF-gamma, and macrophage/NK cell mediated. Th2 cytokine profile on the 
other hand is pro-allergic and IL-4 and IL-5 mediated.   
 
T-reg cell function may also be defective in HIV, resulting in a pathogenic 
antigen-specific response (Dhasmana et al., 2008).  Impaired dendritic cell 
function, vital for antigen processing and immune activation occurs in HIV 
infection and disordered restoration of this population may result in Th1 
imbalance. However, there is no clinical evidence that the dermatological 
Th1/Th2 phenotype of psoriasis/eczema changes after suppressive ART.  In KS 
IRAD it has been hypothesised that the dysregulated recovery of HLA class I-
restricted CD8 T-cell KS-specific cytotoxic responses may have been 
responsible for some paradoxical worsening of KS with suppressive ART 
(Foudraine et al., 1999; Feller & Lemmer, 2008). The mechanism by which 
inflammation might lead to hyperproliferation of HPV infected keratinocytes and 
an explosion of new lesions with immune restoration is obscure, but the driver 
may be the cytokine milieu produced by infiltrating inflammatory cells. It is 
	  known that an increase in CD4 T-cells (particularly) but also CD8 T-cells is seen 
in resolving warts and also that warts enlarge prior to resolution.  In histological 
sections from a patient presenting with inflammatory HPV IRAD, an infiltrate of 
both CD4 and CD8 T-cells has been seen but this was not especially florid; 
Appendix A2.2.1 and Meys et al., (2011).  
 
A cohort of ageing HIV-positive suppressive ART-treated patients has been 
described with persistent indolent KS and a high CD4 T-cell count and low viral 
load (Maurer et al., 2007); there are two explanations for this. Immunological 
‘senescence’ may be occurring in San Francisco’s ageing cohort on 
suppressive ART, or this may be a form of KS IRAD.  Both of these possibilities 
may also be applicable to HPV-related disease in HIV. 
 
Thus, immune dysregulation may be the basis of IRAD but the question 
remains: why should this occur in some individuals and not others? Risk factors 
for IRAD include a low CD4 T-cell nadir (lowest CD4 T-cell count before 
immune restoration), opportunistic infections at suppressive ART 
commencement and rapid concomitant viral load suppression and rise in CD4 
T-cells. Pathogen-specific or disease-specific host immunogenetic 
predispositions may exist in IRAD and may also play an important role 
(Lehloenya & Meintjes, 2006).  Therefore, it is likely that the phenomenon of 
chronic persistent/emergent warts (that is, HPV IRAD) is different aetiologically 
from the inflammatory IRADs, examples of which have been described herein.  
Its pathogenesis is likely to be incomplete reconstitution of the HIV-decimated 
immune system in immunogenotypically (perhaps HLA determined) 
predisposed individuals. 
 
 
1.5 THE HLA COMPLEX   
 
1.5.1 History of HLA  
 
By the early 1900s inherited factors were known to influence the rejection or 
acceptance of transplanted tumours (Thorsby, 2009).  In the 1930s a 
	  histocompatibility antigen was identified through work on mice tumours (Gorer, 
1937).  This was later characterised as the murine major histocompatibility 
complex (MHC) responsible for rejection of allograft tumours (and tissues in 
general) and became known as histocompatibility (H)-2 locus (Thorsby, 2009).   
 
During the second World War unsuccessful attempts were made to treat burn 
victims with skin grafts from donors (Janeway et al., 2005).  The concept that 
skin allograft rejection (in rabbits) might be immune mediated was first mooted 
in a report to the War Wounds Committee of the Medical Research Council 
(Medawar, 1944; Medawar, 1945).  For this Medawar shared a Nobel Prize in 
1960. 
 
Another Nobel prize was awarded in 1980 (shared between Snell, Dausset and 
Benacerraf) for the discovery of the existence of genetically determined 
molecules on the surface of cells that were instrumental in the human immune 
response; or the HLA complex in humans.  This was achieved, firstly, with 
Snell’s identification of the mouse ‘H-2’ locus.  Secondly, a polymorphic system 
of antigens on human leucocytes was identified through experiments examining 
the agglutination of white cells by the sera of multiparous women and multiply 
transfused patients.  Dausett called this the ‘MAC’ antigen (named after his 
donors’ initials) that became HLA-A2, the first human leucocyte antigen 
(Thorsby, 2009).  Therefore, the HLA complex is the MHC in humans; hereafter 
the terms are used synonymously.  
  
The first International Histocompatibility Workshop was conducted in 1964 to 
standardise the serological techniques used to identify leucocyte antigens.  
Subsequently, a World Health Organisation (WHO) Committee was established 
(in 1968) to oversee the system of HLA nomenclature (Thorsby, 2009).  This 
still exists (Marsh et al., 2010). 
 
One further question remained: how could MHC antigens be associated with 
autoimmune disease (such as ankylosing spondylitis) and also be instrumental 
in histocompatibility?  During work conducted in 1974 Zinkernagel and Doherty 
discovered MHC restriction: viral antigens could only be recognised by T-cells if 
	  they were presented in the context of MHC molecules from the same T-cell 
donor (Thorsby, 2009).  For this critical concept Zinkernagel and Doherty 
received a Nobel Prize in 1996.  
 
1.5.2 HLA structure and function 
 
The HLA complex is located on the short arm of chromosome 6 (6p21.3) and 
contains more than 220 genes; it is one of the most polymorphic regions of the 
genome (Little & Stern, 1999; Janeway et al., 2005; Robinson et al., 2011).  
Most have immunological functions: ‘classical’ HLA molecules are involved in 
antigen presentation (class I - HLA-A, -B, -C and class II – HLA-DR, -DP, -DQ); 
the ‘non-classical’ molecules are involved in regulation of classical HLA class II 
(HLA-DM, -DN, -DO) or in the direction cell killing by NK cells/gamma-delta T-
cells (HLA-F, -G, MICA/B - MHC class I polypeptide- related sequence A/B) or 
have unknown functions (HLA-E).  Other HLA complex genes are involved in 
antigen processing and presentation (TAPBP, TAP, LMP), are components of 
complement (the HLA class III molecules C4A, C2, Bf) or encode cytokines 
(tumour necrosis factor - TNF and  lymphotoxin - LT); some have no 
immunological function (HFE - relating to haemochromotosis an iron storage 
disease).  Hereafter, the terms class I and class II relate to classical molecules.  
See Figure 1.2 for human gene abbreviations.  
 
HLA types were originally defined serologically.  However, the development of 
PCR based techniques (utilising, for example, sequence specific 
oligonucleotides - PCR SSO) has had two consequences. Firstly, serological 
and genetic systems are incongruent, and resulted in a change in 
nomenclature.  Secondly, immunogenetics has resulted in an exponential 
growth in the number of HLA alleles identified to date.  Over 6000 HLA alleles 
are now recognised; Figure 1.3.  Ethnicity greatly influences the predominant 
HLA alleles in any given population; for example, the allele frequency of HLA-
A*30 in a sub-Sarahan African population is 16%, but only 2% of individuals in a 
European population have this allele; Meyer et al., (2007) as cited by 
http://www.ncbi.nlm.nih.gov  [last accessed 30th September 2011]).  
 
	   
 
Figure 1.2 The structure of the human MHC/HLA complex. The human HLA complex 
(Chromosome 6) is similar to that of the mouse (Chromosome 17).  Abbreviations of human 
gene names: Bf - (complement) factor B; C4A - complement 4A; C2 - complement 2; HFE – 
high iron Fe; LMP - low molecular weight protein; LT - lymphotoxin; MICA/B - MHC class I 
polypeptide- related sequence A or B; TAP - transporters associated with antigen processing; 
TAPBP - TAP binding protein (tapasin); TNF - tumour necrosis factor; see text for explanation of 
HLA related gene names.  Figure taken from DeFranco et al., 2007; copyright New Science 
Press Ltd. 
 
(DeFranco et al., 2007) –  
 
 
 
Figure 1.3  HLA class I and class II alleles identified to date (2011). Class I alleles are 
shown in red; Class II alleles are in yellow.  Figure used with permission, from 
http://hla.alleles.org/ [last accessed 30th September 2011); Robinson et al., (2011).  Copyright 
Professor SGE Marsh. 
 
	  Class I HLA molecules present antigens from the internal cellular environment.  
They bind peptides that are derived from proteins from intracellular pathogens 
(such as viruses) or self-proteins that are present in the cytosol.  Each class I 
molecule comprises three alpha units that associate with one beta unit 
(invariant beta-2 microglobulin, found on chromosome 15); Figure 1.4.  During 
particle assembly, in the endoplasmic reticulum, peptides of between eight and 
ten amino acids bind a groove located between the HLA class I alpha subunits.  
The complex is transported to the cell surface where antigen specific cytotoxic 
CD8 T-cells can bind (Little & Stern, 1999).  The binding of CD8 T-cells results 
in target cell lysis, such as that which occurs in virally infected cells that present 
foreign viral antigen on their class I molecules.  Conversely, NK cells can also 
bind HLA class I but, in this situation, target cell lysis is inhibited (Little & Stern, 
1999; Janeway et al., 2005).  Thus, for example, cell death can be evaded by 
cancer cells through HLA class I aberrations that prevent presentation of foreign 
tumour antigens to CD8 T-cells but facilitate recognition by NK cells.    
 
  
                            (a)     (b) 
 
 
 
 
 
 
 
 
 
 
Figure 1.4 The structure of classical (a) HLA class I (-A, -B, -C) and (b) HLA class II  
(HLA-DR, -DP, -DQ) molecules. The peptide binding cleft is indicated by the semi-
circular upper surface is formed between alpha-1 and alpha-2 chains in class I molecultes 
(a).  In class II molecules the alpha-1 and beta-1 chains form the peptide binding cleft.  
Abbreviations: α- alpha, β - beta, βm – beta microglobulin.  After Janeway et al., (2005). 
	  Class II molecules bind and present degraded antigens largely derived from the 
external cellular environment. These peptides originate either from ingested 
antigen-antibody complexes or from intracellular vesicles that are not directly 
connected with the cytosol; the latter may contain intracellular pathogens such 
as Mycobacterium tuberculosis (Little & Stern, 1999; Janeway et al., 2005).  
Class II molecules have a similar binding groove to class I molecules but have a 
more open structure and allow greater variability in binding. They comprise two 
subunits (alpha, beta) that are both encoded by genes within the HLA complex; 
Figure 1.4. Whilst in the cytosol CLIP (class II-associated invariant chain 
peptide) blocks the binding groove, preventing contact with endogenous 
peptides.  Once in the lysosome, CLIP is degraded and peptides that are 
between 12-24 amino acids in length can bind (Little & Stern, 1999).  However, 
the distribution of class II molecules is restricted primarily to ‘professional’ 
antigen presenting cells (APC) such as macrophages, dendritic cells and B 
cells. Binding results in activation of CD4 helper T-cells (Th1/Th2) expressing T-
cell receptors specific for the presented antigen, resulting in activation of 
macrophages to kill phagocytosed bacteria and of B cells, to produce antibody 
(Janeway et al., 2005).   
 
HLA polymorphism and polygeny enable efficient pathogen recognition 
(Janeway et al., 2005).  Each individual carries three genes (six alleles) for HLA 
class I.  These are co-dominantly expressed; two alleles for each of the three 
HLA class I loci (around 1000 alleles exist for each locus).  Therefore the vast 
majority of individuals are heterozygous at each allele and express six different 
HLA class I molecules (Janeway et al., 2005; DeFranco et al., 2007); 
www.ebi.ac.uk/imgt/mgt/hla/ [last accessed 30th September 2011]).  HLA class 
II operates in a more complex manner.  There are also three HLA class II 
genes.  However, many individuals also possess an extra copy of the beta HLA-
DR chain.  Thus, the alpha HLA-DR chain can associate with either beta chain, 
increasing the number of different HLA class II molecules that are typically 
expressed in one individual to eight.  The number of class II molecules can 
increased further depending on the combination of alpha and beta chains on 
each chromosome.  There are also around 1000 different alleles for class II loci 
(Janeway et al., 2005).  Polymorphism ‘hot spots’ are centred around the 
	  peptide binding groove and exposed surfaces of the molecule; alpha1 and 
alpha2 subunits in HLA class I and alpha1 and beta1 subunits in HLA class II 
(Janeway et al., 2005; Robinson et al., 2011). 
 
HLA nomenclature 
HLA nomenclature is complicated and has been subject to frequent change.  
The HLA nomenclature committee is due to meet again in 2012.  The present 
system is outlined in Figure 1.5.   
 
 
 
 
 
Figure 1.5 Nomenclature of genetically typed class I and II HLA alleles.  Each allele is 
designated by (up to) four sets of ‘fields’ that indicate the relationship to other alleles, by 
nucleotide sequence.  The first two fields are the most important.  The first field corresponds 
to the HLA type (that often is equivalent to the serological type); in this example HLA-A2.  
The second field assigns the HLA sub-type.  For example: HLA-A*02:01 and HLA-A*02:101 
denotes two alleles (that result in the same HLA type – HLA-A*02) that differ by at least one 
nucleotide, resulting in production of a different amino acid.  Alleles are numbered in the 
order of their discovery.  The remaining fields indicate alleles that encode for the same gene 
product.  The suffix relates to expression. Abbreviation: N – null allele/not expressed. 
Figure used with permission from http://hla.alleles.org/ [last accessed 30th September 2011]; 
(Marsh et al., 2010); copyright Professor SGE Marsh. 
 
	  1.5.3 HLA and disease 
 
The HLA complex is crucial in moderating immunological balances such as 
allergy versus non-response, effective pathogen directed protective immunity 
versus recurrent infections and tumour immunity versus cancer development.  
Because of its instrumental roles in cytokine production, immune regulation, 
antigen presentation and the highly polymorphic nature of HLA alleles, it is not 
surprising that a number of disease associations have been identified with the 
HLA complex; Table 1.7.  Those relevant to HPV and HIV are also considered; 
Table 1.8 and Table 1.9.  The studies shown in Tables 1.7-1.9 have been 
selected for the most important in Caucasian populations (although other ethnic 
groups have also been included). The associations displayed are in current 
nomenclature wherever possible; however, this could not be determined from 
some publications and the nomenclature used by the authors, at the time of 
publication, has been adopted. Older studies that have examined serological 
HLA types are displayed using the terminology used by the study authors.  HLA 
associations predispose to disease, unless indicated otherwise.  
 
HLA predispositions have been well studied, particularly for HIV infection 
(Blackwell et al., 2009).  However, there are a number of inherent difficulties.  
Firstly, HLA alleles are extensively polymorphic and many ethnic populations 
carry distinct alleles.  This means that one allele can confer protection in one 
population but can be deleterious in another.  Secondly, because of this 
polymorphism, large groups of study subjects are required to gain sufficient 
power to identify associations.  Thirdly, the advent of standardised modern 
molecular HLA testing means that it is difficult to extrapolate from previous 
serological studies.  Finally, publication bias towards positive associations 
means that studies finding no association are less likely to be available; for 
example, one recent review identified around 80 studies that found associations 
with HLA in HIV infection contrasted with only 16 studies that demonstrated no 
association (Blackwell et al., 2009).  Consequently, meta-analyses are 
unreliable.  
 
 
	   
 
 	   
Table 1.7 Selected HLA associations with autoimmune diseases and cancers related to 
infectious diseases.  Abbreviations: HAM - HTLV associated myelopathy;  RR - relative risk 
of disease. 
 
}	  
	   
 
 
 
 
Table 1.8 Selected HLA associations with HPV related diseases. 
	   
 
 
 
 
 
 
 
 
 
 
 
} 
Table 1.9 Selected HLA associations with infectious diseases and HIV infection. 
Abbreviations: GWAS - genome wide association study. 
 
	  Other immune-related genes also may be important in infectious diseases, such 
as those coding for mannose binding lectin, TAP (transporters associated with 
antigen processing), TNF and interferon gamma; vitamin D receptor 
polymorphisms may also play a role (Kaslow et al., 1996; Hill, 1998).  Killer 
immunoglobulin-like receptors (KIRs) are found on NK cells and a sub-group of 
cytotoxic CD8 T-cells.  In the context of particular HLA class I molecules they 
mediate (activate or inhibit) cytotoxic killing of virally infected/cancerous somatic 
cells (Janeway et al., 2005).  KIRs are encoded by a group of highly 
polymorphic KIR genes (analogous to the HLA) that are found on chromosome 
19.  There is some suggestion that KIR genes might interact with HLA alleles 
through epistasis (gene-gene interactions).  For example, the activating KIR 
gene (KIR3DS1) may interact with a subset of alleles of the HLA-Bw4 cluster 
resulting in improved HIV infection prognosis (Blackwell et al., 2009) - the Bw4 
cluster is determined at amino acid residues 79-83 and includes the following 
HLA-B subtypes: -B5, -B5102, -B5103, -B13, -B17, -B27, -B37, -B38, -B44, -
B47, -B49, -B51, -B52, -B53, -B57, -B58, -B59, -B63, -B77; and the following 
HLA-A subtypes: -A9, -A23, -A24, -A2403, -A25, -A32; (www.hla.alleles.org [last 
accessed 20/03/2011]; Marsh et al., 2010).  However, if either gene is absent 
then there is either no protective effect (without the KIR3DS1 gene) or more 
rapid HIV disease progression, if the HLA-B allele is absent (Martin et al., 
2002).  The effect of HLA appears to be stronger than the effect of KIR (Pelak 
et al., 2011) but others have not shown the same beneficial HLA/KIR 
interactions (Barbour et al., 2007).  
 
HPV and HLA  
HLA type may determine the expression of HPV associated diseases and the 
predisposition to certain HPV types (IARC, 2007). HLA allele associations have 
been identified in both a protective and deleterious capacity in patients with 
RRP (HPV 6/11 related), cervical cancer, cervical HPV infection, head and neck 
cancers, cutaneous warts and NMSC (Spelten et al., 2004; Madkan et al., 
2007); Table 1.8.   
 
Cervical cancer is probably the most extensively studied HPV related disease. 
HLA-DRB1*13:01/02 and HLA-DQB1*06:03, particularly, have been shown to 
	  be protective for cervical cancer (with odds ratios around 0.3-0.4) and are often 
found together in the same haplotype (Hildesheim & Wang, 2002). HLA 
polymorphisms may contribute to the persistence of HR HPV types (in both HIV 
infected and healthy individuals) and to progression from infection to cancer.  
HPV 16 may have a different spectrum of susceptible HLA types than other 
types (Madeleine et al., 2002) as might HPV 16 type variants (de Araujo Souza 
et al., 2008).  Recent work that has focused on genome wide association 
studies has confirmed the importance of the HLA complex in cervical cancer, at 
the HLA-DR and -DQ loci, MICA (Zoodsma et al., 2005) and HLA-DPB1 
(Ivansson et al., 2011).  Certain KIR/HLA haplotype combinations have 
implicated NK cells in the pathogenesis of  cervical cancer (Carrington et al., 
2005).  Some studies examining host genetics have used cervical tumour tissue 
for HLA typing (Apple et al., 1994; de Araujo Souza et al., 2008), despite the 
possibility of confounding tumour somatic mutations. 
 
In NMSC, HLA associations have also been suggested (Madkan et al., 2007); 
Table 1.8.  Individuals from the general population and OTRs have been 
studied.  It has been proposed that HLA effects may become more important 
with lower levels of UV light exposure (Wu & Orengo, 2002) and that different 
types of NMSC have different HLA profiles (Czarnecki et al., 1994).  Genome 
scanning using microsatellite markers has also affirmed that the HLA complex 
may be important in NMSC (Oka et al., 2003; Dunn et al., 2006).   
 
A large number of studies have examined the possibility of a link between other 
host genetic polymorphisms and HPV related disease (Madkan et al., 2007).  
Retinoid pathways, p53 polymorphisms, IL-10 polymorphisms and EV 
susceptibility loci have been examined (Madkan et al., 2007).  Conflicting 
results and tentative links have been suggested and more research is required 
to confirm associations.   
 
HLA and HIV  
HLA associations that have been identified in HIV infection have recently been 
reviewed in some detail (Blackwell et al., 2009).  Some of these associations 
are highlighted in Table 1.9.  Several studies suggest that HIV infected 
	  individuals can be stratified for their risk of HIV progression by HLA type.  
Generally this has taken the form of class I associations (HLA-B*35, that has 
been associated with greater risk of progression and HLA-B*27, -B*57, 
associated with reduced risk of progression); Table 1.9.  It is thought that the 
protective HLA-B*27, -B*57 alleles mediate their effect through enhancement of 
CD8 cytotoxic T-cells that target a conserved region of the HIV p24 protein; the 
resultant escape mutants have lowered viral fitness (Blackwell et al., 2009).  
However, in Africans other alleles may be important, for example HLA-DR5 (-
DRB1*11:02) or -DR6 (-DRB1*13:01) have been found in 80% (of 18) 
individuals with a CD8 T-cell response and slow progression to disease (Itescu 
et al., 1992).  However, other factors may also influence HIV progression such 
as a mutation in chemokine receptor 5 (CCR5-∆32) that is found on 
chromosome 3, and attenuated HIV strains (McNicholl et al., 1997; Ghodke et 
al., 2005).  Abacavir hypersensitivity has been associated with HLA-B*57:01 
and this intelligence is potentially useful in clinical practice (Mallal et al., 2002). 
 
HLA and IRAD  
Host immunogenetics, such as HLA allele variations, may also play an 
important role in IRAD (Lehloenya & Meintjes, 2006). For example, the 
haplotypes HLA-A2, -B44, -DR4, or HLA-B72, -C*02:02, -DRB4 have been 
associated with CMV or HSV IRAD, respectively (Fox et al., 1999; Price et al., 
2001b; French et al., 2004).  CMV and mycobacterial IRAD have also been 
associated with cytokine gene polymorphisms; IL-12-beta (herpes virus IRAD) 
and mycobaterial IRAD have been associated with IL-6-174*G and TNF-
alpha−308*2 (French et al., 2004).  More recently, it has been shown that HIV 
patients with herpes-associated IRAD have more activating KIR genes (Price et 
al., 2007). Therefore, although a clear association has not been elucidated, the 
major histocompatibility complex (or a closely linked gene) have often been 
implicated in the aetiology of IRAD. 
 
 
 
 
 
	  1.6 SUMMARY  
 
HPV is a pervasive human pathogen that is found in a large proportion of the 
general population. There are many different HPV types that, through evolution, 
have come to inhabit separate ecological niches.  Three groups of HPV types 
are clinically relevant. Firstly, the cutaneous wart associated types and 
secondly, the genital HPV types causing warts, pre-cancer and cancer in the 
anogenital tract.  Finally, beta HPV types that are considered ubiquitous but 
non-pathogenic in health, cause morbidity/mortality in individuals with the rare 
disease EV and have been implicated in skin cancer aetiopathogenesis.  Novel 
broad spectrum PCR techniques have much to add to our understanding of 
HPV disease patterns and pathogenesis.   
 
HPV disease is particularly problematic in immunosuppressed individuals, 
including those with HIV infection, causing significant stigmatisation, morbidity 
and mortality in the form of HPV related cancers.  Despite the amelioration of 
many HIV related diseases that has been correlated with ART, HPV disease in 
HIV shows no evidence of decline. Cutaneous and external genital HPV 
disease in HIV is widespread despite suppressive ART and is poorly 
characterised. 
  
HIV infection in humans results in severely altered immune function.  Immunity 
is not completely ’reconstituted’ with fully suppressive ART and is associated 
with a poorly understood spectrum of disease, associated with immune 
reconstitution, including of the skin and including with HPV.  The concept that 
HPV disease in treated HIV infection may be a chronic form of HPV related 
IRAD has been introduced using the broadest definition.  
   
The immunogenotype of an individual dictates, to some degree, the phenotype 
of skin disease manifested in HIV infection, treated and untreated.  To date, 
HLA associations have been mooted for several HPV related diseases, for HIV 
disease progression and for IRADs, but HPV disease in HIV had not previously 
been investigated until now.  It is possible that immunogenotype, represented 
by HLA type, is an explanation for the clinical observation that most individuals 
	  are exposed to HPV but only some develop disease caused by it.  
Characterising HPV disease in HIV and testing associations with HLA alleles or 
haplotypes may shed light on the mechanisms of susceptibility or resistance to 
HPV in the context of HIV, and on the general experience of HPV infection.    
 
 
1.7 AIMS AND HYPOTHESES 
 
Aims 
To characterise the HPV profile of cutaneous and external genital wart disease 
in HIV infected individuals on suppressive ART, and compare it with wart 
disease found in the healthy population. 
 
To establish the immunogenetic profile of HPV related cutaneous and external 
genital wart disease in HIV infected individuals on suppressive ART and 
compare it with the HPV profile of  healthy individuals with wart related disease 
and the general population, using HLA allele distribution as a marker of 
immunogenotype. 
 
Hypotheses 
The HPV profile of wart related (cutaneous and external genital) disease in HIV 
infected individuals on suppressive ART differs from that seen in HIV negative 
individuals with warts.  
 
The immunogenotype of HIV infected individuals on suppressive ART with wart 
related (cutaneous and external genital) diseases differs from those HIV 
infected individuals without warts.  	  
  
 
 
 
 
 
 
 
 
CHAPTER 2:   
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2.1 STUDY DESIGN 
         
The study design was case-control; Table 2.1.  The following groups were 
recruited: (i) HIV infected cases with warts under treatment with suppressive 
ART; (ii) healthy HIV negative/presumed negative cases with warts, and (iii) HIV 
infected wart-free controls under treatment with suppressive ART.  
 
(i) HIV infected ’cases‘ were defined as HIV-1 infected individuals:  
• with a ≥6 month (‘persistent’) history of cutaneous/genital warts (with or 
without a history of anal/genital pre-cancer); 
• with Caucasian parentage (Table 2.2) and; 
• on fully suppressive ART - defined as a history  of taking ART for ≥1 year 
together with HIV viral load (VL) results of <50 copies/ml for at least six 
months. 
 
 (ii) Healthy ’cases‘ were individuals in good physical health with no clinical 
indicators for HIV infection, no risk factors for HIV on direct specific questioning 
at interview (Table 2.3), and/or who had a negative HIV antibody test, and: 
• persistent HPV disease, as above, and;  
• Caucasian parentage; (Table 2.2).  
 
(iii) HIV infected ’controls‘ were on fully suppressive ART and were defined as 
HIV-1 infected Caucasian individuals with: 
• no clinical lesions consistent with cutaneous or genital warts and HPV 
related anogenital pre-cancers and; 
• no medical history of warts in adulthood (adulthood was defined as an 
age 20 years or more) lasting ≥3 months and; 
• no history of anogenital pre-cancers/cancer. 
 Table 2.1 Participant recruitment. Subjects were either (a) recommended biopsy as part of clinical care for diagnosis (lesions that were atypical or possibly pre-malignant) 
or (b) offered biopsy to remove lesions (clinically benign lesions; warts). Clinically confirmed plantar/palmar warts (clinically a benign diagnosis and difficult to biopsy) were 
pared (no biopsy was done).  
 
 Although they were not included in the molecular HLA analysis, non-Caucasian 
HIV infected and healthy cases were also recruited for the HPV analysis. 
  
 
2.2 PARTICIPANT RECRUITMENT 
     
2.2.1 Ethics 
 
Ethical approval was attained through the NHS Research Ethics Committee 
(NREC); Riverside Research Ethics Committee (London) reference 
07/H0706/65; Appendix 2.1.1.  All participants in this study were recruited 
prospectively and gave consent to provide access to case notes, computerised 
records and to allow the provision and analysis of blood and (fresh/archival) 
tissue samples for the purposes described above and expanded below.  
Examples of the consent and information forms provided to participants can be 
found in Appendix 2.1.  
 
2.2.2 Inclusion and exclusion criteria  
 
HIV infected cases and controls and healthy cases were defined as above.  
Several definitions and exclusion criteria are discussed below.  
  
Ethnicity: definition of Caucasian  
Subjects with (parental, grandparental) descent from countries appearing in the 
top (white) panel of Table 2.2 were classified as Caucasian (including 
individuals from the USA, Australia and New Zealand with a history of 
Caucasian descent).  Subjects with ethnic descent from other countries/regions 
were excluded from the HLA molecular analysis. The definition of Caucasian 
was developed in consultation with a HLA molecular expert (Professor Steven 
Marsh, Anthony Nolan Histocompatibility Laboratories, London, UK, personal 
communication).  
 
 
  
 
 
 
 
 
 
 
Age   
The wart phenotype of children may be different to that in adults and the 
prevalence of warts in school-aged children warts is high (Rubben et al., 1997, 
Sterling & Doorbar, 2001).  No HIV infected children were included.  Therefore, 
healthy and HIV infected subjects aged  <20 years were excluded. 
 
Females with genital warts 
The phenotype of female genital disease may be different to male genital 
disease (Partridge & Koutsky, 2006).  Few HIV infected females with warts were 
available for recruitment (due to the demographics of the cohort sampled) and 
none were Caucasian.  Therefore, females with genital warts were excluded 
from the overall analysis (however, they are considered as a special case).  
Females with cutaneous warts were included because males and females have 
a similar cutaneous wart phenotype. 
 
Childhood warts 
Individuals (including HIV infected controls) with a history of childhood warts 
were included; warts are common in otherwise healthy children; section 1.1.4.  
 
 
Table 2.2 Definition of ‘Caucasian’. Subjects with a history of descent from countries in the 
top panel were classed as ‘Caucasian’ for the purpose of this study (including those with 
Caucasian descent from Australia, New Zealand and the USA).  Examples of countries and 
regions classed as non-Caucasian are shown.   
 
 Past medical history 
Individuals were excluded if the clinical phenotype could not be corroborated by 
clinical history, examination, patient records and/or histology.  Patients with 
diseases such as diabetes mellitus were included but those with rheumatoid 
arthritis, severe eczema and suspected primary immunodeficiency were 
excluded. Individuals with a history of co-morbidities requiring use of oral 
prednisolone (for example temporal arteritis, inflammatory HSV IRAD) within 
one year of wart disease were also excluded.  A number of patients were not 
clearly either cases or controls (‘grey cases’) and were therefore excluded from 
the study; for example, those that had warts for 3-6 months or were unable to 
give a clear history of wart duration ≥6 months. 
 
2.2.3 Clinical features of study participants 
 
All participants were recruited by interview from the Dermatology or Genito-
urinary medicine (GUM) Departments of the Chelsea and Westminster Hospital, 
London, UK; Table 2.1.  A rigorous dermatological assessment (history and 
examination) was performed and the clinical phenotype was ascertained by a 
dermatologist. Healthy subjects were assessed for HIV specific risk factors.  
Demographic information was collected on all patients including: 
• ethnicity (parental, grandparental country of origin, as above);  
• age; 
• sex; 
• total wart disease duration for cases (volunteered by the patient and 
corroborated by patient case notes and computerised patient records) and  
• duration of lesion(s) sampled, for cases. 
 
Demographic information was collected from HIV infected individuals from 
retrospective paper and computerised case records including:  
• the year of diagnosis;  
• the year of ART commencement; 
• current ART regimen. 
 
 Standard sets of phenotypic immunological parameters were also collected 
from HIV infected individuals: 
• HIV VL  (copies/ml); 
• CD4 T-cell count (cells/µl) and  
• CD4 T-cell count nadir (cells/µl).   
 
The CD4 T-cell count nadir was corroborated by the year of ART initiation and 
defined as the lowest historical CD4 T-cell count measurement; in some cases 
the lowest CD4 T-cell occurred some time after treatment commencement.  The 
HIV infected subjects studied were on a ’fully suppressive‘ ART regimen, 
defined by: a HIV VL of <50 copies/ml for at least six months.  Therefore, stable 
HIV infected patients on established therapy with at least one year of ART were 
preferentially recruited.  
 
Risk factors for HIV infection  
HIV-specific risk factors were assessed in each healthy subject in a private 
interview with a clinician; Table 2.3. A negative HIV antibody test was defined 
as one performed during recruitment or a clear history of a previous negative 
HIV antibody test, with no subsequent exposure on history.  Subjects with tests 
within three months of an exposure event (in the ‘window period’) were re-
tested.  All subjects reporting MSM without a recent negative test result 
consented to HIV antibody testing. 
 
  
 Table 2.3  Table of risk factors for HIV infection in healthy subjects.  
 
 
 
 
 
 
 
 ‘Low risk’ healthy individuals were defined as those with negative answers to all 
interview questions; Table 2.3.  Recruitment of subjects commenced prior to the 
‘normalisation’ of HIV testing as outlined in the UK National Guidelines on HIV 
Testing, published in September 2008 (www.BHIVA.org).  In the latter part of 
this recruitment for this study (from 2009) most subjects consented to a HIV test 
as part of routine clinical care. 
 
Reference populations for HLA allele data  
To provide a comparison with HIV infected cases/controls and healthy cases, 
HLA data were utilised that were available from a population of white 
Europeans (Caucasians), unselected for HPV disease.  The HLA molecular 
typing methods used were similar to those used in this study (SSOP-sequence 
specific oligonucleotide probes).  Three English populations were used for the 
analysis; all data were obtained from www.allelefrequencies.net [last accessed 
1st April 2012]; (Gonzalez-Galarza et al., 2011).  Firstly, for HLA-A, -B, and 
HLA-DRB1 loci the population comprised Caucasoid blood donors (n=5024) 
that attended a UK Blood Transfusion Centre (“England Leeds”).  For HLA-C, 
individuals (n=2420) were derived from a sub-group of the same population.  
Secondly, for the HLA-DQB1 locus data from another reference population 
(n=177) were available; “England pop 6” – this population was included in an 
anthropology study based in London; subjects were primarily English but 
Scottish, Welsh, Northern Irish individuals may have been included (Doherty et 
al., 1992, Gonzalez-Galarza et al., 2011).  Finally, a third English population 
(“England North West”; Liverpool) was available, comprising of (n=298) 
Caucasian blood donors, to consider allele sub-group counts for HLA-B. 
 
Clinical cases and images 
Study codes were assigned to the study subjects recruited herein and were 
derived from a mixture of the codes used in the clinic and the subject name.  
However, to ensure anonymity they were changed by a transmutation to the 
codes displayed in the text of this thesis and the tables in the Appendix.  The 
clinical images provided in this thesis were obtained from (and copyright is held 
by) Medical Illustration UK (Chelsea and Westminster Hospital, London, UK) 
 and all patients consented to the use of their images.  Examples of HIV infected 
cases recruited are included in Appendix 2.2. 
 
 
2.3 CLINICAL SAMPLES  
          
2.3.1 Tissue  
 
Wherever possible a representative sample of each morphological lesion was 
sent for histopathology (Dr Nick Francis and Dr Justin Weir, Histopathology 
Departments, St Mary’s and Charing Cross Hospitals, London, UK).  Biopsied 
warts were curettaged (or shaved) flush with the skin surface using aseptic 
technique (Dermatology Department, Chelsea and Westminster Hospital, 
London, UK). This removed the whole wart, while maximizing cosmesis on 
healing.  Incisional biopsies that (included dermis) were necessarily taken of 
suspected pre-cancerous lesions or atypical lesions.  Large/medium sized 
tissue samples were divided into portions and (a) sent for histological 
assessment and/or (b) snap frozen in liquid nitrogen and stored at -80ºC.  When 
only a small amount of tissue was obtained (and the clinical diagnosis 
uncertain) all available tissue was sent for histological assessment in 10% 
formalin, fixed and paraffin embedded (FFPE).  The FFPE specimen was used 
for analysis.  Two samples were derived from FFPE tissue, only one was a wart 
(Chapter 3); the other sample has been included in optimisation (Appendix 3.1).  
 
Warts located on sites not easily amenable to biopsy under local anesthetic 
(such as plantar aspect of the foot, peri-ungual region and finger pulp) were 
pared.  This involved the removal of the top layer with a sharp scalpel or curette 
instrument without local anaesthetic.  The deeper layers were collected in a 
new, sterile cryogenic tube, snap frozen in liquid nitrogen and stored at -80ºC.  
If necessary, silver nitrate solution was applied to the skin to stop any bleeding 
points.  After paring, warts were then treated with cryotherapy.  Multiple lesions 
from the same individual were labelled T1, T2, T3 and so on.  
 
 2.3.2 Blood 
 
All subjects (cases and controls) provided blood for molecular HLA typing.  
Whole blood samples in EDTA (ethylene-diaminetetra-acetic acid) were snap 
frozen in liquid nitrogen and stored at -80oC.  Storage was predominantly 
accomplished within 4-6 hours of collection.   
 
 
2.4 DNA PREPARATION   
        
2.4.1 DNA extraction: blood 
 
DNA was extracted manually using a standard protocol validated by the 
manufacturer of the kit used (Qiagen, Crawley, UK).  No difference in DNA 
quality between fresh and frozen blood was observed in downstream DNA 
analysis.  A 200 µl aliquot of previously frozen, thawed and gently mixed blood 
sample was used; the method followed is detailed in the QIAGEN QIAamp DNA 
Mini Blood Mini Handbook, 2007.  One elution of DNA was conducted from the 
column into 200 µl of elution buffer/molecular grade water.  DNA was stored at -
20oC until required.   
 
2.4.2 DNA extraction:  tissue 
 
The QIAamp DNA Mini Kit (Qiagen, Crawley, UK) was used for tissue extraction 
and the protocols are detailed for tissue in the manual: QIAamp DNA Mini and 
Blood Mini Handbook (2007).  Standard protocols were employed together with 
stringent anti-contamination procedures, extended tissue lysis, a longer elution 
time and a smaller elution volume. 
 
Briefly, approximately 25 mg fresh tissue was thawed and chopped very finely 
with a sterile scalpel on a sterile petri-dish.  This was done in a clean, DNA free 
ultraviolet (UV) light treated, microbiological safety cabinet.  A fresh sterile Petri 
dish and scalpel were used for each sample to avoid cross contamination. The 
 sample was incubated in tissue lysis buffer and Qiagen Proteinase K at 56°C 
for 24-72 hours minimum of extended tissue lysis, with occasional vortexing.  If 
small pieces of tissue were still visible at 24 hours, digestion proceeded to 48 
hours (and then to 72 hours, if required).  DNA extraction was conducted with a 
Qiagen kit, as above, using the manufacturer’s protocol. After washing with 
buffers AW1 and AW2 (Qiagen Crawley, UK), a second stage of AW2 buffer 
elimination was conducted for tissue extraction to avoid carry-over of buffer into 
the DNA sample.  DNA from the column was eluted into two aliquots of 50µl 
elution buffer.  Five to ten minutes were allowed to elapse during the last stage 
of the extraction between applying the elution buffer and eluting (spinning in 
centrifuge).  This is reported by the manufacturer to increase the final DNA 
concentration and the total amount of DNA extracted. Negative controls 
(extraction buffers) and positive controls (placental DNA) were extracted 
alongside tissue/blood samples.  DNA extraction was performed by the author 
in the Immunology Department, Imperial College London Chelsea and 
Westminster Hospital, London, UK 
 
The two FFPE samples were processed in a similar way, as outlined in the 
QIAamp DNA Mini and Blood Mini Handbook (2007).  Briefly, tissue sections 
were cut from the FFPE tissue block (Histopathology laboratory, Charing Cross 
Hospital, London UK), rinsed and vortexed with xylene, then ethanol and 
immersed in tissue lysis buffer.  DNA extraction was performed, as before, for 
fresh tissue.  
 
2.4.3 DNA quantification 
 
DNA extracted from tissue was quantified with a Nanodrop 1000 
spectrophotometer (Thermo Scientific, Lab Tech International, East Sussex, 
UK).  The Nanodrop detected absorbance at 260 nm in 1.5µl aliquots of DNA in 
mol and from this the concentration of DNA was determined (in ng/µl). 
 
 
 
 2.5 HPV TYPING 
 
2.5.1 HPV typing: introduction  
    
Four methods were used to identify a broad spectrum of HPV types; sections 
2.6.2 and 2.6.3 (cutaneous wart associated HPVs), 2.7 (genital HPV types) and 
2.8 (beta HPV types).  All were PCR based and relied on the detection of HPV 
DNA from tissue samples. Each wart was comprehensively typed for all three 
HPV groups.  
 
2.5.2 Polymerase chain reaction (PCR) 
 
PCR reaction mixtures were made in a PCR free room and template DNA was 
added in a microbiological safety cabinet or a designated pre-PCR room to 
reduce contamination.  HPV plasmids were handled in a designated post PCR 
area.  Unless specified, reaction volumes were 50µl; approximately 100-200ng 
in 10µl of template DNA was added.  Reactions were performed on a PTC DNA 
Engine Dyad thermal cycler (MJ Research, Waltham MA, USA).  PCR cycling 
parameters, reaction reagents and concentrations are detailed in each section.   
 
2.5.3 Post PCR processing 
 
After PCR, reaction products were processed as outlined in each section.  
Where indicated, 100ml agarose gels (1-2%) were made by dissolving the 
required weight of agarose in TBE (Tris/Borate/EDTA buffer) and heating in a 
microwave for 60 (100ml gel) to 120 seconds (200ml gel).  For each 100ml of 
warmed liquid gel, 6µl of ethidium bromide wad added (10mg/ml, Sigma-
Aldrich, Gillingham, UK), and it was allowed to set for 30-60 minutes.  Once 
firm, gels were immersed in TBE and loaded with DNA PCR products and DNA 
ladder (NEB, Hitchin, UK) mixed with five times gel loading dye (NEB, Hitchin, 
UK).  Electrophoresis was for 40-60 minutes at 120V.  The gels were visualised 
under UV light (Syngene Gbox, Cambridge, UK).   
 2.6 CUTANEOUS HPV TYPING 
 
2.6.1 Cutaneous HPV typing: introduction  
 
Two different methods were used to detect cutaneous HPV types in study 
samples. The first method involved nested PCR and sequencing; 32 samples 
were typed in this way. All of the samples (including the 32 typed by nested 
PCR) were also typed using a second method that detected cutaneous types 
using a Luminex-based platform: Hyperkeratotic Skin Lesion-PCR/multiplex 
genotyping or HSL-PCR/MPG (de Koning et al., 2010). A comparison of the two 
methods has been made using the results of 32 samples that were HPV typed 
by both methods (Appendix 3.1).  However only the HSL-PCR/MPG results 
have been used in the final analysis of HPV types detected in all samples 
(Chapter 3).   
 
2.6.2 Cutaneous typing methods: nested PCR, gel extraction, purification 
and sequencing 
 
Briefly, the nested PCR/sequencing protocol used well validated degenerate 
cutaneous HPV group specific primers (Harwood et al., 1999).  The outer pair 
(HVP2/B5, amplicon 650 bp) amplified a wide range of cutaneous HPV types.  
Three sets of second round degenerate primers with narrower HPV type 
specificity were nested within the first round amplicon (Harwood et al., 1999).  
The HPV types detected by each set of primers and amplicon sizes were: 
CN3F-CN3R (alpha genus species 2 HPVs: 3, 10, 28, 29, 77; 273 bp), CN2F-
CN2R (alpha genus species 4 HPVs: 2, 27, 57; 294 bp) and CN1F-CN1R 
(genera mu and nu HPVs: 1, 41, 63; 309-328 bp). The work outlined in this 
section was done solely by the author under the supervision of Dr Karin Purdie 
at the Centre for Cutaneous Research (Barts and the London School of 
Medicine and Dentistry, Queen Mary University of London, UK).   
 
Cycling parameters and reaction constituents used in this investigation were 
modified slightly from those published; Tables 2.4 and 2.5 (Harwood et al., 
 (b) (a) 
1999, Shamanin et al., 1994a, Shamanin et al., 1994b). The final concentration 
of reagents in the second round of PCR was the same as for the first round, 
with the exception of MgCl2 (final concentration in second round; 2.0 mM); 
Table 2.4.  Template DNA (approximately 30-60 ng) and molecular grade water 
were also added.  Nested PCR was also performed on negative controls.  
Plasmids containing HPV 1 (CN1 primers), 2 or 27 (CN2 primers) and 3 or 10 
(CN3 primers) served as positive controls; these were kindly provided by Dr 
Ethel-Michelle de Villiers, Deutsches Krebsforschungszentrum/DKFZ, 
Heidelberg, Germany.  Primers were obtained as HPLC (high performance 
liquid chromatography) purified DNA from Invitrogen (Paisley, UK).  The other 
PCR reagents: GeneAmp Buffer, MgCl2, deoxyribonucleic acids (dNTPs) and 
AmpliTaq Gold were obtained from Applied Biosystems (Warrington, UK). 
 
 
 
 
 
 
 
  
Table 2.4 First round nested PCR using HVP2/B5 primers.  (a) Reaction constituents and 
(b) cycling conditions are shown.  
Table 2.5 Cycling conditions for second round nested PCR using CN1-3 primers.   
 
  
 
300bp 
200bp 
100 bp 
PCR products from the second round of nested PCR protocol were run on a 2% 
agarose gel in TBE (Tris/Borate/EDTA buffer) at 120V for 30-40 minutes; Figure 
2.1.  Visible bands of the expected bp length were then separated on another 
2% agarose gel (this time using low melting point agarose) and cut out under 
UV visualisation (Syngene UV visualiser, Cambridge, UK). PCR products were 
purified using the QIAquick Gel Extraction Kit (Qiagen, Crawley, UK) and as 
indicated in the protocol: QIAquick spin handbook (2008).   
 
 
 
 
 
 
 
 
Figure 2.1 Photograph of agarose gel showing PCR products of second round nested 
cutaneous HPV primers CN1-3. A 2% gel has been photographed after 30 minutes of 
electrophoresis.  Plasmids containing HPV types 1, 2, 3, and 10 are represented by lanes 1 to 
4 respectively. Lane 5 and 6 are negative controls.  HPV 1 (lane 1) was amplified best by CN1 
primers.  HPV 2 (lane 2) was amplified best by CN2 primers.  HPV 3 and 10 (lanes 3 and 4) 
were best amplified by CN3 primers.  Some cross reactivity can be seen (HPV 1 with CN3 
primers, HPV 2 with CN1 primers and HPV 3,10 with CN1 primers). PCR amplicons are 273-
328bp.  
 Direct sequencing was performed by staff at the Genome Centre as outlined in 
the Genome Centre’s Standard Operating Protocol (SOP GC0102v1 for the Big 
Dye Version 3.1 DNA Sequencing, Genome Centre, Barts and The London 
School of Medicine and Dentistry, London, UK).  Briefly, samples were cleaned 
up with EXOSAP (Exonuclease I, Cambio Limited and shrimp alkaline 
phosphatase, GE Healthcare, Chalfont Saint Giles, UK) to remove unused 
primers and dNTPs.  A sequencing reaction containing BigDye terminator 
mastermix (Applied Biosystems, Warrington, UK) was performed with standard 
reaction components and parameters in 10µl wells of a 96 well plate using the 
respective CN1-3 forward and reverse primers (10pmol/reaction) and template 
DNA (200-600ng).  Post sequencing clean-up was performed as per protocol 
before loading on to an ABI3730xl (Applied Biosystems, Warrington, UK). 
 
Sequences were visualised and analysed by the author with BioEdit Sequence 
Alignment Tool software (Hall, 1999) and the corresponding HPV type(s) 
identified by comparing to known HPV sequences using BLAST (Basic Local 
Alignment Search Tool, Genbank database); National Centre for Biotechnology, 
National Institute of Health, Bethesda, MD, USA; 
http://blast.ncbi.nlm.nih.gov/Blast.cgi. HPV types were identified by L1 
sequence homology, in accordance with established taxonomy (de Villiers et 
al., 2004); different HPV types are distinguished by more than 10% variation in 
sequence; subtypes have 2-10% variation and type variants <2%.  
 
2.6.3 Luminex-based cutaneous HPV detection: Hyperkeratotic skin 
lesion-PCR/multiplex genotyping (HSL-PCR/MPG)  
 
The HSL-PCR/MPG method identified 23 cutaneous types, a wider spectrum 
than the first method used (PCR and sequencing).  In addition to the types that 
are identified by the nested PCR protocol (HPVs 1, 2, 3, 10, 27, 28, 29, 41, 57, 
63, 77), HSL-PCR/MPG also detected: alpha genus species 2 (HPV 94); 
species 8 (HPVs 7, 40, 43, 91) and gamma genus HPVs 4, 48, 50, 60, 65, 88, 
95 (de Koning et al., 2010).  The work outlined below was done by the author 
and laboratory staff at DDL Diagnostic Laboratory (Voorburg, The Netherlands). 
 (b) (a) 
 
Briefly, broad spectrum PCR (HSL-PCR) was conducted with a mixture of 27 
non-degenerate primers (13 forward and 14 reverse; sequences not published) 
that amplified a 76-84 bp segment of the L1 gene of HPV (Labo Bio-Medical 
Products BV, Rijswijk, Netherlands).  This was done using a strict anti-
contamination protocol.  Reagents (GeneAmp Buffer II, MgCl2, dNTPs, and 
AmpliTaq Gold polymerase) were used as described before; 10 µl of pre mixed 
primer mix was used.  Reaction concentrations and cycling parameters are 
shown; Table 2.6.  
 
The biotinylated PCR products were then hybridised with a panel of 24 DNA 
probes attached to 24 (differently) labelled microspheres (Labo Bio-Medical 
Products BV, Rijswijk, Netherlands).  Briefly, 3B buffer was added to the bead 
mix and then the PCR products added.  The products were denatured by heat 
at 95ºC, hybridised to the microspheres under stringent conditions at 54ºC in a 
thermomixer and then incubated with streptavadin conjugated R-phycoerythrin 
to allow detection of PCR product.  Complexes of PCR product bound to 
microsphere-probes were detected by excitation in a Luminex 100 IS system 
(Luminex, Austin, TX, USA).  A median fluorescent intensity (MFI) reading was 
taken for each bead corresponding to a HPV type for each specimen and 
compared to standards (giving a positive/negative result for each HPV type).  
Negative controls from DNA extraction (extracted placental DNA and extraction 
reagents) were run alongside samples. Figure 2.2 illustrates the Luminex 
method.  
 
 
Table 2.6 Cutaneous HPV HSL-PCR. (a) PCR reaction constituents and (b) cycling conditions 
are shown. 
 
  
 
 
 
 
 
Figure 2.2 Diagram of Luminex based cutaneous HPV typing by HSL-PCR/MPG.  Biotin 
labelled DNA was allowed to bind to DNA probes that were attached to microspheres (beads).  
Each bead was characterised by a tightly controlled mixture of two colour labels that emitted 
signals upon laser excitation (see bottom right panel of diagram).  Streptavidin was added to 
amplimer-bead complexes and complexes were bound to R-phycoerythrethrin, which acted as a 
reporter signal.  From the reporter signal the Luminex machine generated a median fluoresent 
intensity (MFI).  Figure reproduced with permission: Daan Geraets (DDL, Voorburg, The 
Netherlands, personal communication). 
 (b) (a) 
 
2.7 GENITAL HPV TYPING   
 
2.7.1 Genital HPV typing: introduction 
 
The two-stage method used for genital HPV typing has been well described and 
validated both in its original form (Kleter et al., 1999, Kleter et al., 1998) and 
with subsequent modifications (Harper et al., 2004, Levi et al., 2002, Quint et 
al., 2001).  The SPF10-LiPA25 system was used to analyse samples for genital 
HPVs using the L1 gene; SPF10 HPV LiPA version 1, manufactured by Labo 
Bio-Medical Products Rijswijk, The Netherlands (Quint et al., 2001).  The work 
outlined below was done by the author and laboratory staff at DDL Diagnostic 
Laboratory (Voorburg, The Netherlands). 
 
2.7.2 Genital HPV typing: method 
 
Ten microlitres of template DNA was amplified by PCR (in 50µl) with broad 
spectrum SPF10 primers using the parameters shown in Table 2.7 (Kleter et al., 
1999, Quint et al., 2001).   A 65bp PCR product was produced by a group of ten 
consensus primers; the SPF1/2 group, a set of six published primers (Kleter et 
al., 1998) and four additional, unpublished primers (Kleter et al., 1999, Quint et 
al., 2001).     
 
 
 
 
 
  
Table 2.7 Genital HPV SPF10 PCR.  (a) PCR reaction constituents and (b) cycling 
conditions are shown. 
  
In the first stage of HPV detection, PCR products were analysed for the 
presence (or absence) of HPV DNA in microtitre plates with a DNA enzyme 
linked immunoassay (DEIA); Figure 2.3 (Kleter et al., 1998, Quint et al., 2001).  
This was done semi-automatically by a Plato 1300 Robotic Microplate 
Processor (Rosys Instruments AG, Hombrechtikon, Switzerland).  Briefly, 
biotinylated PCR products were hybridised to streptavidin microtitre wells, 
denatured and then hybridised to digoxigenin labelled DNA HPV-specific 
probes.  Unbound products were removed at each stage by a series of washing 
steps.  Colour development was achieved with addition of anti-digoxigenin-
horseradish peroxidase conjugate and tetra-methyl-benzidine substrate (Quint 
et al., 2001).  Optical densities (OD) were measured by the robot at 450nm.  
Positive samples were characterised by an OD450 value that was higher than 
that of the DEIA borderline control (provided in the kit).  Additional negative and 
positive DEIA controls were used for each plate (Kleter et al., 1998).   
 
Figure 2.3 Detection of PCR products in a microtitre plate DEIA. Biotin (B) labelled PCR 
products were allowed to bind to streptavidin (SA) coated microtitre plates.  The bound double 
strands of DNA were denatured by alkaline conditions (NaOH).  Complementary non-bound 
DNA was removed by denaturation and washing.  Digoxigen (Dig) labaelled HPV probes were 
allowed to hybridise to the bound single stranded DNA, excess unbound probes were 
removed by washing and were then detected by conjugate and substrate.  Figure used with 
permission from DDL Laboratories, Voorburg, Netherlands (www.ddl.nl). 
 
 
Check with Maurits re reference for figure 
  
Samples positive with DEIA were then analysed for specific genital HPV types, 
the second stage of the genital HPV detection process.  A RHA, the LiPA25, 
version 1, was used that contained type specific probes to identify 25 HPV 
types; HR HPVs 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68, and 70, 
and LR HPVs 6, 11, 34, 40, 42–44, 53, 54, and 74. Samples were processed at 
DDL Diagnostic Laboratory (Voorburg, The Netherlands) by the laboratory staff 
and the author using an Auto-LiPA machine (Innogenetics NV, Zwijnaarde, 
Belguim) that automated the hybridisation, washing and colour development 
steps. 
 
The protocol for the RHA for the identification of HPV genotypes, was followed 
(Labo Bio-Medical Products, Rijswijk, The Netherlands).  Briefly, 10µl of 
biotinylated PCR product was denatured by alkaline conditions with 10µl 
Denaturation solution in a plastic trough, and incubated for 5 minutes at 15-
25°C.  Two millilitres of hybridisation solution (contained Na citrate 45mM, Na 
nitrate 450mM, 0.1% Na dodecyl sulphate) was added (at 37-50°C) and a 
genital RHA plastic strip bound with 25 genital HPV probes was placed in each 
trough.  Hybridisation was allowed to proceed at 50°C (+/-0.5°C) for 60 
minutes, in a shaking water bath.  This was followed by three washing steps 
with 2ml of stringent wash followed by incubation for a further two respective, 30 
minutes at 50°C (+/-0.5°C).  Conjugate solution (streptavadin labelled with 
alkaline phosphatase) was added and then substrate (BCIP/NBT – 
bromochloroindolylphosphate and nitroblue tetrazolium in dimethylformamide) 
in two 30 minute incubations and washing steps (15-25°C).  Three further 
washes for 10 minutes completed colour development.  Purple horizontal lines 
were generated on the strips that corresponded to the location of the DNA 
hybridised with type specific probes.  The strips were air dried and interpreted 
visually with good light using a chart, supplied with by Labo Bio-Medical 
Products (Rijswijk, The Netherlands).  Positive controls were used in the form of 
HPV 6/11or 16 plasmid and negative controls were also used (extracted 
placental DNA, buffer extraction reagents). The processed genital strips were 
very similar in appearance as the beta RHA strips; Figure 2.4. 
  
2.8 BETA HPV TYPING 
 
2.8.1 Beta HPV typing: method 
 
Typing of samples for beta HPVs was completed solely by the author under the 
supervision Dr Karin Purdie at the Centre of Cutaneous Research, Barts and 
the London School of Medicine and Dentistry, Queen Mary University of 
London, UK.  The beta HPV RHA Kit that was used (Diassay B.V, Rijswijk, The 
Nertherlands) detected 25 beta HPV types - HPVs 5, 8, 9, 12, 14, 15, 17, 19, 
20, 21, 22, 23, 24, 25, 36, 37, 38, 47, 49, 75, 76, 80, 92, 93, and 96 (de Koning 
et al., 2006).  The method used for beta HPV typing was almost identical to that 
used for genital typing, with the following exceptions. 
 
Firstly, sample DNA was amplified by PCR with a group of non-degenerate beta 
HPV primers (two forward and seven reverse; sequences unknown and 
unpublished) that targeted the relatively conserved HPV E1 open reading frame 
(de Koning et al., 2006).  The primers were included in the kit as a solution in 
water.  A biotinylated product, 117bp in length, was produced.  The cycling 
parameters and reaction constituents are shown in Table 2.8. 
 
Secondly, an additional step (to the genital HPV typing method; Section 2.7.1) 
necessitated that 3B buffer (Diassay B.V, Rijswijk, The Nertherlands) was 
added to Denaturation buffer before the PCR product. Samples were processed 
manually using a Barnstead/Labline Max Q 7000 water bath shaker (Thermo 
Fisher Scientific, Epsom, UK) at 50°C.  For the incubations with substrate at 
room temperature, an orbital shaking platform at 80rpm was used.  Strips were 
shielded from ambient light during substrate incubation.  
 
An example of a set of processed strips can be seen in Figure 2.4. Probe 
signals were graded as: +/- (weak; present when viewed on original strip, with 
good light), + (present), ++ (clearly present) and +++ (strong).  
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Figure 2.4 Scanned image of processed beta HPV RHA hybridisation strips.  The numbers 
(1-21) along the top of the strips represent 21 samples and the arrowed labels in the left margin 
indicate probe lines.  An example of a positive strip can be seen in sample 1: a positive 
conjugate line can be seen (assay has been successful), a line can be seen at probe 1 
(universal HPV probe line) and probe 22 (strong signal +++), that identifies HPV 49. Sample 7 
was negative for beta HPVs. Signal strength grading is exemplified by sample 2:  probe line 17 
was clearly present (++); probe lines 7, 16 were present (+); probe lines 4, 8 were present but 
are not visible on this scanned image (+/- weak).   
 
Table 2.8 Beta HPV PCR.  (a) PCR reaction constituents and (b) cycling conditions are 
shown. 
  
2.9 BETA-GLOBIN PCR 
 
The beta-globin house-keeping gene is ubiquitously present in human cells.  
Successful amplification indicates that sample DNA is of sufficient quality to 
perform PCR adequately.  This was performed, as previously described 
(Hiyama et al., 1990) with B1/B19 primers that amplify a 120bp segment of 
human genomic DNA (similar to the bp length of the HPV PCRs used in this 
thesis).  PCR constituents and cycling parameters are shown in Table 2.9. The 
PCR products were examined on a 2% agarose gel after electrophoresis for 45 
minutes.  A positive result was reported as any visible band (under UV light) at 
the expected bp length.  An example of a beta-globin PCR agarose gel can be 
found in Appendix Figure A3.6. 
 
 
      (a)        (b) 
 
 
 
 
 
Table 2.9 Beta-globin PCR using B1 and B19 primers.  (a) PCR reaction constituents 
and (b) cycling conditions are shown. 
 2.10 HPV REAL TIME QUANTITATIVE PCR (q-PCR)  
 
2.10.1 Real time q-PCR: introduction 
 
The estimation of HPV VL (or the number of viral copies that may be found per 
cell) is recognised as a marker of HPV activity within cells (Weissenborn et al., 
2010).  Therefore this can be helpful in evaluating the possible HPV type 
causing disease, when more than one HPV type is present.  HPV VL can be 
calculated by comparing the amounts of HPV DNA with a genomic house-
keeping gene (such as beta-globin) utilising real time quantitative PCR (q-PCR).  
 
2.10.2 Hydridisation probes with the LightCycler platform 
 
The calculation of standard curves and sample HPV concentrations as outlined 
below were conducted by the author under the supervision of Dr Karin Purdie at 
the Centre for Cutaneous Research (Barts and the London School of Medicine 
and Dentistry, Queen Mary University of London, UK).  HPV VL quantification 
protocols for the LightCycler platform using hybridisation probes and HPV type 
specific primers have been published; HPV 5, 8, 15, 23, 24, 38 (Weissenborn et 
al., 2010) and HPV 16 and HPV 18 (Weissenborn et al., 2003). The 
experiments for HPV 6 and 11 were conducted using similar principles (Dr 
Soenke Weissenborn, University of Cologne, Germany, personal 
communication).  A protocol for a similar cutaneous HPV VL assay was not 
available at the commencent of this research, therefore cutaneous HPV VLs 
have not been performed. 
 
The following briefly summarises the principle of the LightCycler hybridisation 
probe method.  A set of two HPV type specific primers (forward, reverse) and 
two HPV type specific DNA probes were available for each of the above HPV 
types. The probes bind with a gap of 1-5 nucleotides between them, at the end 
of the denaturation phase of the PCR cycle and before the phase of primer 
extension.  Probe 1 (5’ probe) is labelled with fluorescein on the 3’ end, and 
probe 2 (3’ probe) has the 5’ end labelled with LightCycler red 640; and the 3’ 
 end was blocked with a phosphate group.  When bound closely to the same 
amplimer, the probes interact.  Emitted light excites the donor fluorophor, that 
leads to an energy transfer to the acceptor fluorophor and this results in a 
quantifiable fluorescent signal; see Figure 2.5.  The use of HPV type specific 
primers and hybridisation probes allowed the detection of each HPV type in 
individual reactions.  This method was employed as it is relatively HPV type 
specific; a non-specific DNA PCR detection system (such as SYBR green) is 
unlikely to differentiate between HPV types, even if HPV type specific primers 
are used.   
 
 
 
 
Figure 2.5 Mechanism of real time quantitative PCR.  The above is a diagrammatic 
representation of primer/probe binding to viral DNA and mechanism of fluorescent signal 
production. Probes bind to amplimers and the attached fluorophors (F1, F2) interact to 
produce a detectable fluorescent signal.  Emitted light (hv1) from the Light Cycler excites F1 
(donor fluorophor) that results in a fluorescence resonance energy transfer (FRET) between 
the probes.  F2 (acceptor fluorophor) emits light (hv2) of a different spectrum to hv1 and hv2 
is detected by the LightCycler platform.  Figure taken from (Weissenborn et al., 2010). 
 
 (a) (b) 
 
2.10.3 Real time PCR equipment and reagents 
 
The LightCycler 480 System real time PCR platform, 96 well LC Multiwell Plates 
and Lightcycler Probes Master PCR mix 2x concentration (Roche, Burgess Hill, 
UK) were used for all reactions.  LightCycler compatible hybridisation probes 
and oligonucleotide primers were obtained as a dry pellet of HPLC purified DNA 
from Sigma-Aldrich (Gillingham, UK); HPV 8 probes and primers were obtained 
from Metabion (Martinsried, Germany).  Before use, stock solutions of primers 
and probes were suspended in molecular water to give a concentration of 100 
µM.  The LightCycler Control Kit DNA (Roche, Burgess Hill, UK) was used to 
quantify the amount of cellular DNA in samples.  Real time PCR reactions were 
done in triplicate, where possible, using 10µl reaction volumes with 2 µl input 
DNA.  When there was limited availability of template DNA, single/duplicate 
reactions were used.  All molecular reagents were stored at -20°C.  See Tables 
2.10, 2.11 and 2.12 for further details. 
 
 
 
 
 
 
 
 
Table 2.10 Components of Roche LightCycler kits. (a) The LightCycler Probes Master PCR 
mix was used for all reactions.  (b) The LightCycler Control Kit DNA for beta-globin contained 
two beta-globin primers and two beta-globin probes (sequences not known). The concentrations 
of some components is not specified by the manufacturer. 
 
 (a) (b) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2.11 Real time quantitative PCR mixture volumes.  The  reaction volumes used 
for (a) HPV type specific real time PCR and (b) beta-globin real time PCR are shown. 
 
Table 2.12 Real time quantitative genital and beta HPV PCR.  The primers, hybridisation 
probes and annealing temperatures are shown in the table above.  The concentration of 
probe and primer (in µM) are those in the final 10 µl PCR. So1 - 5' hybridisation probe 
(fluorescein labelled); So2 - 3' hybridisation probe (labelled with LightCycler Red 640).  
Abbreviations: F- forward primer, R - reverse primer, * concentrations deviated protocol.  
This Figure is based on: Weissenborn et al., (2003) and Weissenborn et al., (2010) and 
personal communication with Dr Soenke Weissenborn, University of Cologne, Germany. 
 
 2.10.4 Reaction parameters  
 
Standard reaction parameters were used for each HPV type; Figure 2.6 shows 
an example.  For HPV 6 and 11 a single cycle ‘touchdown’ was used; see 
Figure 2.7 (Dr Soenke Weissenborn, University of Cologne, Germany, personal 
communication).  This single cycle touchdown was programmed after pre-
incubation and before the commencement of amplification. However, the more 
complicated ten cycle touchdown programs that are detailed in the published 
protocols (to increase HPV type specific binding) were not used for HPV 24 and 
38; at the time of conducting the assays (and before publication of protocols) 
there was insufficient information to do this.  Pilot studies conducted for HPV 24 
and 38 suggested that equivalent results were also obtained if initial touchdown 
cycles were omitted. 
 
 
 
Figure 2.6 Cycling parameters of Lightcycler real time quantitative PCR. The cycling 
parameters are shown as a plot of time and temperature. Firstly, pre-incubation occurs (at 
95°C).  Next, come 45 cycles of amplification: the annealing step is the second target 
temperature (in this case 56°C), the acquisition step (60°C) is indicated by the green dot and 
then elongation proceeds at 72°C before denaturation at 95 °C.  The cycles were then 
followed by a cooling phase. 
 
 
 
 
 
 
 
 
 
Figure 2.7 Single cycle touchdown real time PCR program.  For HPV 6 and 11 the first 
cycle occured with a higher target temperature (59°C); no acquisition reading is taken.  For 
HPV 6 and 11 the annealing temperature was equal to the acquisition temperature and is 
denoted by the green dots. 
 
 
 
 
 
 
 Forty-five cycles of amplification were used for all protocols. For genital types 
(HPV 6, 11, 16, 18) the annealing temperature (Tann) was also used as the 
acquisition temperature (Tacq).  For other beta HPV types (HPV 8, 15, 23, 24, 
38) a Tacq of 60°C was used (in line with the protocol information that existed 
at the time of conducting the experiments).  In the case of HPV 5, a 
temperature of 53°C; one degree less than the published Tann was used to 
increase HPV 5 type-specific binding.  
 
2.10.5   HPV type specific real time standard curves and calculations   
 
Plasmid vectors containing the complete HPV genomes for the target genital 
and beta HPV types (HPV 5, 8, 15, 23, 24, 38 and HPV 6, 11, 16, 18) were 
available; see Table 2.13.  Plasmids had previously been supplied to the 
laboratory from the following sources: 
• HPV 5 - Professor Saveria Campo (University of Glasgow, UK); 
• HPVs 8, 15, 16, 23, 24 and 38 - Dr Ethel-Michelle de Villiers, (Deutsches 
Krebsforschungszentrum/DKFZ, Heidelberg, Germany); 
• and HPVs 6, 11, 18 Professor Alan Storey, (previously at Centre of 
Cutaneous Research, Barts and the London School of Medicine and 
Dentistry, Queen Mary University of London, UK).  
 
The DNA concentration of each plasmid and HPV type insert in existing stock 
solutions was quantified by a Nanodrop 1000 (spectrophotometer), as before.  
Using the concentration (in ng/µl) and the calculated length (in bp) of each 
vector and HPV insert (Table 2.13) the weight (in ng) of a given number of HPV 
copies was calculated. From this the estimated number of HPV copies in each 
stock solution was calculated. 
 
The following Genbank (http://www.ncbi.nlm.nih.gov/genbank/index.html [last 
accessed 13 September 2010]) accession numbers were used to calculate the 
plasmid and HPV insert length in bp:  HPV type 5, NC_001531; HPV type 8, 
M12737; HPV type 15, X74468; HPV type 23, U31781; HPV type 24, 
NC_001683; HPV type 38, U31787; HPV type 6, AF092932; HPV type 11, FN 
 907957; HPV type 16, K02718; HPV 18, X05015. The following plasmids were 
used; pBR322, pUC19 (New England Biolabs, Hitchen, UK), pUC9 (ATCC, LGC 
Standards, Teddington, UK), pAT153 (Mobitech, Gottingen, Germany), pSP64 
(Promega UK, Southampton, UK), pJ4Ω (Storey et al., 1988); Centre of 
Cutaneous Research, Barts and the London School of Medicine and Dentistry, 
Queen Mary University of London, UK); see Table 2.13. 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The following standard estimation was used to calculate the number of 
molecules in a quantity of plasmid and HPV insert DNA, by weight (Dr Soenke 
Weissenborn, University of Cologne, Germany, personal communication and 
Weissenborn, et al., (2010): 
  
Table 2.13 HPV plasmid inserts.  The HPV inserts and plasmid lengths (as 
nucleotide length in base pairs bp) that were used for construction of quantitative 
PCR standard curves.  
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
For example: the calculated weight of 1 x108 molecules of a plasmid and HPV 
insert DNA (that is, for example, 1 x 104 bp in length) is: 
 
 
 
A ten-fold dilution series was constructed using standards in the following copy 
numbers : 107, 106, 105, 104, 103, 3x102, 102, 3x101, 101, 3x100 and 100 copies 
per aliquot. The copy numbers were calculated for a 2µl aliquot of DNA 
template added to each real time PCR reaction. 
 
Standard curves were constructed on the LightCycler 480 for each HPV type, 
with the assistance of LightCycler software; Figure 2.8.  The crossing point or 
cycle threshold (Ct) of each of the HPV standard triplicates was determined by 
the LightCycler software using the second derivative maximum method.  The Ct 
is the point of the amplification curve (measured as the cycle number) when the 
increase in fluorescence becomes linear.  The HPV concentrations of samples 
were then calculated from the Ct by the LightCycler using the standard curve 
that was created for each HPV type.  Sample plots that were oddly shaped 
were discarded prior to calculation; a normal plot consisted of a baseline around 
zero, an exponential phase of amplification and a plateau phase.  Replicates 
should be within 0.5 Ct of each other; if one point in a triplicate used to calculate 
the standard curve showed Ct variability >0.5 it was excluded. Background 
subtraction was used and acquisition was set at 640 nm.   
=  1.1 x 10 -9 g   =  1.1 ng of DNA 
 
[104] x 660 x 108 
   6.022 x 10 23 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.10.6 Beta-globin real time PCR standard curves and calculations   
 
The number of copies of HPV that were detected per human cell was calculated 
to determine the HPV VL.  This required an estimation of the number of cell 
equivalents per aliquot of sample.  This was done using the assumption that 
there are there are 3.2 x 109 bp in (one copy of) the human genome 
(Weissenborn et al., 2010).  
 
From this calculation, the number of copies of a human gene could be 
quantified in a given sample of human genomic DNA.  Therefore, using the 
previous formula, the weight of a single copy of the human genome is: 
Figure 2.8 HPV standard curve generated by LightCycler software. Fluorescence 
measurements of standards during amplification are indicated by the logarithmic dark 
red plots in the top graph.  The standards shown are: 108, 107, 106, 105, 104 and 103 
copies per aliquot.  Negative samples are indicated by the horizontal lines, also in dark 
red. The standard curve generated by the LightCycler software from these known 
concentrations of standards is shown in the bottom panel; the green dots represent the 
Ct of the HPV standard triplicates. 
  
 
Therefore one single copy of a human gene is found in each 3.5 pg of DNA (or 
there are 1/3.5 single gene copies per pg of DNA).  As an example: how many 
cells does 30ng of human genomic DNA represent? 
 
A 110bp segment of the human beta-globin gene was amplified using the 
Lightcycler Control Kit (primer sequences not available).  A genomic DNA 
dilution series of 1:2 (7.5 ng/µl), 1:5 (3ng/µl), 1:10 (1.5 ng/µl), 1:20 (0.75 ng/µl) 
was made from genomic DNA supplied in the kit (15ng/µl).  Hybridisation 
probes labelled with LC Red 640 (included in kit) were used to detect beta-
globin gene copies.  Standard curves were constructed, as before.   
 
 
2.11 IMMUNOGENOTYPE: MOLECULAR HLA TYPING 
 
HLA typing was principally performed by laboratory staff at the Anthony Nolan 
Research Institute (Royal Free Hospital, London, UK), with the author 
observing.  A commercial Luminex-based platform was used; One Lambda 
(LABtype SSO typing test kit, VH Bio, Gateshead, UK, www.onelambda.com).  
A detailed description of the method used and the primer mixes, PCR mix, 
cycling parameters, (Denaturation, Neutralisation, Hybridisation and Wash) 
buffers and microsphere bead mixtures can be found in the LABtype literature 
(One Lambda, VH Bio, Gateshead, UK).  
 
 
[3.2 x 109 ]  x  660   g    = 3.5 x 10 -12 g 
6.022 x 10 23 
 
 
 
= 30 x 103  (pg)  x   1/3.5  (copies per pg) 
= 8570 copies of a single gene  
(or 4286 cells) 
 
 Briefly, study samples containing human genomic DNA (extracted from blood) 
were amplified with six sets of (unpublished, commercial) primers and the 
following eight loci were characterised: Class I: HLA-A, HLA-B and HLA-C and 
Class II: HLA-DRB1, HLA-DRB3/-DRB4/DRB5 and HLA-DQB1 (the three loci 
HLA-DRB3/-DRB4/-DRB5 were typed with one primer mix).  PCR mixtures were 
prepared using a semi-automated Biomek 2000 (Laboratory Automation 
Workstation, Beckman Coulter, Dunstable, UK). Amplified PCR products were 
biotinylated to allow downstream detection by streptavadin conjugated to R-
phycoerythyrin.   
 
PCR products were first electrophoresed on 2% agarose gel in TBE to confirm 
the presence of amplified DNA and visualised with ethidium bromide under UV 
light.  Next, PCR products were hybridised to unpublished sequence-specific 
oligonuceotide (SSO) oligonucleotide probes, as outlined in the LABType 
product literature.  Chemical conditions were used to denature PCR products 
and probes, heat was used to allow hybridisation of amplicons to the beads and 
unbound beads/amplicons were removed by washing.   
 
The oligonucleotide probes that were used are attached to microspheres 
labelled with defined proportions of two fluorescent dyes (One Lambda, VH Bio, 
Gateshead, UK).  The ratio of the two fluorescent dyes was recognised by a 
Luminex flow analyzer (LABScan 200, Luminex, Austin, TX, USA).   The 
reaction pattern was analysed and HLA type assigned according to published 
HLA sequences.  The final HLA haplotype result was reported by an HLA expert 
(Mrs Finnuala Fowles, Anthony Nolan Histocompatibility Laboratories, London, 
UK).  An example of a HLA result for HLA-A is given in the Appendix A2.3; this 
particular individual’s HLA-A assignation was HLA-A*03, -A*23.   
 
 
2.12 STATISTICS 
 
A power calculation to estimate the minimum sample size required to examine 
HLA alleles was performed (Statistical Advisory Service, Imperial College 
 London).  This indicated that n=36 individuals of white European/Caucasian 
descent was the minimum number of subjects required; if 50% of cases harbour 
allele x and 15% of controls harbour the same allele then a calculation using a 
two group c2 test with a 0.05 two-sided significance level would have 90% 
power to detect the difference between Group 1 proportion pr1, of 0.15 and 
Group 2 proportion pr2, of 0.50 (odds ratio of 5.7) when the sample size in each 
group is 36.  
 
Descriptive and analytical statistics for HPV data were computed with the use of 
software programs: Microsoft Excel, Statistical Package for the Social Sciences 
(SPSS), version 20, and Epi Info (Centres for Disease Control and Prevention 
http://www.cdc.gov/epiinfo/ [downloaded 20th January 2009]).  The data were 
non-parametric and therefore the Mann-Whitney U (to compare two samples) or 
the Kruskall-Wallis (to compare three samples) tests were utilised.  For 
categorical data the Yates’ corrected chi-squared or Fisher’s exact tests (two-
tailed) were used to compare two groups; the latter was used when the 
expected value was less than five.  A ‘Clump’ program (Dave Curtis, Queen 
Mary University London, UK  http://www.smd.qmul.ac.uk/statgen/dcurtis/ 
software.html) was performed by Dr Bernard North (Statistical Advisory Service, 
Imperial College London, UK) at each HLA locus that clumps alleles with similar 
data together.     
 
Statistical advice was obtained from Dr Bernard North and Mr Joseph Eliahoo, 
Statistical Advisory Service, Imperial College London, UK (power calculations, 
SPSS, CLUMP and advice on analysis of multi-allelic loci), from Ms Sundhiya 
Mandalia, St Stephens’ Centre, Imperial College London, UK (categorical 
parametric and non-parametric analysis) and from Dr Ann-Margaret Little and 
Professor Steven Marsh, Anthony Nolan Histocompatibility Laboratories 
London, UK (HLA allele counting and immunophenotypic analysis). 
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3.1 INTRODUCTION: HPV TYPING OPTIMISATION  
 
At the time of the inception of this work, sensitive, specific, and validated RHAs 
were available for beta HPV types and for genital types (Kleter et al., 1998; 
Kleter et al., 1999; de Koning et al., 2006).  For cutaneous types, the best 
available technique at the time was degenerate group-specific nested PCR 
followed by sequencing (Harwood et al., 1999).  There are three deficiencies 
with the sequencing technique (a) some important HPV types are not well 
amplified by the CN1-3 primers used (for example, HPV 7 that is of possible 
importance in HIV infected individuals),  (b) mixed infections with two or more 
HPVs (that are common in OTRs and are of potential importance in HIV 
infection) are often not identified, even if PCR products are cloned and (c) 
sequencing has a high false negative rate; a proportion of warts, especially in 
immunosuppressed patients, are negative by nested PCR/sequencing – around 
17-36% of samples (Harwood et al., 1999; Porro et al., 2003).  However, during 
the experimental work for this thesis, a novel technique became available that 
identifies a wide range of cutaneous HPV types; the HSL-PCR/MPG Luminex 
method.  When experiments were commmenced, this system had not yet been 
validated.  Therefore, the attributes of the two cutaneous typing systems have 
been examined and compared (nested PCR/sequencing and HSL-PCR/MPG).  
The HSL-PCR/MPG is probably superior to the older technique; Appendix 3.1 
(de Koning et al., 2010).  In Appendix 3.2, the preliminary results for genital and 
beta HPV VL have also been examined (a cutaneous HPV VL assay was not 
available at the commencement of this work).   
 
The comprehensive HPV typing that has been performed in this study is a 
combination of three similar, highly sensitive techniques. Although this was not 
necessary, the reproducibility, specificity and sensitivity of these typing systems 
have been assessed.  The reproducibility of cutaneous, genital and beta HPV 
typing in (n=26) multiply sampled warts is as follows: 81%, 81% (100% for 
 genital warts only) and 62%, respectively; Appendix 3.3.1.  The HPV VL 
reproducibility for beta/genital HPVs has also been calculated as 63% (in n=10 
multiply sampled warts with VL data); Appendix 3.3.2.  A computational analysis 
of the combined sensitivity of all three HPV typing assays (combined with data 
from HPV VLs and HSL-PCR/MPG MFIs) to identify a probable causative HPV 
type has also been performed (n=26); the overall combined sensitivity is 96%; 
Appendix 3.3.3.  Specificity has been evaluated in a selection of HPV positive 
non-wart lesions (n=17; false positives) and is 82-88%; Appendix 3.4.  HPV 
typing sensitivity has been evaluated by identifying warts that are negative for 
genital and cutaneous HPV types (false negatives) and is 95-97%; Appendix 
3.5.  
 
Of the 19 negative controls from tissue extractions of DNA, 9/19 tested positive 
for cutaneous HPVs, in 1/19 a genital HPV has been identified and 3/19 tested 
positive for beta HPV types (although re-testing for the beta HPVs abolished the 
positive results).  As a consequence, the experiments to extract DNA from 
tissue have been reviewed; Appendix 3.6.  To address possible contamination 
of these negative controls, the results of seven of the samples included in this 
chapter have been adjusted; Appendix Figure A3.11. 
 
 
3.2 COMPREHENSIVE HPV TYPING RESULTS 
 
In this chapter the results of HPV typing are reported and discussed.  See 
Appendix 3.7 for the full table of comprehensive HPV typing results, HPV VLs 
for genital and beta HPVs and MFI levels (from HSL-PCR/MPG) for cutaneous 
HPVs; Appendix Figures A3.12-13.   
 
The subjects presented herein were derived from i) HIV infected cases under 
treatment with suppressive ART, with warts and ii) healthy, HIV negative or 
presumed negative, cases with warts (see section 2.1).  The HPV typing of 
these patients’ warts is reported in three ways: (a) a specific sub-group of 
individuals suitable for the stringent requirements of subsequent HLA molecular 
 analysis, the ‘HLA’ group; see Appendix 3.8, (b) in toto, the ‘All’ group and 
finally (c) as specific special cases.  ‘HLA’ group is printed in italics to 
distinguish it as the group of patients used for the HLA arm of the HPV analysis 
(as distinct from the use of the term HLA to describe HLA alleles).  Similarly, the 
‘All’ group is also denoted by italics. 
 
The detailed composition of these groups and appropriate controls is shown in 
Figure 3.1.  A consequence of the recruitment process is that more individuals 
have been assessed and HPV typed than are suitable for HLA analysis.  
 
The criteria for inclusion in the HLA group of patients suitable for the molecular 
HLA typing analysis were: 
• persistent warts for ≥6 months; 
• Caucasian parentage and 
• ART ≥1 year with HIV VL fully suppressed ≥6 months (HIV infected 
individuals only). 
 
The number of HIV infected individuals that met these stringent requirements 
was 30 (for whom there were 36 appropriate healthy controls with warts); 
Appendix Figure A3.8.   
 
The All group includes the following individuals: 
• the HIV infected and healthy individuals from the HLA group; 
• twenty two non-Caucasian individuals with perisistent warts for ≥6 
months (HIV infected n=12, healthy n=10); 
• three HIV infected individuals with contemporaneous detectable 
HIV VLs despite ART for ≥1 year, with CD4 T-cell counts of >200 
cells/µl (HIV VLs were 608, 500 and 78 copies/ml);  
• two HIV infected individuals with acute inflammatory HPV 
IRAD/IRIS that did not fulfil the criteria for the HLA group (one 
patient had warts for <6 months, the other had a recent HIV 
diagnosis and had been on ART for <1 year). 
 
 The total number of subjects in the All group is: HIV infected n=47, healthy 
n=46.  The All group analysis allows a broader picture of HPV disease in ART 
treated HIV to emerge based on much larger numbers (n=93 individuals with 
144 wart lesions, compared with 66 individuals with 106 wart lesions in the HLA 
group). 
 
 
 
 
 
Figure 3.1 Selection of the All group for HPV analysis.  Table showing the number of 
subjects available for analysis.  Non-Caucasians have been included in the All analysis (n=22) 
and other individuals that have been included are outlined in the text (identified by light grey 
test in uppermost boxes).  Therefore, the All analysis includes individuals from the HLA 
analysis and another 27 individuals (highlighted by the lighter red arrow, labeled “ALL group 
analysis”).  Individuals falling into the classifications shown with bold text in the uppermost 
boxes have been excluded from both HLA and All analyses; females with genital warts 
(n=6+1) and individuals with co-morbidities (n=4+2).  Abbreviations: ART – anti-retroviral 
therapy; VL – HIV viral load. 
 
 Finally, data from the specific special cases of females with genital warts, non-
wart lesions (HPV VL data) and an example of HPV typing from one individual 
(warts, non-wart and normal skin) are presented. 
 
The results of the All group are presented in detail hereafter.  Those for the 
subsidiary HLA group can be found in Appendix 3.8.  The results are very 
similar. 
 
 
3.3 HEALTHY CASES: INCLUSION AND HIV INFECTION RISKS 
  
To recapitulate ‘healthy’ cases were defined as those individuals with persistent 
warts in good physical health with no clinical indicators and no risk factors for 
HIV and/or a negative HIV antibody test (sections 2.1 and 2.2.3).  Fifty-two 
otherwise healthy patients with warts have been recruited (13 females and 39 
males).  They comprised 46 healthy individuals with HPV data (presented in this 
chapter) and another six healthy individuals who have been molecularly HLA  
typed  (but had no clinical warts at the time of recruitment; they have been 
included in chapter 4).  Of these 46 individuals with HPV data, ten are non-
Caucasian. The HIV infection risk factors of healthy individuals are discussed 
further in Appendix 3.9. 
 
 
3.4 HIV INFECTED SUBJECTS: INCLUSION AND ART USAGE  
 
One third of HIV infected patients are on non-preferred or second line ART 
regimens 
Around two-thirds of HIV infected individuals in the All and HLA groups (70% or 
33/46; 67% or 20/30, respectively) were taking one of two preferred first line 
ART combinations; Figure 3.2.  The two BHIVA recommended first line 
regimens are (a) two nucleoside reverse transcriptase inhibitors (2NRTIs) 
together with one non-nucleoside reverse transcriptase inhibitor (1NNRTI) or (b) 
2NRTIs plus a (ritonavir) boosted protease inhibitor (PI) or unboosted 
 atazanavir (Gazzard et al., 2008).  For the purpose of classifying ARTs, 
unboosted atazanavir has been collated as being equivalent to a boosted PI, 
etravirine (a new NNRTI) has been collated as a NNRTI, darunavir (a new PI) 
was collated as a PI and the new drugs (raltegravir and enfuvurtide) have been 
collated under ‘other regimens’; Figure 3.2. 
 
Eight patients (from the All group) were taking alternatives to the above 
preferred regimens, that included the following: 
• three NRTIs alone (n=2); 
• three NRTIs plus either one NNRTI or a boosted PI/unboosted 
atazanavir (n=3);  
• one NRTI, one NNRTI and a boosted PI (n=2). 
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Figure 3.2 ART treatment in HIV infected individuals. Most individuals from the All and 
HLA groups are on standard first line preferred regimens.  ‘Other regimens’ are defined in the 
text. Abbreviations:  NRTI - nucleoside reverse transcriptase inhibitor; NNRTI - non-
nucleoside reverse transcriptase inhibitor; PI protease inhibitor, including darunavir.   
* - individuals taking a PI boosted with ritonavir were collated as taking 1PI; those taking 
unboosted atazanavir were also collated as taking 1PI. 
 
 
 
 
. 
 Seven HIV infected patients in the All group were taking ‘other regimens’, many 
of which included ‘new’ drugs in novel classes, such as raltegravir (an integrase 
inhibitor), enfuvirtide (a fusion inhibitor) or maraviroc (a CCR5 inhibitor). At the 
time of recruitment to this study, these seven individuals had been taking one 
the following regimens: 
• lopinavir/ritonavir (1 boosted PI alone); 
• zidovudine, abacavir, lamivudine, tenofovir (4NRTIs); 
• emtricitabine, tenofovir, darunavir/ritonavir and raltegravir (2NRTIs, 1 
boosted PI and 1 new drug); 
• etravirine, darunavir/ritonavir and raltegravir (1NNRTI, 1 boosted PI, 1 
new drug); 
• abacavir, tenofovir, etravirine, and raltegravir (2NRTIs, 1NNRTI, 1 new 
drug); 
• emtricitabine, atazanavir, darunavir/ritonavir, and enfuvurtide (1 NRTI, 
2PIs – boosted with ritonavir, and 1 new drug); 
• tenofovir, emtricitabine, etravirine and raltegravir (2NRTIs, 1NNRTI, 1 
new drug). 
 
Of the 47 individuals in the All group, eight had been highlighted as possible 
slow progressors or long term survivors (Cao et al., 1995); they have had HIV 
infection for more than 10 years without any ART treatment (self reported). 
However, all are presently on treatment and therefore are not elite controllers.  
The duration of HIV infection in these eight slow progressors ranged from 19-26 
years; median 22 years.  The duration (in years) of diagnosed HIV infection 
prior to ART commencement ranged from 11 to 24 years (self reported); the 
median duration of HIV infection without treatment  was 17.5 years.   
 
Two individuals with chronic hepatitis B and three with (active or past) hepatitis 
C have been identified in the All group; (Centres for Disease Control and 
Prevention; http://www.cdc.gov/hepatitis/ [last accessed 29 March 2012]).  
However, a history of persistent hepatitis B and C infection could not be actively 
corroborated in all patients by patient history, clinical and electronic medical 
records, so it is possible that some individuals have been missed.  
 Table 3.1 All group: ethnicity by parental origin of individuals with wart disease. The 
number of HIV infected and healthy cases with warts are: n=47 and n=46, respectively. The 
category ‘European, other’ comprises individuals with parental origin from Italy, Spain, Greece 
or Bulgaria (HIV infected cases) or Italy, Poland, or Portugal (healthy cases).  ‘Other’ parental 
origin includes individuals of Chinese/Italian, Moroccan and Pakistani descent. 
 
 
 
 
3.5 ALL GROUP HPV ANALYSIS  
 
3.5.1 All group analysis: subject characteristics  
 
Ethnicity in HIV infected and healthy cases   
Although more HIV infected cases are of Afro-Caribbean parental origin than 
healthy cases this is not statistically significant; 5/47 HIV infected compared 
with 1/46 healthy cases (p=0.2, Fisher’s exact test); Table 3.1. 
 
The age and gender distribution is different between HIV infected and healthy 
individuals  
The age range of HIV infected individuals (28-64 years) is narrower than that of 
healthy (21-85 years) individuals and the medians (interquartile ranges - IQR) 
are significantly different: 44 (39-51) years compared with 40 (31-52) years, 
respectively (p=0.02, Mann-Whitney U test); Table 3.2. This is discussed in 
section 3.7.1 
 
The gender distribution (more males among HIV infected cases) and risk factors 
for HIV (HIV infected cases are predominantly MSM) are statistically 
significantly different  between  HIV  infected  and  healthy  cases with warts 
(p=0.002, p<0.0001, Yates’ chi-squared test).  This is discussed later; section 
3.7.1 
 
 
 
 
  
 
 
 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.2 All group: patient characteristics of HIV infected and healthy cases.  The 
characteristic of subjects with warts (cases) included in the HPV analysis are shown.  
Statistical significance has been calculated by Mann-Whitney U test for non-parametric data 
(or Yates’ chi squared test for categorical data - marked with *).  Statistically significant 
associations  (p<0.05) are highlighted in pale yellow. Abbreviations: Inf – infected. 
 
 
 
 
 Most of the HIV infected subjects have stable, prolonged HIV infection (median 
of 14 years HIV infection).  The contemporaneous CD4 T-cell count range for 
the All group is 75-1491 cells/µl; median (IQR) 500 (308-684) cells/µl.  The CD4 
T-cell nadir is lower than might be presently considered to be ideal; range All 
group 1-373 and median (IQR) 140 (36-200) cells/µl.  
 
The range of wart duration duration is slightly greater in healthy individuals (0.5-
25 years) than in HIV infected individuals (range 0.5-15 years) although the 
medians are the same (3 years; p=0.77, Mann-Whitney U test).  The median 
(IQR) duration of wart disease in HIV infected cases whilst on ART is 3.0 (1.5-6) 
years.  The duration of each individual wart sampled was longer in HIV infected 
than healthy individuals with a median of 3.0 and 2.0 years, respectively, but 
the difference is not statistically significant (p=0.10 Mann-Whitney U test); 
duration data were available for n=66 (of 73) and n=62 (of 71) lesions, 
respectively, and have not been corrected for multiple lesions. 
 
3.5.2 All group analysis: subject wart disease characteristics 
 
HIV infected individuals are more likely to have wart disease at both cutaneous 
and anogenital sites than healthy individuals 
In the All group, HPV typing data are available for 144 wart lesions from 47 HIV 
infected and 46 healthy cases; Figure 3.3.  Thirteen percent (6/47) of HIV 
infected cases had both genital and cutaneous warts sampled for HPV typing, 
but none of the healthy cases had both genital and cutaneous lesions (p=0.03, 
Fisher’s exact test).  A higher proportion of HIV infected subjects had ever been 
afflicted with cutaneous and anogenital wart disease (including cutaneous warts 
as an adult and anogenital precancer); this was the case for 23% (11/47) of HIV 
infected but only 4% (2/46) of healthy individuals. (p=0.02, Yates’ chi-squared 
test). 
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Figure 3.3 All group: HPV disease characteristics. Table (a) and chart (b) showing the number 
of warts and subjects analysed in the All group; some subjects provided warts from both 
cutaneous and genital sites. Abbreviation: Inf – infected. 
  
 Figure 3.4 All group analysis: cutaneous wart site and removal (sampling) method. 
The location of cutaneous warts from (a) HIV infected and (b) healthy cases and the wart 
removal (sampling) techniques used in (c) HIV infected and (d) healthy cases are shown.  
3.5.3 All group analysis: cutaneous warts  
 
Cutaneous warts affected more body sites in HIV infected individuals 
Most warts have been sampled from the hands and feet; Figure 3.4. HIV 
infected individuals had a wider distribution of cutaneous wart affected body 
sites than healthy cases. Surgical techniques other than curettage and parings 
have been used more frequently in HIV infected individuals; Figure 3.4.  Eighty 
percent (45/56) of HIV infected lesions have been removed by curettage, 
incision by punch tool/ellipse or excised (allowing histological corroboration) 
compared with 55% (28/51) of healthy cases (p=0.0003, Yates’ chi-squared 
test); see also Appendix 3.10.  Conversely, parings have been performed more 
frequently in the healthy control group (p as before, Yates’ chi-squared test).  
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 3.5.4 All group analysis: genital warts 
  
Anal, perineal and scrotal warts are more common in HIV infected cases 
Anal and penile lesions, combined, are found in similar proportions in HIV 
infected and healthy cases; Figure 3.5. However, more anal (and less penile) 
warts were sampled from HIV infected individuals than healthy cases; anal 
warts: 53% (9/17) compared with 25% (5/20), respectively (p=0.15, Yates’ chi-
squared test); for penile warts the corresponding proportions are: 36% (5/17) 
compared with 60% (12/20), respectively (p=0.12, Yates’ chi-squared test).  
Lesions on the perineum and scrotum were seen in HIV infected patients, 
whereas healthy patients had lesions on the buttock and groin (and anal/penile 
skin).  Sampling methods are similar for HIV infected and healthy cases; Figure 
3.5. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5 All group analysis: genital wart site and removal (sampling) method.  The 
location of genital warts from (a) HIV infected and (b) healthy cases and the wart removal 
(sampling) techniques used in (c) HIV infected and (d) healthy cases are shown.  
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 3.5.5 All group analysis: cutaneous HPV types 
 
Different HPV types are found in cutaneous warts from HIV infected individuals 
compared with healthy individuals 
As expected, the common HPV types that are known to be associated with 
‘common’ warts (HPV 2, 27 and 57) are also the most prevalent types in 
cutaneous warts from both HIV infected and healthy cases; Figure 3.6.  
However, there are several differences in the HPV types found in HIV infected 
compared with healthy cases.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6 All group analysis: cutaneous HPV types found in warts.  The cutaneous 
HPV types found in (a) cutaneous and (b) genital warts are shown on the chart. ‘Nil’ – warts 
negative for cutaneous wart associated HPV types.  ‘Lesions  multiple types’ – warts with 
mixed infection of ≥2 HPV cutaneous HPV types. Abbreviation: Inf – infected *, ** and *** - 
indicate significant differences (p<0.05, Yates’ chi-squared test). 
p=0.0004 
p=0.001 
(a) 
(b) 
p=0.03 
 Firstly, no warts from either study group harbour HPV 1, also a common 
cutaneous HPV type.   
 
Secondly, HPV 2 is seen less frequently in cutaneous warts from HIV infected 
individuals than in those from healthy individuals.  Two percent of lesions (1/56) 
from HIV infected cases yielded HPV 2 compared with 27% (14/51) of lesions 
from healthy individuals (p=0.0004, Yates’ chi-squared test).  When corrected 
for patients in whom multiple lesions have been sampled, the corresponding 
figures are 3% (or 1/40) and 30% (or 9/30) and the corrected probability is 
(pc)=0.002, Fisher’s exact test.  This correction has been done by including one 
lesion at random (the first lesion sampled, usually labelled T1) from each 
patient and discarding the remaining lesions from that individual (T2, T3 and so 
on). 
 
Thirdly, HPV 7 is prevalent in warts from HIV infected individuals and is found in 
21% (12/56) of cutaneous warts but is not seen at all in 51 healthy individuals 
(p=0.001, Yates’ chi-squared test).  This is also statistically significant after 
correction for individuals with multiple lesions; 23% (9/40) and none (0/30), 
respectively (pc=0.008, Fisher’s exact test). 
 
Although HPV 3 is found only in HIV infected individuals, 7% (4/56), this is not a 
statistically significant difference when compared with healthy cases (p=0.11, 
Fisher’s exact test).   
 
Five (of 56) cutaneous warts from HIV infected subjects are negative for 
cutaneous HPV types but only three (of 51) cutaneous warts from healthy 
subjects warts are negative.  This suggests unusual types (or genital/beta 
types) might be involved in wart generation; see Appendix Table A3.9 and 
section 3.5.9. 
 
Warts from HIV infected subjects harbour more cutaneous HPV types  
The median number of cutaneous HPV types in warts (cutaneous and genital 
warts, combined) are the same for HIV infected and healthy cases, although the 
 distribution is significantly different between the groups; median (IQR): 1 (1-1) 
and 1 (0-1) HPV types per wart, respectively (p=0.04, Mann-Whitney U test). 
  
Many genital warts harbour cutaneous HPV types 
A surprisingly high proportion of genital warts from the All group harbour 
cutaneous HPV types; 47% (8/17) of HIV infected and 25% (5/20) of healthy 
genital warts are positive for cutaneous types.  These eight warts from HIV 
infected cases originate from seven individuals: six of the seven had concurrent 
cutaneous warts or a history of cutaneous warts; none of the five healthy 
individuals with genital warts did. 
 
3.5.6 All group analysis: genital HPV types  
 
HPV 11 is seen more often in genital warts from HIV infected cases  
HPV 6 and 11 are the most prevalent HPV types in genital warts; Figure 3.7.  
The main difference observed between HIV infected or healthy study groups is 
the proportion of warts that harbour HPV 6 or HPV 11. 
 
HPV 6 is found in 85% (17/20) of lesions from healthy individuals compared 
with 30% (5/17) of HIV infected cases (p=0.002, Yates’ chi-squared test).  After 
correction for cases with multiple lesions the difference is still statistically 
significant; 81% (13/16) and 23% (3/13), respectively (pc=0.006, Yates’ chi-
squared test). 
 
HPV 11 is more common in HIV infected patients.  However, this is only of 
borderline statistical significance after correction for multiple lesions; the 
number of lesions available for analysis is small.  HPV 11 is found in 54% (7/13) 
of HIV infected and 13% (2/16) of healthy warts (pc=0.05, Fisher’s exact test).  
Before correction, there was no statistically significant difference (47% or 8/17 
in HIV infected compared with 10% or 2/20 in healthy cases; p=0.15, Fisher’s 
exact test). 
 
 In terms of HR HPVs (as defined by Table 1.1) in genital warts, these are only 
found in HIV infected cases.  Two genital warts that harbour HPV 31 or 52 (in 
combination with LR types) have been identified.  HPV 16 is absent from genital 
warts, but has been identified in four cutaneous warts (and in two AIN lesions; 
section 3.6.3). 
 
 
 
 
 
 
 
Figure 3.7 All group analysis: genital HPV types found in warts.  The genital HPVs found in 
(a) genital and (b) cutaneous warts are shown on the chart. ‘Nil’ – warts negative for genital HPVs.  
‘Lesions  multiple types’ – warts with mixed infection of ≥2 HPV genital HPV types. Abbreviation: 
Inf – infected; ns – probability is not significant.   * - indicates a significant difference (p<0.05, 
Yates’ chi-squared test). 
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 Cutaneous warts frequently harbour genital HPV types, mostly as low risk types  
A considerable proportion of cutaneous warts harbour genital types; this is in 
parallel to the observations made above, that cutaneous HPV types are found 
in genital warts.  This is the case for warts sampled from both HIV infected and 
healthy individuals from the All group; 30% (17/56) and 22% (11/51), 
respectively (p=0.42, Yates’ chi-squared test).  HR genital HPV types are seen 
in cutaneous warts from seven of these HIV infected individuals, amounting to 
13% (7/56), and in 8% (4/51) in healthy individuals (p=0.6, Yates’ chi-squared 
test).  
 
For genital HPV types the number of HPV types per wart (cutaneous and 
genital warts combined) is not significantly different (p=0.5 Mann-Whitney U 
test).  
 
3.5.7 All group analysis: beta HPV types 
 
Beta HPVs are detected more frequently in warts from HIV infected individuals 
than in warts from healthy individuals 
A wide distribution of beta HPV types is seen in both cutaneous and genital 
lesions; Figure 3.8.  The commonest beta HPV types are: HPV 5, 8, 9, 15, 17, 
23, 24, 36, 38, 92 and 93 (those HPV types for which VLs are available are 
shown in bold).  Cutaneous warts from HIV infected cases are more likely to be 
beta HPV assay positive for at least one beta type; 80% (45/56) of lesions 
positive in HIV infected subjects compared with 57%  (29/51) lesions  in  healthy  
individuals  (p=0.02, Yates’ chi-squared test).  For genital lesions, the 
percentage of warts that are positive for beta types from HIV infected and 
healthy cases are the same; 55% (9/17) and 53% (11/20), respectively. For all 
lesions, 65% (94/144) are beta HPV positive.   
 
The number of beta HPV types in cutaneous warts from HIV infected subjects is 
greater than in healthy subjects 
Statistically significantly more beta HPV types are seen in cutaneous warts from 
HIV infected cases than healthy cases; the median (IQR) is 3 (1-8) compared 
 with 1 (0-3) beta HPV types per wart, respectively (p<0.0005, Mann-Whitney U 
test); Table 3.3.  This is also true when genital and cutaneous lesions are 
combined. After correction for individuals with multiple lesions the difference 
remains statistically significant (pc=0.006, Mann-Whitney U test).  Therefore, 
most cutaneous warts yield two or more beta HPV types, as mixed infections.  
The beta HPV typing data for mixed infections are examined in the next section. 
 
 
 
 
p=0.02 
Figure 3.8 All group analysis: beta HPV types found in warts.  The beta HPV types found 
in (a) genital and (b) cutaneous warts are shown.  Nil’ – warts negative for beta HPVs.  
‘Lesions  multiple types’ – warts with mixed infection of ≥2 HPV beta HPV types. 
Abbreviation: Inf – infected.  * - indicates a significant difference (p<0.05, Yates’ chi-squared 
test). 
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3.5.8 All group analysis: mixed infections 
 
Lesions have been classified as harbouring a mixed infection if more than one 
HPV type from any one HPV group (cutaneous, genital or beta) is identified.  
The number of warts harbouring multiple cutaneous or genital HPV types are 
shown on the far right of Figures 3.6 and 3.7.   
 
Mixed cutaneous HPV infections are more frequent in HIV infection  
For cutaneous HPV types, a statistically significant difference is observed in the 
proportion of cutaneous warts with mixed cutaneous HPV type infections; 20% 
(11/56) warts from HIV infected subjects have ≥2 cutaneous HPV types 
compared with 4% (2/51) of warts from healthy individuals (p=0.03, Yates’ chi-
squared test); Figure 3.6. Fewer genital warts have been examined and no 
statistically significant difference is seen; 18% (3/17) compared with 1/20 (5%) 
of warts, respectively, harbour mixed cutaneous HPV types  (p=0.31, Fisher’s 
exact test). 
Table 3.3 All group: number of beta HPV types in cutaneous, genital and all warts.  HIV 
infected individuals harbour more beta HPV types in cutaneous warts.  * - indicates a significant 
difference (p<0.05). 
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Number of beta types detected in each lesion 
There is no difference in the number of mixed infections with genital HPV types 
in warts from HIV infected compared with healthy subjects  
For genital HPV types, no statistically significant difference between HIV 
infected and healthy individuals is seen as regards the number of mixed 
infections in all warts; 16% (12/73) and 7% (5/71), respectively (p=0.14, Yates’ 
chi-squared).  This is also the case for cutaneous and genital warts, separately 
(p=0.17, Yates’ chi-squared and p=0.64, Fisher’s exact tests, respectively).    
   
Beta HPV type mixed infection are more common in HIV infected subjects than 
healthy subjects 
The data from the bottom row of Table 3.3 are also shown in a different format; 
in Figure 3.9.  In 55% (40/73) of cutaneous and genital lesions (combined) from 
HIV infected cases in the All group, mixed beta HPV infections are detected 
whereas this is the case for only 29% (23/71) of healthy individuals; see Figure 
3.9, bars ’0’ (samples negative for beta HPV types) and 1 beta HPV type 
compared with bars 2-3,4-6 and >6 beta HPV types (p=0.01, Yates’ chi-squared 
test).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.9 All group: the number of beta HPV types detected in each wart (genital 
and cutaneous warts combined).  Abbreviation: Inf – infected. 
 3.5.9 All group analysis: HPV viral loads (VLs)    
 
HPV VL cut-offs  
There is no clear HPV DNA VL cut-off above which a given HPV type is highly 
likely to be  actively contributing to wart formation.  However, a reasonable cut-
off is one copy/cell, if warts that have HPV VLs of 1-10 copies/cell are examined 
for other potentially causative HPV types (Ball et al., 2011); Appendix 3.2. 
Therefore, VL <1 copy/cell have been considered as ‘low’ and VL >1 copy/cell 
are considerd as ‘high’.  Cutaneous HPV VLs have not been perfomed 
(because an assay was not available at the inception of this work).   
 
Genital HPV VLs overall had high values 
Of the warts from the All group that have been tested for genital HPV VLs, 86% 
(25/29) from HIV infected cases and all (28/28) of the warts from healthy cases 
have detectable genital HPV VLs.  Several points arise in relation to genital 
HPV VL results; Figure 3.10.   
 
Firstly, the range of genital HPV VLs is wide.  The HPV 6 and 11 VLs range 
from 0.0002 to 59,722 copies/cell in genital warts and 0.002 to 4,630 copies/cell 
in cutaneous warts.   
 
Secondly, despite several lesions having low VLs, overall, the genital HPV VLs 
are high.  In genital warts this is predominantly ≥5 copies/cell (in 90% or 28/31 
of warts tested with genital HPV VL assays).  For genital warts the median 
(IQR) genital HPV VL is 573 (20-2,401) copies/cell and 496 (234-999) 
copies/cell for HIV infected and healthy cases, respectively (p=0.74, Whitney-
Mann U test).  
 
Thirdly, two anal warts from one HIV infected individual have extremely high 
VLs for HPV 6; 16,352 and 59,722 copies/cell (lesions 7A.g and 7B.g, 
respectively).  The VL calculations have been reviewed to ensure the result is 
accurate.  The HPV 6 concentrations for the assay duplicates are similar (9.3 x 
107 and 2.6 x 108 with cell equivalents of 5,714 and 4,347 cells respectively, 
 (close to the PCR reaction ‘ideal’ of 4,200 cells). HPV 5 is the only other HPV 
type detected, at low levels (<0.01 copies/cell).  Therefore, these high HPV 6 
VLs are likely to be true results. 
 
Genital HPV VLs in cutaneous warts generally have low values  
Fourthly, the median VL of genital HPVs in cutaneous lesions is much lower 
than for genital lesions, as might be expected.  The median (IQR) genital HPV 
viral load of genital warts (suffix ‘.g’ in Figure 3.10) from both HIV infected and 
healthy cases is 510 (126-1,280) copies/cell, compared with cutaneous warts 
(lesions with ‘.c’ suffix, Figure 3.10) with a median (IQR) VL of 0.06 (0.006-2.1) 
copies/cell (p<0.0005 Mann-Whitney U test). Five cutaneous warts are 
exceptions and did not follow this trend. 
 
Figure 3.10 All group: genital HPV viral loads (VLs) in warts.  HPV VLs for types 6, 11, 16 
and 18 (that are above the limit of detection) are shown on the chart. Multiple lesions in the 
same patient are identified with different capital letters (for example 4A, 4B). Note: the same 
sample patient/lesion numbering system is used for Figure 3.11 and Appendix Figures A3.16 
and A3.17 (HLA group); the study codes corresponding to sample numbers can be found in 
Appendix 3.11.  Abbreviations: c – cutaneous wart; g – genital wart; Inf – infected.  
 Five cutaneous warts have high genital HPV VLs 
The genital HPV VLs of these five exceptions are discussed below, together 
with the MFI results of the cutaneous HSL-PCR/MPG.  MFI data are semi-
quantitative and provide  supplementary information on the relative importance 
of HPV types (de Koning et al., 2010; Schmitt et al., 2011); see also Appendix 
3.2.2.  MFIs of greater than 2,000 units have been classified as ‘high’; those 
less than 500 units have been classified as ‘low’. 
 
Example 1: healthy group lesion 18.c (hM83T).  This sample has been taken 
from a wart on the dorsal finger in a married middle aged female with no past 
history of genital warts.  No cutaneous wart associated types are detectable in 
this lesion but HPV 6 is found with a VL of 4,630 copies/cell.  This suggests that 
the most important HPV type in the generation of this hand wart is likely to be 
HPV 6, a genital type. 
 
Example 2: HIV infected group lesion 5.c (N48T1).  This sample is derived from 
parings of a peri-ungual wart from the finger of a HIV infected individual, with no 
history of genital warts.  Although the cutaneous types HPV 27 (MFI 2,458 
units) and HPV 57 (MFI just above cut-off: 253 units) are also detectable 
alongside HPV 6, the high VL for HPV 6 (950 copies/cell) suggests that this 
type may be important in the lesion.  
 
Example 3: healthy group lesion 10.c (hH70T1).  This lesion was removed by 
curettage from the forehead of an individual with a past history of genital warts.  
HPV 6 has a VL of 361 copies/cell, although HPV 2 (MFI high at 3,507 units, VL 
not known) and HPV 11 are also identifiable (in low levels, <0.01 copies/cell).  
Therefore HPV 6 and also HPV 2 are likely to be the most important types in 
this lesion. 
 
Example 4: HIV infected group lesion 2A.c (C12T3).  This wart on the index 
finger was sampled by paring and many types are detectable. HPV 57 
(cutaneous), HPV 6, 16, 52 (genital) and HPV 8, 9, 17, 23, 38, 93, 96 (beta) are 
found. HPV 16 is detectable in the highest levels (6.7 copies/cell).  Although 
 HPV 57 may also be important in this lesion (and HPV 9 was seen as a strong 
band on the beta RHA), this patient had concurrent penile warts that were not 
sampled (participant declined treatment). This patient’s contemporaneous CD4 
T-cell count is only 222 cells/µl, on fully suppressive ART, and he had a CD4 T-
cell nadir of 5 cells/µl. 
 
Example 5: HIV infected group lesion 3.c (D46T1).  This sample is derived from 
parings taken from a plantar wart.  The genital types HPV 6 (VL 3.4 copies/cell) 
and HPV 11 (VL 0.01 copies/cell) are detectable, together with HPV 27 
(cutaneous), HPV 43, 44 (genital), and HPV 9, 12 (beta).  This patient also had 
anal warts and AIN; HPV types 31, 40, 43, 93 and 2, 16, 40, 43, 54, 66, 68, 74, 
93 are found in those lesions, respectively.  The AIN lesion has a HPV 16 VL of 
1.4 copies/cell.  Because a large number of HPV types are detectable in the 
plantar wart parings, it is difficult to identify the important type(s).  However, 
HPV 6 may have been involved in the generation of the lesion (because the 
HPV 6 VL is >1 copy/cell).  
 
Beta HPV VLs are largely below the limit of detection 
A large proportion of samples from the All group have beta HPV VLs below the 
limit of detection; Figure 3.11.  Only ~30% of warts that are positive for beta 
HPVs on comprehensive typing have detectable beta VLs (range 27-34%), and 
the vast majority have very low VLs (<0.01 copies/cell).  Only two samples are 
exceptions and have ‘high’ beta HPV VLs (>1 copy/cell) and both are from the 
HIV infected group; Figure 3.11.  Two further samples have beta HPV VLs of 
0.1-1 copy/cell.  These are now discussed below. 
 
Some warts from HIV infected cases have high beta HPV VLs  
Example 1: the first sample with a high beta VL (6.c or M83T) is a plane/flat 
wart from a HIV infected patient that had an EV-like eruption on the face.  The 
clinical presentation is detailed in Appendix A2.2.5.  The HPV 5 VL is very high: 
154 copies/cell, suggesting together with the clinical presentation, that HPV 5 is 
most the probable causative HPV type.  
 
 Example 2: the second sample (14.g or C14T1), also from an HIV infected 
case, is derived from curetting of a penile wart.  The only HPV type present is 
HPV 8 (detected with a VL of 36 copies/cell) and therefore, HPV 8 may be 
important in the generation of this lesion. Dysplastic changes had been noted in 
the wart, although these are not sufficient to fulfil a histological diagnosis of 
PCIS or EV. 
 
Beta HPV VLs for HPV 8, found at ‘intermediate’ levels of between 0.1 and 1 
copy/cell, have been detected in two further samples; for full details see 
Appendix 3.12.    
 
It should be noted that the scales on the bar charts of Figures 3.10 and 3.11 
differ (0-6,000 and 0-0.30 copies/cell, respectively). 
 
 
Figure 3.11 All group: beta HPV viral loads (VLs) in warts.  HPV VLs for types 5, 8, 15, 
23, 24, 38 (that are above the limit of detection) are shown on the chart. Warts with HPV VLs 
above the limit of detection are shown on the bar chart.  The numbering system is the same 
as for Figure 3.10 and study codes can be found in Appendix 3.11.  Abbreviations: c – 
cutaneous wart; g – genital wart; Inf – infected. 
 
 3.6 SPECIAL CASES  
 
3.6.1 Females with genital warts  
 
Genital warts from females have been excluded from the HLA and All analyses 
for the reasons already discussed; see Methods, section 2.1.  However, HPV 
typing data are available in Appendix 3.13.   
 
3.6.2 HPV typing results of anal intra-epithelial neoplasia (AIN)  
 
Two lesions of AIN (one AIN grade 2, one AIN grade 3) have been HPV typed 
and both have detectable HPV 16 VLs; 1.4 copies/cell and 34 copies/cell 
respectively. See also Appendix 3.4. 
 
3.6.3 Wart case: HPV typing example from one individual  
 
HPV types are similar in samples taken from one individual 
The comprehensive HPV typing results of five samples from one HIV infected 
individual are available; two cutaneous warts, an actinic keratosis and peri-
lesional normal skin and hair (from around an excised wart).  A similar spectrum 
of HPV types are identified in these lesions; HPV 7 is found in all samples 
except the actinic keratosis; HPV 8 is found in all lesions, in low levels (HPV 8 
VL undetectable).  These results may be due to contamination.  However, if this 
is not the case it illustrates that cross-infection of separate body sites may 
occur.  Full details can be found in Appendix 3.14. 
 
 
3.7 DISCUSSION  
 
Overall perusal of the HPV data from the All (presented in this chapter) and the 
HLA groups (Appendix 3.8) shows that they are very similar. However, unless 
stated otherwise, the remarks in the following discussion are based on the 
results from the All group. This is because the All group comprised a greater 
 number of samples and where there are differences between HIV and healthy 
individuals, higher levels of statistical significance have been observed in this 
larger group.  
 
3.7.1 Subject inclusion and characteristics  
 
HIV infected subjects are survivors of the HIV epidemic  
The high proportion (one third) of individuals on second line ART regimes and 
regimes including new drugs is likely to be related to the extensive involvement 
of the recruitment centre (Chelsea and Westminster Hospital, London, UK) in 
clinical trials, attracting patients with more complex HIV treatment challenges 
and requirements.  Many of the HIV infected individuals recruited into this study 
are survivors of the HIV epidemic, particularly those diagnosed before 
combination ART with PIs became available, around 15 years ago.  Therefore it 
is not surprising that as many as eight may be slow progressors in terms of HIV 
infection.  
 
Co-infection with chronic (PCR DNA positive) hepatitis B and C may have 
induced greater immunosuppression in affected HIV infected individuals than 
might be inferred from their CD4 T-cell counts (although the relative 
innaccuracy of this surrogate marker for immunosuppression is acknowledged).  
Therefore, co-infection might increase opportunistic infections such as HPV 
disease, and influence the risk of IRAD. 
 
A wide range of ethnicities are included in the All group  
Non-Caucasian subjects have been included to increase the number of warts 
examined (in the All group), enabling better characterisation of wart disease in 
HIV infection.  Inclusion of these non-Caucasian subjects might have had an 
influence on the spectrum of HPV types observed in the All group.  However, 
many of the non-Caucasian subjects originated from European countries (for 
example Italy, Spain, Greece, Bulgaria; Table 3.1) and the distribution of HPV 
types is very similar in the All group and the (all Caucasian) HLA group.  
 
 Age: the median ages are similar between groups 
Although the age distriubutions of HIV infected and healthy individuals are 
statistically significantly different, the medians are not greatly different (44 and 
40 years, respectively).  The recruitment of stable HIV infected patients on ART 
may have excluded many younger HIV infected individuals (<30 years), leading 
to a higher median age in HIV infected cases.  A wide age range is seen in 
healthy subjects: failing immunity over 60 years may have led to the 
appearance of warts in these healthy subjects (five healthy individuals are aged 
>60 years).  However, the HIV infected cohort also includes three subjects over 
60 years of age.  It is unlikely that the slight age discrepancy between the 
groups is of biological consequence.  
 
Gender: Caucasian HIV infected subjects are largely MSM 
Two demographic reasons account for the statistically significant differences in 
gender distribution seen in HIV infected compared with healthy individuals. 
Firstly, in the HIV infected clinic population at the recruitment hospital, 
Caucasians are often male (with a HIV risk factor of MSM), whereas HIV 
infected females are often non-Caucasian heterosexuals.  Only one HIV 
infected female (who was non-Caucasian) was assessed during recruitment.   
Healthy females with cutaneous warts included in the All analysis comprise 26% 
(12/46) of the total.  However, it is not likely that the gender distribution affected 
the results because bias has been reduced by excluding females with genital 
warts and because cutaneous wart disease in male/female hetrosexuals is 
probably phenotypically homogenous.  
 
Secondly, the low-risk (in terms of HIV) population from which the healthy cases 
have been sampled, by definition, has fewer MSM than the HIV infected cohort 
sampled.  Cutaneous disease in MSM might differ from that in hetrosexuals, 
potentially through greater exposure to HPV types, particularly genital types.  
Inclusion of a proportion of MSM in the healthy group (17% or 8/46 MSM, All 
group) provides a more useful comparison to HIV infected cases (that are all 
MSM; All group) than if the healthy group had all been heterosexual. 
 
 HIV subjects reached CD4 nadirs lower than guideline recomendations  
The long duration of HIV infection in subjects in this study is a likely 
consequence of recruitment of relatively well individuals with persistent/chronic 
wart disease on ART.   Around a third of HIV infected subjects (15 of 46; All 
group) have contemporaneous CD4 T-cell counts of less than 400 cells/µl.  The 
median CD4 T-cell nadir of 140 cells/µl is much lower than current HIV 
treatment guidelines; nadirs of 200-350 cells/µl are associated with a better 
prognosis (Gazzard et al., 2008).  This  suggests that in many an advanced 
stage of HIV disease had been reached before HIV VL had been completely 
suppressed (median 14 years since HIV diagnosis). Only ~25% of the HIV 
infected patients included in this study have recorded CD4 T-cell count nadirs of 
greater than 200 cells/µl.  However, two thirds of the HIV infected individuals 
included had been diagnosed with HIV prior to the availability of effective 
combined and potentially fully suppressive therapy; 29 (of 47) were diagnosed 
before 1996 and half of these (15/47) before 1990. 
 
3.7.2 Subject wart disease characteristics  
 
Median wart disease duration is more than three years 
The median duration of wart disease in this study is relatively long for both HIV 
infected and healthy groups (around 3 to 5 years). This is as expected because 
individuals with persistent warts for six months have been recruited. Wart 
duration in both groups is self reported, and subjects may have over-estimated 
the length of disease duration.  A similar study that recruited immunocompetent 
individuals with a history of wart disease of at least 18 months, found a similar 
mean disease duration of 2.8 years (self-reported) in younger subjects; the 
mean age was 29-36 years (Spelten et al., 2004).  
 
The median wart disease duration is longer (but not statistically significantly so) 
in healthy cases than in HIV infected individuals from the HLA group.  One 
explanation for this is that the general population is larger and therefore may 
harbour more ‘severe’ cases.  Alternatively, healthy individuals may wait longer 
before seeking medical care for warts outside of general practice.   
 Immunodysfunction may be important for the persistence of individual lesions, 
as suggested by the (not statistically signficant) trend that individual warts from 
HIV infected individuals have been present for longer than healthy individuals’ 
warts.  Others found that between one third and one quarter of cutaneous warts 
had not spontaneously regressed by two years Massing & Epstein, (1963) as 
cited by Sterling et al., (2001).  The median genital wart duration has been 
reported as 4.2-5.8 and 14-28 months in two separate studies (Beutner et al., 
1998a; Sauder et al., 2003).  
 
HPVs may cross-infect genital and cutaneous sites 
A surprisingly large number of individuals, both healthy and HIV infected, report 
recent HPV related disease at cutaneous and genital sites (n=13/93; All group), 
although mostly this was in HIV infected individuals (n=11/13). Of the six HIV 
infected individuals that have had warts sampled from both genital and 
cutaneous sites (none of the healthy cases provided both types of warts) two 
have concordant cutaneous HPV types in both cutaneous and genital lesions 
and two have the same genital HPV types in both sites; Figure 3.3 and 
Appendix 3.7. 
 
The classification of HPV types into cutaneous wart related and genital HPV 
types based on wart site is convenient but a minority of warts probably are 
related to HPV types that classically cause warts at other sites (Birley & Lacey, 
2001).  Cutaneous HPV types have previously been documented in the genital 
warts of children (Aguilera-Barrantes et al., 2007).  However, the finding 
reported (by Oriel, 1971a) that 18% (30/166) of males with genital warts had 
skin warts seems a high proportion if no such cross-over occurs, and raised the 
possibility of genetic susceptibility.   The results herein suggest that cross-over 
of HPV types between sites (in HIV infected MSM) may occur. 
 
A possible explanation for genital/cutaneous HPV cross-over occuring largely in 
HIV infected individuals may be that these individuals might have greater 
exposure to genital and cutaneous HPVs, causing warts in different sites.  
Alternatively, these individuals may be more susceptible to wart disease.  
3.7.3 Cutaneous warts 
 
Site variation is greater in HIV infection 
The greater variation in cutaneous wart sites observed in HIV infected 
individuals compared with healthy cases may be a function of 
immunodysregulation in the former. 
 
Parings have been obtained more often from warts in healthy subjects 
More than double the number of parings have been taken from the cutaneous 
warts of healthy cases than from HIV infected cases; 45% compared with 20%, 
(p=0.003); Figure 3.4.  More surgical techniques have been employed to 
sample warts from HIV infected cases.  One reason for this is that curettage 
(most often) and punch tool or elliptical incision can be used as sampling 
techniques to enable histological assessment of atypical warts at unusual sites; 
9 of 56 warts had atypical features in HIV infected cases whereas 4/51 warts 
from healthy cases have been classed as atypical; for details see Appendix 
3.10.  
 
Patient preference may also be important.  Many healthy individuals requested 
a simpler shorter procedure, whereras HIV infected patients preferred more 
definitive debulking surgery (such as curettage under local anaesthetic with 
electrocautery/silver nitrate for haemostasis).  This may be related to the 
number of treatments tried previously.   Surgical approaches also evolved 
during the study.  During the study, a pilot analysis demonstrated that parings  
are adequate for successful PCR amplification for genomic DNA, and therefore, 
as the study progressed, more patients chose not to have definitive biopsy. 
 
Another contributory reason is that more plantar warts have been sampled from 
healthy individuals – plantar warts comprise 29% (15/51) of cutaneous warts 
from healthy individuals compared with 13% (7/56) of HIV infected cutaneous 
warts (p=0.05); Figure 3.4.  Plantar warts are best sampled by paring because 
of delayed site specific healing.  Paring is a superficial sampling technique and 
because surface contamination with multiple HPV types is possible, this has 
been examined further; Appendix 3.15.  In pared cutaneous warts, there is no 
statistically significant difference in the number of cutaneous, genital and beta 
HPV types identifiable compared with other types of specimens (p=0.43 to 
p=0.06, Mann-Whitney U test); Appendix Table A3.20.  However, there was a 
trend towards HIV infected individuals carrying more cutaneous and genital 
HPV types in parings than non-parings but this is unlikely to have influenced the 
HPV results overall. 
 
3.7.4  Genital warts  
 
Sexual activity or HPV type may influence genital wart site, in males 
Predominantly, in the HIV infected cases examined herein, warts were sited 
around the anal margin; in healthy cases mostly penile lesions were sampled.  
Although, these differences in site are not statistically significant (p=0.12 and 
p=0.15) it may relate to patterns of sexual activity.  Anal intercourse has 
clinically, long been associated with anal and perianal warts (Bunney et al., 
1992; Oriel, 1971b).  It was seen that MSM who presented to a sexual health 
clinic had a higher prevalence of anal warts (2.9%) than heterosexual men 
(0.3%); the corresponding figures for non-perianal genital warts were: 1.7% in 
MSM compared with 6.7% in heterosexuals  (Judson et al., 1980).  Therefore, it 
is likely that the HIV infected MSM studied herein have had increased exposure 
to HPV in perianal sites and perhaps may also have a greater awareness of 
anal lesions than the mostly heterosexual healthy male cases (females with 
genital warts were not included). 
 
Two recent studies that examined male genital wart sites (in populations that 
probably contained mostly heterosexuals) found that, overall, penile warts were 
more common than anal warts.  Firstly: 83% of all male warts were penile warts 
compared with 4% anal warts (Chan et al., 2009); and secondly: 42% penile 
warts were seen, compared with 37% peri-anal warts (Aubin et al., 2008).  
However, comparison with the HIV infected cohort that has been examined 
herein (89-100% MSM) is difficult.   It is not clear from previous work if the site 
of external anogenital warts is related to HPV type in males.   
Although HPV 6 was identified as the commonest HPV type in penile warts from 
both of the above two studies (Aubin et al., 2008; Chan et al., 2009), this may 
be coincidental. Others reported no relationship between the HPV type detected 
in anal condylomas (and AIN lesions – 30%) and HIV antibody status or sexual 
preference: homo/bisexual or heterosexual (Syrjanen et al., 1989). The 
numbers of genital warts in this thesis are too small to examine HPV type and 
site specificity and further studies are required. 
 
Sampling methods 
The sampling methods are very similar for HIV infected and healthy cases.  
  
3.7.5  Cutaneous HPV types   
 
The principal findings in relation to cutaneous HPV typing in this study are 
discussed below.   
 
HPV 1 is absent from cutaneous warts 
To date, HPV 1 was seen as a common HPV type in seven of eight studies that 
used DNA based techniques to HPV type cutaneous warts; Appendix 1.1.  The 
prevalence of HPV 1 ranged from 1-46% of cutaneous lesions; mean: 22% 
(Chen et al., 1993; Rubben et al., 1997; Iftner et al., 2003; Meyer et al., 2003; 
Hagiwara et al., 2005; Lei et al., 2009; de Koning et al., 2010; Tomson et al., 
2011).  It is unlikely that HPV 1 has been missed by the HPV typing methods 
that have been used herein because HPV 1 was identified in 31% of 100 wart 
swabs in a study from The Netherlands, that utilised the same HSL-PCR/MPG 
Luminex technique as in this work; Appendix Table A1.2 (de Koning et al., 
2010).  Geographical variation may account for the different HPV type 
epidemiology; for example HPV 2/27/57 may be more prevalent in Europe and 
HPV 1 in Japanese/Taiwanese/Chinese populations (Rubben et al., 1997; 
Hagiwara et al., 2005).  Although some (continental) European studies reported 
a high rate of HPV 1 detection, a recent UK based study found HPV 1 in only 
1% (1/80) of lesions (Iftner et al., 2003; de Koning et al., 2010; Tomson et al., 
2011).  In the work reported herein, adult subjects with long wart duration have 
been recruited. Therefore, it is possible that HPV 1 related warts have been 
excluded because HPV 1 may have a predilection for children and/or be of 
shorter duration (less than three months) than warts caused by HPV 2/27/57, 
for example, that had a mean duration of 22 months (Rubben et al., 1997).  
Additionally, HPV is found predominantly in plantar warts and, therefore, the 
relatively low prevalence of plantar warts (13% and 29%; healthy and HIV 
infected cases, respectively) may have contributed to the absence of this type. 
 
Unusual cutaneous HPV types are seen in HIV infected cutaneous warts and 
HPV 2 is more prevalent in warts from healthy individuals   
The excess of HPV 2 in warts from healthy cases (compared with HIV infected 
cases; p=0.0004) might be related to the smaller number of healthy patients 
that harbour HPV 57; Figure 3.6.  Therefore, the contributory proportion of the 
commonest types, HPV 2/27/57 combined, might be expected to be similar in 
healthy and HIV infected subjects.  Looking at HPV 2/27/57 positive warts 
further, 90% (46/51) of healthy subjects’ cutaneous warts carry HPV 2/27/57 but 
only 71% of warts from HIV infected individuals carry these types (40/56) of 
(p=0.03 Yates’ chi-squared test).  The proportions of cutaneous warts that are 
negative (for cutaneous HPVs) are similar between the groups: 6% (3/51) and 
9% (5/56), respectively (p=0.72, Fisher’s exact test). In cutaneous warts from 
HIV infected cases HPV 3 and HPV 10 are seen (but not in healthy cases, 
p=0.06).   These data suggest that unusual HPV types (non-HPV 2/27/57) may 
be associated with warts from HIV infected patients; such as HPVs 3, 4, 10, 28, 
43, 63, 95. 
 
There is one caveat: ethnicity may account for the finding of unusual cutaneous 
types in HIV infected individuals, in the All group.  However, if the effect of 
ethnicity is excluded (by looking at the HLA group data; Appendix Figure A3.12) 
the percentages of HPV 2/27/57 warts are 91% and 76% for healthy and HIV 
infected cases, respectively (similar to the All group); but the difference is not 
statistically significant because the numbers are smaller (p=0.11, Yates’ chi-
squared test). The clinical significance of these more unusual HPV types is not 
known.   
HPV 7 is associated with HIV infection 
HPV 7 is identified in 21% (12/56) of cutaneous warts from, and in 23% (9/40) 
of,  HIV infected individuals but in none of the healthy cases.  This is consistent 
with previous studies and is an important finding because a larger cohort of HIV 
infected patients with cutaneous warts has not been published to date (to the 
author’s knowledge).  A number of case reports and case series have 
previously correlated HPV 7 with HIV infection (causing so-called butcher’s 
warts), although mostly these were oro-facial lesions (in HIV); Appendix Table 
A1.3 (Greenspan et al., 1988; de Villiers, 1989; Volter et al., 1996).  The only 
other study that had a substantial collection of HIV infected patients, Porro et al. 
(2003), found HPV 7 in 4% (corresponding to just one of 25) lesions in HIV 
infected individuals but in none of lesions from their control (non-
immunosuppressed) patients.   
 
In non-immunosuppressed patients, HPV 7 has been reported in unusual sites: 
in oro-facial warts, groin warts and toe web warts (Ritzkowsky et al., 2001; 
Matsukura et al., 2010; Sun et al., 2010).  Dogmatically, HPV 7 is still thought to 
cause warts in butchers and meat/fish handlers, although it is not clear why this 
should be the case (Keefe et al., 1994; Meffert & Anthony, 2001).  Butchers do 
have a higher prevalence of warts (perhaps around 2-5 times that of the general 
population).  Although HPV 7 is not exclusively found in butchers, it is one of 
the most frequently identified HPV types, in around a quarter of their warts 
(Jablonska et al., 1988; Melchers et al., 1993; Keefe et al., 1994).  
 
HPV 7 was infrequently (0.5-2%) found in the largest (n>100) comprehensive 
HPV typing studies of cutaneous warts from the general population; Appendix 
Table A1.2 (Rubben et al., 1997; Iftner et al., 2003; Hagiwara et al., 2005; de 
Koning et al., 2010).   However, smaller studies identified HPV 7 in 10% (n=51) 
and in 16% (5/31) of common warts in non-HIV individuals, respectively; 
Appendix Tables A1.2 and A1.4 (Meyer et al., 2003; Sun et al., 2010).   
 
One possible explanation for the relative paucity of HPV 7 in cutaneous warts 
from the general population in previous studies is that some of the HPV typing 
techniques that used to date inadequately identified HPV 7.  However, recent 
studies that have used HPV 7 specific probes have also had low HPV 7 
detection rates (Lei et al., 2009; de Koning et al., 2010; Tomson et al., 2011).  
Therefore, the finding of HPV 7  in association with HIV infection (in 21% of the 
patients presented herein) is likely to be important.   
 
Why HPV 7 might have a predisposition for HIV infected individuals is not 
known.  Immunodysfunction may be important; HPV 7 was found in 17% of 
(n=23) warts from twelve OTR patients (Harwood et al., 1999); Appendix Table 
A1.4.  However, HPV 7 was not identified in other studies in OTRs  (Shamanin 
et al., 1994a; Stark et al., 1994; Kohler et al., 2009; Martelli-Marzagao et al., 
2010). Certainly, corroborating evidence from case series of oral and facial 
warts (Appendix Table A1.3) have suggested the association of HPV 7 with HIV 
infected individuals may be a true finding.  A facial/head predominance is also 
seen in the HPV 7 positive warts described herein; of  twelve HPV 7 positive 
warts, the majority (6/12) are from the face (n=4), neck (n=1) or scalp (n=1); 
other sites are hands (5/12) and foot parings (1/12). It is possible that oro-
sexual transmission (with/without auto-inoculation) might account for this finding 
of HPV 7 in HIV infected individuals. 
 
HPV types 2/4/27/57 are the most common HPV types in hand and foot warts 
Cutaneous HPV types and lesion site is now discussed in greater detail; Table 
3.4.  The common cutaneous HPVs 2/27/57 and HPV 4 have been grouped 
together as they most often cause common warts (on the hands and feet) and 
HPV 3/10 have been grouped together as these types are associated with 
plane/flat warts on the body and limbs (Jablonska et al., 1997; Sterling, 2010).  
 
Predominantly (in 87% or 73/84), HPV 2/4/27/57 positive warts are found on the 
hands and feet; Table 3.4.  Hand and foot warts (from both HIV infected and 
healthy individuals) carry HPVs 2/4/27/57 more frequently than HPV 7 (6/12) or 
HPV 3/10 (1/5) and this difference is statistically significant (p=0.003 compared 
with HPV 3/10; p=0.006 compared with HPV 7, Fisher’s exact test).  HPV 
2/27/57 are the only types detected in plantar warts in healthy individuals, 
compared with HIV infected individuals, where a number of more unusual HPVs 
are found; HPV 7, 43, 63 or 95 (data for plantar warts alone are not shown in 
the table).   
 
 
 
 
Genital warts often harbour cutaneous HPV types; this is more prevalent than 
has been previously reported  
The last important finding relating to cutaneous HPV types in the study herein is 
that a surprisingly large proportion of genital warts are positive for cutaneous 
HPVs (between one quarter and a half).  Possible explanations for these results 
include sample-to-sample cross-contamination during laboratory processing 
and/or  the  very  sensitive  assays used.    However,  this  phenomenon  where 
cutaneous HPV types are found in genital warts has been documented 
previously, but in a small proportion (≤2%) of warts (D'Ambrogio et al., 2009; 
Table 3.4 All group: HPV type and cutaneous wart site.  The percentages shown herein 
have been calculated using a denominator of n=56 for HIV infected and n=51 for healthy 
individuals, and do not total 100%.  The numbers of warts that harbour multiple HPV types 
are indicated by italic superscript numerals and italics (last column).  Abbreviations: n - 
number of lesions; ƒ – the other HPV types identified for HIV infected warts are: HPVs 28, 
43, 63, 77, 95. 
 
 
Barzon et al., 2010).  In certain situations this may be much higher; HPV 2 (a 
cutaneous type) is found in 41% of vulval warts in girls under 5 years but in only 
3% of adults (Aguilera-Barrantes et al., 2007). ‘Untyped’ HPVs have previously 
been reported in genital warts.  This was in the region of 4-7% genital warts and 
might correspond to the detection of cutaneous HPVs; Table 1.4 and Appendix 
Table A1.5. Others noticed that the presence of finger and trunk warts was 
associated with either an increased risk of genital warts and/or the identification 
of untyped HPVs on the penile shaft, in healthy individuals (Hernandez et al., 
2011).  The authors suggested this might indicate a general HPV susceptibility.  
In the subjects included herein, a history of cutaneous warts is common to most 
(6/7) of the HIV infected individuals harboring cutaneous HPV types in genital 
warts, but this is not the case in healthy individuals (0/5).  
 
The clinical effect of these cutaneous HPVs in genital warts is not known; the 
cutaneous wart associated HPVs are not considered carcinogenic. 
 
3.7.6 Genital HPV types 
 
A brief review of the HPV types found, to date, in cervical and genital tissue 
from the general population, is contexually helpful. In scrapes from normal 
cervices (the cervical equivalent of ‘normal skin’) there is a high backgound of 
genital HPVs (2 to 39%); the commonest type is HPV 16 (HR); of the LR types 
HPV 6 was marginally more prevalent than HPV 11 (IARC, 2007).  The 
prevalence of HPV 16 increases with smear abnormality; in 19% of low grade 
and in 45% of high grade abnormal smears (IARC, 2007).  Cervical smears 
from HIV infected patients had a wider distribution of HPV types and multiple 
infecting types were found (Clifford et al., 2006); Table 1.4.  The data for anal 
smears showed many parallels to that for cervical disease.  In the general 
population, HPV 6/11 cause in excess of 90% of genital warts; HPV 16 is 
infrequent in genital warts (IARC 2007).  Therefore, HPV 6/11 have a 
predilection for external genital sites while HPV 16 is  the most common type 
internally, in cervical and anal tissue.  
 
HPV 6 is commoner in healthy cases and HPV 11 is more prevalent in HIV 
infected cases 
The data from healthy genital wart specimens included in this study are in 
accordance with those published to date; HPV 6 is the commonest type in 
healthy cases.  HPV 11 appears to have a predilection (of borderline statistical 
signficance) for HIV infected individuals.  Although the number of genital warts 
included herein is small, this observation is supported by the cohorts of Brown 
et al., (1999) who found 61% of HIV infected individuals carried HPV 11 in 
genital warts compared with 32% of their healthy control group (n=18, n=41, 
respectively).  The corresponding figures for HPV 6 were 90% in healthy and 
27% in HIV infected cases (Brown et al., 1999).  Other data for genital warts 
from HIV infected cases have suggested either a similar distribution HPV 6 and 
11 (Sanclemente et al., 2007; Nunes et al., 2008) or a slightly higher prevalence 
of HPV 6 (Firnhaber et al., 2011), but not the overall predominance of HPV 6 
that has been seen in general population studies (Greer et al., 1995; Beutner et 
al., 1998b; De Marco et al., 2001; Vandepapeliere et al., 2005; Aubin et al., 
2008; Wang & Qiao, 2008; Chan et al., 2009; Barzon et al., 2010; Anic et al., 
2011; Ball et al., 2011).  Thus, in this thesis, HPV 6 has been found in a low 
prevalence in genital warts from HIV infected cases (30%, compared with 85% 
in healthy cases) and HPV 11 has been found with a higher prevalence (47%, 
compared with 10% in healthy cases).  These findings in HIV infected patients 
contrast with the usual predominance of HPV 6 in genital warts from the general 
population (and with the findings for the healthy cohort, herein).  However, the 
number of genital warts examined herein is small. 
 
HPV 11 was linked to recurrent genital warts after surgical treatment in one 
study (D'Ambrogio et al., 2009).  However, it analysed a mixed cohort (HIV 
infected, HIV uninfected and those of unknown status) of genital wart-affected 
individuals that included at least 24% that were infected with HIV and the high 
proportion of HIV infected individuals may have influenced their results.   
 
HPV 11 may persist in the immunosuppressed host, leading to a higher 
prevalence of chronic genital warts in HIV infected (but not healthy) individuals, 
accounting for the observations reported herein.  However, there are several 
caveats to consider.  Both groups of subjects included herein have treated and 
untreated genital wart disease of relatively long duration (median ≥3 years), and 
this may have influenced the proportions of HPV 6/11. Thirdly, the increase in 
prevalence of HPV 11 in genital warts from HIV infected individuals, compared 
with healthy cases, seen herein approaches, but did not achieve statistical 
significance. Perhaps this may be due to the small number of genital warts 
(n=20 healthy, n=17 HIV infected warts) studied. It is also possible that these 
two groups have been sampled from different ‘sexual populations’ and that the 
population of HIV infected cases (largely MSM) has a naturally higher 
prevalence of HPV 11 genital warts.   
 
It cannot be known if the observed predominance of HPV 11 in genital warts 
from HIV infected patients may be clinically relevant.  However, both ‘LR’ HPVs 
6 and 11 have rarely been associated with locally infiltrative Buschke-
Lowenstein tumours and verrucous anogenital (vulval, penile, anal) cancers 
(IARC, 2007).  In immunosuppressed individuals with aggressive metastasising 
Buschke-Lowenstein related SCCs HPV 11 was identified (Manias et al., 1989; 
Handisurya et al., 2009).  HPV 11 has also been associated with more 
aggressive RRP disease although it was also postulated that particular sub-
types of HPV 6 or 11 may be responsible for virulent disease (Donne et al., 
2010).   
 
In the cohort herein, there is no statistically significant relationship between 
HPV type (6 or 11) and genital wart site (penile or anal), although the number 
available are small.  However, none of the HPV 6 positive genital warts are 
anal.   
 
High risk (HR) HPV types are less common in genital warts from HIV infected 
individuals studied herein than in previous studies  
Previous studies in HIV infected subjects found a high proportion of HR genital 
HPV types in genital warts (30-100% of warts in studies that examined at least 
two HR HPV types); Table 1.4.  However, some investigators performed wart 
swabs that could potentially have increased surface contamination (Muller et 
al., 2010; Firnhaber et al., 2011) and the others included genital pre-cancerous 
lesions (Brown et al., 1999; Sanclemente et al., 2007) or lip lesions (Nunes et 
al., 2008).  One study that compared HIV infected individuals and controls 
found more oncogenic HPVs in HIV infected than healthy individuals’ genital 
warts; 100% compared with 42%, respectively (Brown et al., 1999).  
 
In the genital warts examined herein, HR types are seen infrequently, only in 
HIV infected cases, and then in just 12% (2/17) of warts.  This comparatively 
low prevalence of oncogenic HPVs may be related to the inclusion of ART 
treated HIV infected cases, or to the sampling technique (wart biopsies rather 
than swabs) or to the wart site (scrotal, groin and buttock lesions are also 
included herein). 
 
Cutaneous warts frequently harbour genital HPV types  
Analysis of the genital HPV typing data from cutaneous warts reveals that a 
sizable percentage (22-30%; 28/107) of both HIV infected and healthy cases 
yield genital HPV types and around one third of these harbour HR genital types.  
Predominantly, genital HPVs are found in low levels in cutaneous warts (13/28); 
but a VL assay was not available for some (the HPV types found in ten of the 
28 warts).  However, two (cutaneous warts from healthy individuals) are 
probably caused by LR HPV 6 and three (cutaneous warts from HIV infected 
individuals) may be related to other genital HPVs; Figure 3.10.  The HPV 6 or 
16 VLs of these five cutaneous warts are all above one copy/cell – ranging from 
3.4 to 4,630 copies/cell.  For further details see section 3.5.9 (examples 1- 5). 
 
The presence of genital HPVs in cutaneous warts may be explained by cross-
infection of genital HPVs from genital sites to cutaneous sites.  One study 
showed a relatively high pickup of genital HPVs - one third - in finger brushings 
from patients with genital warts (Sonnex et al., 1999).  
 
Laboratory cross-contamination is another possible explanation. The SPF10 
LiPA RHA assay used for genital HPV typing is highly sensitive and can detect 
very small quantities of HPV.  Many of the genital warts have been processed 
alongside the cutaneous warts and some genital wart samples with very high 
HPV VLs may have cross-contaminated the cutaneous wart specimens.  
However, it is reassuring that the vast majority (80%) of the genital HPV VL 
assays that have been performed on cutaneous lesions yield low genital HPV 
VLs (<1 copy per cell) or VLs below the limit of detection.  
 
The prevalence of genital HPV types in cutaneous warts is higher than has 
been found previously 
The finding of genital HPVs in cutaneous warts is not an isolated discovery 
because genital HPVs have been detected previously in 7-15% of cutaneous 
warts from the general population (Chen et al., 1993; Iftner et al., 2003; Meyer 
et al., 2003; Porro et al., 2003; Hagiwara et al., 2005; Kohler et al., 2009); 
Appendix Table A1.2. The proportion of genital HPV types in cutaneous warts 
was increased in immunosuppressed individuals, with a prevalence that ranged 
from 8-26% in HIV infected patients (Porro et al., 2003; Nunes et al., 2008) and 
17-26% in OTRs (Shamanin et al., 1994a; Stark et al., 1994; Harwood et al., 
1999; Meyer et al., 2003; Kohler et al., 2009).  Therefore, the results reported 
herein have a slightly higher prevalence than has been found previously, 
consistent with the high sensitivity of the genital SPF10 LiPA RHA assay used.  
Predominantly, the genital HPV infections that have been detected in cutaneous 
warts studied herein are mixed with other (cutaneous) HPV types, suggesting 
that they may be bystander HPVs. 
 
Nevertheless, the five cutaneous warts from healthy and HIV infected 
individuals that have VLs of >1 copy/cell are probably caused by genital HPVs.  
These are unlikely to be accounted for by contamination.  
 
The issue of contamination aside, the identification of genital HPVs in 
cutaneous warts and vice-versa, (together with the above previous work that 
has corroborated these findings) suggests that cross-infection may occur 
between cutaneous and genital sites in an individual. This may be of some 
clinical importance as some genital types are potentially carcinogenic.  
Carcinogenic genital HPV types have been linked to peri-ungual SCCs 
(Handisurya et al., 2007; Kreuter et al., 2009).  Cutaneous and genital HPVs 
may be more ubiquitous than previously thought and might (at least partially) 
resemble the situation for beta HPVs. 
 
3.7.7 Beta HPV types  
 
Beta HPVs are more prevalent in this work than in previous studies  
A wide range of beta HPV types have been detected herein, particularly in 
cutaneous warts; Figure 3.8.  HPV 5 and 8 are known to be carcinogenic in EV 
patients (IARC, 2007) and others have been suggested to be potentially 
carcinogenic, such as HPVs 14, 15, 17, 19, 20, 24, 36, 38 and 47 (Orth, 2005; 
Bouwes Bavinck et al., 2008).  The proportion of cutaneous warts that are 
positive for any beta HPV (57% in healthy and 80% in HIV infected, p=0.02) is 
high compared to previous studies (Appendix Tables A1.2 and A1.4).  This high 
rate of detection is a likely function of the highly sensitive beta RHA assay.  For 
warts derived from healthy patients the beta HPV prevalence in previous 
publications ranged from 1.5 to 49% (Harwood et al., 1999; Meyer et al., 2003; 
Hagiwara et al., 2005; Kohler et al., 2009).  Kohler et al., (2009), used a 
comparable technique (another type of beta reverse line probe assay) and 
produced a similar beta HPV prevalence in warts (49%) to that seen herein.  In 
OTRs, beta HPVs were found in 43-79% of warts (Harwood et al., 1999; Meyer 
et al., 2003; Kohler et al., 2009), increasing to 86% in atypical warts from sun-
exposed sites (Harwood et al., 1999).  There have been no previous studies in 
HIV infected individuals, but the proportion of beta HPV positive warts (80%) 
herein is analogous to previous data from OTRs.  Clinically, this may be 
important in (non-melanoma) skin cancer, as has been postulated for OTRs; 
sections 1.1.5 and 1.1.7.    
 
HIV infected individuals also have an increase in the number of beta HPV types 
in cutaneous warts (that is statistically significant); this is discussed in the next 
section as it is related to the increase in beta HPV mixed infections that is seen 
in HIV. 
3.7.8 Mixed infections 
 
Mixed cutaneous HPV type infections are seen more frequently in cutaneous 
warts from HIV infected cases  
Mixed infections with cutaneous HPVs are found statistically significantly more 
often in cutaneous warts from HIV infected cases (20%; 11/56) than in those 
from healthy individuals (4%; 2/51); Figure 3.6 and section 3.5.8 (p=0.03).  In a 
study that used the same assay (HSL-PCR/MPG) as this thesis, the proportion 
of mixed infections with cutaneous HPV types in swabbed cutaneous warts 
from healthy patients was 11% (de Koning et al., 2010).  This was higher than 
the 4% of healthy cases with mixed infections identifiable herein; section 3.5.8.  
However, in de Koning’s study, the superficial sampling technique may have 
accounted for the higher percentage mixed infections.  The only other study of 
cutaneous warts from HIV infected individuals by Porro et al., (2003) did not 
identify any mixed HPV infections but the techniques used were probably 
inadequate (36% of warts were HPV negative). 
 
There are no data for cutaneous HPV VLs in warts from this study (because the 
assays were not available prospectively).  The semi-quantitative MFI data 
generated by the HSL-PCR/MPG assay from this study provide some insight 
(de Koning et al., 2010; Schmitt et al., 2011).  In more than two thirds of warts 
that carry mixed infections with cutaneous HPVs, the non-dominant HPVs are 
found in relatively low MFIs (<1,200 MFI units); the strong MFI signals detected 
for the dominant HPV type varied from 300-8,000 MFI units.  Therefore, 
although the excess of cutaneous HPV types in HIV infected indiviudals are 
likely to be as  ‘passengers’, it is also possible in warts with multiple HPV types, 
more than one type may contribute to wart generation. 
 
An excess of genital (and cutaneous) HPV types are detectable in pared 
cutaneous warts from HIV infected individuals  
A trend (that is not statistically significant) is observed that pared cutaneous 
warts from HIV infected individuals have an excess of genital HPV types 
(p=0.08) and cutaneous HPV types (p=0.06) compared with cutaneous warts 
sampled by other techniques; Appendix Table A3.20. These data suggest that 
HIV infected individuals may harbour more genital HPVs (and cutaneous HPVs) 
in low quanties in cutaneous warts that only becomes apparent when lesions 
are superficially sampled.  
 
The number of beta HPVs, as mixed infections, are increased in cutaneous 
warts from HIV infected patients, similar to the situation for organ transplant 
recipients  
Although there may be trends towards a small excess of genital and cutaneous 
HPV types in pared cutaneous warts from HIV infected subjects,  the data are 
more convincing for increased numbers of beta HPVs in cutaneous warts.  The 
median number of beta HPV types in cutaneous warts is statistically 
significantly higher in HIV infected individuals than in healthy individuals: 
median (IQR) of 3 (0-8) beta HPV types per lesion compared with 1 (0-3) type 
per lesion, respectively, (p<0.0005); Table 3.3.  The number of mixed beta HPV 
infections in HIV infected warts (genital and cutaneous combined) is also 
statistically significantly higher (55% compared with 29% healthy, p=0.01); 
Figure 3.9, section 3.5.8.  As has been mentioned previously, beta HPVs 
largely exist in low copy numbers in healthy skin and warts and they have been 
particularly well documented in OTRs; section 1.1.5 and Appendix Table A1.4.  
Therefore, this also appears to be the case for wart tissue from HIV infected 
patients. 
 
This excess of beta HPV types might be related to immunodysfunction (as a 
parallel situation to OTRs) or due to the number of close contacts or lifetime 
sexual partners (as appears to be the case for genital HPVs).  Cutaneous skin 
may also be an important reservoir for bystander genital HPV types, including 
HR genital types in addition to beta HPV types.  Increased longevity of HIV 
infected patients together with exposure to exogenous agents (such as UV 
radiation) and persistent immune dysregulation/inflammation may account for 
the apparently increased incidence of NMSC and ano-genital cancers.  Thus, 
the excess of genital, and particularly beta HPV types, may be of some clinical 
relevance.  The excess of cutaneous wart associated HPVs may be less 
important clinically. 
 
3.7.9 HPV Viral Loads (VLs)  
 
Genital warts can be categorised into two groups: those with high and low 
genital HPV VL copy numbers  
The range of genital HPV VLs in genital warts described herein is very wide, 
reflecting two distinct groups of genital warts.  Firstly, there is a large group of 
genital warts that harbour genital HPVs in high copy numbers (>1 copy/cell), 
sufficient to imply wart causation.  Secondly, there is a smaller group consisting 
(of two) genital warts in which genital HPVs are found in low quantities (<1 
copy/cell) and that harbour another HPV type. A further five genital warts are 
completely negative for genital HPVs; Appendix Table A3.9. 
 
Genital HPV VLs in genital warts are comparable to previous studies 
Overall, the median VL for HPV 6/11 combined in genital warts is 496 
copies/cell; see Table 3.5.  These results are congruent with another study in 
HIV infected men that showed a VL range 37 to 6,435 copies/cell from swabbed 
intra-anal warts and that used HPV VL methodology similar to this thesis 
(Kreuter et al., 2006); Table 3.5.  The highest VLs in the warts studied herein 
are seen in two anal warts from an HIV infected individual - 16,353 and 59,722 
copies/cell.  These levels are higher than genital HPV VLs identified previously; 
Table 3.5.  However, in a study of cutaneous warts, a HPV 27 VL of 348,086 
copies/cell was observed; Table 3.5 (Kohler et al., 2009).  Several explanations 
may account for the high VLs, such as: use of fresh tissue, efficiency of q-PCR 
technique or the patient’s immunodysfunction. 
 
Two groups of cutaneous warts are also categorisable by genital HPV VL copy 
numbers: high and low 
Firstly, as expected, the genital VLs in cutaneous warts are predominantly low; 
section 3.5.9.  However, unexpectedly, three cutaneous warts (examples 1-3, 
section 3.5.9)  have  HPV 6  VLs >361   copies/cell,  consistent  with  being  the 
  
Table 3.5 Selected studies quantifying genital and cutaneous HPV viral loads (VLs) in 
warts.  The ranges of genital HPV VLs identified in previous studies were similar to those 
seen in the present study; see also Figure 3.11.  Abbreviations: AIN – anal intra-epithelial 
neoplasia; min – minimum; max – maximum; ns – not specified; ts – type specific.  * - total 
HPV copy number only was available - viral load (per cell) was not calculated by authors. 
possible causative HPV type.  Two other individuals (examples 4 and 5, section 
3.5.9) have lesions with genital HPV levels of between 1-10 copies/cell as 
mixed infections with other HPV types; it is less likely (but still possible) that 
genital HPVs are causative. 
 
HPV 6 was identified previously as the probable causative HPV type in one 
cutaneous lesion described in a single case report (Blauvelt et al., 1992) but in 
the few studies that examined genital HPVs in cutaneous warts there was little 
attempt to address probable causation.  However, some insight was gained 
from examining the results of two large (n>200) studies of cutaneous warts.  A 
low prevalence of mixed HPV infections was seen in both studies - the 
implication being that HPV types identified were likely to be causative (Iftner et 
al., 2003; Hagiwara et al., 2005).  Both investigations confirmed that a small 
proportion (3-4%) of cutaneous lesions may be caused by genital HPVs and 
that HPV 6 and 16 were the commonest types.  In the HIV infected cohort with 
cutaneous warts described by Porro et al. (2003), HPV 6 was identified in 8% 
(2/25); in healthy individuals the corresponding figure was 7% (1/14).  For the 
cutaneous warts studied herein, the genital HPV detection rates are similar: 3% 
(3/107) of warts are probably related to genital HPVs and a further 2% (2/107) 
are possibly related to genital HPVs; HPV 6 is most frequently identified. 
 
Therefore, in contrast to dogma, the tropism of genital HPVs may not be as 
specific as previously thought. This is supported by the comprehensively typed 
cutaneous wart cohorts described above (Iftner et al., 2003; Hagiwara et al., 
2005) and also by case studies/series of children with genital HPVs at 
cutaneous sites (Cohen et al., 1990; Blauvelt et al., 1992).   Genital HPVs can 
proliferate at cutaneous sites in contrast to the conclusions previously drawn by 
others (Nuovo et al., 1991).  
 
 Low beta HPV VLs characterise the warts studied herein and are comparable 
to previous studies  
Beta HPV VL copy numbers are predominantly below the limit of detection or 
<0.01 copy per cell; Figure 3.11.   The  range  of  VLs studied are in accord with 
previous studies; Table 3.6.  
 
Table 3.6 Selected studies quantifying beta HPV viral loads in skin lesions.  Studies were 
selected that used similar beta HPV quantification techniques to the system used in this thesis.  
Abbreviations: AIN-anal intra-epithelial neoplasia; AK – actinic keratosis; BD – Bowens disease 
(of the skin); BCC – basal cell carcinoma; EV - Epidermodysplasia verruciformis; FFPE – 
formalin fixed, paraffin embedded; Fresh - fresh frozen; PCIS – penile carcinoma in situ; SCC – 
squamous cell carcinoma.  * - the mean beta HPV VL is 4.2 copies/cell but only two values are 
greater than 1 copy/cell (see text).  
In non-EV patients, the upper limit in previous studies was 50 copies/cell, 
(Weissenborn et al., 2005); beta VLs are probably higher in EV patients 
(Dell'Oste et al., 2009).   In plucked hairs and other “skin lesions” the range was 
reported as 0.002 to 5 copies/cell (Weissenborn et al., 2009a).  This suggests 
that low levels (for example <1 copy/cell) of beta HPVs may be ubiquitously 
detected in situations where they are ‘passengers’ on the skin and do not cause 
apparent disease (Hazard et al., 2007).  Beta HPVs have also been identified 
frequently in OTRs, in low HPV VLs (Kohler et al., 2009), similar to the picture 
observed herein.  
 
Two warts have high beta VL levels and are exceptions; section 3.5.9 and 
Figure 3.11. Both examples are from HIV infected individuals – one is a biopsy 
from an EV-like eruption on the face and another is a curettage specimen of a 
penile wart with mild histological dysplasia.  They are now discussed further 
below. 
 
EV-like eruptions in HIV infection  
EV-like eruptions, such as the clinical presentation outlined in Appendix 2.2.5 
have been reported in HIV infected individuals (Jacobelli et al., 2011) and in 
other immunosuppressed patients including OTRs, lupus and lymphoma 
patients (Barzegar et al., 1998).  Predominantly, HPV 5 and 8 beta HPV types 
have been identified in EV lesions, such as in the case herein; section 3.5.9. In 
two patients with congenital (or childhood-acquired) HIV infection and an EV-
like eruption, an EVER2 gene mutation was identified, that is also associated 
with the disease EV (Hohenstein et al., 2009; Burger et al., 2010).  It remains to 
be seen whether there are other immunological or immunogenetic 
predispositions (such as HLA) to account for beta HPV related disease 
(Barzegar et al., 1998).  Testing this patient for mutations in EVER genes might 
provide further insights.  
  
Beta HPVs at high VLs may unusually generate (non-EV-like) warts  
Beta HPVs are not usually considered to be pathogenic in healthy individuals.  
However, HPV 5 has previously been identified as the sole infecting HPV type 
in 1-2% of cutaneous warts from the general population; this was the case for 
2/213 and 1/69 of cutaneous warts from the cohorts of Hagiwara et al., (2005) 
and Chen et al., (1993), respectively; Appendix Table A1.2.  The mildly 
dysplastic penile wart described in section 3.5.9 (14.g or C14T1; Figure 3.11) 
may be related to HPV 8 with a VL of 36 copies/cell.  However, an explanation 
for these findings is that another (unidentified) type is causative. 
 
 
3.8 SUMMARY 
 
A summary of the findings of the comprehenisve HPV typing performed for this 
study can be found in Table 3.7 (and Tables 3.5 and 3.6 for HPV VL data). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.7 Summary of cutaneous, genital and beta HPV typing performed. Percentages 
do not total 100% as multiple types have been identified in some lesions.  Bold type indicates genital 
HPV prevalence in cutaneous warts or the prevalence of HR genital HPVs in genital warts.  
Abbreviations: b - beta HPV type; c – cutaneous wart associated type; g – genital HPV type; FFPE – 
formalin fixed paraffin embedded. 
HIV infected cases with warts are demographically different from healthy cases 
from two aspects.  Firstly, HIV infected cases are all males and almost always 
MSM (p=0.002) and secondly, HIV infected cases are older than healthy cases 
(medians 44 and 40 years respectively; p=0.02).  HIV infected patients have a 
long duration of HIV infection (median 14 years), a moderately high median 
CD4 T-cell count of ~500 cells/µl and a median CD4 T-cell nadir of ~140 
cells/µl.  Collectively, HIV infected and healthy cases have a long median 
duration of wart disease (around 3.0 years).   
 
The main findings of cutaneous HPV typing are: 
• HPV 1 is completely absent from both HIV infected and healthy cohorts; 
• HPV 2 is less common in (2% of) HIV infected individuals, compared with 
(27% of) healthy cases (p=0.0004);  
• HPV 7 is found in (21% of) HIV infected individuals but not at all in 
healthy individuals (p=0.001).  This adds weight to the assembled 
evidence to date (published case reports, case series and a small cohort 
of HIV infected individuals) that HPV 7 is important in HIV infected 
patients.  The facial/head wart predominance in HIV infected individuals 
suggested in previous reports is mirrored herein; 
• cutaneous warts that are HPV negative or harbour unusual HPVs (that is, 
non-HPV 2/27/57 types) occur more frequently in HIV infected cases, 
than healthy cases (p=0.03) and 
• cutaneous HPVs are found in a high proportion (between a quarter and a 
half) of all genital warts.   
 
The main findings for genital HPV typing are: 
• HPV 6 has been identified more often in warts from healthy than HIV 
infected cases (85% compared with 30% of individuals, respectively, 
p=0.002).  Studies conducted to date support this finding, with a overall 
predominance of HPV 6 in genital warts from the general population;   
• HPV 11 is commoner in HIV infected individuals and is found in 47% of 
genital warts compared with 10% of healthy individuals, (borderline 
p=0.15; pc=0.05); this finding contrasts with the predominance of HPV 6 
in healthy cases and the general population. However, the number of 
genital warts examined herein are small and HIV infected and healthy 
individuals may constitute separate sexual populations.  Studies 
published to date have suggested recurrent genital warts might harbour 
HPV 11 more frequently; 
• HR genital types are seen only in HIV infected genital warts (none 
harboured HPV 16); overall, this is infrequent compared with previous 
studies in HIV;  
• genital HPV types are seen in around a quarter of cutaneous warts, 
mostly in low copy numbers but some (n=5) warts harbour genital HPVs 
in high levels.  Therefore, cutaneous and genital HPVs may be more 
ubiquitous than previously thought and might (at least partially) resemble 
the situation for beta HPVs. 
 
The principal findings for beta HPVs are: 
• the prevalence of beta HPVs in warts from healthy cases is at the upper 
end of the spectrum for previous studies (49%) but is comparable with 
those that utilised a similar, highly sensitive beta HPV assay;    
• beta HPVs are detected with a higher prevalence in cutaneous warts 
from HIV infected individuals than healthy individuals (80% compared 
with 57%; p=0.02), analogous to previous data from OTRs; 
• the most important finding for beta HPVs is that the number of beta HPV 
types in cutaneous warts is higher in HIV infected individuals than in 
healthy individuals; a median (IQR) of 3 (0-8) beta HPV types per lesion 
are seen in HIV infected individuals compared with 1 (0-3) type per lesion 
in healthy cases (p<0.0005). 
  
The principal finding relating to mixed HPV infections in cutaneous warts is: 
• mixed HPV infections involving cutaneous and beta HPVs are commoner 
in cutaneous warts from HIV infected patients than healthy individuals 
(p=0.03, p=0.01, respectively).  
 
The range of genital HPV VLs is wide and reflects three distinct groups of warts:  
• cutaneous and genital warts in which genital HPVs are found in low levels 
(<1 copy/cell) suggesting that they are passenger HPVs rather than true 
infecting types;  
• genital warts that harbour genital HPVs in high copy numbers (>1 
copy/cell), sufficient imply causation; 
• cutaneous warts that similarly harbour genital HPV VLs in high levels.   
 
The main finding for beta HPV VLs are: 
• the majority of warts have beta HPV VLs below the limit of detection; 
• two warts have ‘high’ beta HPV VLs (>1 copy/cell); both are from HIV 
infected individuals (one had an EV-like eruption). 
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CHAPTER 4: HLA TYPING 
 
 
4.1 INTRODUCTION 
  
In this chapter the results and analysis of HLA typing are reported and 
discussed.  Four subject groups were available; section 2.1. 
 
(i) Firstly, HIV infected cases with warts, derived from individuals fulfilling the 
following stringent criteria: 
• persistent warts for ≥6 months; 
• Caucasian parentage and 
• ART ≥1 year with HIV VL fully suppressed ≥6 months (HIV infected 
individuals only). 
 
In addition to the 30 individuals that met these criteria (section 3.2 and 
Appendix Figure 3.8), another 19 HIV infected individuals provided blood for 
HLA typing (but not wart tissue); Figure 4.1. These additional individuals had a 
medical history and/or clinical evidence of HPV disease but did not have warts 
amenable to biopsy at the time of review, or declined biopsy.  Therefore, the 
total number of HIV infected cases available for HLA molecular analysis is 49; 
Figure 4.1 and Appendix Table A4.1. 
 
(ii) Secondly, 36 healthy cases with warts were available (section 3.2 and 
Appendix 3.8) in addition to 6 healthy cases who provided blood only (without 
corresponding wart tissue); the total number of individuals available for analysis 
is 42; Figure 4.1 and Appendix Table A4.1. 
 
(iii) Thirdly, a group of HIV infected controls (without warts) has also been 
recruited.  These indviduals fulfilled the above criteria, outlined in (i), except that 
they did not have warts; the number available is 46; see Appendix Table A4.2. 
 
	  (iv) HLA typing data from UK Caucasian reference populations has been used 
to compare with these three groups; section 2.1. 
 
 
 
 
 
 
 
 
 
 
Figure 4.1 Selection of the subjects for molecular HLA typing analysis. Caucasians have 
been included in the molecular HLA analysis, as before; HIV infected and healthy subjects 
with warts for ≥6 months were included.  Appendix Figure 3.8.  HIV infected controls are 
individuals that have had no previous or a short (<3 month) history of cutaneous or genital 
warts.  Individuals falling into the classifications indicated in the uppermost boxes have been 
excluded from the HLA molecular analysis.  Abbreviation: VL – HIV viral load.  
 
	  4.2 HEALTHY CASES 
 
The characteristics of healthy cases have been discussed previously; see 
section 3.3 and Appendix 3.9. 
 
 
4.3 HIV INFECTED SUBJECTS: ART USAGE 
 
Around a quarter of HIV infected patients are on non-preferred or second line 
ART regimens 
ART usage HIV infected cases and controls has been collated the same way as 
for the HPV typing analysis (All and HLA groups); section 3.4.  The percentages 
of HIV infected cases and controls taking standard first line regimens 
(2NRTIs/2PIs or 1NNRTI) are slightly higher than in section 3.4; 71% or 35/49 
and 85% or 39/46, respectively (p=0.18 Yates’ chi squared test).  The number 
of HIV infected cases taking other regimes is similar to controls, as defined in 
section 3.4 (p=0.2, Yates’ chi-squared test).  The ‘other regimens’ that HIV 
infected cases had been taking at the time of recruitment into this study 
included two individuals taking two PIs alone – lopinaivr/ritonavir (n=2) and one 
indivdual taking each of the following regimens: 
• emtricitabine, darunavir/ritonavir (1NNRTI, 1 boosted PI); 
• lamivudine, didanosine, tenofovir, abacavir and atazanavir/ritonavir 
(4NRTIs, 1 boosted PI); 
• etravirine, darunavir/ritonavir and raltegravir (1NRTI, 1 boosted PI, 1 new 
drug); 
• emtricitabine, tenofovir, fosamprenavir/ritonavir and maraviroc (2NRTIs, 
1 boosted PI, 1 new drug); 
• abacavir, tenofovir, etravirine and raltegravir (2NRTI, 1NNRTI, 1 new 
drug); 
• emtricitabine, tenofovir, etravirine and raltegravir (2NRTI, 1NNRTI, 1 new 
drug) and 
• emtricitabine, tenofovir, darunavir/ritonavir and raltegravir (2NRTI, 1 
boosted PI, 1 new drug). 
	  In the HIV infected control group one individual had been prescribed each of the 
following  ‘other regimens’: 
• abacavir, didanosine, tenofovir, efavirenz, timpranavir/ritonavir (3NRTIs, 
1NNRTI, 1 boosted PI); 
• lamivudine, darunavir/ritonavir (1NRTIs, 1 boosted PI); 
• lamivudine, saquinavir/lopinavir/ritonavir (1NRTIs, 2 boosted PIs) and 
• abacavir, lamivudine, atazanavir and raltegravir (2NRTIs, 1 unboosted  
PI, 1 new drug). 
 
Six HIV infected cases and four HIV infected controls are possibly HIV slow 
progressors/long term survivors, defined as before section 3.4.    The median 
duration of HIV infection in these six individuals is  23 years.  Two HIV infected 
cases with chronic hepatitis B and two with hepatitis C infection have been 
identified in the HIV infected control group; as defined before, section 3.4.   
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Figure 4.2 HLA molecular analysis: ART treatment in HIV infected cases and controls.  
‘Other regimens’ are fully defined in the text; patients taking raltegravir, maraviroc or 
enfuvirtide have been allocated to the ‘other regimen’ category.    Abbreviations: Inf – 
infected; NRTI - nucleoside reverse transcriptase inhibitor; NNRTI - non-nucleoside reverse 
transcriptase inhibitor; PI - protease inhibitor, including darunavir.  * -  individuals taking a PI 
boosted with ritonavir were collated as taking 1PI; those taking unboosted atazanavir were 
also collated as taking 1PI. 
 
 
 
 
	  	  4.4 HLA MOLECULAR ANALYSIS 
 
HLA ‘strings’ have been collated by allele groups  
Molecular HLA data has been reported as a standard ‘string’ consisting of two 
fields, as defined by the manufacturer of the assay used (One Lambda); see 
section 2.11, Appendix 2.3 and Figure 1.5 for HLA nomenclature.  HLA results 
reported this way require interpretation of the likely allele and this is dependent 
on the individual’s ethnicity and haplotype, although predominantly it is 
straightforward.  Occasionally, the string may contain two common alleles in a 
population.  For example the string: HLA-C*16:01/02/08 might indicate the 
presence of HLA-C*16:01 (phenotype frequency 9.1%) or HLA-C*16:02 
(phenotype frequency 0.7%), or HLA-C*16:08 (rare); HLA-C*16 phenotype 
frequency derived from the “North West England” population, 
www.allelefrequencies.net as before; section 2.2.3 [last accessed 1st April 
2012].  Although the former (HLA-C*16:01) is 13 times more common than the 
latter (HLA-C*16:02) in this population, the two cannot be distinguished without 
further high resolution HLA testing.  Therefore, for the purpose of this analysis, 
alleles have been analysed by the first field (that is, ‘HLA-C*16’).  Consequently, 
this limits the array of allele groupings, reduces statistical testing and increases 
the number in each allele group.  Hereafter, the term ‘allele’ will apply to both 
the allele group (denoted by the first field) and the allele sub-group, denoted by 
both the first and second fields.  
 
Phenotypic allele counting has been performed: homozygotes contribute one 
allele  
The HLA analysis has been conducted using a simple technique called allele 
counting; the number of individuals who have each allele has been tabulated; 
Tables can be found in Appendix 4.2.  There are two ways homozygous 
individuals for a given HLA locus could be analysed.  Firstly, a genotypic 
analysis could be performed whereby homozygous individuals contribute two 
alleles to the total of the allele count; therefore, the total allele count at that 
locus will equal 2n (or twice the number of individuals).  Alternatively, a 
phenotypic analysis counts a homozygous individual only once towards the 
	  allele total.  The total allele count in this situation will be <2n (the difference is 
the number of homozygotes who contribute only one allele count towards the 
allele total).  A phenotypic analysis gives a more accurate reflection of the effect 
of the allele in a population because there is no ‘dosage effect’ of two alleles in 
homozygotes. Therefore, it is preferable to use a phenotypic analysis (Professor 
Steven Marsh, Anthony Nolan Histocompatibility Laboratories, London, UK, 
personal communication).   
 
For each allele phenotypic allele count data are available for reference 
populations, as before; section 2.2.1.  The allele count from each group has 
been calculated from the given phenotype frequency percentage; Appendix 
Figures A4.3a-f. 
 
4.4.1 HLA molecular analysis: subject characteristics 
 
Subject characteristics are similar in HIV infected cases and controls 
HIV infected cases and controls are similar in terms of: sex distribution, years of 
HIV infection/ART, HIV infection risk factors, current CD4 T-cell count and CD4 
T-cell count nadir; Table 4.1.  HIV infected controls are older than both HIV 
infected and healthy cases but this is of borderline statistical significance; 
median (IQR) 49.5 (44-56) years compared with 45 (41-53.5) years and 
compared with 40.5 (31.8-52.3) years, respectively (p=0.05 and p=0.06, 
respectively, Mann-Whitney U test).   
 
HIV infected individuals are all male and almost all report MSM as a risk factor 
for HIV 
HIV infected and healthy cases are significantly different (as before; section 
3.5.1) for sex (HIV infected cases are all male) and for HIV risk factors (HIV 
infected cases were predominantly MSM); Table 4.1.  The median (IQR) wart 
duration is comparable for HIV infected and healthy cases; 4.0 (1.8-9) years 
compared with 3.5 (1.4-5) years in HIV infected cases (p=0.42, Mann-Whitney 
U test).  
 
	   
 
 
 
 
 
 
 
 
Table 4.1 HLA molecular analysis: patient characteristics.   Statistical significance has 
been calculated by Mann-Whitney U test for non-parametric data (or Yates’ chi-squared test 
for categorical data - marked with *).  Statistically significant associations  (p<0.05) are 
highlighted in pale yellow. Abbreviation: Inf – infected 
 
 
	  4.4.2 HLA molecular analysis: interim analysis  
 
Interim analysis: HLA-DQB1*06 is more common in HIV infected controls  
Firstly, an interim HLA analysis was performed before completion of 
recruitment, including 31 HIV infected cases and 17 HIV infected controls.  
These data have been presented as a poster at the annual meeting of the 
Society of Investigative Dermatology, Montreal, Canada (2009); Appendix 4.3.  
The analysis was conducted by phenotypic allele counting and the statistical 
significance at each allele calculated by categorical tests, with a Bonferroni 
correction (multiplication of the p value by the number of tests performed at 
each locus).  HLA-DQB1*06 was identified more commonly in HIV infected 
controls than in HIV infected cases, but this is not statistically significant after 
Bonferroni correction (p=0.03, Yates chi-squared; pc=0.17, Bonferroni 
correction).  Other alleles that were (non-statistically significantly) more 
common in HIV infected cases than HIV infected controls are: HLA-B*35, HLA-
C*05 and HLA-DRB1*03. 
 
4.4.3 HLA molecular analysis: loci charts  
 
Final analysis: the HLA-B*44 group of alleles are found more frequently in HIV 
infected individuals with HPV disease  
Next, a final analysis has been conducted using all available subjects.  The 
allele count distributions for each of the loci HLA-A, -B, -C, -DRB1 and –DQB1 
are displayed as bar charts (Figures 4.3-4.7) and the phenotype allele 
frequencies can be found in Appendix 4.2.   Although HLA allele testing at the 
three loci: HLA-DRB3, -DRB4 and -DRB5 has been performed, no analysis of 
these loci has been done.   This is because the allele variation is limited (one to 
three alleles at each locus), many individuals lack these loci altogether and 
close linkage disequilibrium to the HLA-DRB1 locus means any significant 
observations made at these loci should also be observed at -DRB1.  
 
The loci charts (Figures 4.3-4.7) have been reviewed with an HLA expert 
(Professor Steven Marsh, Anthony Nolan Histocompatibility Laboratories, 
	  London, UK, personal communication).  There are two major findings.  Firstly, 
as illustrated in Figure 4.4, HLA-B*44 is identified in 47% (23/49) of HIV infected 
cases but only 17% (8/46) of HIV infected controls (p=0.004, Yates’ chi-squared 
test); Appendix Table A4.5.  The HLA-B*44 allele distribution is also statistically 
significantly different between HIV infected cases and the reference population; 
47% or 23/49, as above, compared with 32% or 1608/5024 (p=0.04 Yates’ chi-
squared test).  The HLA-B*44 allele count for healthy cases is intermediate 
between HIV infected cases/controls: at 33% (healthy cases) and similar to the 
reference population (32%).  After Bonferroni correction for multiple testing, the 
differences noted above no longer reached statistical significance (pc=0.54 and 
pc=1.0, respectively).  
 
HLA-C*05 may predispose to HPV disease in HIV infection 
The second finding from the loci charts (Figure 4.5) is that HLA-C*05 appeared 
to be commoner in HIV infected cases than in HIV infected controls; 33% 
(16/49) and 9% (4/46), respectively (p=0.009, Yates’ chi-squared test, pc=0.59 
Bonferroni correction); Figure 4.5.  The difference in HLA-C*05 between HIV 
infected cases and controls and the reference population is not significant; 33% 
and 9% compared with 22% (525/2420), respectively (p=0.05, p=0.10, Yates’ 
chi-squared test); Appendix Table A4.5.  HLA-B*44, -C*05 are in linkage 
disequilibrium (Professor Steven Marsh, Anthony Nolan Histocompatibility 
Laboratories, personal communication) and may be an important haplotype. 
 
HLA-DQB1*06 is found more frequently in HIV infected controls 
The other alleles identified in the interim analysis have also been re-examined.  
No statistically significant differences are seen in HIV infected cases and 
controls for HLA-B*35 or HLA-DRB1*03; Appendix Table A4.5.  HLA-DQB1*06 
is increased in HIV controls 61% (28/46) compared with HIV infected cases 
43% (21/49) but this is not statistically significant (p=0.12, Yates chi-squared).  
This allele is also increased in HIV infected controls compared with the 
reference population; 61% (28/46) compared with 42% or (74/177), respectively 
(p=0.03, Yates chi-squared; pc=0.8, after Bonferroni correction); Appendix Table 
A4.5.   
	   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3 HLA-A allele count distribution.  HIV infected cases (n=49), HIV infected 
controls (n=46), healthy cases (n=42) and a reference population (n=5024) have been 
examined.   Abbreviations: +case - HIV infected case with warts; +control – HIV infected 
control without warts. 
	   
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4 HLA-B allele count distribution. HIV infected cases (n=49), HIV infected 
controls (n=46), healthy cases (n=42) and a reference population (n=5024) have been 
examined. Abbreviations: +case - HIV infected case with warts; +control - HIV infected 
control without warts.  * - indicates an allele at which a comparison between groups is 
statistically significantly different (p<0.05). 
	   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5 HLA-C allele count distribution. HIV infected cases (n=49), HIV infected controls 
(n=46), healthy cases (n=42) and a reference population (n=2420) have been examined.  
Abbreviations: +case - HIV infected case with warts; +control - HIV infected control without 
warts.  * - indicates an allele at which a comparison between two groups is statistically 
significantly different (p<0.05). 
 
	   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6 HLA-DRB1 allele count distribution.  HIV infected cases (n=49), HIV infected 
controls (n=46), healthy cases (n=42) and a reference population (n=5024) have been 
examined. Abbreviations: +case - HIV infected case with warts; +control – HIV infected 
control without warts. 
	   
 
 
 
 
 
 
 
 
Figure 4.7 HLA-DQB1 allele count distribution.  HIV infected cases (n=49), HIV infected 
controls (n=46), healthy cases (n=42) and a reference population (n=177) have been 
examined. Abbreviations: +case - HIV infected case with warts; +control - HIV infected 
control without warts. * - indicates an allele at which a comparison between two groups is 
statistically significantly different (p<0.05). 
	  4.4.4 HLA molecular analysis: Clump analysis  
 
Clump statistical testing did not identify any additional alleles of interest  
Finally, in order to obtain an aggregated probability of a difference at each 
locus, a ‘Clump’ statistical test has been performed by Dr Bernard North, 
(Statistical Advisory Service, Imperial College, London, UK, personal 
communication).  This was performed to reduce testing comparisons between 
subject groups for each allele.  Five group comparisons have been conducted: 
HIV infected cases with HIV infected controls, with healthy cases and with the 
general population; the general population with HIV infected controls and with 
healthy cases.   It had been anticipated that Clump could be used as a 
screening test to identify loci with different allele count distributions; these 
alleles with different distributions have been ‘clumped’ together by the test.  
Subsequently, categorical testing could be used to examine individual alleles. 
 
Three comparisons are statistically significant using Clump; two at HLA-B and 
one at the HLA-DRB1 loci; Table 4.2. However, no further alleles of interest 
have been identified.  The first difference of borderline significance is the 
distribution of HLA-B alleles between HIV infected cases and HIV infected 
controls (p=0.05, Clump aggregated statistic).  This statistic is likely to have 
been produced by the effect of HLA-B*44 (that has already been discussed); 
section 4.4.3 
 
Secondly, statistical significance with Clump has been reached on comparing 
HIV infected controls with the reference population, also at the HLA-B locus 
(p=0.00001, Clump aggregated statistic).  However, this statistic is likely to have 
been produced by one individual who is heterozygous for two unusual alleles 
HLA-B*48 and -B*73.  These alleles are rare in Caucasians and usually 
associated with African heritage (Professor Steven Marsh, Anthony Nolan 
Histocompatibility Laboratories, personal communication).  This individual 
originated from Washington DC, USA, and did not report any mixed parentage – 
however, it is highly likely that this is the case.  Therefore, this result has been 
discarded as clinically irrelevant (despite the p value of p=0.00001).  
	   
 
 
 
 
 
 
 
 
 
 
 
 
 	  
 
 
 
 
 
 
Thirdly, at the HLA-DRB1 locus the comparison of healthy cases with the 
reference population is statistically significant (p=0.04, Clump statistic).  The 
HLA-DRB1*09 and HLA-DRB1*10 alleles have been analysed further.  
However, there is either no statistically significant difference (HLA-DRB1*09, p= 
0.07, Fisher’s exact test) or is only relevant to healthy cases compared with the 
reference population (7% compared with 1.2%, respectively, p=0.01, Fisher’s 
exact test).  Therefore, this Clump statistic has been discarded.  
Table 4.2 Clump aggregate probabilities for each of the alleles for class I and class II 
loci.  Significant (and borderline) comparisons (p≤0.05) are highlighted in grey. 
Abbreviations: +case – HIV infected case with warts; +control – HIV infected control without 
warts. 
	   
4.4.5 HLA molecular analysis: key findings  
 
No statistically significant associations have been identified for HPV disease in 
HIV infection  
In summary, HLA-B*44 is the most important allele of interest identified in this 
study.  It is increased in HIV infected cases with HPV disease compared with 
HIV controls (p=0.004, pc=0.54) and the reference population (p=0.04; pc=1.0).  
HLA-C*05 is also seen with a higher frequency in HIV infected cases (p=0.009, 
pc=0.59).  It is tempting to also include HLA-DQB1*06 as a possible HPV-
protective allele of interest in HIV infected controls (p=0.03, pc=0.8, compared 
with reference population).  However, none of the associations are statistically 
significant after correction.  
 
Haplotype interactions between deleterious and protective alleles, both class I 
and II, may be important  
HLA-B*44 and HLA-C*05 are in linkage disequilibrium and constitute a common 
Caucasian haplotype.  Of the HLA-B*44 positive individuals, 18/49 HIV infected 
cases have the haplotype HLA-B*44, -C*05, whereas 3/46 HIV infected controls 
are HLA-B*44, -C*05 (p=0.001, Yates’ chi-squared; pc=0.07, Bonferroni 
correction).  However, overall this result is not statistically significant, given the 
total number of tests performed. 
 
 Furthermore, the following observation is interesting, although the numbers are 
small: of HLA-B*44, -C*05 positive HIV infected cases, 14/18 lacked the 
(potentially protective) HLA-DRB1*06 allele, but in all (3/3) HIV infected 
controls, the above haplotype was combined with (protective) HLA-DRB1*06; 
4/18 compared with 3/3 (p=0.03, Fisher’s exact test; pc>1.0 Bonferroni 
correction).  No such observation was seen for healthy cases and splitting 
DRB1*06 into DRB1*06:02/03 alleles (see below) abrogated the trend, 
suggesting it is probably not important.  
 
	  The effect of HLA-B*44 appears to be related to the HLA-B*44:02 allele sub-
group  
The HLA-B*44 allele group has been split into allele sub-groups, by 
interpretation from HLA-B strings; Appendix Table A4.6.  In three individuals 
(two HIV infected cases and one healthy case) the allele could not be 
determined without further high resolution HLA testing; these individuals have 
been excluded from the following analysis.  The HLA-B*44:02 allele has been 
calculated to be present in 38% (18/47) of HIV infected cases, whereas only 7% 
(3/46) of HIV infected controls have this allele (p=0.0006, Yates chi-squared 
test, pc=0.04 Bonferroni correction).  The phenotypic allele frequency of HLA-
B*44:02 was 19.1% (57/298) in a UK reference population of Caucasoid blood 
donors (“North West England”, www.allelefrequencies.net, as before) and this 
frequency is statistically significantly different compared with HIV infected 
cases; 18/47 compared with 57/298 (p=0.006, Yates chi-squared test, pc=0.43, 
after Bonferroni correction).  No statistically significant observations have been 
made for HLA-B*44:02 in HIV infected controls or healthy cases, and none have 
been observed for HLA-B*44:03.  However, the corrected p value (as above, 
pc=0.04) should still be viewed with caution given the number of subjects (small) 
and the number of tests performed (great); a value of pc <0.01 or pc<0.001 
(rather than pc<0.05) might be a superior marker of statistical significance.   
 
A trend is seen for the class II allele HLA-DQB1*06 being more prevalent in HIV 
infected controls – a possible HPV-protective effect in HIV infection? 
Previous work had suggested that HLA-DQB1*06:03 may be protective for HPV 
disease but for HLA-DQB1*06:02, previous findings were inconsistent; see 
below and Table 1.8.  Data from this thesis suggest that HLA-DQB1*06 (all 
alleles combined) might be HPV-protective in HIV infection (but this was not 
statistically significant).  No such trend was seen in healthy (non HIV) cases 
with warts, which is difficult to explain.  The distribution of HLA-DQB1*06:02/03 
alleles are not significantly different between HIV infected cases and controls 
(with/without HPV disease), suggesting this allele group is unlikely to be 
singularly important; HLA-DQB1*06:02 was seen in 14/49 HIV infected cases 
compared with 17/46 HIV infected controls and for HLA-DQB1*06:03, the 
	  corresponding figures are: 7/49 compared with 7/46, respectively (p=0.51, 
p=0.71, respectively, Yates’ chi-squared).  These allele sub-groups were 
interpreted from the HLA-DQB1*06 strings, as has been performed for HLA-
B*44 in Appendix Table A4.6. 
 
Homozygosity  
There was no significant difference in the number of homozygous subjects 
studied in this thesis at HLA-A, -B, -C, -DRB1, -DRBQ loci between HIV infected 
cases 41% (20/49), HIV infected controls 43% (20/46) and healthy cases 57% 
(24/42) studied herein (p=0.24, Kruskal-Wallis test). However, three cases (two 
HIV infected cases and one healthy case) are homozygous at four of five loci 
examined and two healthy cases are homozygous at all five loci, but none of the 
HIV infected controls are homozygous at more than three loci. 
 
 
4.5 DISCUSSION  
 
4.5.1 Subject characteristics  
 
Patient characteristics: HIV infected controls are older 
HIV infected cases are younger than HIV infected controls (and this is of 
borderline statistical significance).  However, predominantly, the subject 
characteristics of HIV infected and healthy cases are similar and are unlikely to 
have any bearing on the results presented in this chapter.  
 
Reference population 
The reference populations used have been defined as Western European 
Caucasoid (blood donors from Leeds, UK and individuals from an anthropology 
study from London including primarily English but included Scottish, Welsh, 
Northern Irish individuals).  However, it is possible that a small number of non-
Caucasoid alleles have been included: population ethnic admixing is usual and 
no details of parental/grandparental descent are available.   
 
	  4.5.2 HLA homozygosity  
 
HIV infected and healthy cases are homozygous at more loci  
Although there is no statistically significant difference observed in the number of 
homozygous subjects studied in this thesis, only HIV infected and healthy cases 
are homozygous at four or all (of the five) HLA class I and II loci analysed.  HLA 
heterogeneity may be advantageous to the host organism as it affords many 
opportunities to present antigens (Wang et al., 2002; Ghodke et al., 2005).   It 
may also be important in HPV disease (because HPV is poorly immunogenic) 
and in HIV infection (that directly attacks the immune system, causing 
immunodysfunction).  It has been suggested that HLA homozygosity might 
hasten HIV progression and increase the chance of skin and other cancers 
(Bouwes Bavinck et al., 1991a, Carrington et al., 1999).  Spelten et al., (2004) 
also found individuals homozygous for HLA-DQA1 and HLA-DQB1 loci had a 
(non-statistically significant) propensity for warts (and in particular HLA-
DQB1*03:01 homozygosity).   
 
4.5.3 HLA associations with HPV  
 
HLA class II associations have been identified more frequently for HPV related 
diseases than class I.  This may in part be because molecular testing was first 
established for class II alleles (IARC, 2007).   To recap, the best evidence for 
HPV diseases (cervical and RRP data) suggests a protective effect for HLA-
DRB1*13:01/02, -DQB1*06:03 and inconsistent results (protective, neutral or 
deleterious) for HLA-DQB1*06:02.  Other alleles, such as HLA-DRB1*03:01, 
HLA-DQB1*03:01/02/03, or the haplotype HLA-DRB1*15:01, -DQB1*06:02 
have been found to confer susceptibility; Table 1.8 (Hildesheim & Wang, 2002; 
Gelder et al., 2003; Bonagura et al., 2004). It has been suggested that a single 
HLA allele might confer protection from pathogens but that a combination of 
‘faulty’ alleles may be required to render an individual more susceptible to 
pathogens (Hildesheim & Wang, 2002)  This may explain the relative 
predominance of putative protective genes in cervical cancer. 
 
	  There are no previous HLA class I data concerning HPV disease in HIV 
infection.  Two studies have examined HLA class II in subjects with cutaneous 
warts in immunocompetent individuals (but neglected to test for HLA class I).   
 
Firstly, HLA-DRB1*03 and DRB1*09 were found more frequently in Mexican 
individuals with warts than in the general population and HLA-DR6 was found to 
be protective (Garcia-Corona et al., 2010); the serological type HLA-DR6 (and 
the serological sub-types HLA-DR13, -DR14) relate(s) to HLA-DRB1*13 or -
DRB1*14  alleles (Marsh et al., 2010).  However, the groups tested were 
heterogenous in terms of ethnic descent and some of the findings were 
attributed to the admixture of subjects with Amerindian and European descent.    
 
Secondly, a German study investigated otherwise healthy cases (n=71) with 
HPV 2/27/57 positive cutaneous warts for >18 months and controls (n=92) with 
no history of warts or a wart history spanning <18 months (Spelten et al., 2004).  
A statistically significant increase was seen in HLA-DQB1*03:01 and HLA-
DQA1*03:01 (-DQA1 was not tested in this thesis) in cases compared with 
controls.  This finding is consistent with previous studies in cervical cancer. 
Non-statistically significant trends were also identified for the alleles: HLA-
DQB1*03:02/03, -DRB1*07 and -DRB1*09 (deleterious) and HLA-DQB1*06:03, 
-DRB1*01 and -DRB1*03 (protective).  Homozygotes for HLA-DQA1 and HLA-
DQB1 (particularly HLA-DQB1*03:01) were (non-significantly) more common 
amongst cases.   
 
This previous study of Spelten et al., (2004) used a similar analysis to this 
thesis: a phenotypic “carriership frequency” allele counting procedure was used 
and probabilities were calculated with Fisher’s exact test with a (small) 
Bonferroni statistical correction.  Their study included cutaneous warts that were 
relatively homogenous in terms of HPV types, minimising the influence of HPV 
type specificity, such as has been seen previously with HPV 16 and its variants 
(Hildesheim & Wang, 2002).  One potential weakness of the work of Spelten et 
al. was that, like many of the HPV studies conducted to date (including cervical 
cancer studies), HLA type was determined from wart tissue in affected patients 
	  (but from blood in controls).  It is possible that in some studies tumour-related 
HLA mutations (in cancer studies) may have had an affect on results, but this is 
less likely to occur in wart-affected tissue. 
 
There are few reports describing class I associations in HPV (Hildesheim & 
Wang, 2002).  However, HLA-B*44 was previously correlated, in a small 
number of subjects, with increased progression of HPV 16 related cervical 
dysplasia (Bontkes et al., 1998).  This allele has not been confirmed in other 
cervical cancer studies, that have intimated that HLA-B*15 was protective and 
the haplotype HLA-B*07, -DRB1*03:01 was deleterious (Hildesheim & Wang, 
2002).   
 
4.5.4 HLA associations with HIV  
 
The prevalence of HLA-B*44 observed herein is highest in HIV infected cases 
and lowest in HIV infected controls (47%, 17%, respectively) with intermediary 
levels in the reference population (32%), as might be expected from an 
unselected population.  If HPV is the most important effect, healthy cases 
(prevalence of HLA-B*44; 33%) would be expected to approximate HIV infected 
cases, but this was not the case.  Therefore, this effect may be relevant for HPV 
in the context of HIV infection, because HLA class I associations with HIV 
progression are well established.  HLA-B*27 and -B*57 have most consistently 
association with delayed HIV progression and HLA-B*35 with susceptibility; 
Table 1.9.  
   
The haplotype HLA-A2, -B44, -DR4 has previously been associated with CMV 
related IRAD, in a small number of individuals (Price et al., 2001b); HLA-DR4 is 
equivalent to the allele group HLA-DRB1*04 (Marsh et al., 2010).  However, no 
trend has been observed for the HLA-A*02 allele in the HLA typing results of 
this thesis; Figure 4.3.  
 
HLA mechanisms for HPV disease in treated HIV infection might operate at 
several levels.  Firstly, two viral pathogens are involved.  Predominantly, HLA 
	  class II alleles appear to govern the host response to HPV.  On the other hand, 
HIV progression is principally thought to be HLA class I related.  Alleles 
protective for HIV are thought to generate an effective CD8 T-cell response to 
highly conserved HIV p24 peptide, while deleterious alleles may direct an 
ineffective immune response (Blackwell et al., 2009; Pelak et al., 2011). 
Immune dysfunction due to HIV (treated and untreated) may also be HLA 
dependent. Ultimately, therefore, evaluating HLA related mechanism(s) is 
challenging. 
 
It is possible that the influence of class II alleles on HPV disease (in HIV) may 
be less important than the class I effects on HIV.  One potent class II molecule 
to may be sufficient to present exogenous HPV antigen and trigger an effective 
CD4 (Th1) cell mediated T-cell response; but HPV is known to be of low 
immunogenicity.  The minor role of endogenous antigen presentation by HLA 
class II may also be relevant (Gough & Simmonds, 2007).  Class II HLA 
molecules might affect thymic T-cell education resulting in imbalance between 
active/Th1 or anergic/Th2 responses in HIV infection (Breitburd et al., 1996).  
Thymic function may be of particular importance in ART treated HIV infection 
because of the recognised emergence of naïve CD4 T-cells during immune 
recovery; this ability declines with aging, as does HIV-related prognosis 
(Janeway et al., 2005).  HPV-protective HLA class II alleles may be insufficient 
to prevent  HPV disease in HIV infection and further protective alleles and/or 
fewer predisposing alleles may be necessary (such as haplotype HLA-B*44, -
C*05 in the absence of -DQB1, that is seen in some of the HIV infected cases 
described herein).  In CIN and HPV related cancers, expression of HLA class II 
may be upregulated in epithelial cells and consequently, they can become 
(defective) APCs and result in anergy or a Th2 shift. Therefore, these HPV-
induced modifications may further complicate the picture of HLA in HIV 
infection.   
 
HLA class I expression in HPV infected epithelia may be downregulated by 
HPV, resulting in diminished cytotoxic CD8 T-cell responses in some studies 
(Breitburd et al., 1996; Hildesheim & Wang, 2002).  Therefore, in HPV disease, 
	  evasion of HLA class I mediated killing by NKs during initial interactions with the 
innate immune system and subsequently with CD8+ cytotoxic T cells (Janeway 
et al., 2005) may allow HPV to persist.  This may be especially relevant in HIV 
infection given CD4 T-cell depletion and persistent immune dysregulation 
despite ART.  Strong HIV related CD8 cytotoxic T-cell responses mediated by 
effective class I molecules (such as HLA-B*27, -B*57) appear to be important.  
In contrast to class II effects, HLA class I allele effects on HPV disease may be 
independent of HPV type (Hildesheim & Wang, 2002; Wang et al., 2002).  
 
4.5.5 HLA and killer immunoglobulin-like receptors (KIRs) 
 
HLA-B*44 may have important interactions with killer immunoglobulin-like 
receptors (KIRs) 
The interaction of certain KIR receptors with the HLA-Bw4 cluster (including 
HLA-B*44:02) may influence innate immune responses via KIRs on the surface 
of NK cells and this could be of great clinical interest.  Certain HLA-Bw4 
molecules carry an (isoleucine - Ile) amino acid residue at position 80 located 
on lip of the peptide binding cleft on the alpha-1 helix (such as HLA-B*27:02, -
B*57) - the HLA-Bw4-80Ile group (Barbour et al., 2007).  The HLA-Bw4-80Ile 
group of class I alleles are thought to act as a preferential ligands for inhibitory 
KIR3DL1 and (probably also) activating KIR3DS1 on NK cells.  However, 
another group of alleles, HLA-Bw4-80Thr, characterised by a threonine (Thr) 
amino acid at position 80 (that includes HLA-B*44:02 and HLA-B*27:05/09) also 
act as ligands for inhibitory KIR3DL1, but not activating KIR3DS1 (Martin et al., 
2002; Carrington & Martin, 2006; Pelak et al., 2011).  The activating allele 
(KIRDS1) that promotes killing by NK cells may confer protection in HIV 
infection (Martin et al., 2002; Martin et al., 2007).  Alternatively, it may be 
detrimental in other circumstances, such as herpes associated IRAD, and 
cervical cancer (Price et al., 2001b; Carrington et al., 2005).  However, 
inhibitory KIR3DL1 alleles have also been associated with protection against 
HIV (Martin et al., 2007).  It has been hypothesised that NK education (in the 
thymus or bone marrow) in the presence of these inhibitory KIRs may be 
optimal and result in strong NK responses in the presence of infection (Martin et 
	  al., 2007; Pelak et al., 2011).  The balance and number of activating and 
inhibitory genes may also be important in immune response, as individuals can 
carry varying numbers of KIR alleles (Price et al., 2007; Pelak et al., 2011).  
HLA-C ligands may also interact with other KIRs, specifically HLA-C*05 with 
KIR2DL/KIR2L1 (Carrington & Martin, 2006).  Therefore, although HLA-B*44 
may be one of the ligands that interacts with inhibitory KIRs, HLA-B80Ile alleles 
may be more important.   
 
Some limitations of this investigation and proposals for further work are 
discussed in Chapter 5. 
 
 
4.6 SUMMARY 
 
HLA allele distributions have been examined in HIV infected cases (with warts) 
and controls (without warts) who reported Caucasian parentage. ART usage, 
contemporaneous CD4 T-cell count and CD4 T-cell count nadir are comparable 
between groups.  As before (for the HPV typing results, Chapter 3), HIV infected 
cases/controls are more likely to be male and MSM than healthy subjects. 
 
In summary, several HLA alleles of interest have been identified, although the 
results should be interpreted with caution (despite statistical correction) 
because of the small number of subjects and the large number of comparisons.   
 
The main HLA alleles of interest that emerge from this study are: 
• the HLA-B*44 group: more HIV infected cases with HPV disease have 
this allele than either HIV infected controls without HPV disease 
(p=0.004) or Caucasian bone marrow donors from the UK (p=0.04); 
• the allele HLA-B*44:02 appears to account for the above observation: it 
is present in more HIV infected cases than HIV infected controls 
(p=0.0006) or Caucasian bone marrow donors from the UK (p=0.006);   
• HLA-C*05 has also been seen to have a higher frequency in HIV infected 
cases than controls (p=0.009); 
	  • the allele HLA-DQB1*06 is also of possible of interest: it is increased in 
HIV infected controls (potentially protective for HPV disease), compared 
with Caucasian blood donors from the UK (p=0.03);   
• HLA-B*44, -C*05, as a haplotype, may be associated with HPV disease 
in HIV infected individuals (p=0.001, compared with HIV infected 
controls).   
 
However, correction for multiple testing abolished almost all of the statistically 
significant differences and substantially reduced the p values of the others.  
 
The above alleles of interest suggest a predominant class I effect in 
predisposition and only a moderate, possibly protective, class II effect on HPV 
disease in HIV.  The principal HPV disease associations to have emerged from 
past studies were with HLA class II (in cervical pre-cancer/cancer RRP and 
cutaneous warts).  However, HLA class I is an important influence on HIV 
progression.  Thus, HLA class I also may have an effect on HPV disease in 
HIV.  Recent evidence points to the importance of NK and CD8 T-cell function 
in HPV disease and this may be especially relevant in a CD4 depleted, HIV 
decimated immune system (despite effective ART).  Therefore, further work 
investigating the host genotype (such as HLA class I/II) in HPV disease in HIV 
is required in larger numbers. The host phenotype (such as CD4 Th1/2 
polarisation, HIV CD4 T-cell predominant immune decimation and 
dysregulation, T-reg function, NK cells and/or CD8+ immune responses) may 
also be important. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 5:  
DISCUSSION
CHAPTER 5: DISCUSSION  
 
 
5.1 INTRODUCTION 
 
There are many challenges that HIV dermatology still faces.  One such is HPV-
related cutaneous disease (warts and anogenital pre-cancers and cancers).  
Despite ART, capable of suppressing HIV replication to levels where the virus is 
no longer detectable in the blood, HPV-related diseases still prevail in many 
HIV infected patients.  These individuals with chronic, stable, fully suppressed 
HIV infection still have problematic cutaneous HPV disease despite apparently 
adequate immunorestoration.   
 
To date, cutaneous and genital wart disease has been poorly characterised in 
HIV infected individuals, treated or untreated (although the recent investigation 
of anal canal and cervical HPV disease in this group is illuminating).  Novel, 
validated molecular HPV typing techniques have become available and are 
capable of detecting a broad range of HPV types; 73 HPV types in all; 
cutaneous wart associated, genital and beta HPVs.  These techniques have 
been utilised to characterise HPV diseases in HIV infected and healthy 
individuals.   
 
It is likely that knowledge of the site and lesion specific HPV profile of HIV 
infected patients will be of critical clinical significance for diagnostic therapeutic 
and prognostic purposes.  Examples could include: identification of those with 
wart disease less likely to respond to treatment; highlighting those at increased 
risk of external anogenital pre-cancers and cancers such as of the vulva, penis 
and perianal areas; identification of those at risk of cutaneous BCCs and SCCs; 
or influencing the decision whether HPV vaccination might be indicated (should 
effective therapeutic vaccines become available).  At the inception of this 
investigation, comprehensive HPV typing at this level had not been conducted 
previously in HIV infected or healthy subjects, although one study has 
subsequently documented comprehensively assessed HPV types in OTRs and 
healthy subjects (Kohler et al., 2009).  
 
It has been shown that host immunogenotype may account for some of the 
inter-individual variability observed in HPV diseases (cervical disease, RRP) 
and also for clinical outcome due to HIV infection (HIV progression and IRADs).  
HPV is a common virus and is encountered by most individuals.  Beta HPV 
types are detected in almost all individuals (healthy or otherwise) and genital 
HPVs have been estimated to have infected 80% of human hosts in the general 
population (Koutsky et al., 1988; de Koning et al., 2007).  HIV infection probably 
increases the prevalence of warts and other HPV related diseases, and as 
discussed above, these diseases do not appear to abate with suppressive ART.  
However, many individuals remain disease-free despite presumed HPV 
exposure (widespread seroprevalence and beta HPV detection in the general 
population) whilst others are particularly plagued by these diseases (such as 
the cases examined for this thesis and described in Appendix 2.2). However, 
immunogenotypic influences are unlikely to comprise the entire picture and 
other factors probably are important in HPV disease in treated HIV infection; for 
example as yet unelucidated or unquantified immunodysfunction or variations in 
immune adaptivity (such as thymic generation of naïve CD4 T-cells, and/or 
immunosenescence).  Identification of an immunogenotypic marker such as an 
HLA allele might (a) allow stratification of individuals into high risk/low risk 
groups to better direct treatment (for example, qualification for treatments such 
as laser ablation or immunomodulatory therapies - interferon, or therapeutic 
HPV vaccine); or (b) guide further novel research into the immunopathogenesis 
of HPV in ART treated HIV infected individuals.  Many previously published 
studies have investigated HPV disease, IRAD and HIV but none had examined 
HPV disease in HIV. 
 
The first aim of this thesis was to characterise the viral profile of cutaneous and 
genital wart disease in HIV infected individuals treated with suppressive ART 
using a combination of HPV typing methods.  It was hypothesised that the HPV 
profile of HIV infected subjects’ warts might differ from that of otherwise healthy, 
presumed HIV negative subjects; section 1.7. The HPV typing results have 
been presented in Chapter 3.  
 
The second aim of this thesis was to investigate whether host immunogenotypic 
variables might account for some of the inter-individual variation in HPV 
diseases seen in treated HIV infected persons (and that HLA might represent 
such a marker).  It has been postulated that host immunogenotype (in this work 
HLA genotype distribution) in HIV infected subjects with persistent/emergent 
wart disease on suppressive ART might be different from those without wart 
disease; section 1.7.  Further comparisons have been drawn from the HLA 
typing data of a cohort of healthy individuals with HPV disease and from the 
general population, unselected for HPV disease.  The results of this work can 
be found in Chapter 4. 
 
To the author’s knowledge, this is the largest study to date of cutaneous warts 
in HIV infected individuals.  It is also the most comprehensive, using a 
combination of three sensitive HPV typing assays to identify 73 different HPV 
types.  One other study investigated cutaneous HPV disease in HIV infection 
but examined smaller numbers and used less sensitive HPV typing (Porro et al., 
2003).  Thorough HPV typing of informative numbers of cutaneous warts from 
immunocompetant individuals (and OTRs) has been conducted in only one 
other recent study (to the author’s knowledge) but used relatively insensitive 
cutaneous/genital typing techniques (PCR and sequencing) with a similar beta 
HPV assay and had a low sensitivity to detect a probable causative HPV type in 
only 63% of warts (Kohler et al., 2009).  In this thesis, a probable causative 
HPV type  is identifiable in 95% of cutaneous warts and the same percentage of 
genital warts; section 3.1 and Appendix 3.5.    
 
Others have examined genital warts in HIV infected males (Sanclemente et al., 
2007; Muller et al., 2010; Firnhaber et al., 2011).  Although the number of 
genital warts included herein is small, HPV typing data of these adds to our 
knowledge of genital warts in HIV infection.    
 
The principal findings are now examined for HPV typing and HLA typing.  
 
 
5.2 HPV FINDINGS IN ART TREATED HIV INFECTION  
 
Overall, it has been found that the HPV profile is different in ART treated HIV 
infected subjects compared with healthy subjetcs.  These differences are 
summarised below. 
 
HPV 7 is associated with cutaneous warts in HIV infection  
HPV 7 is found in around a quarter (21%) of cutaneous warts in HIV infected 
persons, but not at all in healthy subjects (p=0.001) and this is statistically 
significant after correction for subjects with multiple warts (pc=0.008, Fisher’s 
exact test).   
 
This is an important finding, confirming (a) case reports in HIV infection that 
have suggested HPV 7 may be important in oro-facial warts (section 1.2.1 and 
Appendix Table A1.3) and (b) the findings of one previous case-control study of 
warts in HIV, that identified HPV 7 in one hand wart (of 25) examined (Porro et 
al., 2003); Table 1.3, sections 1.2.1 and 3.7.5.  HPV 7 in HIV infected 
individuals may also thrive at ‘common’ wart sites (because half of the HPV 7 
positive cutaneous warts were from the hands and feet; the other half were from 
the face/scalp/neck).  This is in contrast to healthy individuals where HPV 7 has 
previously been shown to cause warts in the groin, toe webs and in certain 
circumstances such as so-called ‘butcher’s warts’ on the hands of meat and fish 
handlers; Appendix Table A1.1, and sections 1.1.4 and 3.8.5 (Ritzkowsky et al., 
2001; Matsukura et al., 2010; Sun et al., 2010).  Immunodysfunction may be 
important.  HPV typing of other HIV infected cohorts is required to substantiate 
the finding herein.  HPV 7 is not thought to be carcinogenic. 
 
An excess of beta HPVs in cutaneous warts from HIV infected subjects 
suggests that photoprotection is important in Caucasian HIV infected patients to 
reduce skin cancer risk 
A higher proportion of HIV infected individuals’ cutaneous warts than healthy 
cases’ warts are (a) beta HPV positive (80% compared with 57%, respectively; 
p=0.02) and (b) seen to carry an excess of beta HPV types as mixed infections; 
the median (IQR) number of HPV types was 3 (0-8) compared with 1 (0-3) 
types, respectively (p<0.0005); section 3.5.8.  However, the beta HPV levels 
are predominantly low (beta HPV VL copy numbers below the limit of detection 
or <0.01 copy/cell).  There is no difference in the prevalence of beta HPVs in 
genital warts between HIV infected and healthy subjects. 
 
These data suggest that in cutaneous (that is, non-genital) sites an excess of 
beta HPVs is found in warts from the HIV infected individuals.  However, it is not 
likely that these beta HPVs are directly causing warts, at such low  copy 
numbers.  It is possible that beta HPV types might act indirectly or 
synergistically with cutaneous wart types to, for example, generate a wart.  The 
excess in beta HPV types in HIV infected persons is similar to the situation in 
OTRs, although HIV infected individuals are probably intermediate between 
OTRs and healthy individuals, both in terms of the detection of beta HPV types 
and NMSC risk. This excess of beta HPV types could be postulated to be 
related to immunodysfunction (analagous to OTRs) or be to be due to the 
number of close contacts or lifetime sexual partners (such as may be the case 
for genital HPVs) – the latter situation is unlikely because beta HPVs are 
probably ubiqitous (Antonsson et al., 2000; de Koning et al., 2007) 
 
The exact role of beta HPV types in NMSC remains controversial; section 1.1.5.  
Beta HPVs may be more relevant in OTRs who have a much higher risk of 
NMSC.  In OTRs the risk of NMSC is 50-100 times that of the general 
population, whereas in HIV infected individuals it is three to five times the 
population; section 1.2.  A potential mechanism has been proposed: beta HPVs 
may inhibit UVB induced apoptosis and DNA repair through p53/Bak protein; 
section 1.1.7 (Sterling, 2005; de Koning et al., 2007).  Work on the role of beta 
HPVs in skin cancer (including in HIV NMSC) is ongoing.   
 
The proposed link between beta HPVs and NMSC might have clinical 
implications.  The precautionary message is that sun protection is probably 
important in Caucasian HIV infected patients. HIV infected patients that are at 
highest risk of NMSC with a susceptible phototype, also often lead a sun-loving 
lifestyle with subsequent photodamage.  
 
At the time of the inception of the work in this thesis, HPV typing techniques 
that identified beta HPVs in non-invasively sampled normal skin (plucked hairs, 
forehead swabs) were in development.  The excess of beta HPVs detected in 
cutnaneous warts should also be correlated with normal skin biopsies and/or 
plucked hairs for HIV infected and healthy subjects.  This might help determine 
whether the excess of beta HPV types is an isolated phenomenon in warts from 
HIV infected individuals or whether there is an increase in skin carriage in these 
patients.  
 
HPV 11 appears to have a predilection for genital warts in HIV infected 
individuals and HPV 6 is less common 
HPV 11 is identified more frequently in the genital warts from HIV infected 
cases (47% compared with 10% in healthy cases).  However, this is only of 
borderline statistical significance after correction for multiple lesions, (p=0.15, 
pc=0.05).  On the other hand, HPV 6 is detected more often in genital warts 
from healthy individuals, and this is statistically significant; 85% (17/20) 
compared with 30% (5/17) of HIV infected individuals (p=0.002, pc=0.006).   
 
Although too few genital warts have been studied herein to draw definite 
conclusions, these data suggest that HPV 11 may be an important cause of 
genital warts in HIV infected individuals. The results of others have suggested 
either a higher distibution of HPV 11 related warts in HIV infected patients 
(Brown et al., 1999), similar distributions of HPV 6 and 11 (Sanclemente et al., 
2007; Nunes Mde et al., 2008) or a slightly higher prevalence of HPV 6 
(Firnhaber et al., 2011), but not the overall predominance of HPV 6 that has 
been seen in general population studies (Greer et al., 1995; Beutner et al., 
1998; De Marco et al., 2001; Vandepapeliere et al., 2005; Aubin et al., 2008; 
Wang & Qiao, 2008; Chan et al., 2009; Barzon et al., 2010; Anic et al., 2011; 
Ball et al., 2011).  Therefore, in genital warts, HPV 11 may be an important HPV 
type in HIV infected individuals, in contrast to HPV 6 that is the principal type 
usually seen in the general population. 
 
Further studies of genital warts in HIV infected patients that are controlled for 
sexual activity and draw from contiguous sexual populations are required to see 
if (a) HPV 11 might be increased in other HIV infected cohorts, or (b) anal warts 
and HPV 11 are linked (or if MSM is a confounding factor for the data presented 
herein), or (c) if HPV 11 might be found in recurrent warts, such as was seen in 
the (largely) HIV infected subjects of D’Ambrogio et al. (2009).  There are no 
data to suggest that HPV 6 or 11 is more likely to cause rare (HPV 6/11 related) 
verrucous anogenital SCCs.  However, in immunosuppressed individuals with 
aggressive metastasising Buschke-Lowenstein related SCCs, HPV 11 has been 
identified (Manias et al., 1989; Handisurya et al., 2009). 
 
Unusual cutaneous HPV types may be seen in cutaneous warts from HIV 
infected subjects 
Cutaneous warts from healthy subjects are more likely to harbour common 
cutaneous HPV types (HPV 2/27/57) than warts from HIV infected subjects 
(90% compared with 71%, respectively, p=0.03).   
 
Although one explanation might be that there are more HPV negative 
cutaneous warts in HIV infected subjects, this is not the case herein (HPV 
negative warts in HIV infected cases compared with healthy cases, p=0.72).  
This phenomenon appears to be related to the excess of unusual HPV types in 
HIV infected subjects, such as HPV 7 (see above), and HPV 3/10 (usually 
linked with plane/flat warts) and others such as HPV 4, 28, 43, 63 and 95.  
Variation in HPV type might also occur in different ethnic groups; controlling for 
ethnicity reduces the number of subjects but does not abrogate the trend (91% 
and 76% HIV infected and healthy subjects, respectively, p=0.11).  The clinical 
significance of these more unusual HPV types is not known.  
 
In both HIV infected and healthy individuals, HPVs may cross-infect genital and 
cutaneous sites  
To summarise, there are several points that demonstrate cross-infection of 
HPVs occurs between cutaneous and genital sites.  Firstly, a proportion (14%) 
of individuals with persistent warts studied herein reported HPV related disease 
at both cutaneous and genital sites, and predominantly these were HIV infected 
individuals (p=0.02).  Some concordance of HPV types between cutaneous and 
genital sites has been seen.  Secondly, a proportion (around a quarter) of 
cutaneous warts harbour genital HPVs and around a third of these are positive 
for HR genital HPVs, in low copy numbers. Thirdly, a proportion of cutaneous 
warts (5/107) have genital HPVs with very high VLs that are consistent with 
causation.  Lastly, a similar situation is apparent for genital warts where 
cutaneous HPVs are found in a high proportion (between a quarter and a half) 
of the genital warts that have been studied herein. These findings are not 
confined to HIV infected individuals. 
   
This investigation is probably the first to type HPV genital and cutaneous warts 
with new highly sensitive comprehensive assays that identify most of the 
clinically important HPV types.  The results suggest that HPV tropism may be 
less specific than thought historically. ‘Cutaneous’ HPVs have been detected in 
a high proportion of the genital warts studied herein.  It cannot be implied that 
cutaneous HPVs are involved in the causation of genital warts from the results 
of this work, because: (a) cutaneous HPV VL assays were not available (b) only 
one genital wart has been seen to harbour a cutaneous HPV in the absence of 
genital HPVs and (c) there are too few genital warts in the study.  However, the 
identification herein of cutaneous HPVs in genital warts is corroborated by 
previous data: genital wart cohorts, case series of children with genital warts 
and swabs from normal genital skin (D'Ambrogio et al., 2009; Barzon et al., 
2010; Hernandez et al., 2011); Appendix Table A1.5.  
 
On the other hand, the proposition that genital HPVs may cause cutaneous 
warts and be widely present on cutaneous skin is supported by the results 
summarised above and by previous work where genital HPVs were found in (7-
15%) of cutaneous warts in cohorts of individuals from the general population 
(Chen et al., 1993; Iftner et al., 2003; Meyer et al., 2003; Porro et al., 2003; 
Hagiwara et al., 2005; Kohler et al., 2009), and in swabs from fingers taken from 
subjects with genital warts (Sonnex et al., 1999); Appendix Tables A1.1-1.2.  
 
Although sample-to-sample cross-contamination (during wart harvesting or DNA 
extraction) might account for the results herein, the body of evidence from the 
work of others suggest it is a true finding.  Therefore, the skin may also be a 
reservoir for genital and cutaneous HPV types, not just for the well documented 
beta HPV types.   
 
Therefore, should clinicians alter what they tell patients?  Could one ‘catch’ 
genital warts from common warts (assuming these are predominantly 
cutaneous wart HPV related), and might cutaneous warts be ‘caught’ from 
genital warts (again, assuming genital warts are caused by genital HPVs) - or 
are HPVs ubiquitous?  The majority of warts appear to adhere to the old adage 
of HPV type related site-specificity. However the answer appears to be that 
cutaneous warts can be spread by auto-innoculation from genital sites (but 
these are in the minority).  Moreover, it is likely to be the case that individuals 
harbour low levels of HPVs in many body sites, perhaps representing latent 
infections (Doorbar, 2005) sections 1.1.2 and 1.3.2.  The patient is another 
factor - certain individuals appear to be predisposed to developing HPV-
mediated keratinocyte proliferation (that is, warts) after encountering new HPV 
types or the reactivation of latent infections.  This predisposition may be in part 
due to immunogenotypic factors, such as an individual’s HLA constitution.   
  
 
5.3 HLA ASSOCIATIONS AND THEIR IMPLICATIONS 
 
HLA-B*44:02 is identified more frequently in HIV infected ART treated 
individuals with warts than in controls. 
Our attention has been drawn to several alleles of potential importance.  HLA-
B44* (p=0.004, pc=0.54) and specifically HLA-B*44:02  (p=0.0006, pc=0.04) are 
seen more often in HIV infected ART treated cases with warts, than in similar 
HIV infected ART treated controls without warts (47% compared with 17% for 
HLA-B*44; 38% compared with 7%, for HLA-B*44:02, respectively). The 
difference in the prevalence of the HLA-B*44:02 allele is also greater in HIV 
infected cases than Caucasoid blood donors; 41% compared with 19% of 
n=258 (p=0.006, pc=0.43).  
 
However, these associations should be viewed with caution given the small 
number of subjects and the large number of statistical tests performed; a 
corrected p value of p<0.01 or p<0.001 (rather than p<0.05) might be a superior 
marker of significance.  HLA-C*05 and the haplotype HLA-B*44, -C*05, are 
similarly seen more frequently in HIV infected cases (p=0.009, pc=0.59 and 
p=0.001, pc=0.07). To a lesser degree the (potentially protective) allele HLA-
DQB1*06 is increased in HIV infected controls, compared with the reference 
population (p=0.03, pc=0.8), but no increase is seen in HIV infected controls 
compared with HIV infected cases. 
 
The number of subjects analysed in this thesis is too small to draw any definite 
conclusions.  However, the emergent alleles of interest do fit within the context 
of previous work; Table 1.8 and 1.9.  The progression of HIV infection has been 
extensively studied, given the clinical importance of identifying susceptibility 
markers.  HLA-B*27 and -B*57 have been most consistently associated with 
delayed HIV progression and HLA-B*35 with susceptibility; Table 1.9.  Recent 
work suggests that the HLA-Bw4 group of alleles (of which HLA-B*44 is one) 
may influence the function of the NK receptors, KIRs, in HIV infection (Martin et 
al., 2002; Martin et al., 2007).  However, alleles such as HLA-B*27:02, HLA-
B*57 (rather than HLA-B*44) are preferential ligands for the KIRs 
KIR3DL1/KIRDS1 and therefore, the effect of weaker ligands such as HLA-B*44 
may be clinically insignificant.  It is possible that the allele of interest, HLA-
B*44:02, is not related to HPV disease at all and is seen in more HIV infected 
cases than controls because HPV disease itself is a marker of HIV disease 
progression (that is not reflected in the congruity of cases/controls for variables 
such as duration of HIV infection, contemporaneous CD4 T-cell count, CD4 T-
cell count nadir, slow progressor status).  Although the class II allele HLA-
DQB1*06 is of dubious importance herein, others have suggested that it may be 
protective in other HPV related diseases such as cervical cancer/pre-cancer 
and RRP (Hildesheim & Wang, 2002).  Subject recruitment for HPV and HLA 
analysis is ongoing and the results obtained from this extended cohort may be 
revealing. 
 
 
5.4 STUDY LIMITATIONS  
 
Several limitations have been identified relating to the characterisation of the 
HPV profile of warts in ART treated HIV infection, and to the determination of 
the immunogenotypic HLA influence on this disease. 
 
Patients: definition of clinical phenotype. 
Firstly, limitations were encountered in the definition of a clinical phenotype. 
‘Grey cases’ (such as subjects with warts for 3-6 months) have been excluded; 
it may be interesting to examine these cases post hoc.  For uniformity, a single 
CD4 T-cell count (within 3-6 months of recruitment) has been used to measure 
contemporaneous immunosuppression.  However, collating CD4 T-cell counts 
(from the previous year, or from the time of HIV diagnosis, for example) may 
have increased the precision of this value.  Although CD4 T-cell count is a 
relatively poor marker of immunosuppression, both contemporaneous and 
historical measurements are available, enabling characterisation of the degree 
of maximal immunosuppression. CD4 T-cell count nadir is a relatively 
inaccurate indicator of the immunological ‘bottleneck’ of immunosuppression, 
but was the only such indicator available historically.  
 
Tissue: HPV ‘causation’ of warts  
In the work described in this thesis, HPV type specific DNA VL assays have 
been chosen to generate data on the relative importance of multiple HPVs 
detected in warts.  Protocols for a cutaneous HPV VL assay were not available 
at the commencement of this research.  However, a method has subsequently 
been published; characterisation of the VL of cutaneous wart associated HPV 
types might provide greater insight into the nature of cutaneous HPVs (Kohler 
et al., 2009).  As a semi-quantitative substitute HSL-PCR/MPG Luminex MFI 
data has been used herein to infer a hierarchy of importance of HPV types in 
some warts, but this is an imperfect measure of causation (Schmitt et al., 2011).  
However, wart ‘causation’ is difficult to ascertain with accuracy even with HPV 
DNA VL data and an additional method of quantification, such as HPV RNA VL 
(Ball et al., 2011); section 3.5.9.  For these reasons the HPV analysis has been 
performed on the basis of all of the HPV types identified (not the probable 
causative HPV); see also Appendix 3.3.3.  Variability in the HPV DNA VL assay 
may lead to inaccuracies, if too many uninfected cells (normal keratinocytes) or 
cellular material with degraded DNA (for example, derived from the stratum 
corneum) are sampled; this upsets the ratio of viral DNA compared with host 
DNA.  Other techniques that might have been employed to provide additional 
information  (although they also have disadvantages) include:  
• laser capture microdissection preferentially to sample virally infected cells 
(disadvantages: markedly lowered DNA yields and time consuming); 
• HPV expression data from HPV mRNA VLs using q-PCR 
(disadvantages: hazardous in non-fixed HIV infected tissue and yields 
from FFPE tissue are poor); 
• in situ hybridisation (disadvantages: time consuming and relatively non-
specific)  
 
Subject numbers  
HLA associations are difficult to identify unless studies have been performed in 
a large number of subjects; for example n>1000 (Wang et al., 2005).  The 
strategy employed here to identify possible HLA disease predispositions has 
been wide, with a large number of comparisons necessitating large Bonferroni 
corrections. The relatively small number of subjects available for HLA analysis 
necessitated combination of (a) cutaneous and genital wart disease, and (b) 
warts with a wide array of HPV types.  A HLA analysis separating cutaneous 
and genital disease might have been illuminating. However, the investigation 
described herein is a foundation for an exploration of the role of host 
immunogenetics in HPV disease in HIV infection. 
 
Caucasoid ethnicity  
Purely mono-ethnic populations are difficult to obtain.  Even detailed information 
concerning parentage is insufficient; such as the unexpected appearance of 
non-Caucasian alleles amongst HIV infected controls; section 4.4.5.  Control 
populations with a similar admixture are helpful.   
 
HLA complexity and disease susceptibility markers 
The nature of the HLA locus complicates the identification of any disease 
susceptibility marker from several respects.  Firstly, class I loci HLA-A, -B, -C 
are closely linked with class II loci HLA-DRB1/DQB1 (Gough & Simmonds, 
2007).  Alleles within a haplotype may have a supplementary effect 
(susceptibility/resistance) on any given disease.  Neutral HLA alleles/loci in 
linkage disequilibrium with disease association alleles may muddy the waters.  
Allele predisposition can only be intelligently applied to the same background 
population in which it was identified, because an allele can confer protection in 
one population but might have unpredictable consequences in another 
depending on the background frequency of the haplotypes and alleles 
(Blackwell et al., 2009).  
 
Secondly, HLA genes have a close proximity to other immune genes and non-
immune genes from the MHC complex (such as complement, TNF or 
lymphotoxin genes) and an association may indicate linkage to another gene 
rather than a direct effect; interpretive caution is therefore advised (Blackwell et 
al., 2009).   
  
Thirdly, it is possible that an important disease association allele has been 
missed in this study because allele sub-types (for example HLA-B*44:02/03/05) 
have been grouped together at the first field (HLA-B*44).  Some alleles sub-
types are known to associate with divergent disease influences, for example: 
HLA-B*27:01/04/05 predispose to ankylosing spondylitis but HLA-B*27:06/09 
are protective (Gough & Simmonds, 2007).  In most populations one allele is 
usually dominant in an allele group.  Therefore, it is unlikely that a significant 
disease association has been missed in this work.  The logic of not splitting 
allele groups into sub-groups (that are based on the same amino acid 
sequence) has been discussed above in section 4.1: low subject numbers, 
multiple testing and the difficulty of resolving of ambiguous strings (with further 
molecular testing or selection of the allele sub-group based on known 
population allele frequencies).  
 
 
5.5 FURTHER WORK  
 
The following are areas that might be investigated to elucidate the pathogenesis 
of HPV in HIV infection. 
 
Histology and immunohistochemistry of warts in HIV infection 
Is there a histological or immunohistochemial fingerprint of distinctive cytopathic 
features in warts from HIV infected patients?  Work is underway to examine the 
prevalence of EV-like and HPV related cytopathic features (such as 
koilocytosis, hypergranulosis, papillomatosis) and the pattern of 
immunohistochemical staining (for example CD4 and CD8 markers, CD16 for 
NK cells and CD1a for LCs).  These results could also be correlated with HPV 
typing.  
 
Cutaneous HPV DNA VLs  
Are cutaneous HPV VLs higher in HIV infection?  These data would 
complement those already available for genital/beta HPV VLs and the semi-
quantitative MFI analysis from the HSL-PCR/MPG assay.  
 
The cytokine milieu in viral warts  
Is there altered cytokine expression in the HPV affected epidermis of HIV 
infected warts that allows hyperproliferation of keratinocytes and allows 
continued propagation?  Expression of cytokines (such as interferons, TNF-
alpha, IL-1a, IL-1b, IL-12) and HPV genes (for example L1, E6/7) could be 
characterised by mRNA q-PCR in fresh warts from HIV infected and healthy 
patients and unaffected, site matched skin (Arany & Tyring, 1996; Arany et al., 
2000) 
Peripheral blood immunophenotype and HPV-related immune responses 
Is there an alteration in the systemic immune response of HIV infected 
individuals with warts that might predispose to HPV related pathology? Does 
this relate to immune tissue responses in warts?  Peripheral blood 
immunophentypic data (for example CD4/8, CD4+/CD25+/Foxp3+, CD16, CD1a) 
and HPV-related immune responses measured perhaps by IFN-gamma ELIspot 
or proliferation assays could help identify if there is a defect in the HPV directed 
immune response in HIV infected patients.   
 
Characterisation of HPV serology in treated HIV infected and in healthy subjects 
Is reactivation or exposure (or both) responsible for HPV disease in HIV 
infected individuals?  HPV typing data of persistent warts could be correlated 
with cutaneous HPV type serology in HIV infected cases with cutaneous warts, 
healthy cases with warts and controls.   
 
Non-melanoma skin cancer in treated HIV infection  
How important are beta HPVs in NMSC in HIV infection?  Given the greater 
number of beta HPV types in treated HIV infection identified herein, elucidation 
of the aetiopathogenic role of genital/beta HPV (+/-cutaneous HPV types) in 
(non-melanoma) skin cancer in treated HIV infection could be clinically useful.  
Any such study should consider confounders such as UV exposure and beta 
HPV carriage rate in normal skin.  This work is in progress. 
 
KIR genes and HPV in HIV infection 
Do KIR genes play a role in the pathogensis of HPV in HIV infection?  The 
KIR3DL1 locus could be tested in cohorts of patients described herein to 
determine the presence and copy numbers of activating KIR3DS1 and inhibitory 
KIR3DL1 alleles.  Stratification might also be employed for class I ligand 
functional subgroups, such as the HLA-Bw4 subgroups HLA-Bw4-80Ile and 
HLA-Bw4-80Thr. 
 
Directed exploration of HLA in newly identified HIV infected cohorts  
Can the finding of an association with HLA-B*44:02 be confirmed in another, 
larger, cohort of Caucasian HIV infected individuals with HPV disease?  This 
cohort could also be stratified for genital and cutaneous disease. 
 
Genome studies of HPV disease in HIV infection  
Can the influence of HLA on HPV disease in HIV infection be confirmed through 
other genetic approaches?  Strategies might include a genome wide survey 
(GWAS), genome wide linkage, or functionally directed single nucleotide 
polymorphism genome studies and might determine if the trends noted herein 
are confined to HLA loci or to closely linked regions.  Such approaches have 
recently identified findings of clinical relevance for cervical cancer, diabetes and 
rheumatoid arthritis (Pociot et al., 2010; Wang et al., 2010; Raychaudhuri et al., 
2012).  However, large numbers of subjects (thousands) are required.   
  
HPV type and HLA specificity 
Does HPV type have an influence on HLA associations in HIV infection?  
Greater numbers of individuals with HPV related diseases would allow further 
work to stratify individuals by HPV type. Data collection is ongoing.  As outlined 
above, humoral immunity (section 1.3.1) may be HPV type specific and HLA 
dependent responses may be related to (and specific for) HPV type (Hildesheim 
& Wang, 2002).  Although the number of subjects included in this thesis is too 
few to draw any conclusions, the data herein have been segregated by 
cutaneous HPV type to look for trends.  However, there did not appear to be 
any differences in the HLA alleles of HIV infected and healthy subjects with 
warts who were segregated for common (HPV 27/57) or unusual (HPV 
3/7/72/95) cutaneous HPV types. Therefore the trend from these data herein 
suggests that HPV type may not be important. 
 
 
 
5.6 CONCLUSIONS  
 
This is the first work to HPV type cutaneous and genital warts from a cohort of 
HIV infected, ART treated individuals using a combination of three modern, 
sensitive and comprehensive assays.  It is also the first investigation into a 
possible immunogenotypic aetiopathogenesis of HPV disease in HIV, by 
examining HLA allele distributions.  
 
The HPV profile of warts does appear to be different in HIV infected, ART-
treated cases compared with healthy cases, supporting the first stated 
hypothesis of this study; section 1.7.  Cutaneous warts in HIV infected subjects 
are characterised by unusual HPV types (than healthy subjects).  The most 
important is HPV 7 and next, to a lesser extent, HPV 3 and 10.  HPV 11 has 
been detected more frequently in genital warts from HIV infected patients, 
rather than HPV 6, that is usually the predominant type found in genital warts 
from the general population.  The most important clinical finding is that beta 
HPV types are found in excess in cutaneous (but not genital) warts from HIV 
infected individuals, compared with healthy individuals; an increased proportion 
of warts are beta HPV positive and they harbour an increased number of beta 
HPV types.  Beta HPVs have been postulated to be involved in the 
aetiopathogenesis of NMSC, although this is controversial.  However, 
highlighting sun protection advice to light skinned HIV infected patients is 
important given the high rate of NMSC in this group of Caucasians.  More 
studies are required to confirm these findings. 
 
Extrapolation of some of the findings herein to the clinical problem of warts in 
the general population may be possible, particularly that HPVs have been seen 
to cross-infect genital and cutaneous sites.  This is supported by previous work 
and suggests that HPV may be less tropic than has been acknowledged 
historically.  More work is required to examine cutaneous/genital HPV cross-
infection and presence in normal skin. 
 
The most important HLA allele group to emerge from the study herein is HLA-
B*44 and specifically HLA-B*44:02  (or a closely related gene).  However, the 
number of subjects in this study is too small to establish a significant 
association with disease and it has not been possible to definitively prove the 
second stated hypothesis; section 1.7.  Therefore, further work is required to 
corroborate this putative relationship.  Potential mechanisms have been 
proposed such as an HLA effect on thymic generation of naïve CD4 T-cells or 
immunosenescence and one such interaction with KIRs probably merits further 
investigation.    
 
To conclude, the above findings indicate that HPV disease in HIV infected ART 
treated patients is different from healthy patients in terms of the HPV types 
seen.  It has also been shown that HLA (or a closely related gene) may 
influence this disease.  Further investigation in greater numbers of subjects is 
warranted to substantiate these findings.  
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APPENDIX 1.1 
HPV TYPES OF CUTANEOUS WARTS FROM THE GENERAL POPULATION 
 
 
Selected published HPV typing studies from warts of healthy individuals are 
shown in Appendix Tables A1.1 and A1.2.  Studies have been selected for 
those that included the greatest patient numbers and used broad spectrum HPV 
identification techniques.  Two studies examining HPV typing in cutaneous 
warts in special situations (a) genital HPV typing in cutaneous warts and (b) in 
toe web warts have been presented in Appendix Table A1.1, below.  The 
principal studies of genital warts can be found in Appendix Table A1.2, overleaf. 
 
 
 
 
 
 
 
Group studied 
and reference 
 
Type of 
tissue 
Number of 
lesions 
(number of 
individuals) 
 
Technique of HPV 
identification 
HPV detection 
rate: % HPV 
positive of all 
lesions tested 
 
HPV types identified:  
 % of all lesions tested 
 
Genital HPV types in cutaneous warts 
 
adults and 
children;  
India 
 
(Payal et al., 2006) 
 
cutaneous 
warts 
biopsies 10 
fresh frozen, 
35 FFPE 
 
 
n=45 (45  
individuals) 
 
PCR: consensus 
primers HPVs 16, 18, 
31, 33; type specific 
primers for HPV 16, 
18; direct 
visualization 
 
 
6.6% 
lesions positive 
for HPV 16, 18, 
31 or 33 
 
HPV 16 g 
negative for HPV 
16/18/31/33 
 
6.6% 
 
93.4% 
HPV types in warts from toe web spaces 
 
adults;  
China 
 
 
 
 
 
(Sun et al., 2010) 
 
 
 
 
 
toe web warts 
and common 
warts  
fresh frozen 
wart  biopsies 
 
toe web warts 
n=20 (20  
males) 
 
 
common warts 
n=31 (31  
healthy males 
and females) 
 
 
 
PCR genital and 
cutaneous primers, 
including for HPV 7 
sequencing +/- 
cloning;  
HPV type specific 
primers for HPVs 2, 
4, 6, 7, 11, 16, 18 
 
 
toe web warts 
95% 
 
 
 
 
common warts  
97% 
 
 
HPV 7 c 
HPV 57 c 
HPV 2 c 
HPV 27 c 
HPV 1 c 
HPV 6 g 
HPV 11/16/18 g 
other HPV or  
undetermined 
toe web 
warts 
80% 
nil 
5% 
nil 
nil 
5% 
nil 
- 
 5% 
common 
warts 
16%  
29% 
13% 
13% 
3% 
3% 
nil 
- 
 19% 
Appendix Table A1.1 HPV typing of cutaneous warts in special situations. Percentages do not total 
100% as multiple types were identified in some lesions.  Bold type indicates genital HPV prevalence in 
cutaneous warts.  Abbreviations: b - beta HPV type; c – cutaneous wart associated type; FFPE – 
formalin fixed paraffin embedded;  g – genital HPV type. 
 
 
 
 
  
 
Group studied and 
reference 
 
Type of tissue 
Number of 
lesions 
(number of 
individuals) 
 
Technique of HPV 
identification 
HPV detection 
rate: % HPV 
positive of all 
lesions tested 
 
HPV types identified:  
 % of all lesions tested 
 
adults and 
children;  
UK 
(Tomson et al., 
2011) 
 
cutaneous warts   
parings  (fresh) 
 
n=80 (76  
individuals) 
 
ISH for HPVs 1, 2, 3, 4, 
7, 10, 57 
 
79% of 
lesions 
HPV 2/27/57 c 
HPV 4 c 
HPV 3, 10 c 
HPV 1 c 
inadequate sample 
68% 
5% 
3% 
1% 
3% 
 
adults and 
children; 
The Netherlands 
 
 
 
(de Koning et al., 
2010) 
 
 
 
cutaneous warts  
swabs (fresh) 
 
 
n=100 (100  
individuals) 
HSL-PCR/MPG Ω 
Luminex 
comprehensive 
cutaneous HPV typing: 
same technique as in 
this thesis - see 
Chapter 2  
 
 
96% of 
lesions 
HPV 1 c 
HPV 27 c 
HPV 2 c 
HPV 57 c 
HPV 4 c 
HPV 3 c 
HPV 7 c 
other cutaneous HPVs 
multiple infections 
31% 
31% 
20% 
15% 
5% 
2% 
1% 
3% 
11% 
any cutan HPV c 
HPV 57 c 
HPV 27 c 
HPV 3 c 
HPV 10 c 
63% 
32% 
27% 
15% 
5% 
any β/γ HPV type b 
multiple β/γ HPVs b 
γ HPVs 
49% 
17% 
2% 
immunocompetent 
indivduals; 
Germany 
(Kohler et al., 2009) 
 
SEE TABLE 1.4      
FOR FULL DETAILS 
 
 
 
fresh frozen 
common wart 
biopsies 
 
n=41 (29 
immuno-
competent 
individuals) 
 
for OTRs – 
see Table 1.4) 
comprehensive HPV 
PCR and sequencing 
(cutaneous and genital 
HPVs)  reverse line blot 
for 24 beta/gamma HPVs 
 
SEE TABLE 1.4      
FOR FULL DETAILS 
 
63% lesions for 
cutaneous types 
 
93% lesions 
immuno-competent 
non-OTRs 
(all HPV types) 
 genital HPVs  g 15% 
adults;  
China 
 
(Lei et al., 2009) 
cutaneous wart  
biopsies   
fresh frozen, FFPE 
warts 
 
n=48 (48  
individuals)  
genital primers and 
novel type specific 
primers (HPV 1, 2, 4, 7, 
27, 57, 65) 
 
86% of lesions 
 
HPV 57 c 
HPV 1 c 
HPV 27 c 
HPV 2 c 
31% 
31% 
21% 
10% 
 
HPV 1 c 
HPV 4 c 
HPV 65 c 
HPV 27 c 
HPV 2 c 
HPV 57 c 
HPV 7 c 
HPV 3 c 
other HPVs  
all warts 
44% 
16% 
14% 
6% 
6% 
5% 
0.5% 
0.5% 
3.5% 
plantar warts 
46% 
24% 
12% 
6% 
n/a 
n/a 
n/a 
n/a 
9% 
HPV 5/8 b 
HPV 47 b 
1.4% 
0.5% 
n/a 
n/a 
adults and 
children; 
Japan 
 
 
 
 
 
 
(Hagiwara et al., 
2005) 
 
 
cutaneous wart  
biopsies or    
parings 
preservation not 
specified 
 
 
 
 
n=213 (213 
individuals) 
including 
plantar warts 
n=131 
 
 
 
 
PCR: genital (including 
for HPV 7) , cutaneous 
and beta HPV primers, 
sequencing 
 
 
 
 
100% 
of lesions 
 
 
 
HR genital HPV* 
LR genital HPV** 
3% 
1% 
n/a 
n/a 
 
 
adults and 
children; 
Germany and USA 
 
 
 
 
(Iftner et al., 2003) 
 
 
cutaneous wart  
biopsies   
 
fresh frozen  
 
n=209 (209  
individuals) 
 
n=109 (109  
individuals) 
normal skin 
biopsies (dog 
ears from 
surgical 
excisions) 
 
 
 
PCR: broad spectrum 
(including for HPV 7) 
primers then 
sequencing 
 
 
91% of warts  
 
5% of normal skin 
biopsies HPV 
positive 
(HPV typing 
results not 
shown) 
HPV 1 c 
HPV 27 c 
HPV 57 c 
HPV 2 c 
HPV 10 c 
HPV 4 c 
HPV 65 c 
HPV 7 c 
other 
HR genital HPV* 
LR genital HPV** 
27% 
13% 
12% 
10% 
9% 
8% 
4% 
1% 
8% 
1% 
2% 
HPV 27/57 c 
HPV 3 c 
HPV 2 c 
HPV 7 c 
multiple HPVs 
24% together 
6% 
8% 
10% 
21% 
any β HPV b 31% 
immunocompetent 
warts; 
Germany 
(Meyer et al., 2003)  
               
SEE TABLE 1.4      
FOR FULL DETAILS 
 
 
fresh frozen wart  
biopsies 
 
n=51 (45   
immunocomp
etent  non-
OTRs) 
for OTRs – 
see Table 1.4) 
PCR and RFLP with 
degenerate probes for 
cutaneous/genital 
HPVs  
 
 SEE TABLE 1.4      
FOR FULL DETAILS 
 
94% non-immuno-
suppressed - 
(non OTRs) 
any genital g 10% 
adults and 
children; 
Germany 
 
 
(Rubben et al., 1997) 
 
cutaneous wart  
parings, biopsies   
 preservation not 
specified 
 
 
n=238 (238  
individuals) 
 
 
PCR: 
genital (including for 
HPV 7) and broad 
spectrum primers; 
RFLP 
 
 
95% lesions 
HPV 57 c 
HPV 27 c 
HPV 2 c 
HPV 1 c 
HPV 4 c 
HPV 7 c 
other/unident HPV 
   32%  
                   29%         87% 
   26% 
   3% 
   2% 
   2% 
   3%     
HPV 1 c 
 HPV 2/3 c 
HPV 4 c 
unident HPV 
13% 
7% 
16% 
20% 
HPV 5 b 
HPV 8 b 
2% 
nil 
 
adults and 
children; Taiwan 
 
 
 
 
(Chen et al., 1993) 
 
 
cutaneous wart   
biopsies 
 
fresh frozen warts 
 
 
n=61 (61 
individuals) 
 
 
 
Southern and dot-blot 
hybridization 
(HPV 1, 2/3, 4, 5, 8, 11, 
16, 18 probes) 
 
 
69% lesions 
HPV 11 g 
HPV 16 g 
HPV 18 g 
5% 
2% 
8% 
Appendix Table A1.2 Selected comprehensive HPV typing studies of cutaneous warts from the 
general population. See overleaf for full legend. 
 
 
 
Appendix Table A1.2 Selected comprehensive HPV typing studies of cutaneous warts 
from the general population. Percentages do not total 100% as multiple types were identified 
in some lesions.  Bold type indicates genital HPV prevalence in cutaneous warts. Grey 
highlighting indicates studies included in other tables. Abbreviations: b - beta HPV type; c – 
cutaneous wart associated type; FFPE – formalin fixed paraffin embedded; g – genital HPV type; 
ISH – in situ hybridisation; n/a – data not available; RFLP – restriction fragment length 
polymorphism; unident – unidentified HPV type. * - HR (high risk) HPVs HPVs 16, 31, 33, 56;  ** 
- LR (low risk) genital HPVs HPV 6, 11, 40, 44, 62; Ω – same technique used for this thesis (see 
methods). 
 
 
 
 
 
 
 
 
 
 
 
 
APPENDIX 1.2  
HPV TYPES IN ORAL WARTS  
FROM HIV INFECTED INDIVIDUALS 
 
 
Studies have been selected for those that included the greatest patient 
numbers and used broadest spectrum HPV identification techniques.	  	  
	  	  
	  	  	  	  	  	  	  	  	  	  
 
Type of study and 
reference 
 
Type of tissue 
 
Number of 
lesions 
(number of 
individuals) 
 
Technique of HPV 
identification 
 
HPV detection 
rate: % HPV 
positive of all 
lesions tested 
 
HPV types identified:  
 % of all lesions tested 
 
HIV infected cases; 
USA 
 
 
(Volter et al., 1996) 
 
oral wart biopsies 
 
 
 
fresh frozen 
 
 
n=36 (number 
individuals not 
specified) 
PCR: degenerate and 
multiple broad spectrum  
primers; Southern and 
reverse-blot (HPVs 2, 4, 6, 
7, 13, 16, 18, 32, 40, 59, 69) 
 
 
78% lesions 
 
HPV 7 c 
HPV 32 g 
HPV 6 g 
other HPV 
negative 
 
33% 
31% 
3% 
11% 
22% 
 
HIV infected cases 
Germany, USA  
 
(de Villiers, 1989) 
oral wart and 
cutaneous (facial) 
wart  biopsies 
tissue preservation 
not specified 
 
n=lesions not 
specified  (n=5 
individuals) 
 
Broad spectrum reverse 
blot, Southern blot 
 
80% individuals’ 
warts positive  
(all HPV 7) 
 
HPV 7 c 
other HPVs 
 
80% 
nil 
HIV infected cases; 
USA 
 
(Greenspan et al., 
1988) 
oral wart and flat 
oral wart (FEH)  
biopsies 
tissue preservation 
not specified 
 
 
n=17 (17  
individuals) 
 
 
Southern blot 
 
 
not specified 
HPV 7 c 
HPV 13 g 
HPV 32 g 
HPV 18 g 
other HPV or 
negative 
41% 
6% 
6% 
6% 
- 
41% 
HPV type prevalence in saliva samples 
HIV infected cases - 
67% on HAART;  
USA 
 
 
(Cameron et al., 2005) 
 
saliva samples 
 
fresh 
 
 
n=98 (98  
individuals) 
 
PCR: PGMY09/11 primers 
and Roche linear array‡ 
 
37% 
samples 
HPV 16 g 
HPV 55 g 
HPV 83 g 
other HPV 
unident HPV 
negative 
6% 
5% 
5% 
28% 
8% 
63% 
Appendix Table A1.3 Selected HPV typing studies of oral lesions/saliva samples from 
HIV infected individuals. Percentages do not total 100% as multiple types were identified 
in some lesions.  Bold type indicates genital HPV prevalence in oral warts. Abbreviations: c 
– cutaneous wart associated type; FEH - focal epithelial hyperplasia; g – genital HPV type;  
unident – unidentified HPV type.  
 
APPENDIX 1.3 
HPV TYPES OF CUTANEOUS WARTS  
FROM ORGAN TRANSPLANT RECIPIENTS (OTRS) 
 
Group studied and 
reference 
 
Type of 
tissue 
 
Number of 
lesions 
(number of 
individuals) 
Technique of HPV 
identification 
HPV 
detection 
rate: % 
HPV 
positive of 
all lesions 
tested 
 
HPV types identified: 
% of all lesions tested 
 
 
OTR warts; 
Brazil 
(Martelli-Marzagao et 
al., 2010) 
cutaneous 
wart biopsy: 
preservation 
n/s 
 
n=20 (20 OTRs) 
PCR: 
genital and broad spectrum 
primers; RFLP and sequencing 
 
 
50% 
HPV 2, 57, 34 c 
HPV 27, 29 c 
unident HPV 
any β/γ HPV type b 
10% each 
5% each 
10% 
nil 
 
any cutan HPV c 
HPV 57 c 
HPV 27 c 
HPV 3 c 
HPV 10 c 
OTR 
45% 
2% 
15% 
9% 
4% 
non-OTR 
63% 
32% 
27% 
15% 
5% 
any β/γ HPV type b 
multiple β/γ HPVs b 
γ HPVs 
79% 
62% 
21% 
49% 
17% 
2% 
case control: 
OTR and 
immunocompetent 
warts; 
Germany 
 
SEE ALSO 
APPENDIX TABLE 1.2  
 
(Kohler et al., 2009) 
 
 
fresh frozen 
common 
wart 
biopsies 
 
n=53 (33 OTRs); 
89% renal OTRs; 
others 
heart/lung/both 
 
n=41 (29 
immuno-
competent non-
OTRs) 
 
comprehensive HPV PCR and 
sequencing: BCG-PCR and 
reverse line blot for 24 
beta/gamma HPVs; genital and 
cutaneous warts associated HPV 
primers real time PCR for viral 
loads (HPVs 3, 8, 14, 20, 27, 57 
and HPVs 8, 14, 21, 36). 
91% lesions  
OTRs 
 
93% lesions 
non-OTRs 
(all HPV 
types) - 
63% lesions 
positive 
cutaneous 
types  genital HPVs  g 17% 15% 
any cutan 
HPV c 
HPV 27/57 c 
HPV 3 c 
HPV 2 c 
HPV 7 c 
OTR+IMS* (n=22+8) 
83% 
27% together 
7% 
3% 
nil 
non-OTR 
59% 
24% together 
6% 
8% 
10% 
any β HPV b 
unident β b 
43% 
13% 
31% 
10% 
any genital g 17% 10% 
case control: 
OTR  and  
immunocompetent 
warts; 
Germany 
 
SEE ALSO 
APPENDIX TABLE 1.2  
      
(Meyer et al., 2003) 
 
 
fresh frozen 
wart  
biopsies 
 
 
n=22 (19 OTRs) 
plus n=8 (6 other 
immuno- 
suppressed –
IMS)* 
 
n=51 (45   
immunocompet-
ent  non-OTRs) 
 
 
PCR: combination genital and 
cutaneous primers and RFLP with 
probes; degenerate probes for 
cutaneous and genital HPVs 
 
91% for 
OTRs 
 
94% ICP 
non OTRs 
multiple HPVs 65% (OTRs only) 21% 
cutaneous HPVs 
HPV 57 c 
HPV 2 c 
HPV 10 c 
HPV 29 c 
common w 
22% 
22% 
11% 
11% 
plane w 
nil 
nil 
nil 
33% 
HPV 22,23 b 
HPV 36 b 
HPV 5, 17, 24 b 
HPV 38 b 
22% each 
nil 
11% each 
11% each 
33% each 
33% 
nil 
nil 
OTR warts; 
The Netherlands 
 
 
 
 
 
(Berkhout et al., 2000) 
 
 
 
fresh frozen 
cutaneous 
wart  
biopsies 
 
 
n=12 common 
warts; n=7 plane 
warts 
(n individuals n/s; 
renal OTRs) 
 
 
 
nested PCR: 
multiple cutaneous and beta HPV 
primers , sequencing   
 
(genital HPVs unlikely to be 
detected) 
 
common 
warts: 
75% 
(9 of 12) 
 
plane warts: 
86% 
6 of 7) 
putative new HPVs 
unident HPVs 
33% 
22% 
nil 
67% 
 
HPV 27 c 
HPV 10 c 
HPV 77 c 
HPV 7 c 
HPV 1 c 
HPV 57 c 
other (HPVs 
2,3,4,28,41) c 
all cut HPV c 
OTRw 
35% 
26% 
22% 
17% 
17% 
nil 
- 
35% 
87% 
OTRatw 
32% 
11% 
14% 
nil 
nil 
18% 
- 
50% 
82% 
non-OTR 
nil 
13% 
nil 
nil 
nil 
38% 
- 
38% 
88% 
β HPVs b 78% 86% 13% 
genital HPVs 
(HPV6/11/16) g 
26% 
 
32% 13% (1/8) 
case control: 
OTR and 
immunocompetent 
warts; 
UK 
 
 
 
 
 
 
 
(Harwood et al., 1999) 
fresh frozen 
wart 
biopsies 
n=23 common 
cutaneous warts 
(12 renal OTRs); 
n=28 atw - 
atypical 
cutaneous warts 
- sun exposed 
sites/clinically 
atypical/EV-like 
(15 renal OTRs); 
 
n=8 (6   
immunocompet-
ent non-OTR) 
 
 
comprehensive HPV PCR: 
multiple primers and nested 
protocols for cutaneous beta and 
genital HPVs  
type specific PCR for HPVs 10, 
27, 23, 24 and sequencing 
 
 
 
 
 
 
100% 
 
 
 
 
 
 
 multiple HPVs 87% 96% 13% 
Cutaneous HPVs 
HPV 57 c 
HPV 27 c 
HPV 1 c 
27% 
20% 
20% 
OTR warts; 
UK 
 
(de Villiers et al., 1997) 
 
fresh frozen 
wart  
biopsies 
 
n=15 
(8 renal OTRs) 
PCR and sequencing +/- cloning: 
A,A1, F2-4, F10-12,E, F21-24, B5-
8, B11-12,  HVP2/HVP7, 
HVP2/HVP9 , CP65/CP70, 
CP66/CP69bs 
 
 
80% 
β HPVs: HPV 23 b 13% 
cutaneous HPV 27 c 
HPV 10 c 
HPV 57/28 c 
HPV 29 related c 
13% 
4% 
2% each 
9% 
known β HPVs 
β HPV related (HPV12/15/17/25/49) b 
nil 
13% together 
case control: 
OTR and   
immunocompetent 
warts; 
UK 
 
(Shamanin et al., 1994a) 
 
 
 
 
fresh frozen 
wart  
biopsies 
 
 
 
n=47 
(28 renal OTRs) 
 
 
PCR: broad spectrum PCR  
and Southern blot (probes HPVs 
1, 2, 3, 5, 7, 10, 37, 41) 
 
 
 
60% 
 
 
genital: HPV 6 g 2% 
 
HPV 1 c 
HPV 2 c 
OTR 
Nil 
22% 
non-OTR 
17% 
17% 
HPV 5 b 
HPV 8 b 
17% 
nil 
nil 
nil 
case control: 
OTR and 
immunocompetent 
warts; 
UK 
 
(Stark et al., 1994) 
 
 
fresh frozen 
wart  
biopsies 
n=18 (n renal 
OTRs n/s) 
 
n=6 ( n   
immunocompet-
ent  
non-OTR n/s) 
 
 
Southern blot and PCR with type 
specific primers (for HPVs 1, 2, 5, 
8, 6, 11, 16, 18) 
64% 
OTRs100% 
immunocom-
petent non-
OTR 
HPV 6 g 
HPV 11 g 
7% 
14% 
nil 
nil 
OTR warts; 
France 
 
(Soler et al., 1993) 
wart 
biopsies; 
FFPE, fresh 
frozen 
 
n=18 
(n OTRs n/s; 
renal, cardiac) 
PCR – novel type specific E6 
gene primers HPVs 5, 6/11, 16, 
18; Southern blot and ISH for 
HPVs 1, 2, 5, 6, 11, 16, 18 
 
 
61%  
 
HPV 6/11 g 
other HPV (HPV 5, 16, 18) g 
 
 
22% 
39% 
Appendix Table A1.4 Selected HPV typing studies (and case reports) of cutaneous warts 
from organ transplant recipients (OTRs).  See overleaf for full legend. 
 
 
 
 
 
 
Studies have been selected for those that included the greatest patient 
numbers and used broadest spectrum HPV identification techniques. 
Appendix Table A1.4 continued  
Selected HPV typing studies (and case reports) of comprehensive HPV typing in 
cutaneous warts from organ transplant recipients (OTRs).  Percentages do not total 
100% as multiple types were identified in some lesions.  Bold type indicated genital HPV 
prevalence in cutaneous warts.    Abbreviations: atw – atypical warts; b - beta HPV type; β 
- beta genera HPV types; c – cutaneous wart associated type; cutan – cutaneous HPV; 
FFPE – formalin fixed paraffin embedded; g – genital HPV type; IMS – immunosuppressed 
individuals (other than OTRs); ISH – in situ hybridisation probe; neg – negative for HPV 
DNA; n/s – not specified; RFLP – restriction fragment length polymorphism; unident – 
unidentified HPV type; w – warts; γ - gamma genera HPV types.  
APPENDIX 1.4 
HPV TYPES IN GENITAL WARTS FROM THE GENERAL POPULATION 
 
Group studied and 
reference 
 
Type of 
tissue 
    
Number of lesions 
(number of individuals) 
 
Technique of HPV 
identification 
HPV detection 
rate: % HPV 
positive of all 
lesions tested 
 
genital HPV types identified: 
% of all lesions tested 
 
healthy males;  
Southern USA, 
Brazil, 
Mexico 
 
 
 
 
(Anic et al., 2011) 
 
 
wart swabs,  
healthy 
genital skin 
swabs; fresh 
 
 
n=112 wart swabs (112 
individuals) 
 
 
 
n=2487 skin swabs 
(2487 individuals) 
 
 
 
PCR: single broad 
spectrum  genital 
primers and Roche 
Linear 
Array  
 
 
80% warts HPV 
positive 
 
 
65% healthy 
genital skin 
HPV positive 
HPV 6 
HPV 11 
HPV 62 
HPV 84 
HPV 16 
HPV 18 
HPV 52 
HPV 51 or 66 
multiple infections 
undetermined HPV 
44% 
11% 
10% 
9% 
10% 
4% 
6% 
5% each 
46% 
5% 
immunocompetent 
individuals; 
UK 
(Ball et al., 2011) 
 
wart 
biopsies;  
fresh frozen 
n=31 genital warts  
(31 individuals);  
males and females, 
proportions n/s 
 
Roche Linear 
Array  
 
100% HPV 
positive 
HPV 6 
HPV 11 
any HR HPV 
multiple infections 
90% 
32% 
48% 
71% 
men referred for 
HPV testing; 
Italy 
 
 
 
 
(Barzon et al., 2010) 
swabs from 
penis/peri-
anal area/ 
urethra; 
semen 
samples; 
fresh 
 
adequate skin swabs 
n=947 (947 men)  
 
included n=61 (n=61 
men with anogenital 
warts) 
 
 
 
PCR: two broad 
spectrum genital 
primers 
 
42% of swabs 
skin HPV 
positive 
 
93% wart swabs 
HPV positive 
 
HPV 6 
HPV 16 
HPV 66 
HPV 11 
HPV 10 or 43 c 
HPV 2 or 3  c  
HPV 57 c 
multiple HPVs 
all swabs 
13% 
7% 
2% 
2% 
0.3% each 
0.1% each 
0.1%  
2% 
wart swabs 
67% 
nil 
3% 
8% 
nil 
nil 
nil 
5% 
 
 
HPV 6 
HPV 11 
HPV 16 
HPV 2/27 c 
healthy 
and 
HIV infected 
individuals; 
Switzerland 
 
(D'Ambrogio et al., 
2009) 
 
wart 
biopsies, 
surgically re-
treated if 
recurrent;  
fresh/ FFPE 
 
n=n/s (140 individuals): 
n=105 non-recurrent 
warts, 
n=35 recurrent warts; 
88% male; 
24% HIV infectedƒ 
7% unknown statusƒ 
69% HIV ‘negative’ƒ 
 
PCR:  single broad 
spectrum  genital 
primers and line blot 
for 31 genital HPVs:  
96% HPV 
positive overall 
 
HPV 11 
associated 
with recurrent 
warts (<12 
months) 
HIV infected 
HIVnegative 
non-recurrent 
warts 
65% 
26%* 
5% 
~1% 
85% (28/33) 
69% (67/97) 
recurrent 
warts 
46% 
54%* 
nil 
nil 
15% (5/33) 
31% (30/97) 
adult males; 
Hong Kong 
 
(Chan et al., 2009) 
 
anogenital 
wart (cyto) 
brushings; 
fresh 
 
n=130 (n=130) 
fresh 
PCR:  single broad 
spectrum  genital 
primers and  and 
Roche Linear 
Array  
 
 
96% HPV 
positive 
HPV 6 
HPV 11 
HPV 16 
HPV 18 
multiple HPVs 
~55% 
~41% 
~6% 
~3% 
34% 
non-immuno-
suppressed adults; 
France 
 
 
 
 
(Aubin et al., 2008) 
genital wart 
(cyto) 
brushings: 
vulva, 
perineum, 
penis, 
perianal, 
other; fresh 
n=423 (n=423  
individuals) 
 
immunocompetent, no 
known HIV infection; 
51% males; 
37% history of recurrent 
warts 
 
INNO-LiPA  Ω 
HPV genotyping v2 
test; PCR based 
SPF10 with RHA for 
24 genital HPV types 
 
 
 
99.5% HPV 
positive 
HPV 6 
HPV 11 
HPV 16 
HPV 51 
HPV 52 
HPV 66 
HPV 53 
HPV 31 or 18 
undetermined HPV 
68% 
16% 
9% 
8% 
7% 
6% 
5% 
3% each 
4% 
meta-analysis of 43 
studies 1999-2006; 
China 
 
(Wang et al., 2008) 
fresh/FFPE 
biopsies 
(n=4764) 
 
exfoliated 
cells (n=483) 
n=5247 genital warts 
(n individuals,  
male/female ratio n/s);  
70%/30% 
clinically/histologically 
diagnosed  
variety of techniques: 
HPV type specific 
primers and/or 
universal HPV 
primers 
 
overall 84% 
lesions HPV 
positive 
HPV 6 
(HPV 6 range North-South) 
HPV 11 
(HPV 11 range North-South) 
HPV 40 
HPV 42 
55% 
(60% - 53%) 
41% 
(52% - 38%) 
3% 
2% 
adults with warts in 
HPV therapeutic 
vaccine trial; 
eight countries 
(Vandepapeliere et 
al., 2005) 
 
 
anogenital 
wart 
brushings 
 
n=457 
males 59% 
(including n=142 recent 
warts, n=315 recurrent 
warts) 
PCR: multiple broad 
spectrum genital 
primers EIA; 
reverse line blot, line 
probe assay for HPVs 
6,11,16,18,31,33,35,39,
40,42-5,51,52,56, 58, 
59,66,68 
 
 
100% 
HPV 6 
HPV 11 
any HR type 
no significant difference in 
new/recurrent disease and 
HPV types 
67% 
20% 
40% 
males/females; 
Italy 
(De Marco et al., 
2001) 
 
anogenital 
warts 
 
abstract only  
(n=40) 
 
PCR: single broad 
spectrum genital 
primers and RFLP 
 
 
95%  
 
HPV 6 
HPV 11 
HPV 16 
undetermined HPV or HPV neg 
78% 
18% 
nil 
5% 
adults; 
USA 
 
 
(Greer et al., 1995) 
penile, vulval 
wart and 
non-wart 
skin swabs; 
fresh 
n=37 
 
(n=25/12 
males/females - normal 
cervical smears) 
 
PCR: single broad 
spectrum genital primer 
with 27 type specific 
probes genital HPV 
probes 
 
100% 
 
non-wart skin 
51% 
 
HPV 6 
HPV 11 
other 
warts 
94% 
8% 
30% 
normal skin 
30% 
3% 
16% 
Appendix Table A1.5 Selected genital HPV typing studies of genital warts from the 
general population: data from males and males/females combined. See overleaf for full 
legend. 
 
 
 
 	  	  
Studies have been selected for those that included the greatest patient 
numbers and used broad spectrum HPV identification techniques.	  
 
 
 
 
 
 
 	  
Group studied and 
reference 
 
Type of 
tissue 
Number of lesions 
(number of 
individuals) 
 
Technique of HPV 
identification 
HPV 
detection 
rate: % HPV 
positive of all 
lesions tested 
 
genital HPV types identified:  
 % of all lesions tested 
 
young females in 
control arm of 
HPV vaccine 
study; 
“worldwide”  
(Garland et al., 
2009) 
 
wart 
biopsies, 
swabs;  
preservation 
n/s 
 
 
n=520  incident genital 
warts (n=351 
15-26 year olds) 
 
 
multiplex PCR 
based assay (for 
genital HPVs), +/- 
HPV 6, 11, 16, 18 
type specific primers 
 
91% lesions 
positive 
(n=520) 
 
 
HPV 6 
HPV 11 
HPV 6/11 
HPV 16 
HPV 18 
(n=520 
lesions) 
76% 
13% 
86%  
8% 
5% 
(n=351 
patients) 
74% 
14% 
85% 
n/a 
n/a 
females with 
genital warts, 
cervical, vaginal 
vulval neoplasia; 
USA  
(Reid et al., 1987)  
 
fresh frozen 
biopsies 
 
cervical wart 
specimens n=35  
 
vulval wart specimens 
n=68 
 (n individuals n/s) 
 
Southern blot and 
RFLP probes for 
HPVs 6, 11, 16, 18, 
31 
 
79-93% HPV 
positive (warts, 
low grade 
CIN/VIN) 
 
HPV 6 
HPV 11 
HPV 16 
HPV 18 
untyped  
neg 
cervical warts 
43% 
20% 
3% 
3% 
11% 
20% 
vulval warts 
60% 
18% 
3% 
1% 
10% 
7% 
Appendix Table A1.6 Selected female-only genital HPV typing studies of genital warts 
from the general population. Percentages do not total 100% as multiple types were identified 
in some lesions.  Bold type indicates HR genital HPV prevalence, as defined by Chapter 2 
and/or the study authors. Abbreviations:  n/a – data not available; n/s – not specified RFLP – 
restriction fragment length polymorphism.   
 
 
 
Appendix Table A1.5 continued  
Selected genital HPV typing studies of genital warts from the general population: data 
from males and males/females combined. Percentages do not total 100% as multiple types 
were identified in some lesions.  Bold type indicates HR genital HPV prevalence, as defined 
by Chapter 2 and/or the study authors.  Abbreviations: c – cutaneous wart associated type.; 
EIA - enzyme immunoassay; FFPE – formalin fixed paraffin embedded; n/a – data not 
available; ns – not specified; RFLP – restriction fragment length polymorphism. Ω – 
methodology almost identical to that used in thesis; ƒ – HIV antibody testing not performed 
(HIV status disclosed by patient questionnaire/chart review) and individuals with ‘unknown’ 
status were not analysed for recurrent/non-recurrent disease; * - Yates’ chi squared test for 
significance p=0.004 (highlighted in grey). 
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APPENDIX 2.1 ETHICAL APPROVAL 
 
APPENDIX 2.2 CLINICAL CASES AND HISTOLOGICAL EXAMPLES  
      2.2.1  Acute inflammatory HPV IRAD/IRIS; one case  
      2.2.2  Chronic persistent/emergent HPV disease in HIV; four 
cases (a) to (d). 
      2.2.3  Extensive ano-genital HPV disease  
      2.2.4  Large plantar wart  
      2.2.5  HIV associated EV-like eruption 
      2.2.6  Florid cutaneous/genital HPV disease in HIV infected 
patient with herpes simplex virus related inflammatory 
IRD (on oral prednisolone). 
      2.2.7  Dermis poor and dermis rich warts may have led to 
over or under estimation of HPV viral loads (VLs) 
      2.2.8  Example of the histology of a wart-like lesion (non-wart: 
dermatofibroma) 
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APPENDIX 2.1 ETHICAL APPROVAL 
 
 
The following pages comprise the following: 
• Research ethical approval letters; Riverside Research Ethics Committee 
(2 letters) 
• Study participant consent forms (3 forms) 
• Study participant information forms (3 forms) 
 
 
 
 
 
 
Riverside Research Ethics Committee 
Room 4W/12, 4th Floor West 
Charing Cross Hospital 
Fulham Palace Road 
London 
W6 8RF 
Telephone: 020 8846 7282  
Facsimile: 020 8846 7280 
Professor Christopher Bunker 
Consultant in Dermatology 
Chelsea and Westminster Hospital, NHS 
Dermatology Outpatients Department,  
369 Fulham Rd, London 
SW10 9NH 
 
10 July 2007 
 
Dear Professor Bunker 
 
Full title of study: Immunogenotypic (HLA genotype) and 
Immunophenotypic (including neuro-immunologic) 
Characteristics of Skin Disease in Treated and Untreated 
HIV Infected Individuals. 
REC reference number: 07/H0706/65 
 
The Research Ethics Committee reviewed the above application at the meeting held on 02 
July 2007.  
 
Documents reviewed 
 
The documents reviewed at the meeting were: 
  
Document    Version    Date    
Application  1  19 June 2007  
Investigator CV       
Protocol  1  01 June 2007  
Covering Letter    19 June 2007  
Letter of invitation to participant  1  01 June 2007  
Participant Information Sheet: Archival Samples  3  01 June 2007  
Participant Information Sheet: Controls  2  01 June 2007  
Participant Information Sheet: Patients  1  01 June 2007  
Participant Consent Form: Blood & Tissue (Archive Use)  1  01 June 2007  
Participant Consent Form: Blood Only  1  01 June 2007  
Participant Consent Form: Blood & Tissue  1  01 June 2007  
Letter Regarding Peer Review    19 June 2007  
Letter from Funder / Sponsor    02 April 2007  
Student CV    19 June 2007  
 
Provisional opinion 
 
It was noted that the Scientific Justification and Summary of the Purpose, Design & 
Methodology of the study (questions A9 & A10 of the application) was not written in 
language comprehensible to a lay person.   
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The Committee would be content to give a favourable ethical opinion of the research, 
subject to receiving a complete response to the request for further information set out 
below. 
 
Authority to consider your response and to confirm the Committee’s final opinion has been 
delegated to the Chair. 
 
Further information or clarification required 
 
1. All Participant Information Sheets.  
(a) In the sections titled "Are there any risks associated with being involved in the study?", it 
is stated that there is "a very small risk of loss of privacy". The Committee is of the opinion 
that the privacy and confidentiality of participants ought to be guaranteed. This sentence 
should be removed and the Information Sheets updated to state that privacy of participants 
will be maintained.   
(b) In the section titled "What are the benefits of taking part?" it is stated that participants 
are "unlikely" to benefit from taking part. This section should be reworded to state that there 
are no immediate benefits of taking part but that it may benefit patients in the future.   
2. Archival Samples Participant Information Sheet.   
(a) Paragraph three states that stored samples have the potential to be used as a part of 
the usual medical care of the participant. The committee requests assurance that only the 
minimum amount of tissue required for the purpose of the study will be taken and that the 
use of these samples will not compromise the future care of the participants. The 
information sheet should be updated to reflect this.  
(b) It was noted that the font size used in paragraph three differs from that used elsewhere 
in the document. The formatting ought to be consistent with the rest of the document.   
3. All Consent Forms.   
(a) In the sections relating to participants consenting to having their tissue stored for future 
research, the Committee felt that the use of the word "OK" was too informal. This should be 
rephrased.   
 
When submitting your response to the Committee, please send revised documentation 
where appropriate underlining or otherwise highlighting the changes you have made and 
giving revised version numbers and dates.   
 
The Committee will confirm the final ethical opinion within a maximum of 60 days from the 
date of initial receipt of the application, excluding the time taken by you to respond fully to 
the above points.  A response should be submitted by no later than 07 November 2007. 
 
Ethical review of research sites 
 
 After consideration of the research procedures involved in the study, the Committee 
decided that an assessment should be made locally of the suitability of the investigator, site 
and facilities (“site-specific assessment”).  The lead researcher at each site should be 
designated as the local Principal Investigator. 
 
You should therefore arrange for the Site-Specific Information Form to be submitted to the 
Research Ethics Committee for each site (SSA REC), together with a copy of the local 
Principal Investigator’s curriculum vitae, as soon as possible. In the case of research sites 
outside the NHS, the following should also be provided: 
 
• A copy of the participant information sheet, as submitted to this Committee, on local 
headed paper and incorporating relevant site-specific information including contact 
points 
• Evidence of the PI’s professional registration. 
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• Evidence of insurance or indemnity cover for the PI and where applicable the 
Contract Research Organisation. 
 
SSA RECs have 25 days in which to notify this Committee whether or not there is any 
objection on site-specific grounds.  The Committee would then confirm the favourable 
ethical opinion for each site in writing to you. 
 
Membership of the Committee 
 
The members of the Committee who were present at the meeting are listed on the attached 
sheet. 
 
Statement of compliance  
 
The Committee is constituted in accordance with the Governance Arrangements for 
Research Ethics Committees (July 2001) and complies fully with the Standard Operating 
Procedures for Research Ethics Committees in the UK.  
 
07/H0706/65   Please quote this number on all correspondence 
 
Yours sincerely 
 
 
 
 
Dr Steve Yentis 
Chair 
 
Email: JAMurphy@hhnt.nhs.uk 
 
Enclosures: List of names and professions of members who were present at the 
meeting and those who submitted written comments. 
 
 
Copy to: Joint Research Committee at Chelsea and Westminster 
Hospital(JRC) 
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Riverside Research Ethics Committee 
 
 
Attendance at Committee meeting on 02 July 2007 
 
  
Committee Members:  
 
Name   Profession   Present    Notes    
Dr Mark Atkins  Consultant Virologist  Yes    
Mrs Jane Bruton  Nurse  No    
Mr John Clifford  Lawyer  Yes    
Mrs Claudia Court  Lay Member  No    
Mr  Iain  Davidson  Pharmacist  No    
Dr Gillian Elam  Senior Social Scientist  No    
Dr Michael Feher  Consultant Physician  Yes    
Dr  Jerry Healy  Consultant Radiologist  No    
Dr  Graeme  Moyle  Associate Specialist in 
HIV & GU Medicine  
Yes    
Dr Arghya Sarkhel  Psychiatrist  Yes    
Miss Anna Smajdor  Lay Member  Yes    
Mr Mike Stafford  Consultant 
Gynaecologist  
Yes    
Mr Peter Thomas  Lay Member  Yes    
Dr  Sabita Uthaya  NeoNatologist  Yes    
Dr Steve Yentis  Consultant Anaesthetist  Yes    
  
Also in attendance:  
 
Name   Position (or reason for attending)   
Mr James Murphy  Co-ordinator  
  
Written comments received from:  
 
Name   Position   
Mr  Iain  Davidson  Pharmacist  
 
 
Riverside Research Ethics Committee
Room 4W/12, 4th Floor West
Charing Cross Hospital
Fulham Palace Road
London
W6 8RF
Telephone: 020 8846 7282 
Facsimile: 020 8846 7280
Professor Christopher Bunker
Dermatology Outpatients Department, 
Chelsea and Westminster Hospital
369 Fulham Rd, London
SW10 9NH
02 August 2007
Dear Professor Bunker
Full title of study: Immunogenotypic (HLA genotype) and 
Immunophenotypic (including neuro-immunologic) 
Characteristics of Skin Disease in Treated and 
Untreated HIV Infected Individuals.
REC reference number: 07/H0706/65
Thank you for your letter of 19 July 2007, responding to the Committee’s request for further 
information on the above research and submitting revised documentation.
The further information has been considered on behalf of the Committee by the Chair.
Confirmation of ethical opinion
On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for the 
above research on the basis described in the application form, protocol and supporting 
documentation as revised.
Ethical review of research sites
The favourable opinion applies to the research sites listed on the attached form. 
Confirmation of approval for other sites listed in the application will be issued as soon as 
local assessors have confirmed they have no objection.
Conditions of approval
The favourable opinion is given provided that you comply with the conditions set out in the 
attached document.  You are advised to study the conditions carefully.
Approved documents
The final list of documents reviewed and approved by the Committee is as follows:
 
Document   Version   Date   
 Application 1 19 June 2007 
 Investigator CV    
 Protocol 1 01 June 2007 
 Covering Letter  19 June 2007 
 Letter of invitation to participant 1 01 June 2007 
 Participant Information Sheet: Controls 2, Draft 2 17 July 2007 
 Participant Information Sheet: Patients 1, Draft 2 17 July 2007 
 Participant Information Sheet: Archival Samples 3, Draft 2 17 July 2007 
 Participant Consent Form: Blood & Tissue 2 17 July 2007 
 Participant Consent Form: Blood Only 2 17 July 2007 
 Participant Consent Form: Blood & Tissue (Archive Use) 2 17 July 2007 
 Response to Request for Further Information  19 July 2007 
 Student CV  19 June 2007 
 Letter Regarding Peer Review  19 June 2007 
 Letter from Funder / Sponsor  02 April 2007 
 
R&D approval
All researchers and research collaborators who will be participating in the research at NHS 
sites should apply for R&D approval from the relevant care organisation, if they have not yet 
done so.  R&D approval is required, whether or not the study is exempt from SSA.  You 
should advise researchers and local collaborators accordingly.
Guidance on applying for R&D approval is available from http://www.rdforum.nhs.uk/
rdform.htm.
Statement of compliance
The Committee is constituted in accordance with the Governance Arrangements for 
Research Ethics Committees (July 2001) and complies fully with the Standard Operating 
Procedures for Research Ethics Committees in the UK.
Feedback on the application process
Now that you have completed the application process you are invited to give your view of 
the service you received from the National Research Ethics Service.  If you wish to make 
your views known please use the feedback form available on the NRES website at:
https://www.nresform.org.uk/AppForm/Modules/Feedback/EthicalReview.aspx
We value your views and comments and will use them to inform the operational 
process and further improve our service.
07/H0706/65 Please quote this number on all 
correspondence
With the Committee’s best wishes for the success of this project
Yours sincerely
Chair
Email: JAMurphy@hhnt.nhs.uk
Enclosures: Standard approval conditions SL-AC2
Site approval form
Copy to: Joint Research Committee at Chelsea and Westminster Hospital
(JRC)
Riverside Research Ethics Committee
LIST OF SITES WITH A FAVOURABLE ETHICAL OPINION
For all studies requiring site-specific assessment, this form is issued by the main REC to the 
Chief Investigator and sponsor with the favourable opinion letter and following subsequent 
notifications from site assessors.  For issue 2 onwards, all sites with a favourable opinion are 
listed, adding the new sites approved.
REC 
reference 
number:
07/H0706/65 Issue 
number:
0 Date of 
issue:
02 August 
2007
Chief 
Investigator:
Professor Christopher Bunker
Full title of 
study:
Immunogenotypic (HLA genotype) and Immunophenotypic (including neuro-
immunologic) Characteristics of Skin Disease in Treated and Untreated HIV 
Infected Individuals.
This study was given a favourable ethical opinion by Riverside Research Ethics Committee on 
30 July 2007. The favourable opinion is extended to each of the sites listed below.  The 
research may commence at each NHS site when management approval from the relevant 
NHS care organisation has been confirmed.
Principal 
Investigator
Post Research site Site assessor Date of 
favourable 
opinion for 
this site
Notes (1)
Dr Rhonda  
Meys
Specialist 
Registrar in 
Dermatology
Chelsea and 
Westminster 
Hospital
Riverside 
Research 
Ethics 
Committee
02/08/2007
Approved by the Chair on behalf of the REC:
.……………………………………………… (Signature of Chair/Co-ordinator) 
(delete as applicable)
………………………………………………. (Name)
(1) The notes column may be used by the main REC to record the early closure or 
withdrawal of a site (where notified by the Chief Investigator or sponsor), the suspension 
of termination of the favourable opinion for an individual site, or any other relevant 
development.  The date should be recorded.
 
 
BLOOD AND TISSUE 
 
CONSENT FORM: Prospective Use 
 
 
 
 
         Please initial box 
1.  I confirm that I have read and understand the information sheet dated 17/07/2007 Version 1, 
Draft 2 or Version 2, Draft 2.  I have had the opportunity to consider the information, ask 
questions and have had these answered satisfactorily. 
                   
             
2.  I understand that my participation is voluntary and that I am free to withdraw at any time, 
without giving any reason, without my medical care or legal rights being affected. 
  
            
  
3.   I understand that relevant sections of any of my medical notes and data collected during the 
study, may be looked the members of research team which are employed NHS Trust. ONLY 
those individuals who would normally have access to my notes will view them (doctors, nurses 
within the trust) and I give permission for ONLY these individuals to have access to my records .    
 
                     
 
4. I understand that all of the data collected in this study will be coded and only these codes used 
when the data is being analysed. I agree to this use of coded data. 
: 
                      
 
5. I understand that an extra sample of my blood will be taken and used by the researchers to 
analyse specific DNA (genes) as and I agree to this. 
                     
 
6. I understand that very small part of surplus tissue from my skin biopsy specimen (taken in clinic 
for diagnostic reasons) may be used for analysis for this study as outlined in the information sheet 
version 1, Draft 2 or Version 2, Draft 2 dated 17/07/2007. 
                    
  
7.  I have read the part of this form about storing my tissue for future research.  My choice about 
having my sample stored and used for future skin and HIV research is: 
 
(a ) I refuse to have my tissue stored or used for any kind of future research on HIV or skin 
disease. 
 
OR            
 
(b) I agree that my tissue can be stored with a code number for use in future research on HIV and 
the skin.           
            
8.  I understand that my individual results from the study will not be given to me, unless by special 
arrangement.   
            
Patient Information Sticker 
Title of Project:  Immunopathogenesis of Skin Disease in HIV/AIDS 
Name of Researcher:  Dr Rhonda Meys 
 
 
9.   I agree to take part in the above study.    
            
 
 
 
________________________  _______________ ____________________ 
Name of Patient   Date   Signature 
 
 
 
_________________________  ________________ ____________________ 
Name of Person taking consent  Date   Signature 
(Researcher/Doctor) 
 
 
 
BLOOD ONLY 
 
CONSENT FORM: Prospective Use 
 
 
 
         Please initial box 
1.  I confirm that I have read and understand the information sheet dated 17/07/2007 version 1, 
Draft 2 or version 2, draft 2.  I have had the opportunity to consider the information, ask questions 
and have had these answered satisfactorily. 
                   
             
2.  I understand that my participation is voluntary and that I am free to withdraw at any time, 
without giving any reason, without my medical care or legal rights being affected. 
            
 
3.   I understand that relevant sections of any of my medical notes and data collected during the 
study, may be looked the members of research team which are employed NHS Trust. ONLY 
those individuals who would normally have access to my notes will view them (doctors, nurses 
within the trust) and I give permission for ONLY these individuals to have access to my records . 
                     
                                                                                                                                  
 
4. I understand that all of the data collected in this study will be coded and only these codes used 
when the data is being analysed. I agree to this use of coded data. 
: 
                      
 
5. I understand that an extra sample of my blood will be taken and used by the researchers to 
analyse specific DNA (genes) as and I agree to this. 
                     
 
6  I have read the part of this form about storing my tissue for future research.  My choice about 
having my sample stored and used for future skin and HIV research is: 
 
(a ) I refuse to have my tissue stored or used for any kind of future research on HIV or skin 
disease. 
OR            
(b) I agree that my tissue can be stored with a code number for use in future research on HIV and 
the skin.           
            
7.  I understand that my individual results from the study will not be given to me, unless by special 
arrangement.   
            
8.   I agree to take part in the above study.    
            
 
 
________________________  _______________ ____________________ 
Name of Patient   Date   Signature 
 
 
_________________________  ________________ ____________________ 
Name of Person taking consent  Date   Signature(Researcher/Doctor) 
Patient Information Sticker 
Title of Project:  Immunopathogenesis of Skin Disease in HIV/AIDS 
Name of Researcher:  Dr Rhonda Meys 
 
 
 
BLOOD AND TISSUE 
 
CONSENT FORM: ARCHIVE USE 
 
 
 
         Please initial box 
1.  I confirm that I have read and understand the information sheet dated 17/07/2007 version 3, 
Draft 2.  I have had the opportunity to consider the information, ask questions and have had these 
answered satisfactorily. 
                   
             
2.  I understand that my participation is voluntary and that I am free to withdraw at any time, 
without giving any reason, without my medical care or legal rights being affected. 
            
 
3.   I understand that relevant sections of any of my medical notes and data collected during the 
study, may be looked the members of research team which are employed NHS Trust. ONLY 
those individuals who would normally have access to my notes will view them (doctors, nurses 
within the trust) and I give permission for ONLY these individuals to have access to my records .    
 
                     
 
4. I understand that all of the data collected in this study will be coded and only these codes used 
when the data is being analysed. I agree to this use of coded data. 
                     
 
5. I understand that archived blood and surplus tissue may be used for analysis for this study as 
outlined in the information sheet version 3, Draft 2  17/07/2007. 
                    
6.  I have read the part of this form about storing my tissue for future research.  My choice about 
having my sample stored and used for future skin and HIV research is: 
(a) I refuse to have my tissue stored or used for any kind of future research on HIV or skin 
disease. 
OR            
 
(b) I agree that my tissue can be stored with a code number for use in future research on HIV and 
the skin.           
            
7.  I understand that my individual results from the study will not be given to me, unless by special 
arrangement.   
            
 
8   I agree to take part in the above study.    
            
 
 
________________________  _______________ ____________________ 
Name of Patient   Date   Signature 
 
 
_________________________  ________________ ____________________ 
Name of Person taking consent  Date   Signature 
(Researcher/Doctor) 
Patient Information Sticker 
Title of Project:  Immunopathogenesis of Skin Disease in HIV/AIDS 
Name of Researcher:  Dr Rhonda Meys 
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Study Title: 
Immunopathogenesis of Skin Disease in HIV/AIDS 
 
 
What is the research about? 
 
We are conducting a study into the genetics behind certain forms of HIV skin disease. There is a 
lot of scientific theory which suggests that many skin diseases which are inflammatory may have 
a genetic component. It is felt that some people with skin diseases which involve 
inflammation (for example eczema, psoriasis, wart virus and herpes virus) may have an 
overactive immune system. We are looking at many different individuals with and 
without skin disease to see if we can find a difference in the genes that code for the 
immune system. Ultimately, we would like to try to try to help some people with skin disease 
and HIV. 
 
Why have I been selected? 
 
We are looking for a wide variety of people to participate, including people with skin problems, 
without skin problems and those with and without the HIV virus.  
 
How will I be involved if I choose to take part? 
 
There are three ways you will be asked to participate -  
(1) We would like to take an extra blood sample from all participants and analyse this for 
certain genes.  
(2) Some people with skin problems have either had, or will have been recommended a 
skin biopsy, as a part of their treatment in the dermatology clinic. We would like to 
take some of the spare tissue from the biopsy and examine this in the lab for some 
extra studies in addition to the usual look under the microscope that is needed to find 
out what is wrong with the skin. 
(3) We will also assess your skin and ask some questions relating to your skin at a 
clinical appointment. 
Blood 
 
Taking an extra blood sample will not be too difficult. Most of the time when patients come to the 
dermatology clinic, we take a blood test to find out what is wrong with them. This sample can be 
taken as an extra tube, when we are taking blood for other reasons and therefore minimise the 
inconvenience to you. Sometimes we may ask if you wouldn’t mind to have a blood test at a visit 
when you would not otherwise be having one.  
 
Everyone taking part in the study will be asked to give a blood sample. 
 
Participant Information Sheet  
 
For  
Patients 
 
Dermatology Department Chelsea and Westminster Hospital  
 
Participant Information Sheet For Patients 
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Biopsy  
(this will not apply to everyone, it will depend on which part study you are in) 
 
We will also, as part of your care in the dermatology department, recommend that we make 
absolutely sure of the diagnosis of your skin disease. This is important to make sure we look very 
carefully at the differences in the genes. This almost certainly will be a part of your treatment of 
that skin condition (as we cannot treat something without first knowing what it is). A small skin 
biopsy under local anaesthetic may be recommended to make sure that we have the correct 
diagnosis for each person with skin problems. 
 
We will test this skin for a number of things; changes under the microscope (called histology), for 
viruses or bacteria, and by special stains to look for particular cells. 
 
More information on the genes 
 
We would like to look at a certain type of gene called the MHC genes or ‘tissue type’. Tissue 
typing is done, for example, when a person, needs to receive an organ from another individual 
and the closer the match, the better the organ will ‘take’. The tissue type therefore is important in 
the way the immune system recognises something as foreign (such as a bacteria or virus) or as 
self (belonging to that individual). This is a little like blood typing to see if blood can be donated 
from one person to another, but tested in a slightly different way.  
 
Your blood will be used to look at the specific part of the DNA that includes these MHC (tissue 
typing) genes. We will not look at the other genes or look for genetic abnormalities – what we are 
looking for are variants of normal. 
 
If are interested to find out your tissue type, we are happy to inform you, if you wish at the end of 
the study. You can contact the investigators and make a special arrangement. 
 
How will this help HIV patients? 
 
By doing this study, we hope to find out more about the skin diseases in HIV and why some 
individuals are affected and not others. A genetic link is one reason that this may occur, and a 
number of other diseases have been shown to have links with the particular genes we are 
studying. By finding out which genes are associated with which diseases, doing the simple 
genetic test might enable us to treat these diseases before they become a problem to the 
individual. 
 
Further information 
We may need to collect more (fresh) blood on a further occasion at a later date to identify the 
different immune cells in your blood. This can be done at a follow up appointment at any of the 
Chelsea and Westminster clinics 
 
It is important that you understand that you are under no obligation to be 
involved in the study and deciding not taking part will not compromise 
your care in any of the clinics you attend at Chelsea and Westminster or 
any other hospitals. 
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If I do take part: 
Will taking part in the study be kept confidential? 
The investigators will code the data we collect on each person and store it under that code. 
Nothing identifiable will held in association with the data. 
 
What are the benefits of taking part? 
There is no immediate benefit for participants taking part in the study on the whole, however it 
may benefit patients in the future. 
 
Are there any risks associated with being involved in the study? 
As far as individual participants go the only thing we are requesting is that you allow us to take 
an extra blood sample from you. There is nothing else you will need to do after that. There is no 
risk associated with taking blood and most people will have had this done many times in their 
lifetime. Privacy of participants will be maintained and every effort will be made to ensure that 
participant identities will remain confidential. We will keep all clinical records at Chelsea and 
Westminster, as part of your clinical hospital notes, and code all the data we collect. 
 
What will happen to the blood samples (and the extra tissue from my biopsy – if 
applicable)? 
At the completion of the study, we would like to store the sample in a coded way. This could be 
used for future use, but the future researchers would need to obtain ethics approval to do so, much 
as has been done for this study. You may wish to have your sample destroyed at the end of the 
study if you prefer this, there is a box to tick on the consent form for this. 
 
If I decide I would like to withdraw from the study? 
We will destroy the samples that can be identified as yours.  
 
What will happen to the results of the study? 
The study samples will add to our knowledge about skin disease in HIV and skin disease as a 
whole. We are studying groups of people rather than individuals and the study will not test your 
medical status as an individual. The genes we are testing at the moment do not have any medical 
implications for individuals except in some very specific diseases and in patients who are being 
investigated to have an organ transplant. However, if you would like to know what your tissue 
type is we can arrange to have your particular type sent out to you. The study will be published 
for medical professionals in the form of scientific papers. If you would like further information, 
you can contact the researchers. 
 
Who has reviewed the study? 
The Riverside Ethics Committee, based at Charing Cross 
 
Who has funded the study? 
The Chelsea and Westminster hospital and Medical School Research Trust through the Joint 
Research Committee. 
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Study Title: 
Immunopathogenesis of skin disease in HIV/AIDS 
 
What is the research about? 
 
We are conducting a study into the genetics behind certain forms of HIV skin disease. There is a 
lot of scientific theory which suggests that many skin diseases which are inflammatory may have 
a genetic component. It is felt that some people with skin diseases which involve 
inflammation (for example eczema, psoriasis, wart virus and herpes virus) may have an 
overactive immune system. We looking at many different individuals with and without 
skin disease to see if we can find a difference in the genes that code for the immune 
system. Ultimately, we would like to try to try to help some people with skin disease and HIV. 
 
Why have I been selected? 
 
We are looking for a wide variety of people to participate, including people with skin problems, 
without skin problems and those with and without the HIV virus. We are asking you to take part 
as a person without HIV who either has no skin disease, or a has wart virus related skin problems. 
 
How will I be involved if I choose to take part? 
 
There are three ways you will be asked to participate -  
(1) We would like to take an extra blood sample from all participants and analyse this for 
certain genes.  
(2) Some people with skin problems have either had, or will have been recommended a 
skin biopsy, as a part of their treatment in the dermatology clinic. We would like to 
take some of the spare tissue from the biopsy and examine this in the lab for some 
extra studies in addition to the usual look under the microscope that is needed to find 
out what is wrong with the skin. (This will only be done if you have a skin problem, 
for diagnosis). 
(3) We will also assess your skin and ask some questions relating to your skin. 
 
Blood 
 
Taking an extra blood sample will not be too difficult. Most of the time when patients come to the 
dermatology clinic, we take a blood test to find out what is wrong with them. This sample can be 
taken as an extra tube, when we are taking blood for other reasons and therefore minimise the 
inconvenience to you. Sometimes we may ask if you wouldn’t mind to have a blood test at a visit 
when you would not otherwise be having one.  
 
Everyone taking part in the study will be asked to give a blood sample. 
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Biopsy  
(this will not apply to everyone, it will depend on which part study you are in) 
 
We will also, as part of your care in the dermatology department, recommend that we make 
absolutely sure of the diagnosis of your skin disease. This is important to make sure we look very 
carefully at the differences in the genes. This almost certainly will be a part of your treatment of 
that skin condition (as we cannot treat something without first knowing what it is). A small skin 
biopsy under local anaesthetic may be recommended to make sure that we have the correct 
diagnosis for each person with skin problems. 
 
We will test this skin for a number of things; changes under the microscope (called histology), for 
viruses or bacteria, and by special stains to look for particular cells. 
 
More information on the genes 
 
We would like to look at a certain type of gene called the MHC genes or ‘tissue type’. Tissue 
typing is done, for example, when a person, needs to receive an organ from another individual 
and the closer the match, the better the organ will ‘take’. The tissue type therefore is important in 
the way the immune system recognises something as foreign (such as a bacteria or virus) or as 
self (belonging to that individual). This is a little like blood typing to see if blood can be donated 
from one person to another, but tested in a slightly different way.  
 
Your blood will be used to look at the specific part of the DNA that includes these MHC (tissue 
typing) genes. We will not look at the other genes or look for genetic abnormalities – what we are 
looking for are variants of normal. 
 
If are interested to find out your tissue type, we are happy to inform you, if you wish at the end of 
the study. You can contact the investigators and make a special arrangement. 
 
How will this help HIV patients? 
 
By doing this study, we hope to find out more about the skin diseases in HIV and why some 
individuals are affected and not others. A genetic link is one reason that this may occur, and a 
number of other diseases have been shown to have links with the particular genes we are 
studying. By finding out which genes are associated with which diseases, doing the simple 
genetic test might enable us to treat these diseases before they become a problem to the 
individual. 
 
Further information 
We may need to collect more (fresh) blood on a further occasion at a later date to identify the 
different immune cells in your blood. This can be done at a follow up appointment at any of the 
Chelsea and Westminster clinics 
 
It is important that you understand that you are under no obligation to be 
involved in the study and deciding not taking part will not compromise 
your care in any of the clinics you attend at Chelsea and Westminster or 
any other hospitals. 
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If I do take part: 
Will taking part in the study be kept confidential? 
The investigators will code the data we collect on each person and store it under that code. 
Nothing identifiable will held in association with the data. 
 
What are the benefits of taking part? 
There is no immediate benefit for participants taking part in the study on the whole, however it 
may benefit patients in the future. 
 
Are there any risks associated with being involved in the study? 
As far as individual participants go the only thing we are requesting is that you allow us to take 
an extra blood sample from you. There is nothing else you will need to do after that. There is no 
risk associated with taking blood and most people will have had this done many times in their 
lifetime. Privacy of participants will be maintained and every effort will be made to ensure that 
participant identities will remain confidential. We will keep all clinical records at Chelsea and 
Westminster, as part of your clinical hospital notes, and code all the data we collect. 
 
What will happen to the blood samples (and the extra tissue from my biopsy – if 
applicable)? 
At the completion of the study, we would like to store the sample in a coded way. This could be 
used for future use, but the future researchers would need to obtain ethics approval to do so, much 
as has been done for this study. You may wish to have your sample destroyed at the end of the 
study if you prefer this, there is a box to tick on the consent form for this. 
 
If I decide I would like to withdraw from the study? 
We will destroy the samples that can be identified as yours.  
 
What will happen to the results of the study? 
The study samples will add to our knowledge about skin disease in HIV and skin disease as a 
whole. We are studying groups of people rather than individuals and the study will not test your 
medical status as an individual. The genes we are testing at the moment do not have any medical 
implications for individuals except in some very specific diseases and in patients who are being 
investigated to have an organ transplant. However, if you would like to know what your tissue 
type is we can arrange to have your particular type sent out to you. The study will be published 
for medical professionals in the form of scientific papers. If you would like further information, 
you can contact the researchers. 
 
Who has reviewed the study? 
The Riverside Ethics Committee, based at Charing Cross 
 
Who has funded the study? 
The Chelsea and Westminster hospital and Medical School Research Trust through the Joint 
Research Committee. 
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Study Title: 
Immunopathogenesis of Skin Disease in HIV/AIDS 
 
 
What is the research about? 
 
We are conducting a study into the genetics behind certain forms of HIV skin disease. There is a 
lot of scientific theory which suggests that many skin diseases which are inflammatory may have 
a genetic component. It is felt that some people with skin diseases which involve inflammation 
(for example eczema, psoriasis, wart virus and herpes virus) may have an overactive immune 
system. We are looking at many different individuals with and without skin disease to see if we 
can find a difference in the genes that code for the immune system. Ultimately, we would like to 
try to try to help some people with skin disease and HIV. 
 
Why have I been selected? 
 
We are looking for a wide variety of people to participate, including people with skin problems, 
without skin problems and those with and without the HIV virus. Because you had skin problems 
in the past, some of the samples taken have been stored in case we need them again. We would 
like to ask your permission to use these samples in our study which is outlined below. The 
samples we would like to test are blood samples and tissue (skin biopsy) samples. 
 
How will I be involved if I choose to take part? 
 
Because the samples are already in storage there is nothing you will need to do further. These 
samples are kept for a number of reasons, including for your own benefit if doctors need to look 
back at them as a part of your usual medical care. We are asking to use these stored samples for 
the specific uses outlined below. The minimum amount of archived tissue and blood will be used 
in the course of the study, and the use of these samples will not compromise future patient care. 
 
Blood 
 
If you have blood stored, we would like to analyse the samples for the genes we have discussed 
further on in this information sheet. This will be done by PCR (polymerase chain reaction) 
methods in a laboratory. 
Biopsy  
(this will not apply to everyone, it will depend on which samples you have) 
 
If you have had a skin biopsy taken in the past, we would like your permission to analyse it in the 
laboratory. We will test this skin for a number of things; changes under the microscope (called 
histology), for viruses or bacteria, and by special stains to look for particular cells. 
 
 
Participant Information Sheet  
 
For  
Archival Samples 
 
Dermatology Department Chelsea and Westminster Hospital  
 
Participant Information Sheet For Archived Samples 
Version 3, Draft 2  17/07/2007 2 
More information on the genes 
 
We would like to look at a certain type of gene called the MHC genes or ‘tissue type’. Tissue 
typing is done, for example, when a person, needs to receive an organ from another individual 
and the closer the match, the better the organ will ‘take’. The tissue type therefore is important in 
the way the immune system recognises something as foreign (such as a bacteria or virus) or as 
self (belonging to that individual). This is a little like blood typing to see if blood can be donated 
from one person to another, but tested in a slightly different way.  
 
Your blood will be used to look at the specific part of the DNA that includes these MHC (tissue 
typing) genes. We will not look at the other genes or look for genetic abnormalities – what we are 
looking for are variants of normal. 
 
If are interested to find out your tissue type, we are happy to inform you, if you wish at the end of 
the study. You can contact the investigators and make a special arrangement. 
 
How will this help HIV patients? 
 
By doing this study, we hope to find out more about the skin diseases in HIV and why some 
individuals are affected and not others. A genetic link is one reason that this may occur, and a 
number of other diseases have been shown to have links with the particular genes we are 
studying. By finding out which genes are associated with which diseases, doing the simple 
genetic test might enable us to treat these diseases before they become a problem to the 
individual. 
 
Further information 
We may need to collect more (fresh) blood on a further occasion at a later date to identify the 
different immune cells in your blood. This can be done at a follow up appointment at any of the 
Chelsea and Westminster clinics. 
 
 
 
 
 
 
 
 
 
 
 
 
 
It is important that you understand that you are under no obligation to be 
involved in the study and deciding not taking part will not compromise 
your care in any of the clinics you attend at Chelsea and Westminster or 
any other hospitals. 
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If I do take part: 
Will taking part in the study be kept confidential? 
The investigators will code the data we collect on each person and store it under that code. 
Nothing identifiable will held in association with the data. 
 
What are the benefits of taking part? 
There is no immediate benefit for participants taking part in the study on the whole, however it 
may benefit patients in the future. 
 
Are there any risks associated with being involved in the study? 
As far as individual participants go the only thing we are requesting is that you allow us to take 
an extra blood sample from you. There is nothing else you will need to do after that. There is no 
risk associated with taking blood and most people will have had this done many times in their 
lifetime. Privacy of participants will be maintained and every effort will be made to ensure that 
participant identities will remain confidential. We will keep all clinical records at Chelsea and 
Westminster, as part of your clinical hospital notes, and code all the data we collect. 
 
What will happen to the blood samples (and the extra tissue from my biopsy – if 
applicable)? 
At the completion of the study, we would like to store the sample in a coded way. This could be 
used for future use, but the future researchers would need to obtain ethics approval to do so, much 
as has been done for this study. You may wish to have your sample destroyed at the end of the 
study if you prefer this, there is a box to tick on the consent form for this. 
 
If I decide I would like to withdraw from the study? 
We will destroy the samples that can be identified as yours.  
 
What will happen to the results of the study? 
The study samples will add to our knowledge about skin disease in HIV and skin disease as a 
whole. We are studying groups of people rather than individuals and the study will not test your 
medical status as an individual. The genes we are testing at the moment do not have any medical 
implications for individuals except in some very specific diseases and in patients who are being 
investigated to have an organ transplant. However, if you would like to know what your tissue 
type is we can arrange to have your particular type sent out to you. The study will be published 
for medical professionals in the form of scientific papers. If you would like further information, 
you can contact the researchers. 
 
Who has reviewed the study? 
The Riverside Ethics Committee, based at Charing Cross 
 
Who has funded the study? 
The Chelsea and Westminster hospital and Medical School Research Trust through the Joint 
Research Committee. 
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APPENDIX 2.2 
CLINICAL CASES  
AND HISTOLOGICAL EXAMPLES  
 
 
Firstly, examples of clinical cases are presented from two main categories of HPV 
disease:  
• Acute inflammatory HPV IRAD/IRIS - one case Appendix 2.2.1; 
• Chronic persistent/emergent HPV disease in HIV - four cases (a) to (d) 
Appendix 2.2.2. 
 
Next, four cases (with clinical photographs) demonstrating clinical examples of 
presentations of HPV disease in treated HIV:  
• Extensive ano-genital HPV disease - Appendix  2.2.3; 
• Large plantar wart - Appendix 2.2.4; 
• HIV associated EV-like eruption - Appendix 2.2.5; 
• Florid cutaneous/genital HPV disease in HIV infected patient with herpes 
simplex virus related inflammatory IRD (on oral prednisolone) - Appendix 
2.2.6. 
 
Finally, examples of histological sections of haematoxylin and eosin stained warts 
are displayed:  
• Examples of the histology of dermis-poor and dermis-rich warts – section 
Appendix 2.2.7; 
• Example of the histology of a wart-like lesion (non-wart: dermatofibroma) -
 Appendix 2.2.8. 
 
 
 
 
 
 
 
 
2.2.1 Acute inflammatory HPV IRAD (IRIS)  
 
Appendix Figure A2.1 Clinical photographs and CD4 T cell count, percentage and viral 
load taken from the same patient, with inflammatory HPV IRD.  (a) and (b) persistent warts 
on the neck at diagnosis of HIV infection; (c) and (d) nine months after ART initiation the patient 
presented with a disfiguring scaling hyperkeratotic inflammatory eruption of viral warts on the 
face and neck.  (e) Line chart of the same patient’s CD4 T cell count (blue), CD4 percentage 
(green) and HIV viral load (red) at ART initiation and in following months.  The points (in time) at 
which neck warts that were present at diagnosis firstly, flared and secondly, were photographed 
is indicated (Meys et al., 2011).  Photographs (a)-(d) courtesy of Medical Illustration, UK.  
(e) 
This patient was a 33 year old Italian man seen in our department for 
generalized pruritus.  HIV infection was diagnosed from screening tests for his 
condition. He had had four persistent warts for more than 6 months on the 
preauricular area and lateral neck associated with cryotherapy scarring from 
treatment in primary care (Appendix Figure A2.1a and b).  After initiation of ART 
(tenofovir, emtricitabine, efavirenz) his CD4 T-cell count rose from 12 to 104 
cells/µl over 9 months and his viral load fell from 65,506 to less than 50 
copies/ml (Appendix Figure A2.1e). During this time he re-presented with a 
disfiguring and widespread scaling hyperkeratotic inflammatory eruption of 
multiple viral warts on the lower face and neck; Appendix Figure A2.1c and d. A 
biopsy showed classical HPV histology, with a minimal lymphocytic 
inflammatory infiltrate containing similar numbers of CD4 and CD8 T-cells; 
Appendix Figure A2.2. He was commenced on acitretin 10 mg once daily and 
within 1 week had noticed significant improvement (Meys et al., 2011).   
As mentioned in the above paper, the pictures demonstrate the features of an 
inflammatory IRAD related to HPV. The patient case number is D94. 
 
 
 
  
 
 Appendix Figure A2.2 Histological photographs of a facial wart biopsied from the HPV 
IRIS patient (above) nine months after ART initiation. (a) Low power view x40 magnification 
showing the characteristic histological changes of a viral wart, manifest as thickening of the rete 
pegs (P-peg thickening) and hyperkeratosis (arrow).  (b) At higher power (x400 magnification) 
signs of HPV infection are seen; an increase in the number of prickle layer cells (A-acanthosis) 
and thickening of the granular cell layer (H-hypergranulosis) associated with koilocytes (circled) 
- HPV infected keratinocytes with condensed contracted nuclei. (c) A minimal perivascular 
lymphocytic infiltrate is indicated by the blue arrow; x400 magnification. (d) CD4 and (e) CD8 
antibody immunohistochemistry stains showing a similar numbers of each type of T cell (ratio of 
CD4:CD8 cells of 1:1.2); (a)-(c) stains: haematoxylin and eosin (H&E).   Photographs courtesy 
of Dr Justin Weir, Chelsea and Westminster Hospital NHS Foundation Trust. 
 
 
 
2.2.2 Chronic persistent/emergent HPV disease in HIV; four cases  
 
Four case examples of chronic HPV disease in treated HIV are presented below 
Appendix Table A2.1a-d. 
 
(a) Patient 1: emergent HPV disease despite ART with high CD4 T cell count  
(>400 cells/µl) in a patient with probable ‘ slow progressor ‘ HIV status 
A 53 year old Italian male was diagnosed with hepatitis C and HIV infection 24 
years previously (1984).  The patient reported starting anti-retroviral treatment 
in 2003, after his lowest recorded CD4 T cell count was recorded at 241 cells/µl 
(in 2002). His attendance at HIV clinic since this time has been sporadic. 
Additional past history pre-ART included septacaemia secondary to injectable 
drug use, shingles, and presumptive oespohageal candidiasis (in 2001).  
Because this patient survived without anti-retroviral treatment for 19 years 
(1984-2003) it is likely that he is a slow progressor.  At the time of review he 
had had extensive warts on the hands and feet for the last two years; the warts 
emergent despite ART and an increasing CD4 T-cell count (574 cells/µl) and 
HIV VL <50 copies/ml; for over four years (since the beginning of 2004); 
Appendix Figure A2.3. The patient case number is B98. 
Emergent HPV disease  
despite ART 
Persistent HPV disease  
despite ART 
(a) patient 1 with  
high CD4 T cell count  (>400 
cells/µl) – probable slow progressor 
(c) patient 3 with  
high CD4 T cell count  (>400 
cells/µl) 
(b) patient 2 with  
low CD4 T cell count (<400  
cells/µl) 
(d) patient 4 with  
low CD4 T cell count (<400  
cells/µl) 
Appendix Table A2.1 Examples of four patient cases from each category (a) to (d) 
with chronic HPV disease. Representative cases of each category of disease 
(persistent, emergent, low CD4 T cell count, high CD4 T cell count) have been outlined 
below.  Included are examples with ‘high’ and ‘low’ current CD4 T cell counts (>400, 
<400 cells/µl respectively). 
  
(b) Patient 2: emergent HPV disease despite ART in a patient with a low current 
CD4 T cell count (<400 cells/µl).   
A 65 year old Caucasian man was diagnosed with HIV infection in 1989, at 
which time AZT monotherapy was commenced.  Didanosine was added 1992 
and to date 13 regimens have been taken by the patient.  His ART regimen at 
the time of review was darunavir, etravirine, raltegravir and ritonavir.  His past 
history included ischaemic heart disease (treated with coronary artery bypass), 
renal impairment, tuberculosis (1996), recurrent herpes and BCC.  He had a 
very low CD4 T-cell count nadir; the lowest recorded was 5 cells/µl in 1995; at 
review in 2009, his CD4 T-cell  count had increased to 222 cells/µl. 
 
On examination, he had emergent hand and foot warts, persistent for the past 6 
years, despite stable ART. The patient also gave a history spanning 15 years of 
Appendix Figure A2.3 Patient 1: chronic hand and foot warts in a treated HIV 
infected patient. Warts on the (a) hand and great toes (b) and (c).  Photographs courtesy 
of Medical Illustration, UK. 
intermittent penile warts, the current episode had lasted 1 year (he declined 
examination and penile wart biopsy).  His HIV VL had been <50 copies/ml since 
2006; previous to this it was briefly undetectable in 2003 and again in 2004 but 
was otherwise detectable.  The patient case number is C12. 
 
(c) Patient 3 - persistent HPV disease despite ART in a patient with a high CD4 
T cell count (>400 cells/µl).  
A 44 year old Caucasian male was diagnosed with HIV infection 5 years prior to 
review.  He had started ART immediately (atazanavir, emtricitabine, ritonavir, 
tenofovir).  His CD4 T-cell count nadir at diagnosis was 279 cells/µl; at review it 
was 875 cells/µl.  His HIV VL has been <50 copies/ml since commencing 
treatment.  He has had hand warts on and off since the  age  of 14 years and 
persistent verrucas on his feet for the past 5 years. He declined wart biopsy at 
review but consented to provide blood for immunogenotyping. The patient case 
number is C32. 
 
(d) Patient 4 - persistent HPV disease despite ART in a patient with a low CD4 
T cell count (<400 cells/µl)  
A 58 year old Caucasian male was diagnosed with HIV infection in 1989 and 
commenced AZT monotherapy in 1990, later switching to triple therapy (1997).  
At review (2008) he was taking abacavir, didanosine, ritonavir and saquinavir.  
His CD4 T-cell count nadir in 2000 was 62 cells/µl; his CD4 T-cell count at 
review was 278 cells/µl.  His HIV VL <50 copies/ml since 2000, after 
commencing his current regimen.  He had a past history of (now quiescent) 
Crohn’s disease diagnosed 20 years previously and treated with ileostomy.  He 
had a 15 year history of persistent cutaneous (hand) warts commencing three 
years after AZT commencement (but seven years prior to ART and persisting 
for eight years on ART). The patient case number is M36.  
 
 
 
 
2.2.3 Extensive ano-genital HPV disease in HIV infection 
 
 
 
The patient was a 55 year old Caucasian male with a 18 year history of HIV 
infection.  He started AZT monotherapy when he was diagnosed in 1990, and 
combined treatment in 1996.  The lowest nadir CD4 T-cell count on record was 
89 cells/µl in 1999.  In 1998 he developed PCIS despite circumcision at birth 
Appendix Figure A2.4a.  In 2000 a large mass of right groin warts was excised; 
Appendix Figure A2.4b.  In 2004 he developed anal cancer that was treated 
with radiotherapy and chemotherapy; Appendix Figure A2.4c shows residual 
AIN.  Other HIV-related past history included Kaposi’s sarcoma present from 
1994 to 1999 (treated by ongoing ART only), peripheral neuropathy, 
seborrhoeic dermatitis and inverse psoriasis that involved the flexures; it is 
possible that application of topical steroid in the groin area may have 
exacerbated the warts shown in Appendix Figure A2.3b.  At the time of review 
he was taking abacavir, didanosine, nevirapine and tenofovir and his CD4 T-cell 
count was 409 cells/µl. His HIV VL was <50 copies/ml.  The patient case 
number is I07.    
Appendix Figure A2.4 Severe chronic ano-genital HPV disease in an individual with 
longstanding HIV infection. (a) penile warts – black arrow, and penile in-situ cancer 
(PCIS) – white arrow; (b) large groin wart; (c) external anal in situ neoplasia (AIN).   
Photographs courtesy of Medical Illustration, UK.  
  
2.2.4 Large plantar wart in HIV  
 
  
A 43 year old Algerian (non-Caucasian) male was diagnosed with HIV infection in 
1995.  He commenced treatment immediately but has taken it continuously only 
for the last two years before review.  His treatment was atazanavir, emtricitabine, 
ritonavir and tenofovir.  His CD4 T-cell count was 1242 cells/µl and his HIV VL < 
50 copies/ml.  His CD4 T-cell count nadir was not known.  He had had persisent 
anal warts for seven years, penile warts for five years and verrucas for two years.  
The lesion pictured in Appendix Figure A2.5 was present on the left sole; on 
incisional biopsy only viral changes were seen; no dysplasia was evident.  
Treatment was initially with cryotherapy, but further incision and laser ablation 
was curative.  Other past history of note was past Hepatitis B infection.  After 
inclusion review of case notes showed he had had Mycobacterium intracellulare 
complex related IRAD/IRIS treated with 20-25mg oral prednisolone; the course 
was completed six months prior to review.  However, because he had the wart for 
>1 year prior to prednisolone, on ART, it was included in the All analysis of HPV 
types (but not in the HLA molecular analysis).  The patient case number is T05. 
Appendix Figure A2.5 Warty lesion on sole of foot.  (a) plantar aspect of foot and (b) 
close up of lesion. Incisional biopsy was undertaken to exclude SCC, but only viral changes 
were seen with no dysplasia.  Photographs courtesy of Medical Illustration, UK.  
 
  
2.2.5 HIV-associated epidermodysplasia verruciformis (EV)-like eruption 
 
A 38 year old HIV infected male of Afro-Caribbean descent (non-Caucasian) 
was first diagnosed with HIV infection in 1994.  He commenced ART at 
diagnosis; his nadir CD4 T-cell count was 10 cells/µl in 1996.  At review he was 
taking Atripla (efavarinz, emtricitabine, tenofovir) and his HIV VL was <50 
copies/ml, with a CD4 T-cell count of 903 cells/µl (2008).  Since 1995 he 
complained of flat, hypo-pigmented, scaling plane wart-like lesions on his face; 
Appendix Figure A2.6.  EV-like changes were seen on histological examination; 
Appendix Figure A2.7.  He also had penile and anal warts (intermittently 
between 1997 and 2004).  Previously, he received interferon in 1999 (three 
treatments) that resulted in significant improvement of the flat plane warts on 
the face.  However, they recurred and cidofovir cream, isotretinoin gel, topical 
imiquimod, laser and oral acitretin (25mg) have all been unsuccessful 
treatments.  Other past history included Kaposi’s sarcoma diagnosed in 1995, 
Appendix Figure A2.6 Clinical photographs HIV-associated EV lesions.  The patient had a 
13 year history of flat, hypo-pigmented, scaling wart-like lesions (a)-(c).  (d) After nine months of 
oral isotretinoin, most of the hypo-pigmented macules remained.  However, many of the papular 
lesions had resolved and scaling had improved.  Photographs courtesy of Medical Illustration, 
UK. 
 
steatocystoma multiplex (2000), SCC finger (2001) and anal warts for six 
months (2003/4). This patient was included in the All group HPV analysis (but 
not in the HLA molecular analysis, as he is non-Caucasian)   
 
Upon review in 2008 oral isotretinoin (20/40mg alternate days) was commenced 
for seven months with topical azelaic acid 15% and a moderate response and 
he is currently maintained on isotretinoin cream.  Although most of the hypo-
pigmented macules remained and some plane warts, many of the papular 
lesions resolved and scaling improved.  The patient case number is M83.  
 
Appendix Figure A2.7 Histological photographs of HIV-associated EV-like lesion 
from the patient pictured in Figure A2.6.   A mildly thickened epidermis contains large 
keratinocytes with atypical nuclei and blue-grey cytoplasm that is suggestive of EV-like 
changes (large arrow).  Koilocytic cells with contracted nuclei consistent with HPV 
infection can also be seen (small arrow).  Stain: haematoxylin and eosin (H&E), x400 
magnification.  Photograph courtesy of Dr Nick Francis, Chelsea and Westminster 
Hospital NHS Foundation Trust.   
 
2.2.6 Florid cutaneous/genital HPV disease in HIV infected patient with 
herpes simplex virus related IRD (on oral prednisolone) 
The above patient has not been included in the HPV typing or HLA analyses; 
his photographs are included here to illustrate the morbidity associated with 
HPV disease.  A 31 year old male, originally from Sub-Saharan Africa was 
diagnosed with HIV infection in 2000. He had a history of intermittent facial and 
penile warts since diagnosis.  ART treatment had been intermittent since 
diagnosis; from 2003 he was on Kaletra and switched to tenofovir, lopinavir, 
abacavir in 2006. His HIV VL has been mostly been <50 copies/ml since 2005 
(he had a blip of 236 copies/ml in 2007). The CD4 T-cell count mid 2008 was 
361 and his nadir was 4 cells/µl (2000).  He was first diagnosed with extensive 
scrotal ulceration due to HSV IRIS/IRAD in 2000; it recurred in 2006 and 
recurred again in 2009/10, subsequent to study recruitment.  He had 
cryptococcal meningitis in 2000 and cryptococcal IRIS/IRAD 2007, and  VZV 
retinitis 2006/7.  He had received multiple courses of oral prednisolone since 
2004 and recently completed a five month course reducing from 50mg. He was 
excluded from the study as prednisolone may have been a possible precipitant 
to the appearance of his extensive warts.   
Appendix Figure A2.8 Florid HPV disease on the face of a patient treated with 
prednisolone for herpes simplex virus IRIS/IRAD. (a) Extensive, stigmatising lesions were 
seen on the face, primarily but not exclusively in the beard area; the patient had very limited 
facial hair and the patient was unshaven.  (b) Close up of warts, showing exophitic 
hyperkeratoses.  Photographs courtesy of Medical Illustration, UK. 
2.2.7 Dermis poor and dermis rich warts may have led to over or under 
estimation of HPV viral loads (VLs)  
 
Appendix Figure A2.9 shows histological sections of two warts as an example 
of (a) a dermis poor, hyperkeratotic wart sampled by curettage from the palmar 
aspect of the hand and (b) a dermis rich, unkeratinised anal wart that was snip 
excised. The HPV VL may have been overestimated in dermis poor lesions 
(due to fewer uninfected dermal cells material compared with HPV epidermal 
containing cells).  In dermis rich lesions the opposite may have occurred, 
resulting in an underestimation of HPV VLs.   
 
 
  (a)         (b) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix Figure A2.9 Photographs of histological frozen sections taken from wart 
biopsies representative of (a) dermis poor and (b) dermis rich specimens.  In the left panel, 
hyperkeratosis - k - and thickened epidermis - e - can be seen. There is no dermis - d - is 
missing at the deep margin.  In the right panel, the wart surface is unkeratinised and consists of 
nucleated cells above an acanthotic (thickened) epidermis - e.  Abundant dermis is seen - d - in 
contrast to the left panel. Stain: H&E; x 40 magnification. Tissue has been fixed, cut, stained and 
photographed by the author. 
 
2.2.8 Example of the histology of a wart-like lesion (non-wart: 
dermatofibroma) 
 
 
    (a)          (b) 
 
Appendix Figure A2.10 Histological photographs of an example of a non-wart 
lesion (dermatofibroma)  from Appendix Tables A3.1 and A3.8.  (a) low power view 
of surface of lesion: hyperkeratosis and hypergranulosis (increased granular cell layer) 
but no koilocytosis.  (b) Higher power view of the underlying dermatofibroma containing 
characteristic spindle cells.  Stain: H&E x40 magnification and x100 magnification, 
respectively.  Photographs courtesy of Dr Nick Francis, Chelsea and Westminster 
Hospital NHS Foundation Trust, London, UK. 
  
 
APPENDIX 2.3 
HLA RESULT  
 
 
The page overleaf shows a scan of the printout of a One Lambda Luminex 
molecular HLA result of an individual for HLA-A locus: the patient is HLA-A*03, -
A*23. 
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APPENDIX 3.1 
CUTANEOUS HPV TYPING BY SEQUENCING AND  
HSL- PCR/MPG LUMINEX METHODS: A COMPARISON 
 
 
The total number of samples obtained (n=218) included: warts from HIV 
infected and healthy patients, wart-like lesions and female genital warts.   The 
first 32 wart (and wart-like) samples to be processed (from 28 patients) were 
analysed with both sequencing and HSL-PCR/MPG methods.  One sample was 
extracted from formalin fixed, paraffin embedded tissue (because the lesion 
was small and after histological assessment there was no tissue remaining for 
snap freezing); Appendix Table A3.1.  Twenty-five of these 32 samples (from 22 
patients) are clinically and/or histologically confirmed warts. Seven samples 
(from seven patients) are wart-like lesions on clinical appearance that, 
histologically, proved to not to be viral warts; Appendix Table A3.1. 
 
One of these non-wart lesions (sample 28) was from a sun-exposed site (scalp).  
The histological slides from sample 28 were reviewed by two independent 
specialist cutaneous consultant pathologists; one pathologist classified it as a 
seborrhoeic keratosis with no viral changes, the other reported it as a viral wart 
with definite HPV changes.  It has been included in this comparison in the non-
wart group, but has been excluded from comprehensive typing analyses. 
 
Sequencing Results 
During sequence reporting, each forward and reverse sequence was entered 
individually into the BLAST search database.  In most cases (40 of 47 
sequences analysed) a close (99-100%) match with previously published HPV 
sequences could be obtained because the sequence trace was clean; Appendix 
Figure A3.1.  Some were of poor quality or mixed (7 of 47) sequences; 
Appendix Figures A3.2 and A3.3.  In mixed sequences, two or more 
superimposed sequences are present and a consensus sequence was 
determined where possible: forward and reverse sequences were aligned in the 
Appendix Table A3.1 Comparison of HPV types detected by (i) nested PCR/ 
sequencing and (ii) HSL-PCR/MPG techniques. A traffic light system indicates 
which samples are identical/concordant (green) and which are discordant (red).  Grey 
shading indicates HPV types that are not cutaneous HPVs.  Each patient is numbered 
1-28; some provided multiple samples – these are labelled a or b.  Sample 10b,c is 
pooled from two small but discrete lesions from the same site (face).  Samples 1-22 
are clinically and/or histologically confirmed viral warts (w); Samples 19b-28 
histologically are not warts.  Abbreviations - Site: H - hand; F - foot; Ung - peri-
ungual (sited around the nail bed); Fa - face; Fa-EV - Epidermodysplasia 
Verruciformis-like lesion from the face; L - limb; T - trunk; S - scalp.  Type of 
specimen: Cur - curette; In - incisional biopsy; Pa - parings; Pun - punch biopsy.  
Clinico-pathological Diagnosis: W - viral wart; Vir Ker - viral keratosis; Act Ker–
FFPE - actinic keratosis analysed from formalin fixed, paraffin embedded tissue; DF - 
dermatofibroma; Seb Ker - seborrhoeic keratosis; Act Ker - actinic keratosis.  Results: 
neg – negative for HPVs; Concord - concordant; Disc - discordant; Ident - identical; 27 
sub? - possible HPV 27 sub-type; 5var - probable HPV 5 variant.  Symbols:  † - HPV 
3 has been detected by HSL-PCR/MPG with a low MFI of 156 (below cut off);  * - HPV 
4 or HPV 7 are not identified by CN1-3 sequencing primers;   ‡ - HPV 8 is the 
probable cause;  Ψ - HPV 5, 49, 72 and 84 are not detected by HSL-PCR/MPG. 
 
BioEdit program and the nucleotide bases modified manually using both 
forward and reverse traces as a guide. 
   
  
 
 
 
 
 
Appendix Figure A3.2 Unreadable DNA sequence trace from BioEdit program 
with dye blobs (large peaks). N - points at which nucleotide sequence could not be 
determined. 
Appendix Figure A3.1 Clean DNA HPV CN2 reverse primer sequence trace from 
BioEdit program.  The sequence extends from 86 to 165bp.  It was derived from 
sample 11 and was identified as HPV 27. A. C, G, T – adenine, cytosine, guanine, 
thymine nucleotides. 
Appendix Figure A3.3 Mixed DNA sequence trace from BioEdit program.  It is 
most likely to represent two different HPV types but could also be superimposed 
human genomic/HPV sequences.  A, C, T - adenine, cytosine, thymine nucleotides; N 
– points at which nucleotide sequence could not be determined. 
  
The commonest HPV types detected in warts by sequencing are HPV 27 
(11/25; 44%), 57 (6/25; 24%) and 28 (4/25; 16%); Appendix Figure A3.4.  HPV 
2 and 3 are each seen in 2/25 (8%).  A number of non-cutaneous HPV types 
that are not the intended target of CN1-CN3 primers have also been detected.  
HPV 5 and HPV 49 (beta HPV types) and HPV 72 and 84 (HPV types from 
alpha group, species 3, and are an infrequent cause of genital lesions) have 
been detected in four separate lesions.  Six of the seven non-wart samples are 
negative for HPV by sequencing; the one that is positive for HPV 27 is a stucco 
keratosis (and this type has been confirmed by HSL-PCR/MPG). 
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Appendix Figure A3.4 HPV types detected in wart samples by both sequencing, 
HSL-PCR/MPG Luminex methods (and both methods combined).  HPVs 27, 57, 28 
and 7 are the commonest types identified. HPV 4 and 7 are not detectable by sequencing 
(they are not complementary to the primers used) and HPVs 5, 49, 72, 84 are not 
detectable by the probes included in the HSL-PCR/MPG assay (they are beta or genital 
types).  
 
Of the HPV types identified by sequencing, one is likely to be a HPV type 
variant; sample 17. The consensus sequence differed by nine of 213 base pairs 
(95% homologous) to the HPV genome sequence but was homologous (100%) 
with the three HPV 5 variants FC1 L1, Waf2 L1 and Sam4 L1  (Genbank 
accession numbers U49472.1, U49471.1 and U49468.1 respectively; 
http://www.ncbi.nlm.nih.gov/genbank). Without sequencing the whole of the L1 
open reading frame (ORF) from the HPV in question, it is not possible to 
ascertain if it is indeed a variant or a subtype with complete accuracy.  
However, it is most likely a variant of HPV 5 (rather than a subtype) given the 
homology to the variants above.  FC1 L1, Waf2 L1 and Sam4 L1 may in fact be 
the same variant that has been partially sequenced with different fragments; 
only once the whole sequence is submitted to Genbank can they be classified 
with complete certainty.  
 
A possible HPV 27 variant/sub-type has been identified from sample 20.  The 
consensus sequence of 189 bp had 93% homology with HPV type 27 (there a 
were 13 mismatches); Appendix Figure 3.5.  However, five of these mis-
matches were indeterminate nucleotides (see nucleotides highlighted in yellow 
– ‘N’); Appendix Figure 3.5.  One mis-match was a possible a nucleotide 
deletion in the sample (see nucleotides highlighted in green); Appendix Figure 
A3.5.  Therefore, if only the deletion and mis-matches are included the 
homology with HPV 27b is 181/189 (96%).  Because the sequence is a short 
segment of the HPV genome (~8000bp) the true homology can only be 
estimated.  If this 189bp segment is deemed to be representative of the whole 
L1 gene found in the sample, then it would be classed as a HPV 27 subtype (2-
10% difference).  
 
HSL-PCR/MPG Luminex and sequencing results: comparison  
The combined results of sequencing and HSL-PCR/MPG have been examined: 
HPV 27, 57 and 28 are still the commonest HPV types in warts, found in 44%, 
32% and 16% of lesions respectively; Appendix Table A3.1 and Figure A3.4.  
HPV 7 (only detected by HSL-PCR/MPG) is found in 4/25 lesions or 16%.  
 
  
 
 
 
 
 
 
 
 
 
 
Non-wart samples 
One (of seven) non-wart lesions (sample 23, a stucco keratosis) has been seen 
to be HPV positive with sequencing (HPV 27) and HSL-PCR/MPG (HPVs 27, 
57, 95).  
 
Negative samples 
Seven samples (one wart and six non-warts) are negative for cutaneous HPV 
types by both methods.  The wart specimen sample 8 (I63T) is positive for beta 
HPVs, one of which may be important; Appendix Table A3.1.  Four of five non-
wart samples are also positive for beta HPV types.  The non-wart sample 26 is 
positive for the universal probe on the beta HPV assay (suggesting an 
unidentified HPV type was present).  All of these HPV negative samples have 
 
AGTGGT-CTTTTGATGTACAACTCATCTGGGATGGTGTCACCCATCTTACCACCCCTATT 
|||||| ||||| |||||||||||||||||||| |||||||||||||||||| ||||||| 
AGTGGTACTTTTAATGTACAACTCATCTGGGATTGTGTCACCCATCTTACCAGCCCTATT 
 
GAAAAAATGACGAGTGAACATTTGTTCTCTNCGCAGGGAAAAGAACATGGAATCACCATA 
||||||||||||||||||||| |||||||| ||||| ||||||||||||||||||||||| 
GAAAAAATGACGAGTGAACATCTGTTCTCTACGCAGCGAAAAGAACATGGAATCACCATA 
 
AGGNTCTGCAGCCATTTTCAGTTAATCTGGATATTTACATANGTTTGTACAAATATCCAA 
||| ||||||||||||||||| ||||||||||||||||| | |||||||||||||||||| 
AGGCTCTGCAGCCATTTTCAGGTAATCTGGATATTTACAGACGTTTGTACAAATATCCAA 
 
 NGGNACATC  SAMPLE SEQUENCE 
  || ||||| 
 AGGAACATC  HPV 27b (HPV type 27 accession AB211993.1) 
 
Appendix Figure A3.5 Nucleotide sequence of sample 20 compared with HPV27b 
sequence (HPV 27).  The top line (in blue) represents the 189bp nucleotide sequence from 
sample 20.  The bottom line (in black) is the sequence from the complete genome of HPV 27b 
(HPV27); nucleotides 6597 to 6409.  The nucleotides highlighted in green are mismatches in 
the sample sequence, compared with the HPV 27 reference sequence (the deletion after the 
6th nucleotide from sample 20 is included as a mismatch).  Abbreviations:  A, C, G, T - 
adenine, cytosine, thymine nucleotides; N – points at which nucleotide sequence could not be 
determined.  Figure taken from GenBank BLAST query: www.blast.ncbi.nlm.nih.gov (HPV 27b 
accession AB211993.1). 
 
been successfully amplified for a 120bp segment of the beta globin ‘house 
keeping’ gene; see Appendix 3.5 for further details of beta globin PCR. 
 
HSL-PCR/MPG Luminex HPV typing and sequencing: concordance of results  
Results have been classed as concordant if at least one type is detected in 
common (the identification of additional types by either method was acceptable 
as concordant).  Discordant samples had different HPV types.  The two 
techniques of sequencing and HSL-PCR/MPG demonstrate a high level of 
concordance.  Most (92% of) wart samples have identical (15/25) or concordant 
(8/25) results.  Some of the variation in concordant samples may have been 
due to HPVs 5, 49, 72 and 84 not being identified by HSL-PCR/MPG.  All of the 
non-warts are identical/concordant.   
 
Two warts are discordant, sample 10a and 16a.  In both cases the most 
important type identified on HSL-PCR/MPG was HPV 7 or 4, respectively; these 
are not amplified by the CN1-3 sequencing primers.  However, the other 
discordant types identified through sequencing (3 and HPV 27, 28 respectively) 
are also included in the HSL-PCR/MPG and it is plausible that these may have 
been present in lower quantities than HPV 7 or HPV 4.  Therefore, intrinsic 
differences in the assay may account for the discordance observed.  
 
Comparison of methodologies 
The HSL-PCR/MPG technique is much more efficient than nested PCR 
sequencing: there is only one round of PCR, the samples can be processed in a 
much shorter time and it detects mixed infections in a single step.  Additionally, 
the size of the amplicons are small (76-84bp) compared with the nested PCR 
used (273-328bp).  Although sequencing can detect mixed infections, it must 
usually be done via cloning which is laborious.  Cloning involves inserting HPV 
PCR products into plasmid vectors and then allowing bacterial colonies carrying 
the clones to replicate. If the sequences from ten colonies, for example, are 
examined then a HPV type making up 10% of the PCR product could be 
identified. 
 
Both techniques are liable to problems with PCR competition as primers 
inherently have different binding affinities for each HPV type and therefore can 
preferentially detect certain types.  For HSL-PCR/MPG, the PCR competition 
can be at least partially corrected by adjusting individual HPV type probe 
signals.  HPV 1 and 2 are detected with the highest sensitivity (1-10 input 
copies/PCR); the assays for HPV 3, 27, 57 (100-1000 copies) and HPV 28 
(1000-10,000 copies) are less sensitive (de Koning et al., 2010).  Therefore, it is 
possible that the results of sample 13, 16a and 16b  (HPV 28 not detected by 
HSL-PCR/MPG in the presence of HPV 4 or HPV 27) are at least partly 
explained by this. 
 
PCR contamination 
One of the potential problems with nested PCR is contamination. This might 
manifest as false positivity of DNA extraction negative controls, or detection of 
HPV as single or mixed infection(s) in a sample, where one or more are 
contaminants.  Precautions against contamination have been taken. Dedicated 
clean UV treated microbiological hoods have been used for DNA extraction and 
PCR preparation.  A pre-PCR (forensics) room has been used for making PCR 
master mixes.  Plasmids are separated from samples and prepared in a post-
PCR area.  Also, negative controls have been used.  Twelve negative controls 
in total were also amplified in the same nested PCR; three samples of genomic 
DNA that were extracted alongside the samples and nine negative controls 
(water).  None was positive. 
 
In addition, results are highly concordant between the two methods using one 
or two rounds of PCR (HSL-PCR/MPG and sequencing respectively), 
suggesting that PCR contamination is not a significant issue.  However, the 
identification of mixed HPV types, by either method, in a quarter of samples 
(9/32) means that this cannot be discounted.  Tissue from HIV infected patients 
may complicate this issue further, as mixed types have previously been 
identified in warts from immunosuppressed patients (Harwood et al., 1999). 
 
 
HSL-PCR/MPG and novel HPV types/variants 
One potential disadvantage of the HSL-PCR/MPG technique is that it may not 
detect all novel types or variants.  However, all known subtypes/variants with 
published sequences (by the end of 2009) in the region amplified by the HSL-
PCR/MPG primers (76-84bp section of the L1 HPV gene) have been included in 
probe development (Dr Maurits de Koning, DDL, The Netherlands, personal 
communication).  Therefore, most variants/subtypes are potentially identifiable 
by the existing probes – they are detected as closest related type.  In practice, 
novel cutaneous types probably occur relatively infrequently; this contrasts with 
beta types whereby novel/related types are often detected when sequencing is 
used (Harwood et al., 1999).  
 
In this study, HSL-PCR/MPG detected HPV 27 (and HPV 3, 7, 57) in lesion 20, 
whereas sequencing identified a possible subtype/variant of HPV 27 (and also 
HPV 84).  There are several explanations for this; firstly, the HPV 27 
subtype/variant sequence was part of a true HPV 27 subtype/variant that was 
reported as HPV 27 by HSL-PCR/MPG.  Secondly, HPV 27 and HPV 27 
subtype/variant were both present.  Thirdly, the sequence was in fact from HPV 
27 but the amplicon was too small to identify it as true HPV 27.  
 
Non-cutaneous HPV types were detected by sequencing  
Four HPV types that are not preferentially amplified by the CN1-3 premiers 
have been identified by sequencing; HPVs 5, 49, 72 and 84.  HPV 5 is a beta 
HPV type that was detected (alongside HPV 57) by sequencing in sample 17; 
Appendix Table A3.1.  HPV 5 is not detectable by HSL-PCR/MPG because this 
assay does not include beta HPV probes.  However, this particular individual 
(pM83) had an interesting EV-like clinical presentation and a high HPV 5 VL 
was detected on HPV VL (154 copies/cell) meaning it may be important in the 
generation of the lesion; see Appendix 2.2.5. 
 
Another beta HPV type, HPV 49, is found in sample 10b,c – a combination of 
two tiny lesions on the lip/peri-oral area; Appendix Table A3.1.  HPV 49 was 
later confirmed by comprehensive typing on beta RHA.  However, HPV 3 and/or 
HPV 7 are probably the most important HPV types as these are both cutaneous 
wart-associated types.  
 
The genital HPV types (HPV 72 and 84) have been identified in two hand warts; 
samples15 and 20, respectively, Appendix Table A3.1.  HPV 72 is the only type 
identified in sample 15.  However, HPV 84 is seen alongside a other types In in 
sample 20  (HPV 3, 7, 27/ 27?subtype, 57) and the detection of HPV 84 may 
represent skin contamination.  This individual had a concurrent genital wart in 
which high levels of HPV 11 were found but HPV 84 could not be confirmed on 
the genital HPV assay as it is not included in the genital panel of probes. 
APPENDIX 3.2 
GENITAL AND BETA HPV VIRAL LOADS: PRELIMINARY RESULTS  
 
 
3.2.1 Genital and beta HPV viral loads: introduction 
 
HPV VLs were conducted for the commonest genital and beta HPV types; 
protocols existed for HPVs 5, 8, 15, 23, 24, 38 (beta) and HPVs 6, 11, 16 and 
18 (genital).  All samples that were positive for these HPV types on 
comprehensive HPV typing were tested for VLs.  Those samples that had a 
detectable HPV VL were then quantitatively tested for the beta-globin house 
keeping gene (to determine the number of human cells in the sample) enabling 
calculation of the HPV VL.  Overall, 273 HPV VL tests were performed in 148 
lesions, see Appendix Table A3.2.  Protocols for a cutaneous HPV VL assay 
were not available at the commencement of this research.  However, semi-
quantitative MFI data from the HSL-PCR/MPG assay provided complementary 
data.  A method of quantifying VLs for HPVs 3, 27 and 57 has been 
subsequently published and may have provided additional information to MFIs 
(Kohler et al., 2009). 
 
3.2.2 Results and discussion – genital and beta HPV viral load range 
 
A wide range in the calculated VL values has been observed (range 0.00004 to 
59,722 copies/cell); Appendix Table 3.2.   Low viral load values are likely to be 
inaccurate (<0.01 copies/cell), because many Ct values have been extrapolated 
from the standard curve.  
 
A HPV type for every wart: identifying a causative HPV type  
In the era of sensitive assays (such as the HSL-PCR/MPG, SPF10 LiPA and 
beta RHA) multiple HPVs are frequently identified in one lesion; such as in the 
warts studied herein.  Beta and genital VL assays together with semi-
quantitative HSL-PCR/MPG data provide an indication of causative type.  
However, even combining these results, it is difficult to be certain of a causative 
HPV type for each wart.  HPV VL data is not always accurate (Ball et al., 2011) 
and HPV types are still often missed despite the highly sensitive combination of 
HPV detection methods used herein (the warts with negative HPV typing 
results; see Appendix 3.5).  There is also evidence suggesting that different 
HPV types can be found in different portions of the same lesion (Harwood et al., 
1999). 
 
There is no clear VL cut-off above which a given HPV type is likely to be 
‘causative’ or actively contributing to wart formation.  It is possible that HPV VL 
levels of greater than ten copies/cell may be causative (Ball et al., 2011). In 
genital warts, Ball et al., (2011) correlated mRNA levels by q-PCR with DNA 
viral loads and found the absolute levels of RNA and DNA did not correlate well.  
However, DNA VLs of >1 copy/cell were consistently matched by mRNA levels 
of >1 copy/cell (22/24 specimens).   
 
Thus, a reasonable HPV VL cut-off might be one copy/cell.  However, the other 
HPV types detected in the lesion should also be considered, particularly in 
warts with HPV VLs of between 1-10 copies/cell. Copy numbers over one 
copy/cell allows for some uninfected cells from a lesion (healthy keratinocytes, 
degraded surface keratinocytes and those derived from the dermis) to contibute 
to the genomic DNA level (cell count).  HPV types with VL levels of <0.01 
copies/cell (even accounting for variations in assay) are unlikely to contribute to 
wart generation.  
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
Appendix Table A3.2 Viral loads: number of lesions tested and range of values 
calculated. The number of lesions that were examined for each HPV type specific viral 
load is shown; many lesions were tested more than once. The ‘HIV infected’ and ‘healthy 
individuals’ groups included here are the same as those in the All group HPV analyses 
(see Chapter 3).  ‘Other’ - refers to samples that were not included in the All group HPV 
analysis and have been taken from the following groups: females with genital warts (HIV 
infected and healthy), duplicate lesions (HIV infected and healthy), non-wart lesions (HIV 
infected and healthy) and a patient case (N58). 
APPENDIX 3.3 
OPTIMISATION OF COMPREHENSIVE HPV TYPING: 
REPRODUCIBILITY - MULTIPLY SAMPLED LESIONS 
 
 
3.3.1 Reproducibility of cutaneous, beta and genital HPV type assays - 
multiply sampled lesions 
 
Reproducibility has been assessed by evaluating the comprehensive typing 
results of paired (duplicate) samples.  Two or more samples from the same wart 
(or very similar warts at the same site) were available from twelve HIV infected 
individuals (n=27 samples) and 14 healthy individuals (n=28 samples). Twenty 
four patients in total had paired (duplicate) lesions; one individual had triplicates 
and in another quadruplicates available.  The same wart was sampled in 14 
individuals (individuals 1, 5, 6, 7, 8, 11, 12, 14, 18, 20, 21, 22, 23, 25).  Another 
ten individuals provided samples that were taken from clinically separate 
lesions that were located on the same body site (individuals 2, 3, 4, 9, 10, 13, 
15, 16, 17, 19).  Three individuals had recurrent lesions after initial biopsy and 
these were biopsied again, when they recurred at the same site (individuals 11, 
24, 26); Appendix Tables A3.3-5. 
 
The reproducibility of specimen collection to the end point of HPV typing result 
has been examined; each specimen was sampled separately and snap frozen 
in an individual pot and each DNA extraction, PCR and line probe or HSL-
PCR/MPG assay conducted independently.  Reproducibility has been examined 
for each HPV group; cutaneous, genital and beta HPVs. As before (Appendix 
3.2), results have been classed as concordant if at least one type is detected in 
common (the identification of additional types by either method was acceptable 
as concordant).  Discordant samples harbour different HPV types. 
 
 
   
Appendix Table A3.3 Reproducibility: results of cutaneous HPV typing for multiply 
sampled lesions.  Concordant results are highlighted in light green.  Discordant results are 
highlighted in red.  Bold type indicates which samples were selected for inclusion in the final 
analysis of comprehensive HPV typing.  Individuals numbered 1-12 are HIV infected 
individuals and those numbered 13-26 are healthy individuals.  Abbreviations: C - 
cutaneous wart(s); contam – contaminated lesion; Discord – discordant results (different 
HPV types were found); ex derm – excess dermis in lesion; G – genital wart(s); Ident – 
identical results; Sim – similar results (the same types were detected in both specimens, but 
one harboured additional HPV types); T1-Tx -tumour/wart lesion numbers. 
 
  
 
  
 
 
Appendix Table A3.4 Reproducibility: results of genital HPV typing for multiply 
sampled lesions. Concordant results are highlighted in light green.  Discordant results are 
highlighted in red.  Bold type indicates which samples were selected for inclusion in the final 
analysis of comprehensive HPV typing.  Individuals numbered 1-12 are HIV infected 
individuals and those numbered 13-26 are healthy individuals.  Abbreviations: C - 
cutaneous wart(s); contam – contaminated lesion; Discord – discordant results (different 
HPV types were found); ex derm – excess dermis in lesion; G – genital wart(s); Ident – 
identical results; Sim – similar results (the same types were detected in both specimens, but 
one harboured additional HPV types); T1-Tx - tumour/wart lesion numbers. 
 
  
 
 
Appendix Table A3.5 Reproducibility: results of beta HPV typing for multiply 
sampled lesions. Concordant (similar or identical) results are highlighted in light green.  
Discordant results are highlighted in red.  Bold type indicates which samples were 
selected for inclusion in the final analysis of comprehensive HPV typing.  Individuals 
numbered 1-12 are HIV infected individuals and those numbered 13-26 are healthy 
individuals  Abbreviations: C-cutaneous wart(s); contam – contaminated lesion; Discord 
– discordant results (different HPV types were found); ex derm – excess dermis in lesion; 
G – genital wart(s); Ident – identical results; Sim – similar results (the same types were 
detected in both specimens, but one harboured additional HPV types); T1-Tx - 
tumour/wart lesion numbers. 
 
Overall, HPV typing results of multiply sampled lesions show acceptable 
reproducibility. Results of cutaneous and genital HPV typing are most 
concordant at 81% each; beta HPV typing has 62% concordance.  
 
Cutaneous HPV assay variability 
Five individuals (of 26) have discordant results; most are healthy individuals.  
Primarily, the differences have been seen as a consequence of one duplicate 
testing positive, and the other negative, for a single cutaneous HPV type.  This 
may represent a ‘false negative’ for the HPV type in question in the negative 
sample, or a false positive in the positive sample.  The reproducibility of the 
HSL-PCR/MPG has been estimated at >95% (de Koning et al., 2010).  
However, variability is likely to be higher in the duplicate lesions examined 
herein because many were re-treated or contiguous lesions on the same body 
site, rather than continuous lesions sampled contemporaneously (that is: 
individuals 11, 24, 26 and 2, 3, 4, 9, 10, 13, 15, 16, 17, 19, respectively).   
 
Most of the duplicates are from cutaneous sites; therefore, cutaneous types are 
likely to be present in high VLs (and have less variability).  The lower sensitivity 
of the HSL-PCR/MPG assay (detecting 1 to 10,000 copies/reaction) compared 
with the beta RHA (detecting ten and 100 HPV copies/reaction) may have 
contributed to the greater concordance for cutaneous types than beta HPBV 
types (de Koning et al., 2006; de Koning et al., 2010). 
 
Genital HPV assay variability 
Genital HPV typing also had high reproducibility (81% concordance); Appendix 
Table A3.4.  Most of the lesions examined are cutaneous lesions, where one 
would expect to see genital types found less frequently and/or in lower copy 
numbers.  If only genital lesions are considered, all (of five) had identical results 
(100% reproducibility).   
 
A sampling discrepancy rate of approximately 10% has been estimated for the 
genital RHA used (Quint et al., 2001), although this was performed in cervical 
scrapes.  Therefore, the variability of the genital HPV typing results included in 
this thesis is similar.  
 
Beta HPV assay variability 
Beta HPV typing is the least reproducible (62% concordance); 11 of 26 
individuals have discordant results (42%); percentages do not add up to 100 
because one triplicate had both concordant and discordant results, Appendix 
Table A3.5.  Results were classed as ‘similar’ (or concordant) if at least 50% of 
the beta types found the sample with the fewer types were seen in both (all) 
lesions.  For example, in T1/2 samples from individual 7, the beta HPV types 5, 
8, 17 and 5, 8, 12, 14, 17, 24 were detected, in each lesion, respectively; the 
results are in fact quite similar.  Although 43% of the types from T1 were found 
in T2, 100% of the HPVs found in T1 were detected in T2 (the lesion with the 
least types).  Therefore, this was classed as a concordant result.  
 
The slightly lower concordance for beta type results may be partly explained by 
the greater number of beta HPV types detected in each lesion, decreasing the 
probability of obtaining matching results. Low copy numbers of beta HPVs 
detected by the highly sensitive assay may also have contributed.  The beta 
HPV assay has been shown to have a reproducibility of 91-98% when the same 
batch of input DNA is used for PCR for the beta RHA (de Koning et al., 2006).  
If the same criteria for reproducibility used herein are then applied to the 
samples of de Koning et al. (2006) then their respective figure would have been 
73% (compared with 62% for the samples herein).  However, in the samples 
herein, additional variables were assessed: lesion sampling, processing and 
DNA extraction were also examined.  
 
Sources of variability 
Several potential sources of variability during sample processing have been 
identified.   
 
Firstly: lesion sampling variability - different HPV types have previously been 
identified in independently extracted DNA from different portions of the same 
wart (Harwood et al., 1999).  Laser capture microdissection of separate parts of 
a lesion may have been able to differentiate two separate parts of the lesion. 
However, there did not appear to be any relationship between the HPV type 
reproducibility and whether lesions are continuous, separate or re-treated.  The 
concordance rates of all HPV types for identical/similar lesions are: 72% for 
continuous lesions, 80% for separate lesions and 66% for re-treated lesions; 
overall, the rate is 75%.  
 
Secondly: tissue processing variability - some of the HPV types found in lower 
VLs may have been missed in small samples (because the number of cells 
sampled is smaller) or large samples (because only part of the lesion may have 
been processed).  Standardising the amount of tissue sampled may have 
avoided this; for example sampling all warts by 4mm punch biopsy tool or taking 
swabs from the wart surface. 
 
Thirdly: DNA extraction variability - variation in the size of tissue particles that 
entered the DNA extraction columns (many of the specimens are chopped with 
a scalpel, by hand) and in the amount of HPV DNA eluted, may have prevented 
some HPV types from being released.  This is particularly the case for very 
hyperkeratotic specimens from hands and feet that are firm and difficult to chop 
finely.  Sampling warts from only one body site or using skin swabs might have 
standardised the physical characteristics of tissue fragments. 
 
Fourthy: DNA input variability - variations of input DNA quantities (in to the 
PCR) may also be important in variability.  In a recent study utilising the same 
beta HPV assay, a mean of 2.4 additional types were detected in concentrated 
specimens when compared with dilute ones; range 35 to 54,350 copies of beta 
globin per 10µl of sample aliquot (Weissenborn et al., 2009a).  The intended 
concentration of input DNA for our PCRs was 10-20 ng/µl per specimen (~15ng 
ng/µl corresponds to approximately ~45,000 beta globin copies/10µl) but the 
actual range for our specimens, as calculated from all of those specimens that 
were analysed for HPV VLs was 4,130 to 220,000 beta-globin copies/10µl.  
However, this may be an over-estimation as only those that were HPV positive 
on beta or genital RHAs were analysed for HPV VL; samples with the lowest 
total DNA concentrations are likely to test negative for HPV.  Therefore, 
variation in the amount of cellular DNA may have influenced the number of 
types detected in each specimen.  However, as was suggested by Weissenborn 
et al. (2009a), the types that were ‘missed’ in samples with lower concentrations 
of input DNA are likely to be in low copy numbers, and therefore, of lesser 
significance. 
 
Fifthly: PCR variability and competition in PCR - specimens may contain many 
HPV types, especially beta types.  The more HPV types present in the DNA 
specimen, the more likely that competition may have played a part in variability 
of the HPV types detected. Variability is partly dependent on HPV epidemiology 
– over 100 types are known (64 from a possible 73 HPV types included in the 
assays were identified in our samples).  Also, sensitive broad-spectrum assays 
such as the RHAs and HSL-PCR/MPG that identify multiple HPV types with low 
VLs (<0.01 copies/cell) may have high variability purely due to chance.  For 
example, variability is likely to be less in an assay that identifies one or two HPV 
types than one that identifies 5-10 HPV types in each lesion.  
 
Finally:  HPV assay variability error - minor inconsistencies in HPV type binding 
of the probes to RHA strips and in the HSL-PCR/MPG probe mix between 
assay runs may also have led to variability. 
 
3.3.2 Reproducibility of genital and beta HPV viral loads - multiply 
sampled lesions 
 
The HPV VL has been examined in duplicate lesions from ten of the 26 
individuals with duplicate samples; Appendix Table A3.6.  Sample duplicates 
from HPV typing reproducibility (Appendix Tables A3.3-5) that are both positive 
for a given HPV type on comprehensive typing have been quantified for HPV for 
VL. 
The HPV VL results are remarkably similar.  Sixteen duplicates from these ten 
individuals have been tested for VLs and two thirds (63%) are concordant.  The 
concordant samples are predominantly lesions with HPV VLs of >1 copies/cell.  
One sample from each of the six discordant paired samples has an 
undetectable HPV VL and the other (detectable sample) has a low (<0.4 
copies/cell) or very low (<0.03 copies/cell) VL.  These results are consistent 
with a high level of concordance. 
Appendix Table 3.6 Reproducibility: viral load results for multiply sampled lesions. 
Individuals numbered 5, 7, 9-11 are HIV infected individuals and those numbered 16, 17, 
19, 21, 22 are healthy individuals.  The sample numbering system is the same as for 
Appendix Tables A3.3-5.  Cells highlighted in green denote concordant/similar results; 
cells highlighted in red denote discordant results. Bold type indicates which samples (and 
results) have been selected for inclusion in the final analysis of comprehensive HPV 
typing. Abbreviations: T - tumour/wart; C - cutaneous wart(s); contam – contaminated; G 
– genital wart(s); nd - not detected. 
 
3.3.3 Reproducibility of (probable) causative HPV type – computational 
analysis of multiply sampled lesions 
 
The particular comprehensive typing systems used to detect cutaneous, genital 
and beta HPVs has the advantage of being very sensitive, and all the types that 
are present in a sample have been detected, even those present at very low 
levels.  The disadvantage of this system is that finding the most important HPV 
type in a wart can be difficult. 
 
In order to examine if the comprehensive HPV typing system can identify the 
probable causative type reproducibly, the multiply sampled lesions from 
Appendix Tables A3.3-6 have been reported for probable causative HPV types 
only, in a computational analysis; Appendix Table 3.7  
 
This has been done using a three-step process.  Firstly, all beta types with HPV 
VL results of <0.2 copy/cell have been removed from the result of samples also 
harbouring genital and/or cutaneous types.  The less common beta HPV types, 
without viral load data (for example HPV 93), have also been discarded as the 
probable causative HPV type because the beta type is unlikely to generate the 
wart in the presence of genital or cutaneous types. 
 
Next, in the absence of cutaneous HPV VL data (because this has not been 
performed) the MFI data from the HSL-PCR/MPG have been used semi-
quantitatively for cutaneous HPV types; as has been done by others previously 
(de Koning et al., 2010; Schmitt et al., 2011).  In samples with mixed cutaneous 
HPV type infections where one type had a MFI of <300 units, the non-dominant 
type(s) have been removed.  An MFI <200 units is the cut-off for a positive 
signal.  Therefore, it is unlikely that a HPV type identified at a low level can be 
causative in a lesion that also contains another type that is detected with a 
strong signal (for example, 3000-8000 MFI units). 
 
Finally, the genital typing results have been examined.  Genital HPV types with 
an undetectable or viral load result of <0.2 copies/cell have been removed from 
the sample results.  The genital types with no available HPV VL assay have 
been deemed as a possible cause (unless cutaneous types with high MFIs 
were also present, in which case the cutaneous HPV has been deemed the 
likely cause). 
 
For one sample (from individual 5) sequencing data has been used (as this 
method identified the most likely causative type).  It should be noted that for 
individual 26 that HPV 8 is the only type found in one duplicate; the viral load is 
0.2 copies/cell and therefore is unlikely to be causative (and the sample has 
been deemed negative).  The most likely explanation is that the lesion is related 
to a cutaneous (or genital) HPV type that has not been identified by the genital 
RHA or HSL-PCR/MPG assays. 
 
Reproducibility assessed in this way increased to 96% overall for all HPV types. 
 
Although this approach might have been performed for the analysis in Chapter 
3, this has not been done for several reasons.  Firstly, causation is difficult to 
determine with certainty, despite comprehensive HPV typing, as a causative 
HPV type can still be missed (for example, HPV 72, identified by sequencing in 
lesions from individual 5).  Secondly, multiple methods of quantification are 
necessary to provide collaborating quantification data, such as HPV DNA VLs, 
HPV expression data from RNA q-PCR, and/or in situ hybridisation.  Therefore, 
the HPV analysis in Chapter 3 has been performed including all of the HPV 
types identified (not only the probable causative HPV).   
  
 
 
 
 
Appendix Table A3.7 Reproducibility: results of combined HPV typing taking into 
account probable ‘cause’ of lesion. Individuals numbered 1-12 are HIV infected 
individuals and those numbered 13-26 are healthy individuals.  The sample numbering 
system is the same as for Tables 3.2-3.5 in Chapter 3.  Cells highlighted in green denote 
concordant/similar results; cells highlighted in red denote discordant results. Bold type 
indicates which samples (and results) were selected for inclusion in the final analysis of 
comprehensive HPV typing. Abbreviations: C - cutaneous wart(s); contam - 
contaminated; G – genital wart(s); nd - not detected; T - tumour/wart; * - denotes a major 
HPV type – the likely cause of the lesion; Ψ − denotes minor HPV type (less likely to be 
the cause, but present in amounts sufficient to cause the lesion). 
 3.3.4  Selection of multiply sampled lesions for inclusion in HPV typing 
analyses 
 
For the analysis of comprehensive HPV typing that is presented in Chapter 3 
one sample has been selected from each of the 
duplicate/triplicate/quadruplicate samples (from 26 individuals); Appendix 
Tables A3.3-3.6.  Lesions have been selected at random (n=18), unless one of 
the following four criteria were present: 
• sample depth – the deepest part of the lesion has been included to 
reduce surface contamination (n=5 individuals); 
• multiple/confluent lesions – samples from single lesions have been 
chosen in preference to combined or confluent lesions (n=1 individual); 
• dermal tissue - one (recurrent) lesion was sampled twice using two 
sampling methods, one by punch biopsy and one by curettage – the 
latter has been chosen as it is more likely contain HPV infected 
epidermal keratinocytes  and less dermis (n=1 individual); 
• contamination - finally, a duplicate sample from one individual has been 
discounted from comprehensive typing analysis, as contamination might 
have occurred at collection (n=1); this is the only sample that may have 
been contaminated at collection.   
 
 
 
 
 
 
 
 
 
 
 
 
APPENDIX 3.4  
OPTIMISATION OF COMPREHENSIVE HPV TYPING: SPECIFICITY - HPV 
TYPING OF NON-WART SPECIMENS/FALSE POSITIVES 
 
 
Cutaneous and genital HPV types - specificity  
Twenty five lesions were wart-like on clinical appearance but have been given 
other histological diagnoses. They have been excluded from HPV typing 
analysis because, histologically, none were entirely consistent with warts.  They 
can be found in Appendix Table A2.8.  They have been comprehensively HPV 
typed to provide data on specificity.   
 
A relatively high proportion of non-wart samples are positive for cutaneous and 
genital HPVs: cutaneous HPV types are found in 16% (4 of 25) and genital 
types in 40% (10 of 25) of lesions; Appendix Table A3.8.  Three of these genital 
non-wart lesions are pre-cancers (related to HPV);  sample 16 (AIN3) and 
sample 15 (AIN2) harbour HR HPV 16 (with VLs of 34 and 1.4 copies/cell, 
respectively) and HR HPV 33 is identifiable in sample 19c (PCIS).  HPV types 
have also been identified in two lesions that histologically are keratoses without 
clear HPV cytopathic changes (sample 1 and 18a) and two further lesions, 
genital seborrhoeic keratoses (samples 18b and c); Appendix Table 3.8.  
Histological confusion between seborrhoeic keratoses and warts may occur and 
HPV was previously detected in a proportion of seborrhoeic keratoses (Gushi et 
al., 2003).  Consequently, samples that are pre-cancers and also those with 
equivocal histologically (that is: wart/non-wart) have been highlighted in grey in 
Appendix Table A3.8 and have been excluded from the calculation of 
specificity.  
 
Eighty eight percent and 82%, respectively, of non-warts are negative for 
cutaneous and genital HPV types (15/17; 14/17 respectively).  This could 
represent a crude calculation of specificity, as the denominator (n=17) contains 
both true negatives and ‘false’ positives.  These ‘false’ positives included in the 
analysis can be explained; a proportion of seborrheoic and stucco keratoses 
may harbour HPV (Gushi et al., 2003; Stockfleth et al., 2004).  Therefore, these 
results are consistent with the known high sensitivity of the tests used.   
 
 
   
 
Appendix Table A3.8 Specificity: table of HPV typing results for non-wart lesions.  Lesions 
highlighted in grey had equivocal histology (for being wart/non-wart), in addition to HPV-related 
genital pre-cancers. Blank cells in the viral load column correspond to lesions that were not 
tested or not detectable. Samples 1-16 – healthy; 17-19 – HIV infected individuals.  
Abbreviations: Lesion type: C - cutaneous; G - genital.  Lesion site: An - anus; F - foot; Fa - 
face; H - hand; L - limb; Ne - neck; Pe - penis; S - scalp; Sc - scrotum; T - trunk.  Biopsy type: 
Cur - curette; In - incisional biopsy; Pa - parings; Pun - punch biopsy.  Clinico-pathological 
Diagnosis: Act Ker - actinic keratosis; FFPE - formalin fixed paraffin embedded; AIN2/3 - anal 
in-situ cancer grade 2/3; Bow - Bowen’s disease (skin); DF - dermatofibroma; Foll Pl - follicular 
plugging; Ker - keratosis; Ker/infl - keratosis with chronic inflammation; PCIS - penis cancer in-
situ; Polyp - fibroepithelial polyp/skin tag; Psor/W - psoriatic lesion with some warty features 
(insufficient to be classed as a wart); SCC - cutaneous squamous cell carcinoma; Seb Ker - 
sebborrhoeic keratosis; Stuc ker - stucco keratosis.  Results: neg - negative no HPV types 
identified. Symbols: * - Positive control from DNA extraction batch was positive for HPV 27; 
most probably represents contamination-reported as negative;  **  - beta HPV universal positive 
but no types identified on any assay;  †   - no HPV viral load is available for genital HPV 33; Ψ - 
tested for beta-globin amplification – all were positive on gel after electrophoresis. 
 
 
Beta HPV types - specificity 
For beta HPV types the specificity has been calculated to be much lower, as 
might be expected, at 41% (or 7/17 of lesions positive) because beta HPV have 
been found in normal skin and plucked eyebrow hairs.  A recent study found 
beta HPV in 49-59% of normal skin biopsy samples (Asgari et al., 2008).  The 
nested PCR protocol that was used in the study of Asgari et al., (2008) is 
probably less sensitive than the beta HPV RHA used herein. One publication 
examining fresh frozen normal skin biopsies (n=7) analysed with the beta HPV 
RHA (Mackintosh et al., 2009) had a detection rate of 57%.  However, plucked 
eyebrow hairs from 84-91% of immunocompetent individuals without SCC 
(n=845) were positive (with the same beta RHA) for at least one type of HPV 
and the mean number of beta HPV types was between four and six (de Koning 
et al., 2009).  Eyebrow hairs may actually provide a reservoir of stem cells, 
believed to be important for beta HPV persistence, so the level of detection may 
be higher (de Koning et al., 2007).  In a familial study of beta HPV prevalence, 
skin swabs were positive in all individuals (n=40) with the same beta HPV RHA, 
with a median of 4 types (Weissenborn et al., 2009a). 
 
Although the results in Appendix Table A3.8 are comparable with these 
previous studies, the higher sensitivity of the beta RHA (used herein) probably 
means the rate of detection should be higher than in the study by Asgari et al. 
(2008).  However, the non-wart lesions in Appendix Table A3.8 are not identical 
to normal skin or to plucked hairs. Ideally, including normal skin biopsies taken 
from HIV infected and healthy individuals in our study would have provided 
useful information about the prevalence of beta types (and also cutaneous and 
genital types) in normal skin in HIV infected patients.   The lesions used for this 
specificity analysis are wart-like or HPV-related conditions (actinic keratoses, 
polyps, Bowen’s disease, SCC, seborrhoeic keratoses, dermatofibroma, 
follicular plugging, AIN and  PCIS).  They can mimic warts clinically to produce 
a hyperkeratotic surface that may harbour excess beta HPV types, leading to 
the detection of more HPV types than might be found on normal skin, for 
example. 
 
APPENDIX 3.5 
OPTIMISATION OF COMPREHENSIVE HPV TYPING: SENSITIVITY  
- HPV NEGATIVE WARTS/FALSE NEGATIVES  
 
 
Of the 144 warts tested (including multiply sampled lesions and special cases), 
none are entirely negative for all three HPV groups, indicating the high 
sensitivity of the comprehensive HPV typing methods.  However, this 100% 
detection rate is probably not a true assessment of sensitivity because beta 
types are frequently detected in normal skin by the RHA beta HPV assay.   
 
To assess the sensitivity of comprehensive HPV typing to detect a HPV type 
that is likely to be relevant in each wart, the genital warts that are negative for 
genital HPVs (n=5) and the cutaneous warts that are negative for cutaneous 
HPV types (n=8) have been assessed (n=13); Appendix Table A3.9. The 
available beta and genital HPV viral loads have also been analysed.  Seven 
warts (five cutaneous and two genital) are likely to be truly negative. 
 
Cutaneous HPV negative cutaneous warts  
Of 107 cutaneous warts that have been HPV typed (from the All group, see 
Chapter 4), eight are negative for cutaneous HPV types.  However, two of these 
eight cutaneous warts are positive for HPVs in high viral loads (HPV 6, a genital 
type or HPV 5, a beta type); Appendix Table A3.9.  In another, HPV 72 was 
clearly identified by sequencing (Appendix Table A3.1) and no other likely 
infecting types have been detected.  Therefore, only 5% (5/107) of cutaneous 
warts are negative and the sensitivity of comprehensive HPV typing in 
cutaneous warts is  95%.  
 
Genital HPV negative genital warts  
Of 37 genital warts that have been HPV typed, five had a negative result by the 
genital HPV assay.  Of these, three warts are positive for other HPV types that 
are likely to be causative; one harboured HPV 91 (a muco-cutaneous HPV), in 
the second, HPV 27, a cutaneous HPV type has been identified with a high MFI 
(of 2,734 units); Appendix Table A3.9.  In the third genital wart, HPV 8 is the 
likely causative HPV as it has been found with a VL of 36 copies/cell, in the 
absence of other HPV types.  Therefore, 5% (2/37) of genital warts are falsely 
negative by comprehensive HPV typing giving a sensitivity of 95%. 
 
  
Appendix Table A3.9 Sensitivity: HPV typing results - HPV negative cutaneous and 
genital warts.  Warts 1-8 are cutaneous warts negative for cutaneous HPV types and warts 
9-12 are genital warts negative for genital HPV types. HIV infected cases are identified by 
‘+’; warts from healthy samples are identified with ‘h’.  Samples with at least one probable 
causative HPV type have been highlighted in grey.  Samples 3 and 7 are probably also 
negative; HPV 8 viral loads (in italics) of between 0.1-1 copies/cell.  Beta HPV types printed 
in bold are detected as strong probe bands; viral loads are not available for HPVs 12, 76, 
80, 92, 93.  Abbreviations: C - cutaneous; Cur - curette; Fa - face; Fa-EV - 
Epidermodysplasia verruciformis-like lesion from the face; G - genital; H - hand; In - 
incisional biopsy; L - limb; neg - HPV negative; Pe - penis; Pun-punch biopsy; Vir Ker-viral 
keratosis/viral wart; W - wart; W-EV - wart with features of Epidermodysplasia Verruciformis; 
W-dyspl - wart with some dysplastic (Bowenoid) features.  Symbols:  * - no beta HPVs were 
identified, but the universal HPV probe was positive, suggesting a HPV type was present 
that could not be identified.  ** seq 72 - HPV 72 was identified on sequencing.  *** - pM83T 
is positive for HPV 27 and M02T2 is positive for HPV 6 but the DNA extraction negative 
controls are positive for HPV 27 or HPV 6, and the results of these samples have been 
adjusted (see Appendix 3.6);  Ψ – samples tested by PCR for beta globin; † - HPV 91 is a 
an uncommon muco-cutaneous type. 
 
 Overall sensitivity 
The overall sensitivity of comprehensive HPV typing, to detect at least one likely 
causative HPV, is 95% (137/144).  Of the seven negative warts (n=5 cutaneous; 
n=2 genital), HPV 8 (a beta type) has been found in levels between 0.1 and 1 
copy/cell in two warts: sample 3 and 7, with HPV 8 VLs of 0.23 and 0.21 
copies/cell, respectively.  This level is unlikely to cause the wart and they are 
probably HPV negative.   
 
Therefore, the comprehensive typing system used is highly sensitive.   
 
HPV negative samples: Discussion 
Samples that are classed as negative for comprehensive HPV typing (that is:  
samples 1, 3-4, 7-8, 10, 12; Appendix Table A3.9) could be so for four reasons: 
• the wart is probably caused by a HPV type not included in the panel of 73 
types probed (for example, in sample 2, comprehensive HPV typing lacks 
probes for HPV 72 but it has been identified by sequencing; Appendix 
Table A3.1);  
• a HPV type variant that is not identified by the relevant HPV type probe is 
the cause of the lesion - at the time of assay development (1998-2001 for 
the genital SPF10-LiPA25, 2004/2005 for the beta RHA and mid 2008 for 
the cutaneous HSL-PCR/MPG) all the variants with published sequences 
in the probe target region were included during probe development (Dr 
Maurits de Koning, DDL, The Netherlands, personal communication);  
• a beta type may have been important in the generation of the lesion, but it 
is not one of the six types analysed for HPV VL (for example: in sample 1, 
HPV 93 has been detected with a strong probe line but a VL assay is not 
available to determine if the viral load was sufficient to be causative); 
• the likely HPV associated with the lesion is one of the 73 types probed, but 
the assays have failed to identify it.  This may have occurred because of 
an excess of PCR inhibitors or degraded or insufficient DNA in the sample. 
 
This point last is now examined further. 
 
All HPV negative samples have a positive beta-globin PCR result  
All of the wart samples that are negative for genital and cutaneous HPV have 
been amplified for the beta-globin ‘housekeeping’ gene (amplifying a 120bp 
segment); Appendix Figure A3.6.  This is indicated by “Ψ” in Appendix Table 
A3.9 (samples 5, 9 have not been tested as very high beta HPV VLs were 
detected).  All of the samples tested produced a band visualised with UV light 
on agarose gel after electrophoresis indicating successful extraction of genomic 
DNA and the absence of PCR inhibitors. Although all tissue samples might 
have been tested many samples had insufficient DNA remaining for this to be 
done.  All the samples that were not tested were positive for a likely causative 
(cutaneous or genital) HPV type.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
120bp 
Appendix Figure A3.6 beta-globin PCR using B1/19 primers. This photograph taken 
under UV light shows a 2% agarose gel after 45 minutes of electophoresis at 120v.  
Fluorescent DNA bands represent PCR products (amplified with B1/19 beta-globin 
primers) derived from samples, except where indicated.  All samples that have been 
tested are positive for beta-globin.  Abbreviations:  pc - positive controls (placental DNA 
at a concentration of 15ng/µl); nc - negative controls (water); * - 100bp DNA ladder. 
 
 
 
APPENDIX 3.6 
OPTIMISATION OF COMPREHENSIVE HPV TYPING: CONTAMINATION - 
NEGATIVE CONTROLS 
 
 
Introductory comments 
Two levels of negative controls have been used.  Firstly, negative (and positive) 
controls have been used for each HPV assay reaction (each PCR, RHA or HSL-
PCR/MPG).  All of the assay negative controls are negative; all the positive 
controls are positive.   
 
Secondly, negative controls have been used in the twelve tissue extractions.  
They consisted of (a) one ‘DNA positive’ - where blood or genomic DNA has 
been extracted and (b) one ‘DNA negative’ – where tissue lysis buffer and/or 
normal saline have been extracted.  In total, 19 negative controls have been 
comprehensively tested for cutaneous, genital and beta HPV types alongside 
DNA from tissue samples.  Extractions were numbered 1-12 and herein they 
are denoted as E1-E11 (and controls as DNA positive or DNA negative); for 
E12 only one control has been used (the DNA and buffer control have been 
combined); Appendix Table A3.10.   
 
Results: negative controls - cutaneous HPV types 
Nine of 19 negative controls (from eight extractions) are positive for cutaneous 
HPVs; Appendix Table A3.10.  Each of the extraction controls with a positive 
result are now discussed, together with the results of genital and beta HPV VLs 
and the semi-quantitative MFI results of the cutaneous HSL-PCR/MPG; MFIs 
>2,000 units are classified as ‘high’; low MFIs are those <500 units. 
 
Extraction 4: the DNA positive control E4 is positive for HPV 27, but at a low 
level (MFI 267 units), just above cut-off MFI (200 units) and is unlikely to be 
important.  All of the samples extracted in E4 that are also HPV 27 positive 
have much higher signals (MFI >7000 units).  The E4 DNA negative control, on 
the other hand, is also positive for HPV 2 (MFI 486 units), HPV 57 (MFI 1,149 
units) and HPV 7 (MFI 3,285 units).  The detection of HPV 2 in the control is 
unlikely to be important as all the other HPV 2 positive wart samples extracted 
in E4 have high MFIs.  HPV 57 is detectable with high MFI levels in all but one 
of the warts extracted in E4.  In this one wart sample (pM83T), HPV 57 has 
been detected at a borderline low MFI (569 units) and a very high VL of HPV 5 
is also seen (and is more likely to be the causative HPV type); therefore, the 
HPV 57 result has been adjusted.  HPV 7 is found in just one sample from E4 
and had a very high MFI of 8,253 units (suggesting this is probably not 
contamination). 
Outcome: HPV 57 has been removed from the results of the wart sample 
pM83T. 
 
 
 
 
 
 
 
Appendix Table A3.10 Table of HPV typing results of extraction controls.  During 
DNA extractions (numbered 1-12) one or two negative controls have been extracted 
alongside wart samples.  These have been tested for beta, genital and cutaneous HPV 
types. Controls that are positive for any HPV are highlighted in orange.  The controls 
marked in yellow tested positive for HPV 8, but on repeat PCR and LiPA, they are 
negative. Grey highlighting identifies the DNA positive controls; DNA negative controls are 
white/not highlighted.  Abbreviations: neg – negative; neg-R – negative on repeat testing 
(PCR and RHA repeated); *- cutaneous HPV types that were detected in low levels (MFI 
<500). 
 
Extraction 5: the E5 DNA positive control is positive for HPV 2 at a low level, 
just above cut off (267 units). Three samples from E5 are HPV 2 positive, all 
with very high MFIs (5,463-8,099 units).  
Outcome: none of the results of the wart samples have been adjusted  
 
Extraction 6: HPV 7 and HPV 4 have been identified in the E6 DNA positive 
control, with relatively high MFIs (4,587 and 2,965 units, respectively).  Two 
samples from E6 have high MFIs for HPV 7 (sample T05T2 with a MFI of 7,008 
units) and for HPV 4 (M36T1 with a MFI of 5,238 units) and represent possible 
sources of contamination.  All of the samples in the extraction have been 
reviewed.  Two wart samples are positive for HPV 7.  One (M36T1) had an HPV 
7 MFI (1,065 units) that was much lower than the level in the control (4,587 
units) and therefore, possibly represented contamination; also detectable are 
HPV 4 with a high MFI (of 5,238 units, as above) and HPV 27 with a MFI of 
1,182 units; this suggests that HPV 7 may be a contaminant.  The other sample 
(N05T2) that contains HPV 7 (with a MFI similar to the E6 control, 4,254 units) 
also harbours co-infecting HPVs with much lower MFIs; HPV 4 (MFI 2,113 
units) and HPV 57 (MFI 334 units).  Therefore, it is possible that HPV 7 is a true 
positive.  Upon reviewing the other wart samples from E6, HPV 4 is seen in one 
(N05T2) sample (MFI of 2,113 units), less than the E6 control.  This wart also 
harbours HPV 7 with a high MFI of 4,254 units and HPV 27 (MFI 334 units); 
thus, HPV 4 is likely to be contamination. 
Outcome:  HPV 7 has been removed from the results of M36T1 and HPV 4 has 
been removed from the results of N05T2. 
 
Extraction 7: E7 DNA positive control is positive for HPV 27 (MFI 3,025 units) 
and for HPV 57, with a low MFI (384 units).  Only one sample has a similar level 
of HPV 57 (H71T2; MFI 396 units) and this may be contamination. A number of 
samples in the extraction are strongly positive for HPV 27 (MFI range 3,296 to 
9,226 units).   Two wart samples have HPV 27 MFIs below this.  Firstly (C45T), 
a genital wart with a high HPV 6 VL (362 copies/cell) also has a HPV 27 MFI of 
1,692 units; in this context it is possible that the detection of HPV 27 is 
contamination.  Secondly, the aforementioned sample (hH70T2; a facial 
curettage specimen) has a HPV 27 MFI below that of the E7 control (MFI 2,558 
units).  However, other HPV types have been found in that lesion: HPV 57 
(probable contamination, MFI 396 units) and HPV 24 (undetectable VL); the 
detection of HPV 27 is likely to be a true result. 
Outcome: HPV 27 has been removed from the results of C45T and HPV 57 
removed from the results of hH70T2. 
 
Extraction 8: the E8 DNA negative control is positive for HPV 7 (MFI 1,806 
units) and HPV 57 (MFI 1,490 units).  Two samples are positive for these types; 
one for each of HPV 7 and 57.  The MFIs of the two samples are much higher 
than the controls; the MFI for HPV 7 is 4,254 units and for HPV 57 it is 8,897 
units.  Therefore, HPV 7 and HPV 57 detection in the control probably is 
unlikely to indicate contamination of wart sample results. 
Outcome: no sample results have been adjusted. 
 
Extraction 10: the E10 negative control is positive for HPV 27 with a low MFI 
(336 units).  Most of the HPV 27 positive samples from E10 extraction batch 
have very high MFIs (range 8,546-2,563 units).  Only one non-wart sample 
(I08T2) has low MFI (MFI 220 units), a genital seborrhoeic keratosis with a high 
HPV 6 VL (34 copies/cell); HPV 27 is likely to be contamination. 
Outcome: the HPV 27 positive result for I08T2 was removed. 
 
Extraction 11: the E11 DNA negative control has been found to harbour HPV 65 
at a low level (MFI 212 units).  Of all samples comprehensively typed only one 
sample (X25T1) that has also been extracted in E11 is HPV 65 positive (MFI 
1,083 units) and this is likely to be a true result (and a possible source of 
contamination).  
Outcome: no adjustment to HPV 65 results has been made to HPV 65. 
 
The same E11 DNA negative control is also positive for HPV 27 (MFI 828 
units).  All the samples from E11 (n=43) have been reviewed.  Sixteen are HPV 
27 positive: 11/16 have high MFIs (MFI range 2,458-9,170 units), 2/16 are 
single infections with HPV 27 MFIs above the E11 control (MFIs 1,361 and 837 
units) and 1/16 harboured HPV 27 as single infection (MFI 384), and is probably 
a true result.   The two remaining lesions are genital lesions (I92T2 and C71T2) 
have a low HPV 27 MFIs just above cut off (MFIs 227 and 286 units, 
respectively) and a high VL for HPV 6 or 11 (>200 copies/cell).   
Outcome: The result of I92T2 and C71T2 have been adjusted by removing HPV 
27. 
 
Extraction 12:  the E12 (combined) control is positive for HPV 27 with a low MFI 
of 486 units.  Nine samples (of 21 extracted in E12) are HPV 27 positive.  Six of 
these have high HPV 27 MFIs (range 4,902-5,880 units).  One, a cutaneous 
wart (H36T1) has an intermediate MFI of 601 units (and genital HPV type HPV 
53 was also detected); this may be a true result.  The remaining two (a genital 
wart and a non-wart - penile keratosis) have low MFIs (383 and 463 units, 
respectively) and either genital HPVs have also been detected (HPV 11 - the 
wart) or no other types have been detected (the penile keratosis).  
Outcome: HPV 27 has been removed from the results of these latter two lesions 
(N40T and N17T). 
 
Results: negative controls - genital HPV types  
One negative control from the DNA extraction is positive for a genital HPV. 
 
Extraction 11: HPV 6 has been detected in the E11 DNA negative control; 
Appendix Table A3.10.  The corresponding E11 (DNA positive) control is 
entirely negative.  The E11 DNA negative control has a relatively low DEIA 
OD450 signal of 0.95 units (the DEIA non-specifically detects most HPV types). 
Therefore, as a precaution, all the samples processed on the same day as the 
control have been reviewed (n=45).  Of these, 13 samples are positive for HPV 
6; 11/13 have HPV 6 VLs of >200 copies/cell, making contamination unlikely.  
Therefore, only two of the 13 lesions required further consideration of whether 
HPV 6 was likely to be contamination.  One (B98T1) was a hand curettage 
specimen in which HPV 57 (cutaneous HPV) and HPV 66 (genital HPV) have 
also been detected.  The HPV 6 VL is below the limit of detection and this result 
has been adjusted.  The other (M02T2) was a curettage specimen from a 
genital wart in which HPV 27 (MFI 2,734 units) is also found and the HPV 6 VL 
is low (0.08 copies/cell). The high DEIA signal for M02T2 (OD450 2.8 units) has 
been attributed to HPV 27 and HPV 6 has been removed. 
Outcome: HPV 6 has been removed from the results of B98T1 and M02T2. 
 
Results: negative controls - beta HPV types  
Three of 19 extraction controls are positive for beta  HPV types.  
 
Extraction 4: HPV 5 has been seen in the E4 DNA negative control, as a strong 
signal.  The same beta HPV RHA tray (that contains eight RHA strips) also held 
a positive control for the assay (HPV 5 plasmid) and a sample (pM83T) 
harbouring very high levels of HPV 5 (7x105 copies), in addition to the other E4 
control (DNA containing) that was negative for all beta HPVs; Appendix Figure 
A3.7c.  From the same tray one sample (KJ39T3) had for a positive HPV 5 
probe but on repeat sample testing HPV 5 has not been not identified. 
Outcome: The repeat K39T3 result of has been used. 
 
Extraction 11: Both the DNA positive and DNA negative E11 controls tested 
positive for HPV 8. However, HPV 8 has been detected in 40/48 (83%) samples 
from the same PCR batch; Appendix Figures A3.7a.  Therefore, the PCR has 
been repeated and widespread HPV 8 positivity disappeared and both controls 
are negative for all beta HPVs; Appendix Figure A3.7b. 
Outcome: the results of the repeated beta PCR and RHA have been used. 
 
Summary of contamination results 
Nine of 19 negative controls tested positive for cutaneous HPV types; the 
results of twelve samples have been adjusted (only seven of these wart 
samples have been included in the HPV typing analysis in Chapter 3); Appendix 
Table A3.11.  One extraction control tested positive for a genital HPV type and 
two sample results have been adjusted as a consequence.  Two of 19 negative 
controls tested positive for beta HPV types.  However, the samples from that 
assay have been retested for beta HPVs and the repeat beta HPV results have 
been used; Appendix Table A3.11. 
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Appendix Figure A3.7 Scanned images of beta HPV RHA strips showing (a) and (b) HPV 
8 contaminated samples and (c) HPV 5 contaminated samples.  Panel (a) show samples 
from the E11 extraction; the red arrows indicate the HPV 8 negative samples; all of the others 
are weakly HPV 8 positive except for the HPV 8 plasmid positive control (strongly positive).  
Many bands are weak on this scanned image but are seen on the original.  Panel (b) shows 
the repeated RHA; only sample 4 (black arrow) is HPV 8 positive.  Sample 20 and 23 are the 
repeated DNA negative controls (both negative), sample 24 is the (HPV 5 plasmid) positive 
control and is strongly HPV 5 positive.  Panel (c) Extraction 4: the black arrows represent 
sample pM83T and the assay positive control (both have a strong HPV 5 signal). Sample 3 
(K39T3, red arrow) is weakly positive for HPV 5.  It is negative on repeat RHA assay.  
  
Ideally, none of the negative controls should have been positive.  However, 
comprehensive HPV typing has been performed on a large number of samples 
(n=218) with three different HPV typing systems, generating 654 results. 
Overall, 2%  (12/654) of all the tests performed have been adjusted.  Of the 
samples included in the comprehensive HPV typing analysis (Chapter 3), the 
same percentage (2%, 7/432) of tests have been adjusted.  Therefore, 
compared with the large number of tests performed, the number of adjusted 
samples are comparatively few. 
 
Discussion of contamination 
A number of precautions were taken to avoid contamination: the extractions 
have been done in one laboratory (Immunology Department, Imperial College, 
Chelsea and Westminster Hospital, London, UK) where no HPV plasmids are 
kept, and no other workers are using HPV.  The assays have been conducted 
Appendix Table A3.11 Summary of the twelve samples adjusted after analysis of DNA 
extraction controls.  The results of the negative controls for DNA have been analysed and 
the above sample results have been adjusted as a consequence; seven of these samples 
have been included in the HPV typing analysis. Abbreviation: PCIS – penile in situ cancer.  
Note: Hereafter, where the lesions above are displayed in tables and figures the adjusted 
result is shown.   
in a second (Centre for Cutaneous Research, Barts and the London School of 
Medicine and Dentistry, Queen Mary University of London, London, UK) or a 
third (DDL Diagnostic Laboratory, Voorburg, The Netherlands) laboratory.  All 
samples have been kept in sterile screw top containers and have only been 
opened in a cleaned, UV irradiated hood. 
 
Because beta HPV types are almost ubiquitous (wherever human cells can be 
found), low levels of beta HPV DNA may be present in laboratory dust or on 
clothing containing human hair/shed keratinocytes.  The beta HPV RHA assay 
used is very sensitive and previous work demonstrated that mixed infections 
with multiple beta HPV types are common (de Koning et al., 2006; de Koning et 
al., 2007; de Koning et al., 2009).  Therefore, the negligible rate of beta 
contamination suggests that environmental contamination is not likely to 
account for HPV being detected in DNA extraction controls.  
 
It is improbable that genital and cutaneous wart associated HPV types would be 
found in the laboratory environment.  Therefore, sample-to-sample cross 
contamination is the likely source. Although a microbiological safety hood has 
been used, gloves have been changed frequently and positive controls 
(plasmids) kept in separate laboratories, the nature of the very high viral loads 
harboured by some wart specimens means that contamination may have been 
very difficult to avoid.  VLs are highest for HPV 6 – many wart samples contain 
HPV 6 copy numbers >1000 copies/cell.  The same is probably true of 
cutaneous warts, with many samples having higher MFIs than the assay 
positive controls (range for Luminex assay positive controls was 7550-9840).  
Technically, the extraction stage of tissue processing is the most likely time for 
contamination to occur, particularly during buffer addition and spinning stages.  
The tissue harvesting and PCR/RHA stages are less exposed from a technical 
aspect.  Reagents kept in stocks of communal laboratory (such as proteinase K 
or ethanol) are not a likely source because no one contaminating type has been 
uniformly identified (and because precautions such as aliquoting have been 
taken to avoid it).   
 
Overall, sample contamination may have resulted in a slight decrease in the 
proportion of HPV negative warts and/or an increase in the number of multiple 
infections; however, adjusting the results may have compensated for this.  
 
  
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
APPENDIX 3.7 
COMPREHENSIVE HPV TYPING RESULTS  
 
 
The following pages comprise the complete comprehensive HPV typing results 
for: 
• HIV infected cases with warts; Appendix Table A3.12 and   
• healthy cases with warts; Appendix Table A3.13. 
 
These tables also display the subject characteristics for both patient groups. 
 
 
 
HPV type viral load (copies/cell) HPV type MFI (units)
* B98T2 C H Cur w m 53 o 2 24 5 574 241 < 50 57 (HPV 6 rem) 93str  -  - 57 2,706
HLA C12T1 C Fa Cur w m 64  c 6 20 20 222 5 < 50 3   27 16  51 16  <0.01 3 1,706
23 n/d 27 2,563
HLA C12T2 C H-Ung Pa w 57 16  52 16 0.74 57 2,526
8  23 n/d
HLA C12T3 C H Pa w 16 6.7 57 2,472
6 0.13
8  23  38 n/d
HLA C12T4 C F-Pl Pa w 57 6  35  52 53 9,23 6  23 n/d 57 2,465
HLA C47T1 C H Cur w m 35  c 13 11 2 810 194 < 50 23  24 ND 7 7,841
15 <0.01
HLA C59T C F Cur w m 41  c 3 16 8 695 270 < 50 27 neg 12w,93  -  - 27 7,391
HLA C98T2 C H Cur w m 42  c 6 14 13 275 61 < 50 27 neg  9, 17  -  - 27 6,931
HLA D15T2 C H Cur w m 51  c 3 16 12 847 38 < 50 8 <0.01 27 7,532
5   15   23 n/d
* D46T1 C∆ F-Pl Pa w m 50 o 4 21 2 287 88 < 50 27  43 6 3.4 27 3,296
11 0.01 43 3,096
* D94T1 C Fa Cur w m 34 o 1.5 0.5 0.5 75 12 < 50  7  10 neg 8   38 <0.01 7 6,737
10 450
HLA E25T C F-Pl Cur w m 38  c 2 8 6 527 50 < 50 57 neg neg  -  - 57 2,955
* E77T C H Pa w m 42 o 3 13 11 989 209 < 50 4  7  57 neg   8   23  <0.01 4 206
15   24 n/d 7 5,534
27 1,608
HLA F23T2 C T Pu w m 45  c 1.5 19 18 336 140 < 50 3 neg 24,36,92 24 n/d 3 1,699
HLA F23T3 C H Pa w 3  43 neg 15  23  <0.01 3 408
8 n/d 43 359
24 ND
* G13T1 C H Cur w m 39 o 3 15 12 579 200 < 50 28 neg 8w, 19 8 n/d 28 3,208
* G13T2 C H Cur w 28 neg unident  -  - 28 3,258
HLA G15T1 C∆ H Cur w m 28  c 4 4 1.5 507 205 < 50 27 neg 8,17,21,36,38 8 <0.01 27 3,435
38 n/d
8w,9,15,19,23,24,
36,93 
8,9,15,17,19w,23,
24str,37str,38,76,
92str,93,96
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(copies/ml)
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* H36T1 C H Cur w m 53  c 7 23 9 296 56 608 27 53 9,24,93w 24 n/d 27 601
* H36T2 C H Cur w neg neg 5   23 <0.01 neg
15  24 n/d
HLA pH70T2 C∆ H Pa w m 36  c 4 5 5 437 10 < 50 57 6  11  74 15,93 11 <0.01 57 1,561
6 n/d
15 ND
HLA I41T C H Cur w m 55  c 5 23 9 322 160 < 50 2 neg 5,9w,12w,14,17w,
23,24,36w,37,75,
92,93str,96
5  23  24 n/d 2 7,937
HLA I63T C H In w m 42  c 15 19 10 308 12 < 50 neg neg 5 <0.01 neg
8 0.22
HLA I70T C F-Pl Pa w m 44  c 1.5 12 12 865 204 < 50 57 neg negative  -  - 57 2,208
* K14T2 C Fa Cur w m 60  c 0.75 12 0.5 695 373 < 50 7 43 8,12,20w,24,49 8  24 n/d 7 8,032
* K14T3 C Fa Cur w 3   7 neg 12w,14w,17w,25w
,49
 -  - 3 284
7 7,228
HLA K39T1 C H Cur w m 39  c 10 12 10 406 n/a < 50 27 neg 15,22,23,24,80,93 15 <0.01 27 9,058
HLA K39T2 C H Cur w 27 neg 17,24,92,96 24 n/d 27 6,980
HLA K39T3 C H Cur w 27 neg 8 <0.01 27 7,406
23  24  38 n/d
HLA K50T2 C F-Pl Pa w m 39  c 5 8 1 438 273 < 50 27 neg 24 <0.01 27 7,687
5  15  38 n/d
HLA M08T1 C H Cur w m 44  c 3 12 8 542 130 < 50 57 56 5w,8w,12,14w,15
w,23,38w,49str
5  8  15  23  
38
n/d 57 2,735
HLA M08T2 C H Cur w 57 neg 5 <0.01 57 2,966
8  23 n/d
HLA M32T2 C H Cur w m 49  c 5 17 11 591 1 < 50 neg (72seq) neg 5w,12str,17,23,76
str,80str,92str, 93
5  23 n/d neg (72seq)
HLA M36T2 C H Cur w m 58  c 15 18 18 278 62 < 50 4 neg 9str,14,17,23,38,7
5, 92,96
23 n/d 4 4,551
HLA M36T3 C H-Ung Pa w m 27 neg 9str,14,17,23,38, 
75str, 92str,93,96
23 n/d 27 6,472
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* pM83T C Fa Pu w EV-like m 37 o 8 14 14 903 10 < 50 (57rem) neg  5str 5 154 (57rem) (569)
HLA N05T2 C S Cur SK/w m 50  c 2 19 3 740 14 < 50 7  57 (4rem) neg 15 15 n/d 7 4,254
 -  -  57 (4rem) 334 (2,113)
* N25T1 C H Cur w f 43 o 2 12 12 141 115 < 50 7 neg 5,8,17 8 <0.01 7 6,375
 - 5 n/d
* N25T3 C H Cur w 7 40 unident  -  - 7 6,183
HLA N48T1 C H-Ung Cur w m 58  c 3 22 20 1491 240 < 50 27 57 6 neg 6 950 27 2,458
 -  - 57 253
HLA N58T1 C Fa Cur w m 41  c 1 17 17 292 156 < 50 7 neg 8str 8 n/d 7 7,479
HLA N58T2 C Ne Ex w 7 neg 8str,24,36 8  24 n/d 7 6,894
HLA N64T1 C H-Ung Cur w m 52  c 0.75 5 5 377 36 < 50 27 neg 24 <0.01 27 6,828
8  38 n/d
HLA Q96T1 C L Cur w m 29  c 1.5 12 5 552 157 < 50 27 neg neg  -  - 27 837
* S85T2 C F Cur w m 51 o 10 19 5 500 n/a < 50 27 neg neg  -  - 27 6,254
* T05T2 C∆ F-Pl Pa w m 43 o 7 13 13 1242 n/a < 50 7    57   63 neg 19  -  - 7 7,008
 -  - 57 291
 -  - 63 1,128
* T40T1 C∆ H Cur w m 30 o 10 4 3 444 107 < 50 11 0.1 7 1,157
16 0.02 27 2,209
15 <0.01 57 648
8  24 n/d
HLA T45T2 C∆ L Pu w m 46  c 1.5 4 2 401 170 < 50 27 neg neg  -  - 27 1,361
HLA U01T2 C F-Pl Cur w m 49  c 10 15 14 673 204 < 50 95 neg neg  -  - 95 8,091
HLA U78T1 C H Cur w m 42  c 2 1 1 163 9 < 50 57 44, 53, 70 5,15, 22,24, 76w, 
80w, 92w
5   15 <0.01 57 1,847
HLA U78T2 C H Cur w 57 44 5w 5 n/d 57 3,381
HLA U78T4 C H Cur w 57 neg neg  -  - 57 2,671
HLA X79T2 C L Cur vir ker FFPE m 64  c 3 6 6 457 35 < 50 neg neg 36w  -  - neg
* X81T1 C Fa Cur w m 41  c 6 n/a 23 507 43 78 6 0.01 27 2,138
8  38 n/d 57 440
* X81T2 C F Cur w 57 6 neg 6 n/d 57 1,882
HLA X82T2 C H Cur w m 45  c 1 13 13 604 11 < 50 38 <0.01 57 1,768
11 n/d
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27  57 6 8,38w
57
11, 52, 53 20,38,49,75,80,93
str
8,24str,36,38w,80,
92
11, 16, 18, 527   27  57 8,9,12w,14,15,24,
36,92,93
HPV type viral load (copies/cell) HPV type MFI (units)
Genital         
HPV types
Beta                    
HPV types 
ART 
(years) 
Contemp 
CD4 
(cells/µl)
CD4 
nadir 
(cells/µl)
HIV VL 
(copies/ml)
Cutaneous 
wart            
HPV types        
HIV infected cases: comprehensive HPV typing results of cutaneous warts 
HPV viral loads Median fluorescent intensity (MFI) Group Sample code
Cutan 
or 
genital
Body 
site 
Wart 
removal 
method
Clin-path 
diagnosis Sex
Age 
(years) Ethnic
Wart 
duration 
(years)
HIV 
duration 
(years)
HLA C14T1 G Pe Cur w-dyspl m 55 c 8 20 9 684 317 <50 neg neg 8str 8 35  -  -
HLA C61T2 G An Sn w m 46 c 5 26 2 459 156 <50 neg 6 5 6 16,353  -  -
5 n/d
HLA C61T2 G An Cur neg 6 5w 6 59,722  -  -
5 <0.01
HLA D33T2 G An Cur w m 48 c 2 23 1 257 179 < 50 neg 11 8st,9,15,17,22,23, 11 816  -  -
8  15  <0.01
23 n/d
* D46T2 G∆ An Sn w m 50 o 4 21 2 287 88 < 50 40  43 31  40 93  -  - 40 6,859
43 1,969
HLA G15T2 G∆
Per Cur
w m 28 c 4 4 1.5 507 205 < 50  2   27 6   11 8,17,21,36w, 38, 
80
6 0.01 2 239
11  38 <0.01 27 5,808
8 n/d
HLA G15T3 G∆ Per Sn c 2 6   52 neg 6 573 2 3,777
* H45T1 G An Sn w m 50 o 6 9 6 850 168 < 50 neg 11 neg 11 3,100  -  -
HLA H70T3 G∆ Pe Cur w m 36 c 4 5 5 437 10 < 50 2 11 neg 11 668 2 3,684
HLA H70T4 G∆ Pe Pu neg 11 neg 11 89  -  -
HLA H70T6 G∆ An Pu neg 6 neg 6 1,704  -  -
* H82T G Sc Pu w m 49 o 0.5 17 15 566 n/a < 50 neg 11 9str 11 35  -  -
* I65T G An Cur w m 41 o 9 6 3 436 154 < 50 91 44 negative  -  - 91 2,384
* M88T G Pe Cur w m 37 c 1 14 13 273 99  500 neg neg 8 8 n/d  -  -
* T05T1 G∆ An Sn w m 43 o 7 13 13 1242 n/a < 50 7   95 11 80w 11 5 7 284
95 4,533
* T40T2 G∆ An Cur w m 30 o 10 4 3 444 107 < 50 29 11 neg 11 217 29 222
HLA T45T1 G∆ Pe Pu w m 46 c 1.5 4 2 401 170 < 50 91 neg neg  -  - 91 2,591
Appendix Table A3.12 Comprehensive HPV typing results of cutaneous and genital warts from HIV infected subjects.  
Abbreviations:  An - anal; C - cutaneous wart;  c - Caucasian; Contemp - contemporaneous; Cur - curette; Ex - excision; F - foot; f- female; Fa - face; FFPE- formalin fixed paraffin 
embedded; F-Pl - plantar wart on foot; G - genital wart; H - hand; HLA-subjects included in the HLA and All groups of HPV typing analysis; In - incisional biopsy; L - limb;  m - male; neg - HPV 
negative; ND - not done; n/d - not detected; Pa - pared warts; Pe - penis; Pun-punch biopsy; Per-perineal;  S - scalp; Sc-scrotum; Sn - snip excision; str - strong beta HPV probe line;  T - 
trunk; Ung - peri-ungual (sited around the nail bed); vir ker - viral keratosis; w - beta HPV probe line; w - wart; w-dyspl - wart with mild dysplasia; wEV-like - Epidermodysplasia verruciformis-
like lesion; Vir Ker-viral keratosis/viral wart.  Symbols:  * - subjects that have been included in All group HPV typing analysis; ∆ - subjects providing both cutaneous and genital warts.                             
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HPV type viral load (copies/cell) HPV type MFI (units)
HLA B04T1 C H-Ung Cur w f 42 c 0.75 27 neg 24,36 24 n/d 27 8003
HLA B04T2 C H Cur w 27 neg 24str,36 24 n/d 27 8725
HLA B04T3 C F-dorsal Cur w 27 neg neg  -  - 27 7311
HLA B04T5 C F-Ung Pa w 27 neg neg  -  - 27 7797
HLA B06T1 C H Cur w f 40 c 15 28 neg 23 23 n/d 28 2068
HLA B06T2 C L Cur w 27 neg neg  -  - 27 3747
HLA B52T C F-Pl Pa w m 31 c 5 2 51 76w  -  - 2 4173
HLA B77T2 C H Cur w f 32 c 0.5 27 neg 96  -  - 27 7204
HLA C13T C F-Pl Pa w f 40 c 5 2 neg neg  -  - 2 6780
HLA C18T1 C H Pa w m 52 c 25 57 45   52   68 8   38 <0.01 57 3378
15   23   24 n/d
HLA C18T2 C F-Pl Pa w 57 neg 9w,12,17str,20,22, 
23, 24,38,80,92,93
23  24 <0.01 57 3021
HLA C42T1 C H Cur w m 34 c 1.5 27 neg neg  -  - 27 9005
HLA C42T3 C H Cur w 2 6 23 6 0.02 2 8193
23 n/d
HLA C42T4 C H Cur w 2 neg neg  -  - 2 8099
HLA C42T5 C H Cur w 2 6 neg 6 0.15 2 7556
HLA C42T6 C H Cur w 2 neg neg  -  - 2 5463
HLA D83T2 C H Pa w f 42 c 3 57 neg 23, 38 23   38 n/d 57 3342
HLA D83T3 C H Cur w 57 6 38 6 0.05 57 2687
38 <0.01
HLA D83T4 C H Cur w 57 neg 38 38 n/d 57 3418
HLA G00T1 C H Cur w m 57 c 5 2 6 neg 6 0.24 2 6190
HLA G00T2 C H Cur w 2 neg 25  -  - 2 6376
HLA G00T3 C H Pa w 2 neg neg  -  - 2 6414
* G04T1 C H Cur w m 43 o 2.5 57 neg unident  -  - 57 246
HLA G39T C F-Pl Pa w f 53 c 5 57 neg neg  -  - 57 523
HLA G85T2 C L Cur w m 81 c 1 27 neg 9,22,24str,93str 24 n/d 27 341
HLA H22T C L Cur w f 66 c 10 2    27 neg 14,15,76 (8,9,12 
vw)
15 n/d 2 1386
27 1443
HLA H70T1 C Fa Cur w m 52 c 2 2 6   11 9w,24,38 6 361 2 3507
11   38 <0.01
24 n/d
HLA H70T2 C Fa Cur w 27 (57rem) neg 24 24 n/d 27 (57rem) 2558 (396)
Healthy cases: comprehensive HPV typing results of cutaneous warts 
Appendix Table A3.13 Comprehensive HPV typing results of cutaneous and genital warts from heathy subjects.  
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Wart 
removal 
method
Clin-path 
diagnosis
HPV type viral load (copies/cell) HPV type MFI (units)
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Sex Genital         HPV types
Age 
(years) EthnicGroup 
Wart 
duration 
(years)
Cutaneous 
wart            
HPV types        
HPV viral loads Median fluorescent intensity (MFI) Sample 
code
Cutan 
or 
genital
Body 
site 
Beta                          
HPV types 
Wart 
removal 
method
Clin-path 
diagnosis
HLA H71T1 C H Pa w m 48 c 20 2    77 neg unident  -  - 2 395
77 5101
HLA H71T2 C H Pa w 77 neg unident  -  - 77 5083
* I71T1 C F-Pl Pa w f 24 o 1.5 27 neg unident  -  - 27 7589
* I71T2 C F-Pl Pa w 27 neg neg  -  - 27 8623
HLA I91T2 C H Cur w 2 6   11   42 5,21,23,80str 6 0.06 2 3950
11 <0.01
5   23 n/d
HLA L94T1 C H Pa w m 53 c na 27 neg 23   38 <0.01 27 5457
15   24 n/d
HLA L94T2 C F-Pl Pa w 27 neg 15,23 15 n/d 27 5466
23 n/d
HLA hM83T1 C H Cur w f 47 c 5 neg 6 8str,17,23,25 6 4630  -  -
8   23 n/d
HLA N89T C F-Pl Pa w m 40 c 5 57 neg neg  -  - 7 571
HLA S39T1 C F-Pl Pa w f 28 c 5 27 neg neg  -  - 27 7967
HLA S39T2 C F-Pl Pa w 27 neg 24 <0.01 27 6154
5   38 n/d
HLA S76T1 C H Pa w m 38 c 8 4 51 25 str,92  -  - 4 6012
* T01T2 C F-Pl Pa w m 21 o 2 27 neg 17  -  - 27 8546
HLA T10T1 C H Cur w m 23 c 4 27 neg 8,9w,22 8 <0.01 27 9226
HLA T10T2 C H Cur w 57 31 8,22w 8 <0.01 57 3473
HLA T10T3 C Fa Cur w 27 neg neg  -  - 57 8938
HLA U57T C F-Pl Pa w m 53 c 1 27 neg neg  -  - 57 4902
HLA X00T1 C Fa Cur w m 39 c 0.75 neg neg 12w, 24 24 n/d  -  -
HLA X25T2 C F-Pl Pa w f 45 c 2.5 27 neg 17,23w, 36, 23 n/d 27 5753
HLA X68T C F-Pl Pa w f 30 c 4 2 neg 5,8,9,15w,17,23,36,
38
8   23 <0.01 2 5809
5   15   38 n/d
* S59T2 C Fa Cur w m 31 o 1.5 neg neg 8 0.21  -  -
15   23 n/d
HLA Z85T1 C F-Pl Pa w m 27 c 5 27 neg neg  -  - 27 5580
HLA Z85T2 C H Pa w 27 neg unident  -  - 27 5880
Appendix Table A3.13 Comprehensive HPV typing results of cutaneous and genital warts from heathy subjects.  
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HPV type viral load (copies/cell) HPV type MFI (units)
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Sex Genital         HPV types
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(years) EthnicGroup 
Wart 
duration 
(years)
Cutaneous 
wart            
HPV types        
HPV viral loads Median fluorescent intensity (MFI) Sample 
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Cutan 
or 
genital
Body 
site 
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Wart 
removal 
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Clin-path 
diagnosis
HLA C00T G An Sn w m 28 c 6 neg 11 neg 11 104  -  -
HLA C45T G Pe Sn w m 29 c 0.5 91  (27rem) 6 neg 6 362 91  (27rem) 437 (1,692)
* C97T1 G An Sn w m 33 o 3 neg 6 neg 6 1,280  -  -
HLA C71T2 G Pe Cur w m neg (27 rem) 11 22 11 865  (27 rem) (286)
HLA D23T1 G Pe Cur w m 39 c 10 neg 6 neg str non spec 6 483  -  -
HLA D23T2 G Pe Cur w 10 neg 6 14 6 711  -  -
HLA E52T G Pe Cur w m 42 c 3 neg 6 9srt 6 1,784  -  -
* E17T3 G Pe Sn w m 27 o 1.5 7 6 neg 6 204 7 1,248
* E17T5 G Pe Sn w neg 6 15 6 126  -  -
15 n/d
* F36T1 G Pe Cur w m 52 o 5 neg 6    74 24 6 510  -  -
24 n/d
HLA H24T2 G Butt Pu w m 30 c 15 neg 6    44 19 6 0.26  -  -
HLA H24T1 G An Sn w 15 neg 6 19w,93 6 562  -  -
* H37T G Pe Cur w m 31 o 2 2 6 neg non spec 6 334 2 275
HLA I03T2 G An Sn w m neg 6 15w,17, 24 6 5,015  -  -
15    24 n/d
HLA I08T1 G Pe Pu w m 64 c 3 neg 6 neg 6 905  -  -
* I92T1 G Gr Cur w m 37 o 1.5 neg 6 49 6 245  -  -
* I92T2 G Gr Cur w neg (27 rem) 6 49w 6 283  (27 rem) (227)
HLA M02T2 G Pe Cur w m 25 c 2 27 neg (6 rem) 80,96 (6 rem) (0.08) 27 2,734
HLA N97T G An Cur w m 35 c 2 2    7   27  6 neg 6 4,382 2 1,266
7 310
27 679
* Q41T1 G Pe Cur w m 33 o 9 neg neg neg non spec  -  -  -  -
Appendix Table A3.13 Comprehensive HPV typing results of cutaneous and genital warts from heathy subjects.  
Abbreviations: An - anal; C - cutaneous wart; c - Caucasian; Contemp - contemporaneous; Cur - curette; F - foot; f- female; Fa - face; FFPE-
formalin fixed paraffin embedded; F-Pl - plantar wart on foot; G - genital wart; Gr - groin; H - hand; HLA - subjects included in the HLA and All groups of 
HPV typing analysis; L - limb; m - male; neg - HPV negative; ND - not done; n/d - not detected; Pa - pared warts; Pe - penis; Pun-punch biopsy; S -
scalp; Sn - snip excision; str - strong beta HPV probe line; T - trunk; Ung - peri-ungual (sited around the nail bed); vir ker - viral keratosis; w - beta HPV
probe line; w - wart; w-dyspl - wart with mild dysplasia; wEV-like - Epidermodysplasia verruciformis-like lesion; Vir Ker-viral keratosis/viral wart.
Symbols:  * - subjects that have been included in All group HPV typing analysis; ∆ - subjects providing both cutaneous and genital warts.                             
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APPENDIX 3.8 
HLA GROUP HPV ANALYSIS 
 
 
The composition of the HLA group is shown in Appendix Figure A3.8.  Similar 
results have been observed in the HLA group as in the All group.  However,  
because of the smaller numbers in the HLA group, fewer differences between 
the groups are statistically significant. 
 
 
 
 
Appendix Figure A3.8 Selection of the HLA group for HPV analysis.  Table showing  
exclusions applied to recruited subjects and numbers of subjects available for analysis.  
Non-Caucasians have been excluded from the HLA group HPV analysis.  Also excluded are: 
HIV infected individuals with detectable HIV viral loads, all females with genital warts and 
individuals with co-morbidities (indicated in light grey text in uppermost boxes with numbers 
(n) of individuals indicated in brackets after).  ‘Other’ refers to two individuals who presented 
with acute worsening of HPV with ART or probable acute inflammatory HPV IRAD or IRIS. 
Abbreviation: VL – HIV viral load.  
 
3.8.1 HLA group analysis: subject characteristics 
 
The subject characteristics of the HLA group are similar to those from the All 
group 
The subjects in the HLA group are almost identical to the All group in terms of 
age, gender, and HIV risk factors; Appendix Table A3.14.  Ethnicity is not 
relevant: by definition all the subjects in the HLA group are Caucasian. 
 
Contemporaneous CD4 T-cell counts in the HLA group are also very similar to 
that of the All group.  The range for HLA group is 163-1491 cells/µl, the median 
(IQR) is 458 (319-676) cells/µl.  The range of CD4 T-cell count nadirs in the 
HLA group is 1-317 cells/µl, the median (IQR) is 140 (37-199) cells/µl, similar to 
the All group. 
 
Although HIV infected indivduals have a shorter wart disease duration than 
healthy cases in the HLA group the difference is not statistically significant; the 
median (IQR) is 3.0 (1.5-5.4) years compared with 5.0 (2-6) years, respectively 
(p=0.35, Mann-Whitney U test).  The wart duration of individual lesions sampled 
from HIV infected cases and healthy individuals is similar; the median (IQR) 
duration of each wart sampled is 2.0 for both groups; IQR 1.5-6 and 1-5 years, 
respectively (p=0.34, Mann-Whitney U test). 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix Table A3.14 HLA group: patient characteristics of HIV infected and 
healthy subjects with warts (cases) included in the HPV analysis.  Statistical 
significance has been calculated by Mann-Whitney U test for non-parametric data (or 
Yates’ chi squared for categorical data - marked with *).  Statistically significant 
associations  (p<0.05) are highlighted in pale yellow. Abbreviations: Inf – infected. 
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3.8.2 HLA group analysis: subject disease characteristics 
 
In the HLA group, HPV typing data are available for 106 wart lesions from 30 
HIV infected and 36 healthy subjects; Appendix Figure A3.9.  Three HIV 
infected cases provided samples of both genital and cutaneous warts.  There is 
no statistically significant difference in the number of individuals in the HLA 
group with both cutaneous and genital disease (in contrast to the All group); 
14% (7/30) of HIV infected cases compared with 8% (3/36) of healthy cases 
(p=0.10, Fisher’s exact test). 
 
(a) 
 
 
 
 
 
 
(b)  
 
 
 
 
 
 
 
 
Appendix Figure A3.9 HPV disease characteristics of the HLA group: HIV infected and 
healthy individuals. Table (a) and chart (b) showing the number of warts and subjects 
analysed in the HLA group; some subjects provided warts from both cutaneous and genital 
sites. Abbreviation: Inf – infected. 
 
 
 
  
3.8.3 HLA group analysis: cutaneous warts 
 
The distribution of the site of warts from HIV infected and healthy cases in the 
HLA group is shown in Appendix Figure A3.10.  More biopsy techniques have 
been used in HIV infected cases and parings have been performed more 
frequently in healthy individuals.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix Figure A3.10 HLA group analysis: cutaneous wart site and removal (sampling) 
method. The location of cutaneous warts from (a) HIV infected and (b) healthy cases and the wart 
removal (sampling) techniques used in (c) HIV infected and (d) healthy cases is shown.  
 
 
 
 
 
 
 
(a) (b) 
(c) (d) 
3.8.4 HLA group analysis: genital warts 
 
The sites of genital warts and the removal methods used for genital warts from 
the HLA group are shown in Appendix Figure A3.11; there are no scrotal or 
groin warts in the HLA group (as opposed to the All group). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix Figure A3.11 HLA group analysis: group analysis: genital wart site and removal 
(sampling) method.  The location of genital warts from (a) HIV infected and (b) healthy cases and 
the wart removal (sampling) techniques used in (c) HIV infected and (d) healthy cases is shown.  
(b) 
(c) (d) 
(a) 
3.8.5 HLA group analysis: cutaneous HPV types 
  
HPV 7 is more common in HIV infected cutaneous warts and HPV 2 less 
common 
The HLA group (Appendix Figure A3.12) have a similar distribution of 
cutaneous HPV types to the All group; Figure 3.6. HPV 2 is also more frequent 
in healthy cases than HIV infected cases (p=0.002) in the HLA group.  In HIV 
infected individuals from the HLA group, HPV 7 is also more prevalent (p=0.04, 
Fisher’s exact test), but this difference is not statistically significant in the HLA 
group after correction for multiple lesions because of the smaller number of 
warts: 3/27 HIV infected and 0/26 healthy individuals (pc=0.2, Fisher’s exact 
test).  As for the All group cutaneous HPV types are common in genital warts.       
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
Appendix Figure A3.12 HLA group analysis: cutaneous HPV types found in (a) 
cutaneous and (b) genital warts. ‘Nil’ – warts negative for cutaneous wart associated HPV 
types.  ‘Lesions  multiple types’ – warts with mixed infection of ≥2 HPV cutaneous HPV 
types. Abbreviation: Inf – infected.   * and ** -  indicate significant differences (p<0.05, 
Yates’ chi-squared test). 
 
(b) 
(a) 
p=0.002 
p=0.04 
3.8.6 HLA group analysis: genital HPV types 
 
HIV infected cases had a low ratio of HPV 6 to HPV 11  
The genital HPV typing results  for the HLA group are see in Appendix Figure 
A3.13.  HPV 11 is found more frequently in HIV infected individuals, whereas 
HPV 6 appears to have a predilection for healthy individuals.  However, these 
differences are not statistically significant in the HLA group, that is smaller than 
the HLA group (p=0.34, p=0.38 respectively, both Fisher’s exact test).  As can 
be seen in the All group, in around one quarter of cutaneous lesions from HIV 
infected and healthy cases genital types are detected; 26% (10/38) and 24% 
(11/46), respectively.   
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix Figure A3.13 HLA group analysis: genital HPV types found in (a) genital 
and (b) cutaneous warts. ‘Nil’ – warts negative for gential HPVs.  ‘Lesions  multiple 
types’ – warts with mixed infection of ≥2 HPV genital HPV types. Abbreviations: Inf – 
infected.; ns – probability is not significant (Yates’ chi-squared test). 
 
 
(a) 
(b) 
3.8.7 HLA group analysis: beta HPV types 
 
More warts from HIV infected than healthy cases are beta HPV positive  
The distribution of beta HPV types in warts the HLA group can be seen in 
Appendix Figure A3.14.  Beta HPV types are more commonly detected in 
cutaneous lesions from HIV infected cases than in lesions from healthy cases 
and this difference is statistically significant; 82% (31 of 38) lesions positive in 
HIV infected individuals compared with 59% (27 of 46) lesions in healthy 
individuals (p=0.04, Yates’ chi-squared test).  The results are similar to the All 
group; Figure 3.8.   
 (a) 
 
 
 
 
 
 
 
 
(b) 
 
 
 
 
 
 
 
Appendix Figure A3.14 HLA group analysis: beta HPV types found in (a) genital and (b) 
cutaneous warts.  Nil’ – warts negative for beta HPVs.  ‘Lesions  multiple types’ – warts with 
mixed infection of ≥2 HPV beta HPV types. Abbreviation: Inf – infected.  * - indicates a 
significant difference (p<0.05, Yates’ chi-squared test). 
 
p=0.04  
3.8.8 HLA group analysis: mixed infections 
 
The number of cutaneous and genital HPV mixed infection are the same in HIV 
infected compared with healthy cases  
The data for mixed infections in the HLA group are very similar to those from 
the All group.  There were no significant differences in HIV infected compared 
with healthy cases as regards cutaneous and genital HPV types in all warts 
(p=0.62 and p=0.41, respectively, Mann-Whitney U test).   
 
HIV infected cases’ warts harboured more beta HPV types 
However, a greater number of beta HPV types is found in cutaneous warts from 
HIV infected cases than healthy cases (p=0.001, Mann-Whitney U test); 
Appendix Table A3.15 and Appendix Figure A3.15.  The difference is also 
statistically significant when data from both cutaneous and genital warts are 
combined (p=0.002, Mann-Whitney U test); Appendix Table A3.15, bottom row. 
 
 
 
 
 
 
HLA group 
HIV Infected cases 
number of beta HPV 
types per wart  
 
median (IQR) 
HIV Infected cases 
number of beta HPV 
types per wart  
 
median (IQR) 
Probability (p)  
Mann-Whitney U 
test 
Genital 
warts 0.5 (0-2.5) 1 (0-1.8) p=0.87 
Cutaneous 
warts 3.5 (1-8.3) 1 (0-3) *p=0.001 
All warts     
combined 3 (0.3-8) 1 (0-2) *p=0.002 
Appendix Table A3.15 HLA group: median (IQR) number of beta HPV types in 
cutaneous, genital and all warts.  HIV infected individuals harbour more beta HPV types in 
cutaneous warts.  * - indicates a significant difference (p<0.05). 
 
 
 
3.8.9 HLA group analysis: HPV viral load (VL) 
 
Viral load (VL) results  
The HLA group (Figures A3.16 and A3.17) have a similar pattern of genital and 
beta HPV VL results as the All Group; Figures 3.10 and 3.11. It should be noted 
that the scales on the bar charts of Appendix Figures A3.16 and A3.17 differ (0-
6,000 and 0-0.30 copies/cell, respectively). 
 
 
 
Appendix Figure A3.15 HLA group: bar chart showing that a greater number of beta 
HPV types are detected in lesions from HIV infected individuals. 
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Appendix Figure A3.16: HLA group: genital HPV viral loads (VLs); HPV types 6, 11, 16 
and 18.  Warts with HPV VLs above the limit of detection are shown on the bar chart. Note: 
the same sample patient/lesion numbering system is used for Appendix Figures A3.17 (HLA 
group) and Figures 3.10 and 3.11 (All group); the corresponding study codes can be found 
in Appendix 3.11.  Abbreviation: c – cutaneous wart; g – genital wart; Inf – infected. 
 
 
Appendix Figure A3.17 HLA group: beta HPV viral loads (VLs); HPV types 5, 8, 15, 
23, 24, 38.  See Figure legend for Appendix Figure A3.16, above.  
 
 
 
 
APPENDIX 3.9 
HEALTHY CASES: SELECTION AND HIV INFECTION RISKS 
 
 
Appendix Figure A3.18 shows the HIV risk factors of healthy individuals 
recruited.  The 52 subjects included are those from the healthy group of the All 
HPV analysis (Chapter 3) and also those healthy indivduals that have been 
included in the HLA molecular analysis (Chapter 4). 
 
Overall, 81% (42/52) of healthy individuals have no risk factors for HIV (low 
risk); those that had risk factors were HIV antibody negative. Fifty seven percent 
(24/52) have had a previous negative HIV antibody test or consented to a HIV 
antibody test.  None of the 52 individuals had any conditions (other than warts) 
suggesting HIV infection. MSM is the only risk factor that has been identified, in 
ten males.  These ten individuals either had a recent negative test (n=6 within 
the last year and n=2 more than a year previously together with a reliable 
history of no subsequent exposure) or consented to a test in the study (n=2). 
 
(a)             (b) 
 
 
 
 
 
 
 
Appendix Figure A3.18 HIV risk factors and HIV antibody testing for healthy 
individuals recruited. (a) Of 39 males most (74%, 29/39) are low risk for HIV infection.  
Most low risk males had a recent negative test (31%, 12/39) or consented to testing at 
study interview (13%, 5/39).  Thirty one percent (12/39) of low risk males declined testing. 
(b) All healthy females (n=13) are low risk for HIV infection.  Most (54%) accepted a HIV 
test for the study (15%, 2/13) or had a previous test with no history of subsequent 
exposures (5/13, 38%).  Six (46%) low risk females declined testing.  Abbreviations: LR 
– low risk. 
 Discussion: the risk of missing undiagnosed HIV in healthy cases is low  
Healthy cases were mostly recruited prior to the ‘normalisation’ of testing for 
HIV (this occurred from late 2008).  All were offered a HIV test but (because of 
the conditions of prior ethical approval) it was not made a pre-requisite for 
subject inclusion.  Ideally, all healthy individuals might have been re-tested 
regardless of the clinically assessed risk.  
 
Anonymised, retrospective HIV antibody testing of stored blood samples from 
healthy cases was considered and discussed informally with the (Riverside) 
Ethics Committee.  However, study subjects had not routinely consented to 
subsequent contact with researchers after recruitment.  The unexpected (but 
low probabilty) result of a positive HIV antibody test might have led to a breach 
of subjects’ confidentiality.  Therefore, for this reason, anonymised testing has 
not been performed. 
 
However, the absence of risk factors (including ‘indicator’ dermatological 
diseases) in healthy subjects with warts means the chance of missing a 
previously undiagnosed HIV infected individual must be small.  Two estimates 
of the HIV prevalence in UK: one from blood donors (in 2002-2003) and another 
(in 2009) of male and female heterosexuals living in the UK (who were born in 
the UK/abroad, but not in Africa), both suggest that the estimated prevalence of 
undiagnosed HIV infection in the UK population is around 0.006% or six per 
100,000 persons; http://www.ons.gov.uk/ons/index.html [last accessed 
14/01/2012] (HPA, 2010; Soldan et al., 2005). These data suggest that the risk 
of a ‘missed’ HIV infection in 18 healthy hetrosexual individuals with no risk 
factors would be very low (around 1 in 10,000). 
 
 
 
APPENDIX 3.10  
CUTANEOUS WARTS: SAMPLING TECHNIQUES AND ATYPICAL LESIONS 
 
 
Sampling methods that allowed histological corroboration (punch, incision and 
excision) of atypical warty lesions have been used more frequently in HIV 
infected individuals (p=0.0003, Yates’ chi square test).  Sixteen percent (9/56) 
of lesions from HIV infected cases were classed clinically as atypical warty 
lesions in HIV infected cases whereas 8% (4/51) were clinically atypical in 
healthy cases (p=0.31, Yates’ chi square test).  However, all lesions have been 
histologically confirmed warts.  Details of method of sampling, body site and 
clinical differential diagnoses can be found below; Appendix Table A3.16.  
 
Appendix Table A3.16 List of lesions with clinical diagnostic uncertainty. 
Abbreviations:  AK – actinic keratosis; Bowen’s - Bowen’s disease of the skin; DF – 
dermatofibroma; EV – epidermodysplasia verruciformis; F- foot; Fa – face; H – hand; L – 
limb; S- scalp; Seb Ker – seborhoeic keratosis; T- trunk. 
 
APPENDIX 3.11 
SAMPLE STUDY CODE KEY FOR  
FIGURES 3.10-11 AND APPENDIX FIGURES A3.16-17  
 
 
 
  
  
Appendix Table A3.17 Key of study codes for lesions with genital HPV viral load data 
(Figure 3.10 and Appendix Figure A3.16).  Samples have been designated a lesion code (1-
13 for HIV infected warts and 1-21 for healthy warts).  
 Appendix Table A3.18 Key of study codes for lesions with beta HPV viral load data 
(Figure 3.11 and Appendix Figure A3.17).  Samples have been designated a lesion code (1-
21 for HIV infected warts and 1-8 for healthy warts).  
APPENDIX 3.12 
ALL GROUP BETA HPV VIRAL LOADS:  
SAMPLES WITH INTERMEDIATE LEVELS 
 
 
The first sample with an intermediate beta HPV VL is 1.c (I63T), an incisional 
biopsy from the dorsal wrist of a HIV infected individual.  In this wart sample, 
only beta types were detected on comprehensive HPV typing  (HPVs 5, 8, 12, 
14, 19, 23, 36, 38, 92).  Strong HPV 8 probe bands (+++) were seen on the 
beta RHA and the HPV 8 VL has been calculated as 0.23 copies/cell.  The 
other types (HPVs 5, 23, 24) have VLs of <0.01 copies/cell; HPVs 12, 14, 19, 
36, 92 were not tested.  On clinical examination the lesion had a slightly atypical 
appearance and an incisional biopsy was taken to exclude squamous cell 
cancer or a dermatofibroma (histology is consistent with mild viral dysplasia).  
The low copy number of HPV 8 might be explained by the large amount of 
dermis in the incisional biopsy; a high ratio of (HPV uninfected) dermal genomic 
DNA might reduce the HPV (see Appendix Figure A2.9).  Therefore, the most 
important HPV type identified is HPV 8.  However, it is possible that an unusual 
HPV type, not included in the comprehensive assays has been missed. 
 
The second sample is from a healthy individual, 4c (S59T2).  This individual 
had a wart on the chin (T1) that recurred during the study and it has been 
curetted again (T2).  The duplicate lesion S59T1 has been excluded from HPV 
analysis. T2 has been found to harbour HPVs 8, 15 and 23 (HPV 9, 76 have 
also been identified on the beta RHA but with weak probe lines).  No cutaneous 
or genital types have been detected.   HPV 8 with a clearly present  (++) probe 
line on the beta RHA was found to have a VL of 0.21 copies/cell (the HPV 15 
and 23 VLs are not detectable).  As HPV 8 is the only HPV type detected, it 
may be important.  Although, as before, an unidentified unusual or new variant 
type not included in the panel of probes cannot be excluded. 
 
 
 
APPENDIX 3.13 
SPECIAL CASES: FEMALES WITH GENITAL WARTS  
 
 
Genital warts from females have been excluded from the HLA and All analyses 
but HPV typing data are available. Eight warts from six individuals were 
sampled.  Multiple genital HPV types were not detected in any lesions.  Most 
(6/8) had very high HPV 6 VLs (> 100 copies/cell).  
 
One HIV infected (non-Caucasian) female provided two genital warts samples.  
She was on ART but had a detectable HIV VL (163 copies/ml) and probably 
had incomplete compliance; the contemporaneous CD4 T-cell count was 312 
cells/µl and nadir was 32 cells/µl). The HPV 6 VLs were found to be 1636 and 
3579 copies/cell, respectively.  Five healthy females provided six genital wart 
specimens and HPV 6 has been found to be the most frequently detected type 
(range <0.01 to 710 copies/cell).  However, the highest HPV VL in females was 
seen for HPV 11: 1,883 copies/cell.   
 
Beta types were detectable in three lesions.  Beta HPV VLs have been assayed 
in two lesions; both have low beta HPV VLs of <1 copy/cell.  The range is 0.7 to 
0.01 copies/cell.  Only one genital wart from a female harboured a cutaneous 
type (HPV 2 MFI 2,599 units).  
 
In two lesions, from two healthy individuals, the likely HPV type is difficult to 
ascertain.  In one wart (snip biopsy), HPV 6 has been detected but in a very low 
VL (<0.01 copies/cell); the HPV 23 VL is only 0.7 copies/cell (despite a strong - 
+++ - band seen on beta RHA).  No other types have been detected, raising the 
possibility that this lesion may have been caused by HPV 23, a beta type.   In 
another (curetted) female genital wart only HPV 6 was identified, but with a HPV 
6 VL of 0.02 copies/cell, making this less likely to be an important in wart 
generation.  It is possible that an unidentified or novel HPV type may account 
for the observations in these two lesions. 
APPENDIX 3.14 
SPECIAL CASES: WART CASE 
 
 
Normal skin was not obtained routinely from study participants.  However, 
patient N58 requested a wart on his neck to be removed with excision.  A 
thorough discussion was undertaken with the patient about the alternative 
modalities of treatment (no treatment, curette, liquid nitrogen) and the side 
effects of excision (scar, recurrence).  However, the patient still preferred 
excision and the site is cosmetically suitable (in line with a skin crease on the 
anterior neck).  No recurrence after excision has been reported; the cosmetic 
result was excellent at follow-up review.  The patient was 41 years old, male, 
with a contemporaneous CD4 T-cell count of 292 and a CD4 nadir of 156; HIV 
VL was undetectable and he had taken ART for 17 years (emtricitabine, 
tenofovir, saquinavir and ritonavir, at the time of review). 
 
Five samples from this individual have been comprehensively HPV typed; two  
cutaneous warts, - a facial wart (sample 1a), a neck wart (1b); peri-lesional 
normal skin (1c) and peri-lesional hair (1d) from the neck wart, and lastly an 
actinic keratosis from the leg (1e); Appendix Table A3.19.  The results of 1a and 
1b were included in the All group HPV analysis; Appendix 3.7.  Sample 1e has 
been discussed in the non-warts group; Appendix Table A3.8 (it is labelled 
sample 4).   
 
Several discussion points arise from the results of this subject.   Firstly, it is 
striking that the HPV types from this individual are very similar.  HPV 7 has 
been detected in all samples excepting the actinic keratosis and HPV 8 has 
been found in all, in low levels (HPV 8 VL undetectable).  None of the lesions 
harboured genital HPV types; the patient did not report any genital warts. 
 
 
 
 
  
  
 
 
Secondly, both cutaneous and beta HPVs have been detected in hair (1c) and 
in macroscopically normal peri-lesional skin (1d).  Although beta HPVs have 
previously been well characterised in hair and normal skin (Antonsson et al., 
2003; Antonsson et al., 2000; Astori et al., 1998; Weissenborn et al., 2009a; 
Weissenborn et al., 2009b) this was not the case for cutaneous HPV types.  
The finding of cutaneous HPVs in normal skin/hair may be explained by the 
close proximity to the wart on the neck.  Furthermore, specimen processing 
may have contributed; one half of the excision (an ellipse approximately 1.2 cm 
x 0.5 cm) had been snap frozen at collection and the other half sent for 
histology.  The relevant parts (abnormal tissue, peri-lesional normal tissue, hair) 
had been dissected out after thawing and just prior to DNA processing (that is, 
the hairs were not plucked from the patient and snap frozen separately from the 
tissue).  If these results do represent uncontaminated specimens, the HPV 
carriage in peri-lesional tissue and hair is remarkably similar to both warts from 
the neck and the face. 
 
 
Appendix Table A3.19 Comprehensive HPV typing results of five lesions from one 
(HIV) infected individual.  Two warts, peri-lesional clinically normal tissue, peri-lesional 
hairs and an actinic keratosis were included.  The HPV typing results are remarkably similar 
for all samples.  The HPV type shown in bold (beta HPV column) was detected as a strong 
probe line band.  Abbreviations: Act ker - actinic keratosis on histology; Cur - curettage; Ex 
- excision; hair Ex-hair from excision (peri-lesional skin); Fa - face; L - limb; N - clinically 
normal peri-lesional tissue; nd - not detected; Ne - neck; neg - negative; W - wart. 
APPENDIX 3.15  
PARINGS AND NON-PARINGS:  
NUMBER OF HPV TYPES IN CUTANEOUS WARTS 
 
 
Pared warts did not harbour more cutaneous or genital HPV types  
In cutaneous warts, there is no statistically significant difference in the number 
of cutaneous, genital and beta HPV types that have been found in parings 
compared with other types of specimens from cutaneous warts from healthy 
and HIV infected cases (p=0.43-0.06, Mann-Whitney U test); Appendix Table 
A3.20.  In HIV infected individuals the difference between parings and non-
parings for cutaneous and genital HPV types approaches significance (p=0.06 
and p=0.08, respectively, Mann-Whitney U test).  A greater number of parings 
was taken from healthy cases than HIV infected cases but it is not likely that this 
has influenced the results. 
 
More beta HPV types are seen in warts from HIV infected cases, independent 
of paring 
One further point emerges from Appendix Table A3.20.  Although pared warts 
did not harbour more beta HPV types than other types of specimens (p=0.47 
and p=0.43, HIV infected and healthy cases, respectively, Mann-Whitney U 
test); the number of beta HPV types is statistically significantly increased in HIV 
infected compared with healthy individuals (p=0.02 parings, p=0.007 non-
parings, Mann Whitney U test).  This statistically significant finding is also 
apparent in Table 3.3 and section 3.5.8.  Therefore, as seen in Table A3.20, the 
increase in beta HPV types in warts from HIV infected subjects is most apparent 
in tissue obtained by techniques other than paring.  A possible explanation is 
that pared samples from the warts of healthy cases may increase the number of 
types found in healthy cases and partially ‘bridge the gap’ between HIV infected 
and healthy cases.   
 
Tape strippping warts prior to paring was seen to reduce contaminating HPVs 
(Forslund et al., 2004), this effect may be limited to beta HPVs.  Warts from 
healthy individuals sampled by swabbing (without pre-stripping) were shown to 
harbour multiple infections in 11% of 100 cases (de Koning et al., 2010), that is 
higher than the proportion of mixed infections in healthy cases (4%) but lower 
than that seen in HIV infected cases (20%).  This implies that swabbing may 
increase the number of mixed infections in warts but that HIV infection status 
may also have an influence on the number of types detected.   
 
 
 
 
 
 
 
 
 
 
 
 
Appendix Table A3.20 All group: the median number of HPV types (IQR) in each 
cutaneous wart by method of lesion removal: parings compared with non-parings.  There 
is no statistically significant difference between parings and other methods of wart sampling.  
There is no difference in the number of cutaneous or genital HPV types between HIV infected 
and healthy cases (last column).  However, there is a statistically significant difference in the 
number of beta HPV types in each lesion for HIV infected cases compared with healthy cases 
(p=0.02 and p=0.007, Mann-Whitney U test).  Significant associations are indicated by grey 
shading (p<0.05).  
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APPENDIX 4 
APPENDIX 4  
 
APPENDIX 4.1 CHARACTERISITCS OF SUBJECTS EXAMINED IN THE 
MOLECULAR HLA ANALYSIS 
 
APPENDIX 4.2  ALLELE COUNTS AND PERCENTAGES: HLA-A, HLA-B, 
HLA-C, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5 
AND HLA-DQB1  
 
APPENDIX 4.3 INTERIM HLA ANALYSIS 
 
APPENDIX 4.4  TESTS OF SIGNIFICANCE:  ALLELES OF INTEREST  
 
APPENDIX 4.5  HLA-B*44 GROUP ALLELE STRINGS 	  	  	  	  	  	  	  	  
 
C32 C m 44 c 4 4 4 875 279 < 50
C43 G m 41 c 0.75 17 4 428 115 < 50
C57 G m 38 c 1 15 8 n/a n/a pt/r < 50
C59 C m 36 c 2 14 14 665 16 < 50
D02 C m 32 c 1.2 5 4 628 433 < 50
D16 G m 50 c 8 23 19 333 91 < 50
G69 C m 39 c 5 10 5 870 254 < 50
G99 C m 48 c 4 5 5 712 222 < 50
I07 C/G m 55 c 8 18 18 89 409 < 50
I42 C/G m 42 c 6.5 10 7 962 293 < 50
I98 C m 41 c 2 15 13 326 306 < 50
J63 C/G m 43 c 5 14 11 386 122 < 50
N01 C/G m 61 c 5 23 21 457 105 < 50
N06 C/G m 60 c 1 7 7 744 186 < 50
O15 C/G m 55 c 10 11 11 600 160 < 50
S97 C m 50 c 3 3 3 239 137 < 50
T66 C m 62 c 10 13 12 517 197 < 50
T89 C/G m 44 c 10 20 12 378 28 < 50
T92 G m 55 c 1.5 15 15 862 6 < 50
G69 G m 33 c 3  -  -  -  -  -
I32 G m 29 c 0.66  -  -  -  -  -
N31 G m 37 c 0.5  -  -  -  -  -
Q81 G m 63 c 1.25  -  -  -  -  -
T53 G m 43 c 3  -  -  -  -  -
T86 C/G f 45 c 4  -  -  -  -  -
Appendix Table A4.1 HIV infected and healthy subjects included in the molecular
HLA analysis (provided blood only). Abbreviations: C - cutaneous wart; c -
Caucasian; Contemp - contemporaneous; f- female;  G - genital wart; m- male. 
                     
                     
                     
Age 
(years) Ethnic
Wart 
duration 
(years)
HIV 
duration 
(years)
ART 
(years) 
Sample 
code
Cutan or 
genital Sex
Contemp 
CD4 
(cells/µl)
CD4 nadir 
(cells/µl)
HIV VL 
(copies/ml)
HIV infected cases with warts: blood only for molecular HLA analysis
Healthy cases with warts: blood only for molecular HLA analysis
HIV 
duration 
(years)
ART 
(years) 
Contemp 
CD4 
(cells/µl)
CD4 nadir 
(cells/µl)
HIV VL 
(copies/ml)
Age 
(years) Ethnic
Wart 
duration 
(years)
Cutan or 
genital Sex
Sample 
code
B48 m 67 c 11 11 544 11 < 50
B54 m 30 c 11 7 658 248 < 50
C35 m 62 c 18 17 166 1 <50
C59 m 44 c 24 11 780 19 < 50
C64 m 46 c 8 2 252 66 < 50
C86 m 53 c 21 3 592 160 < 50
C98 m 32 c 3 3 352 130 < 50
D33 m 63 c 24 18 427 198 < 50
D35 m 40 c 4 3 350 186 < 50
D40 m 48 c 3 3 498 216 < 50
D79 m 44 c 8 8 626 79 < 50
E82 m 49 c 4 2 741 222 < 50
E70 m 56 c 20 3 331 162 < 50
F72 m 44 c 7 6 618 141 < 50
F75 m 47 c 6 5 743 152 < 50
G18 m 50 c 24 19 390 180 < 50
H02 m 55 c 24 11 819 254 < 50
H17 m 70 c 22 22 500 15 < 50
H78 m 56 c 16 11 674 284 < 50
I51 m 65 c 12 12 382 177 < 50
I59 m 37 c 4 3 829 203 < 50
I67 m 47 c 20 20 594 40 < 50
K53 m 58 c 7 7 930 111 < 50
M23 m 52 c 9 9 736 16 < 50
N38 m 60 c 8 6 691 184 < 50
N40 m 60 c 21 11 580 85 < 50
N40 m 44 c 8 8 523 212 < 50
O42 m 33 c 8 8 504 314 < 50
Q16 m 37 c 11 5 105 5 < 50
Q21 m 48 c 21 15 1003 18 < 50
Q85 m 42 c 15 11 483 36 < 50
Q99 m 52 c 15 11 757 230 < 50
S14 m 53 c 12 12 541 40 < 50
S45 m 48 c 13 7 435 133 < 50
S62 m 28 c 5 2.5 592 91 < 50
S65 m 42 c 10 10 602 209 < 50
S86 m 57 c 16 14 570 60 < 50
S98 m 49 c 26 22 360 50 < 50
T54 m 55 c 5 3 n/a 500 < 50
T81 m 48 c 24 14 796 66 < 50
W58 m 55 c 22 12 503 200 < 50
W80 m 44 c 7 7 593 99 < 50
X10 m 67 c 6 6 200 29 < 50
X11 m 52 c 4 3 463 251 < 50
X63 m 52 c 10 10 462 98 < 50
X90 m 53 c 15 11 529 173 < 50
Appendix Table A4.2 HIV infected controls without warts included in the
molecular HLA analysis (provided blood only). Abbreviations: c - Caucasian;
Contemp - contemporaneous; m- male. 
                     
Sex Age (years) Ethnic
ART 
(years) 
HIV infected controls without warts: blood only for molecular HLA analysis
HIV 
duration 
(years)
Contemp 
CD4 
(cells/µl)
CD4 
nadir 
(cells/µl)
HIV VL 
(copies/ml)
Sample 
code
APPENDIX 4.2 
ALLELE COUNTS AND PERCENTAGES: HLA-A, HLA-B, HLA-C,  
HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5 AND HLA-DQB1. 
(a) 
 
(b) 
  
 
(c) 
 
 
 
 
 
(d) 
 
 
 
 
 
 
 
 
 
 
(e) 
  
(f) 
 
Appendix Tables A4.3a-f Allele counts (and percentage) for loci (a) HLA-A, (b) HLA-B, 
(c) HLA-C, (d) HLA-DRB1, (e) HLA-DRB3/4/5, and (f) HLA-DQB1.  The HLA allele 
distributions have been analysed for: HIV infected cases, HIV infected controls, healthy cases 
and a reference population of anonymous Caucasian blood donors (uncharacterised for HPV 
diseases).   No reference population is available for HLA-DRB3/4/5.  Abbreviations: +Case – 
HIV infected case with warts; +Control – HIV infected control without warts. 
 
 
 APPENDIX 4.3 INTERIM HLA ANALYSIS  
 
 
Appendix Figure A4.4 Poster presentation of interim HLA analysis.  This was presented 
at the Annual International Investigative Dermatology meeting, Montreal, 2009. 
APPENDIX 4.4  
TESTS OF SIGNIFICANCE:  ALLELES OF INTEREST  
 
 
  	  	  	  
 
 
 
 
Appendix Table A4.5 Differences in allele distributions between groups for HLA-B*35, -
B*44, HLA-DRB1*03 and HLA-DQB1*06.  Statistical testing for each group comparison was 
performed with the Yates’ chi-squared test.  Statistically significant values (uncorrected for 
multiple testing) are highlighted in yellow (p<0.05) and those that approached statistical 
significance (p=0.05) are shown highlighted in grey.  Corrected statistics are not shown.  
Those comparisons that were clearly similar on loci charts were not tested.  Abbreviations: 
+cases - HIV infected cases with warts; +controls – HIV infected controls without warts. 
 
APPENDIX 4.5  
HLA-B*44 GROUP ALLELE STRINGS  
 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
 
Appendix Table A4.6 Alleles strings for HLA-B*44 allele group.  The following numbers of 
subjects were analysed.  HIV infected cases (n=49), HIV infected controls (n=46) and healthy 
cases (n=42).  The HLA-B*44 sub-groups shown above are the most likely HLA-B*44 allele.  
The following subjects have been excluded from the analysis because the HLA-B*44 strings 
were indeterminate (HLA-B*44:02/03 could not be differentiated): HIV infected cases (n=2) and 
HIV infected cases and healthy cases (n=1).  Note: allele strings have changed over the period 
of reporting, accounting for slight variation in the composition of strings.  § - Homozygotes for 
HLA-B*44:02, -B*44:03 in the healthy cases group are displayed twice in this table, once under 
each allele. 
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Summary
Human immunodeficiency virus (HIV)-related cutaneous and anogenital disease in
the highly active antiretroviral therapy (HAART) era presents challenging problems
for dermatologists. Immune reconstitution-associated diseases (IRADs) are com-
mon and important consequences of HAART. Dermatologists should be aware of
the cutaneous manifestations of IRAD. The prevalence of clinical human papillo-
mavirus (HPV)-related disease is increased in HIV and does not appear to be
diminished by HAART. Many patients on HAART are dogged by persistent cutane-
ous warts. Anogenital precancer is also common in HIV and may be burgeoning
with HAART. Clinicians should be aware of the increased risk of cervical, penile
and vulval ⁄vaginal cancers in treated and untreated patients with HIV. The increase
in HPV infection in HIV-infected individuals may be, at least partly, due to
increased exposure to diverse HPV types, particularly high-risk types that might be
able to persist for longer in anogenital regions. Alternatively, persistent ⁄emergent
HPV disease in HIV infection might represent persistent or modulated immuno-
dysregulation after HAART and be viewed as a form of IRAD. The immunopatho-
genesis of HPV IRAD is fascinating and possibly determined by host genotype.
Human immunodeficiency virus (HIV) dermatology is chang-
ing. In the era since the introduction of highly active anti-
retroviral treatment (HAART), patients with HIV are living
longer in better health and presenting new challenges to der-
matologists. One such challenge is dermatological disease asso-
ciated with immune reconstitution that manifests during
HAART. Human papillomavirus (HPV) disease in HIV-positive
individuals is persistent, stigmatizing and therapeutically chal-
lenging. This review is in three parts: (i) a discussion of the
phenomenon of immune reconstitution-associated disease
(IRAD) from a dermatological perspective, (ii) a treatise on
HPV disease in HIV infection before and after HAART and
(iii) the argument for considering post-HAART HPV disease to
be a manifestation of IRAD.
What is immune reconstitution-associated
disease?
Since targeted anti-HIV treatment was introduced in 1987 phys-
icians have noticed that paradoxical phenomena develop in
some patients when the immune system is ‘recovering’ from
the burden of HIV infection. These reactions are analogous to
lepromatous reversal reactions or the paradoxical worsening of
Mycobacterium tuberculosis infection that can occur when cell-medi-
ated immunity is restored with antituberculous treatment. Both
of these clinical manifestations associated with immune recon-
stitution were well characterized prior to the advent of HIV.1,2
IRAD was initially observed in HIV-infected individuals after
the commencement of zidovudine (AZT ⁄ZDV) monotherapy.
Some patients with Mycobacterium avium intracellulare (MAI) deteri-
orated or developed atypical manifestations such as atypical
localized infection, nodal disease and fever in the weeks after
AZT commencement. An associated improvement in cutaneous
delayed-type hypersensitivity to tuberculous antigens was also
described in the original cases.3 Subsequently, atypical mani-
festations of a spectrum of other opportunistic infections such
as tuberculosis, Cryptococcus, cytomegalovirus (CMV) and hepa-
titis B were noted to present after antiretroviral (ART) com-
mencement.4 More potent combination ART, or HAART,
which can fully suppress HIV replication, has been used in the
U.K. since the advent of protease inhibitors in 1996.5 This has
led to greater recognition of the high frequency of presenta-
tions and the wide spectrum of disorders that may eventuate
during immune reconstitution in individual patients. These
phenomena have become broadly known as IRAD or immune
restoration inflammatory syndrome (IRIS). However, there is
much disagreement over which term should be used, and
many use the terms interchangeably.
Various attempts have previously been made to define and
to characterize IRD ⁄ IRIS.1,4,6–8 It is difficult because a large
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number of opportunistic infections can precipitate IRD ⁄ IRIS
and they can present in many organ systems. Table 1 details a
proposed consensus definition based on that used by the
recently formed International Network for the Study of HIV-
associated IRIS (INSHI; http://www.inshi.umn.edu; last
accessed 17 August 2009).
French (credited with first describing a syndrome associated
with immune reconstitution), writing recently, was careful in
his approach to ‘reappraising’ this problem.9 He reserves ‘IRIS’
for entities with a large inflammatory component (such as
tuberculosis, central nervous system cryptococcosis, CMV-
related immune recovery uveitis and John Cunningham (JC)
virus causing multifocal leucoencephalopathy). Certainly, IRIS
implies that inflammation must be present. Some authors7,10
have overlooked this, as they include the common form of her-
pes simplex virus (HSV) IRD and varicella zoster virus (VZV)
IRD as IRIS (Table 2). However, as both can be manifest by an
increase in the number of attacks of orogenital HSV or shingles
in patients after the commencement of HAART, and are clini-
cally indistinguishable from episodes occurring outside the con-
text of immune reconstitution, they are not strictly hyper-
inflammatory or atypical.11 Most authors recognize a paradoxi-
cal type of IRIS (presenting with paradoxical worsening of an
opportunistic infection under antimicrobial treatment) and an
unmasking type (where the first presentation of a disease is
unveiled by HAART).7 French uses ‘IRD’ strictly for diseases
characterized by a restoration of pathogen-specific immunity.9
French has also introduced a third term: ‘immune reconsti-
tution-associated autoimmune disease’ to describe entities such
as Graves disease and diseases of unknown aetiology, such as
sarcoidosis, that are unveiled by HAART.9 However, given that
IRIS is restricted by definition to inflammatory diseases, and
that IRD is widely regarded as being synonymous with IRIS
(even though this is probably erroneous), it seems useful to
us to appropriate and modify French’s terminology to define
IRAD broadly to include four subtypes: (i) inflammatory dis-
orders labelled as IRD ⁄ IRIS; (ii) disorders associated with
immune reconstitution having a pathogenesis other than
inflammation, such as Kaposi’s sarcoma (KS) IRD, which may
be proliferative in nature;9 (iii) autoimmune diseases such as
Graves disease, lupus and those of unknown aetiology, such as
sarcoidosis, that are not associated with a return of pathogen-
specific immunity; and (iv) those diseases found with a
greater frequency in HAART-treated patients, including HSV,
shingles, molluscum and HPV. IRAD therefore embraces all
abnormal patterns and ⁄or emergent ⁄persistent disease in HA-
ART-treated HIV infection. Hereafter we use the terms IRD,
IRIS and IRAD as defined immediately above.
IRAD has been reported in 15–25% of individuals com-
mencing HAART, but is probably higher (around 30–45%) in
those with a pre-existing opportunistic infection.1,7,12,13 It has
been stipulated that IRAD should occur within 3 months after
HAART.6,8 While this time constraint may be suitable for a
definition of IRIS, many disorders develop later in the setting
of HAART-treated chronic HIV disease, such as presentations
of autoimmune disease, and may occur up to 3 years after
HAART initiation.9
Cutaneous immune reconstitution-associated
disorders
Cutaneous IRADs are common yet can be diagnostically chal-
lenging for dermatologists. Studies that have included derma-
tological manifestations of IRAD intimate that 50–75% of all
IRAD presentations are dermatological.7 One of the most com-
mon of these is mucocutaneous herpes viruses (HSV orogenital
recurrences and VZV presenting as shingles), together, occur-
ring in 0Æ5–12% of individuals.6,7 There is also a much rarer
form of inflammatory HSV IRAD characterized by chronic
anogenital ulceration with a low pathogen load.14 HPV is
manifest by a paradoxical increase in warts after introduction
of HAART or by inflammation of existing warts. It is also
common. In one study 23% (10 ⁄44) of patients developed
oral warts while receiving HAART.7,15 Lehloenya and Meint-
jes7 and, more recently, Huiras et al.16 have reviewed the cuta-
neous forms of IRIS ⁄ IRD ⁄ IRAD in some detail (Table 2).
What is thought to be the
immunopathogenesis of immune
reconstitution-associated diseases?
The pathogenesis of IRAD is incompletely understood. Current
dogma is that latent antigen becomes recognized by the recov-
ering immune system under the influence of HAART and
results in antigen-directed pathological inflammation.4,7,13,17
However, this does not adequately explain why such unusual
patterns of disease are observed. The literature on the patho-
genesis of IRAD is difficult to assimilate because of disparate
definitions and the difficulty in correlating immunological
parameters with immunological function or dysfunction.10
IRADs have been described as ‘protean’, consisting of a
variety of presentations due to many opportunistic infections
and inflammatory disorders with diverse aetiologies.12 They
are often organ specific. Immune reconstitution may be
compartmentalized; consequently measuring systemic changes
Table 1 Consensus criteria for immune reconstitution inflammatory
syndrome (IRIS)
1 HIV positive on ART and virological response to ART with
viral load decrease > 1 log10copies ⁄mL
2 Clinical deterioration of infectious or inflammatory
condition temporally associated with ART
3 Exclusions not consistent with:
Expected course of previously recognized and treated
infection
Medication toxicity or side-effect
Treatment failure
Complete nonadherence
After: International Network for the Study of HIV-associated IRIS
(http://www.inshi.umn.edu) and Ref. 1.
HIV, human immunodeficiency virus; ART, antiretroviral therapy.
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may be irrelevant. For example, in CMV IRD there appears to
be little correlation between severity and increase of CD4+ T
cells in peripheral blood.13
A number of mechanisms (or a combination of mecha-
nisms) have been proposed to explain the immunopatho-
genesis of IRAD. Restoration of CD4 cells in response to
HAART occurs in two phases. The first is rapid and related to
redistribution of circulating memory CD4+ (CD45RO+) T
cells from the gut ⁄ lymphoid tissue. The second is more grad-
ual over months to years and involves the production of naive
(CD45RA+) T cells from the thymus.13 Therefore memory
T cells which exist in smaller numbers (for example those T
cell clones responsible for tetanus-specific immune responses)
may be more susceptible to HIV-induced deletion than those
T cells that are circulating in higher numbers due to repeated
antigen exposure ⁄reactivation (for example cytomegalovirus-
CMV-specific clones).18
A shift from a HIV CD4 T-cell depleted T helper (Th) type
2 phenotype to a proinflammatory Th1 phenotype during
dysregulated immune restoration under the influence of HA-
ART may contribute to IRIS.7 Regulatory T-cell function may
also be defective in HIV.10 Impaired dendritic cell function,
vital for antigen processing and immune activation occurs in
HIV infection and disordered restoration of this population
may result in Th1 imbalance. However, there is no clinical
evidence that the dermatological Th1 ⁄Th2 phenotype of
psoriasis ⁄eczema changes post-HAART.
Immune dysregulation therefore may be the basis of IRAD
but the question remains: why should this occur in some
individuals and not others? Risk factors for IRAD include low
CD4 nadir (lowest CD4 T-cell count before immune restora-
tion), opportunistic infections at HAART commencement and
rapid concomitant viral load suppression and CD4 rise. Patho-
gen-specific or disease-specific host immunogenetic predispo-
sitions may exist in IRAD and may also play an important
role.7 For example the phenotype HLA-A2, -B44, -DR4 and
the phenotype HLA-B72 and the alleles, -Cw*0202 and
-DRB4 have been associated with CMV and HSV IRAD,
Table 2 Clinical spectrum of cutaneous manifestations of immune reconstitution disease (IRD) ⁄ immune reconstitution inflammatory syndrome
(IRIS) ⁄ immune reconstitution-associated disease (IRAD)
Infection ⁄disease Type Disease description
Infections
Human herpes viruses Herpes simplex virus (HSV) type 1 and 2 Common presentation: increased episodes of recurrent
oronasal, anogenital HSV
Rare presentation: persistent
chronic oronasal, anogenital ulceration
Varicella zoster virus Dermatomal shingles, rarely myelitis, keratitis
Kaposi sarcoma (KS) herpes virus ⁄human
herpes virus8 (HHV-8)
KS presenting ⁄worsening on HAART
Cytomegalovirus Multifocal cutaneous ulceration
Other viruses Human papillomavirus (HPV) Persistent ⁄emergent cutaneous ⁄oral warts
Inflammation of existing warts
Molluscum contagiosum virus As for HPV
Mycobacteria Mycobacterium avium complex and M. maninum Soft tissue abscesses, cutaneous papules ⁄nodules
M. tuberculosis Cutaneous nodules, lymph node rupture
M. leprae Inflammatory reversal reactions
Fungi Cryptococcus neoformans Subcutaneous nodules
Candida albicans Inflammatory candidal angular cheilitis
Dermatophytes Generalized tinea corporis
Histoplasma capsulatum Papular ⁄nodular rash
Parasites Leishmania Post-kala-azar dermal leishmaniasis
Diseases
Inflammatory
reactions (infective)
Immune recovery folliculitis
(Demodex ⁄Malassezia)
Severe seborrhoeic dermatitis
Inflammatory
reactions (idiopathic)
Papular pruritic eruption
Eosinophilic folliculitis
Acne
Reiter’s syndrome
Sarcoidosis
Tattoo and foreign body reactions (granulomatous)
Lupus erythematosus
Repigmentation of vitiligo
Alopecia
After Refs. 7,16,21.
HAART, highly active antiretroviral therapy.
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respectively.4,14,19 CMV and mycobacterial IRAD have also
been associated with polymorphisms of interleukin (IL) and
tumour necrosis factor (TNF) genes (IL-12B and TNFa-
308*2).4 More recently, it was shown that more activating
killer immunoglobulin-like receptor (KIR) genes were present
in patients with herpes-associated IRAD.20 KIRs are important
for cytotoxic killing of virally infected cells by natural killer
cells. Therefore, although a clear association has not been
elucidated, the major histocompatibility complex (or a closely
linked gene) is often implicated in the aetiology of IRAD.
What is the burden of human papillomavirus
disease in human immunodeficiency virus
infection?
The vast majority of individuals (> 80%) will contract HPV at
some point in their lives, although most infections are asymp-
tomatic. HIV-positive individuals are more likely to have an
increased exposure to HPV both in terms of the number of
inoculations and exposure to a greater number of types.
Cutaneous warts are more prevalent in HIV-infected indi-
viduals than in the general population and this may be in-
creasing in the post-HAART era.21 Cutaneous warts in HIV
disease are a clinical challenge from three perspectives: (i)
paucity of effective treatments, (ii) high cost of treatment and
(iii) patient stigmatization. Current evidence (largely from
case reports) suggests that HPV types seen in HIV infection
may differ from those found in the general population. HPV
type 6 (a genital type) and HPV type 7 (causing butcher’s
warts) have been identified in cutaneous lesions from HIV-
positive individuals.22,23 There are also case reports of HIV-
positive patients presenting with pityriasis-like lesions and
unusual flat plane warts mimicking the pattern of warts found
in epidermodysplasia verruciformis (EV), and EV-associated
HPV types such as HPV 5 and 8 have been isolated from
these.24–26 Genital types, particularly oncogenic types (HPV
16, 31, 33, 35) may be found in cutaneous warts in HIV-
positive individuals27 (as cited by Porro et al.23). Mixed HPV
types in the same lesion and novel types are also common in
immunosuppressed organ transplant recipients (OTRs).28,29
This may also be true of HIV-positive individuals, although
more data are needed. OTRs and HIV-infected patients, how-
ever, may differ in a number of respects including the mecha-
nism, intensity and duration of immunosuppression and host
interactions with HPV.30,31 The clinical picture of cutaneous
warts seen in OTRs may be influenced to a large degree by
persistence ⁄reactivation of HPV. In HIV-infected patients both
immunosuppression (leading to persistence ⁄reactivation) and
increased exposure to more HPV types may be important.
There are three factors associated with the development of
HPV-related anogenital precancers: (i) the presence of high-
risk HPV types, (ii) the site of infection (principally anus and
cervix), and (iii) HPV persistence (molecularly and ⁄or clini-
cally). HIV infection may allow HPV to persist despite a
‘reconstituted’ immune system. Anal and cervical epithelia
have distinct transformation zones that appear to be highly
susceptible to HPV-mediated dysplasia, perhaps because HPV
cannot complete its lifecycle in cells of columnar epithelia,
leading to so-called abortive infections.32
Molecularly detected genital HPV infections are found more
frequently in HIV-positive individuals.33 HIV-positive women
have been shown to be more likely to carry and acquire HPV
infection, have higher risk types and have more persistent in-
fections. Therefore these women are less likely to clear HPV
infections.33 Mixed HPV infections are also more common in
the cervix of HIV-positive women and in the anus in men
who have sex with men (MSM).33,34 There is also evidence
to suggest that reactivation may be an important part of the
increased detection of HPV in HIV-positive individuals.35
Precancerous anogenital HPV-related disease is also
increased in HIV. Cervical intraepithelial neoplasia (CIN),
vulval ⁄vaginal intraepithelial neoplasia (VIN ⁄VaIN) and penile
carcinoma in situ seem more prevalent in HIV infection.36–38
The occurrence of anal intraepithelial neoplasia (AIN) in
HIV-positive men and women is high; in one study 81% of
HIV-positive MSM had AIN.33,39,40 HIV-positive patients are
more likely to have high-grade lesions, increased rates of
progression (from HPV infection to CIN ⁄AIN), and a reduc-
tion in regression of CIN ⁄AIN.33
Cervical cancer is an AIDS-defining diagnosis and has a mod-
erately increased relative risk in HIV infection of five times that
of the general population.41 Anal cancer is increased in HIV in-
fection compared with the general population: there is a seven-
fold increased risk in HIV-positive women, a 37-fold increased
risk in HIV-positive men and a 60-fold increased risk in HIV-
positive MSM.41 Penile, vulval and vaginal cancers are also in-
creased in HIV infection but probably to a lesser extent.37,41
Human papillomavirus and highly active
antiretroviral therapy
Studies show no demonstrable effect of HAART in reducing
the prevalence ⁄ incidence of cutaneous warts.42,43 Persistent
cutaneous HPV disease despite HAART has been described in
the form of widespread warts occurring late in the course of
immune reconstitution, often more than 3 years after HAART
initiation.17 Others have reported that a proportion of HIV-
positive individuals on HAART display persistent cutaneous
HPV disease; the CD4 T-cell count nadirs were lower in the
subset of patients whose warts did not regress (median of 50
vs. 258 cells lL)1).44 Although this effect may be partially
explicable by CD4 T-cell nadirs acting as an ‘evolutionary
bottleneck’, constitutive immunity (immunogenetics) may also
have an influence.44 Our clinical observations coincide with
those described above and suggest that cutaneous warts may
persist or occur late after HAART initiation in a subset of
patients.17,44 The consensus from a number of reports appears
to be that oral warts increase following HAART.15,45,46
The effect of HAART on genital warts and precancer is not
entirely consistent. Overall, there is probably no reduction in
the prevalence of HPV infection or precancer with HAART.37
Not all studies have taken absolute CD4 T-cell counts and CD4
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T-cell count nadirs into account, yet such parameters are
probably important. Studies on CIN (and VIN) have either
shown no change in its natural history or a modest positive
effect on reducing incidence, progression and increasing
regression of HPV with HAART.37,38 There is very little, or no
apparent beneficial effect of HAART on anal HPV infection or
AIN and the incidence of both appears to have been rising
rapidly in HIV-positive MSM since the introduction of
HAART.37,40 High-grade CIN and AIN do not regress more
frequently with HAART.33 Therefore, although HIV infection
itself increases the prevalence of anogenital precancer, the
present evidence suggests that HAART does not appear to
confer a substantial beneficial effect on anogenital precancers.
In the U.K. the incidence of anal cancer in HIV-positive
men has risen from 35 to 92 per 100 000 in the period
since the introduction of HAART.41,47 There is also no evi-
dence that cervical cancer has declined in the HAART era.48
Therefore, there does not appear to a beneficial effect of
HAART on cervical or anal cancer.35,37 The impact of HA-
ART on vulval and vaginal cancer has been incompletely
investigated but, at present, HAART does not appear to be
beneficial.37 Penis cancer is more frequent in HIV-infected
patients, although the number of affected patients is too
small to allow a definitive conclusion regarding the influ-
ence of HAART.34,37,41 Therefore, decreased regression of
anogenital precancers (which can take years or decades to
progress to invasive cancer), or at least no change in
regression with HAART, combined with increased lon-
gevity of HIV patients, may lead to further rises in anal
cancer and to an increase in cervical cancer in the post-
HAART era.33
Can the effects of human papillomavirus in
human immunodeficiency virus infection be
viewed as an immune reconstitution-
associated disease?
HPV IRIS may manifest as inflammation of pre-existing warts;
in some cases there can be massive enlargement.49 Noninflam-
matory HPV-related IRAD has also been described. Greenspan
et al.15 showed that treatment with HAART regimens that
included protease inhibitors significantly increased the risk of
developing oral warts. Twenty-three per cent of patients on
ART including a protease inhibitor were affected, compared
with 15% of patients receiving therapy without a protease
inhibitor and 5% on no treatment. King et al.50 showed that in
HIV-positive patients, the incidence of oral warts has been ris-
ing significantly since the introduction of HAART. Greenspan
et al.15 and King et al.50 propose that this is due to a complica-
tion of HAART or immune reconstitution. Other workers have
also remarked on the increase in oral warts and increased HPV
DNA prevalence in patients on HAART.45,46,51
Persistent cutaneous HPV disease despite effective HAART
has also been described.17,44 Although HAART-induced regres-
sion of HPV-associated warts can occur in some patients, we
propose that in a subset of patients, persistent cutaneous and
oral HPV disease occurs despite HAART. This might be viewed
as an IRAD. Therefore, we propose that both the established
increase in oral warts and the phenomenon of persistent cuta-
neous warts described by Price et al.17 and Rodrigues et al.44
might represent HPV IRAD.
Maurer et al.52 described a cohort of ageing HIV-positive
HAART-treated patients with persistent indolent KS and a high
CD4 count and low viral load; there are two explanations for
this. Immunological ‘senescence’ may be occurring in San
Francisco’s ageing cohort on HAART, or this may be a form
of persistent ⁄emergent KS IRAD. Both of these possibilities
may also be applicable to HPV-related disease in HIV.
We propose that, because HPV is causally linked to warts
and anogenital precancer and cancer, these are all different
facets of the same entity, i.e. persistent ⁄emergent HPV disease
in HIV – and what might be viewed as HPV IRAD.
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A large number of human papillomavirus (HPV) types, distributed over five papillomavirus genera, are
detectable in the skin. HPV types belonging to the alpha, gamma, and mu genera have been detected in
cutaneous warts. A state-of-the-art HPV genotyping assay for these cutaneous wart-associated HPV types does
not exist although warts constitute a highly prevalent skin condition, especially in children (33%) and organ
transplant recipients (45%). Cutaneous warts are again the focus of attention as their clinical relevance rises
with the increasing number of chronically immunosuppressed patients. The objective of this study was to
develop and evaluate a DNA-based genotyping system for all known cutaneous wart-related HPV types using
PCR and Luminex xMAP technology. The broad-spectrum PCR amplified DNA of all known wart-associated
HPV types from the genera alpha (HPVs 2, 3, 7, 10, 27, 28, 29, 40, 43, 57, 77, 91, and 94), gamma (HPVs 4, 65,
95, 48, 50, 60, and 88), mu (HPVs 1 and 63), and nu (HPV41). The probes were evaluated using plasmid HPV
DNA and a panel of 45 previously characterized cutaneous wart biopsy specimens showing high specificity.
HPV was also identified in 96% of 100 swabs from nongenital cutaneous warts. HPV types 1, 2, 27, and 57 were
the most prevalent HPV types detected in 89% of the swabs. In conclusion, this Luminex-based genotyping
system identifies all known cutaneous wart HPV types including phylogenetically related types, is highly HPV
type specific, and is suitable for large-scale epidemiological studies.
Papillomaviruses (PV) constitute a group of viruses associ-
ated with benign and malignant proliferative lesions of cuta-
neous and mucosal epithelia. The taxonomic family of PV
includes 16 genera (5). More than 100 human papillomavirus
(HPV) types have been fully sequenced. The number of HPV
types that are not yet fully characterized is probably much
larger. HPV types, distributed over five genera (alpha, beta,
gamma, mu, and nu) and 16 species, infect the skin (5). HPV
types belonging to species of three genera (alpha, gamma, and
mu) have most frequently been detected in hyperkeratotic skin
lesions (warts).
The alphapapillomavirus (alpha-PV) types infecting the gen-
ital mucosa (e.g., HPV16, HPV18, HPV6, and HPV11) are the
best understood. HPV16 and HPV18 are the most prevalent
types involved in the pathogenesis of anogenital (e.g., cervical)
cancer, and HPV types 6 and 11 cause genital warts and laryn-
geal papillomas. The alpha-PV types belonging to species 2, 4,
and 8, which have been detected in cutaneous warts, have been
studied less thoroughly. At present the most frequently de-
tected alpha-PV types in cutaneous warts are HPV types 2, 3,
10, 27, and 57 (3, 10, 12–16, 18, 19). Gamma-PV types, includ-
ing HPV4, HPV60, and HPV65, have also regularly been de-
tected in cutaneous warts (4, 10, 12, 15). Mu-PV types, HPV1
and HPV63, have also been detected in cutaneous warts (7).
HPV types included in the beta and nu genera have rarely been
detected in cutaneous warts. Only Harwood and coworkers
(13) have described the presence of beta-PV types in cutane-
ous warts of immunosuppressed patients. The nu-PV genus
consists of only one HPV type (HPV41), which was originally
isolated from a facial wart (11).
In general, cutaneous warts from immunocompetent and
immunocompromised patients appear to show the same geno-
type distributions (16, 19). This has to be confirmed by a
large-scale study comparing the distributions in the two pop-
ulations with the same techniques. The number of detected
types per lesion appeared to differ between immunocompetent
and immunosuppressed patients (13). Currently, cutaneous
warts are again the focus of attention with the increasing num-
ber of chronically immunosuppressed patients (9, 20). Signifi-
* Corresponding author. Mailing address: DDL Diagnostic Labora-
tory, Fonteijnenburghlaan 7, 2275 CX Voorburg, Netherlands. Phone:
31 703401670. Fax: 31 703401671. E-mail: w.g.v.quint@ddl.nl.
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cant physical and psychological morbidity in these patients may
result from the existence of confluent plaques of warts present
on cosmetically sensitive areas such as the face and hands and
the presence of large warts occurring on pressure-bearing ar-
eas such as the feet.
Although cutaneous warts constitute a highly prevalent skin
condition, especially in children (33%) (22) and organ trans-
plant recipients (45%) (2), only a few large-scale epidemiolog-
ical studies including more than 100 lesions have investigated
the distribution of HPV types in cutaneous warts. These studies
utilized different detection methods, such as general primer-
mediated PCR followed by HPV typing with direct sequencing
(12, 15) or by restriction enzyme cleavage of the PCR product
(18). Other methods employed were multiple-type-specific
PCR combined with direct sequencing (3), in situ hybridization
(8), and (Southern) blot hybridization (6, 10). Although these
methods are in general type specific, they are time-consuming
and therefore less suitable for large scale-epidemiological
studies. In the case of multiple infections, reliable typing might
also be difficult with direct sequencing of the PCR amplimer
without prior molecular cloning. Therefore, we have evaluated
a novel broad-spectrum PCR–multiplex genotyping (MPG) as-
say called the hyperkeratotic skin lesion (HSL) PCR/MPG for
identification of established and candidate cutaneous wart
HPV types. These types are included in the alpha genus species
2 (HPVs 3, 10, 28, 29, 77, and 94), species 4 (HPVs 2, 27, and
57), and species 8 (HPVs 7, 40, 43, and 91); gamma genus
species 1 (HPVs 4, 65, and 95), species 2 (HPV48), species 3
(HPV50), species 4 (HPV60), and species 5 (HPV88); mu
genus species 1 (HPV1) and species 2 (HPV63); and nu genus
species 1 (HPV41). In this study the sensitivity, the HPV type
specificity, and the clinical performance of the HSL-PCR/
MPG broad-spectrum assay have been investigated.
MATERIALS AND METHODS
Clinical materials. Two panels of clinical samples were available. The first
panel consisted of purified DNA obtained from 45 nongenital cutaneous warts
that were taken from immunocompetent patients, immunosuppressed organ
transplant patients, and HIV-positive patients. These samples had been previ-
ously HPV genotyped by DNA sequencing using a purified PCR product from
two rounds of nested PCR utilizing the primer pair HVP2-B5 for the first round
and the pairs CN1F-CN1R, CN2F-CN2R, and CN3F-CN3R for the second
round (sequencing) or the single-round primer pair C4F-C4R (PCR and se-
quencing), as described by Harwood and coworkers (13). The use of separate
reaction mixtures with different primer pairs allowed the identification of mul-
tiple HPV types. In some cases DNA sequencing was not carried out with all of
the primer pairs (Table 1).
A second panel comprised swabs taken from 100 cutaneous warts derived from
100 individuals (age of !4 years) with one or more cutaneous warts who self-
presented to their general practitioners. The warts were present mainly on hands
and feet. The swabs were taken from one wart from each patient by firmly
rubbing a prewetted cotton-tipped stick five times over the surface of the lesion.
Next, the swabs were put in 1 ml of saline solution, and 10 "l was used directly
in the novel HSL-PCR/MPG assay.
Plasmids. For the evaluation of the analytical type specificity of the HSL-PCR/
MPG assay (Labo Biomedical Products BV, Rijswijk, Netherlands), amplimers
were generated using plasmid clones containing sequences of the following types:
HPV types 1, 2, 3, 4, 7, 10, 27, 28, 29, 40, 41, 43, 48, 50, 57, 60, 63, 65, 77, 88, 91,
94, and 95. Plasmids containing HPV genomic DNA were kindly provided by
E.-M. de Villiers (HPVs 1, 4, 7, 41, 48, and 63), O. Forslund (HPV88), M. Favre
(HPV10), T. Matsukura (HPV60), R. Ostrow (HPV3), G. Orth (HPVs 28, 29,
and 50), and A. Lorincz (HPV43). For HPV types 2, 27, 40, 57, 65, 77, 91, 94, and
95, the relevant HPV sequence was synthesized, cloned, and sequenced (Gen-
Script USA, Inc.). In order to confirm amplification of an HPV-specific frag-
ment, gel electrophoresis was performed with 2.2% FlashGel agarose gels
(Lonza, Basel, Switzerland). To determine the analytical sensitivity of the assay,
DNA concentrations of the plasmids were determined using a NanoDrop 2000
instrument (Thermo Fisher Scientific Inc.), and 10-fold serial dilutions were
made in a background of 12 ng/"l human genomic DNA. This background
human DNA is equivalent to approximately 24,000 cells per 10 "l of plasmid
sample.
TABLE 1. Comparison of HSL-PCR/MPG assay results with
direct DNA sequencing on PCR amplimers obtained from
purified DNA from 45 warts
Sample
no.
HPV type(s) by: Comparison of
resultsfHSL-PCR/MPG DNA sequencing
1 27 27 I
2 27 27 I
3 27 27, 94 C
4 27 27, 94 C
5 27 27 I
6 28 28 I
7 27 27 I
8 2 2 I
9 Negative Negative I
10 27 27 I
11 (3)a, 7 3 C
12 (3)a, 7 3 C
13 27 27 I
14 2 2 I
15 57 57 I
16 57 57 I
17 57 28, 57 C
18 57 57 I
19 57 57 I
20b 57 72 D
21b Negative 72 I
22c 4 27, 28 D
23 27 27, 28 C
24 57 57 I
25 27 27 I
26 27 27 I
27 27, 57, 95 27 C
28 27, 57 27 C
29 57 57 I
30 57 57 I
31 1, 3, 57 3 C
32 3, 57 57 C
33 57 57 I
34 4 4 I
35 2 2 I
36 2 2 I
37d 7 10 D
38 4, 7, 10 7, 10, 27 C
39 4, 7, 10 7, 10, 27 C
40 7 7, 10 C
41 7, 10 10, 27 C
42 10, 27 27 C
43e 63 27 D
44 27 27 I
45 4 4 I
a Elevated signal but below cutoff for HPV3 with the HSL-PCR/MPG. There
was no sequencing result for HPV7; HPV7 was confirmed by a third assay.
b HPV72 not included in the HSL-PCR/MPG assay.
c No sequencing result for HPV4 available.
d Repeated DNA sequencing negative.
e Repeated DNA sequencing did not confirm HPV27.
f I, both methods yielded completely identical genotyping results (concordant);
C, both methods showed one or more of the same genotype(s) (compatible); D,
no similarity between genotypes detected by both methods (discordant).
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HSL-PCR/MPG assay. The HSL-PCR/MPG assay comprises the HSL-PCR
generating a biotinylated amplimer of 76 to 84 bp from the L1 region and a
genotyping assay with bead-based xMAP suspension array technology, which is
able to simultaneously identify 23 HPV genotypes. Within the L1 gene of HPV
a region suitable for broad-spectrum PCR and genotyping was used (Fig. 1). The
primer set consisted of 27 nondegenerate primers (13 forward and 14 reverse)
without inosines. All PCRs were carried out with all precautions to avoid con-
tamination, as described by the manufacturer (Labo Biomedical Products BV,
Rijswijk, Netherlands).
Briefly, HSL-PCR was performed in a final reaction volume of 50 "l, contain-
ing 10 "l of the isolated DNA, 2.0 mM MgCl2, 1# GeneAmp PCR Buffer II, 0.2
mM deoxynucleoside triphosphates (dNTPs), 1.5 U of AmpliTaq Gold DNA
polymerase, and 10 "l of the primer mix. The PCR was performed by a 9-min
preheating step at 94°C, followed by 35 cycles of amplification comprising 30 s at
94°C, 45 s at 55°C, and 45 s at 72°C. A final elongation step at 72°C for 5 min
ended the PCR.
The HSL-PCR/MPG assay permitted the simultaneous identification of mul-
tiple HPV genotypes in a single hybridization step. Twenty-four genotyping
probes were selected from the PCR target region (Fig. 1) and were immobilized
on color-coded beads. Since the HPV genotypes included in the assay often differ
by only a few nucleotides in the probe region, well-controlled assay conditions
and probe selection were required. The HSL-PCR/MPG assay was performed
according to the manufacturer’s instructions in a Luminex 100 IS System (Lu-
minex Corporation, Austin, TX) that was calibrated weekly. Briefly, 3B buffer
was added to the provided bead mix to minimize background in the final Lumi-
nex readout. Subsequently, HSL-PCR products were added. Next, heat denatur-
ation, hybridization under stringent conditions, and incubation with streptavidin-
conjugated R-phycoerythrin detection conjugate, followed by readout according
to the specified instrument settings, resulted in median fluorescence intensity
(MFI) levels per HPV type for each specimen. No distinction was made between
samples positive for HPV type 2 variant (HPV2var) and HPV2 as they are both
scored as HPV2 positive.
Sequence analysis. For sequence analysis of the HSL amplimers from the
plasmid clones generated with use of type-specific primers, amplimers were
treated with ExoSAP-IT (USB, OH) to remove unconsumed dNTPs and prim-
ers. Purified amplimers were directly sequenced according to the manual of the
Big Dye Terminator Cycle Sequencing kit using forward and reverse HSL-PCR
primers. The sequence products were subsequently read using a 3100-Avant
Genetic Analyzer. The resulting DNA sequences were analyzed with Vector NTI
Advance, version 9.0, software and compared with all known HPV types present
in the National Center for Biotechnology Information (NCBI) database utilizing
nucleotide-nucleotide BLAST (BLASTN) searches (1) (http://www.ncbi.nlm.nih
.gov/BLAST/).
HPV sequences from GenBank. The following are accession numbers of HPV
sequences obtained from GenBank (http://www.ncbi.nlm.nih.gov/GenBank
/index.html) and used as references for the corresponding HPV genotypes: HPV
type 3, X74462; HPV type 10, X74465; HPV type 28, U31783; HPV type 29,
U31784; HPV type 77, Y15175; HPV type 94, AJ620211; HPV2var, DQ080000;
HPV type 2, X55964; HPV type 27, X73373; HPV type 57, X55965; HPV type 7,
X74463; HPV type 40, X74478; HPV type 43, AJ620205; HPV type 91,
AF419318; HPV type 4, X70827; HPV type 48, U31789; HPV type 50, U31790;
HPV type 60, U31792; HPV type 65, X70829; HPV type 88, EF467176; HPV
type 95, AJ620210; HPV type 1, V01116; HPV type 63, X70828; HPV type 41,
X56147.
RESULTS
Analytical type specificity of the HSL-PCR/MPG. DNA
from 24 plasmids containing partial or complete HPV genomic
sequences representing established types from alpha-, gamma-,
mu-, and nu-PV genera was analyzed by HSL-PCR/MPG. Am-
plimers were identified on agarose gels, and a fragment of the
expected size (76 to 84 bp) was present (data not shown).
Subsequent sequence analysis (data not shown) confirmed that
the correct genotypes were amplified. For all HPV sequences
the genotyping assay showed type-specific hybridization, with
MFI values ranging from 2,133 to 7,667 for targeted HPV types
(Fig. 2).
Analytical sensitivity of the HSL-PCR/MPG. Sensitivity tests
were performed on 10-fold serial dilutions of plasmid clones of
HPV types 1, 2, 3, 4, 7, 10, 27, 28, 29, 40, 41, 43, 48, 50, 57, 60,
63, 65, 77, 88, 91, 94, and 95 made in a background of 12 ng/"l
human DNA. The analytical sensitivity of the HSL-PCR/MPG
assay ranged from 1 to 10 copies per PCR for HPV types 1 and
2; from 10 to 100 copies per PCR for HPV types 2 variant, 4,
7, 10, 43, 48, 63, and 95; from 100 to 1,000 copies per PCR for
HPV types 3, 27, 29, 57, 60, 65, and 77; and from 1,000 to
10,000 copies per PCR for HPV types 28, 40, 41, 50, 88, 91, and
94 (data not shown).
FIG. 1. Nucleotide sequence alignment of the target region for the HSL-PCR for 23 HPV types. The nucleotides identical to the top sequence
(HPV3) are indicated as dots. Within the alpha genus the HPV types are ordered per species, with species 2 consisting of HPV types 3, 10, 28,
29, 77, and 94; species 4 consisting of HPV types 2, 2 variant, 27, and 57; and species 8 consisting of HPV types 7, 40, 43, and 91.
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Clinical performance of the HSL-PCR/MPG. The HSL-
PCR/MPG yielded an HPV genotyping result identical to that
of sequencing in 26 of the 45 nongenital cutaneous wart DNA
samples derived from immunocompetent patients, immuno-
suppressed organ transplant patients, and HIV-positive pa-
tients. In 15 of 45 cases the result was compatible (i.e., an
additional HPV type was detected by either method [21]) (Ta-
ble 1). In four of 45 cases the results were discordant. In two of
these four cases the result with one or both assays was positive
for an HPV type that was not included in the other assay, and
these two samples were excluded. Two other discordant results
remain unresolved since repeated sequencing did not confirm
the first result.
Second, the performance of the HSL-PCR/MPG assay was
evaluated on cutaneous wart swabs. The positivity rate was
96% in swabs taken from nongenital cutaneous warts mainly
present on hands and feet of 100 patients (see Materials and
Methods). The most prevalent HPV types were HPV1 (genus
mu species 1) and HPVs 2, 27, and 57 (genus alpha species 4).
Together, these HPV types were detected in 89% of the cuta-
neous wart swabs. Other HPV types detected were HPVs 3, 4,
7, 63, 65, and 95 (Table 2). In one case the generated amplimer
of the expected size, as visualized by agarose gel electrophore-
sis, did not hybridize with the available genotyping probes. In
three other cases the HSL-PCR/MPG did not generate an
amplimer of the expected size and did not give a positive signal
with the genotyping assay. Within these 100 samples, 11 mul-
tiple infections were observed; of these 10 contained two HPV
types and 1 was positive for three types.
DISCUSSION
In this study, we have described the evaluation of a novel,
sensitive, single-step broad-spectrum PCR targeting the HPV
L1 region combined with a Luminex-based hybridization assay
for the detection and genotyping of HPV types associated with
nongenital cutaneous warts. The HSL-PCR was able to amplify
FIG. 2. Analytical type specificity of the HSL-PCR/MPG. Indicated are the MFI readouts (without background subtraction) of HSL-PCR
amplimers generated from 6# 108 to 7# 107 copies of different HPV plasmids (listed on top) in relation to the bead-bound capture probes (listed
on the left). The conjugate control (conj) serves as the positive control for correct incubation with the detection conjugate for each separate
specimen. HPV2 and HPV2var (2v) are both scored as HPV2 positive.
TABLE 2. HPV type distribution in 100 swabs taken
from a single wart of 100 persons
Genus Species no. Genotype % Positivitya
Alpha 2 HPV3 2
4 HPV2 20
HPV27 31
HPV57 15
8 HPV7 1
Gamma 1 HPV4 5
HPV65 1
HPV95 1
Mu 1 HPV1 31
2 HPV63b 1
a Eleven samples showed multiple infections; 10 of these samples were positive
for two types and 1 was positive for three types. Four samples were negative with
the genotyping assay.
b Only detected once in a multiple infection with HPV1.
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HPV DNA from various sources and showed an analytical
sensitivity of 1 to 10,000 HPV copies per PCR in a human
genomic DNA background. The analytical HPV type specific-
ity was 100%, as shown by analyzing amplimers generated from
all 23 included HPV types at a concentration ranging from 6#
108 to 7 # 107 viral genome copies per PCR. When the novel
HSL-PCR/MPG method was compared with an established
DNA sequencing method (13) targeting a different part of the
L1 open reading frame, the results were highly concordant.
Forty-one of the 43 included samples gave identical or com-
patible results (95%), and two gave discordant results, con-
firming the high analytical specificity of the novel genotyping
method.
The reproducibility of the Luminex system which was used
for the HSL-PCR/MPG assay has been extensively investigated
by an analogue, broad-spectrum PCR genotyping assay
(Digene HPV Genotyping LQ Test package insert) and was
higher than 95%.
The median MFI values, representing the general back-
ground signals in all 130 analyzed clinical samples consisting of
swabs and biopsy specimens, were very low, ranging from 1 to
9 MFI for the different probes. The observed cross-reactions in
clinical samples were all confirmed by experiments with plas-
mid dilutions using an input of up to 108 viral genome copies
per PCR. Furthermore, DNA sequence alignments between
the probes and cross-hybridizing HPV types (data not shown)
indicated that a small number of mismatches explained the
cross-hybridization reactions with a maximum signal of 131
MFI. Whereas the general background signals were between 1
and 9 MFI, theoretically allowing for a low cutoff, the detected
cross-hybridization reactions with some probes resulted in the
use of a conventional cutoff of 200 MFI for all types. Using this
high cutoff for all HPV types included in the assay could cause
an underestimation of the prevalence of certain HPV types.
Amplimers of HPV27 gave cross-hybridization reactions
with the probe for HPV2var that resulted in MFI signals higher
than 200 MFI. The highest observed cross-reactive signal was
detected in purified DNA from a cutaneous wart positive for
HPV27, with an MFI value of 9,226. The cross-reactive signal
for HPV2var was 534 MFI in this case. Therefore, the cutoff
for HPV2var positivity was set at 700 MFI in multiple infec-
tions with HPV27 signals above 7,500 MFI.
Similarly, amplimers of HPV10 and HPV28 gave cross-hy-
bridization reactions with the probe for HPV94 that resulted in
MFI signals higher than 200 MFI, with a maximum of 221 MFI.
Consequently, we used a cutoff for HPV94 positivity of 500
MFI in a multiple infection with HPV10 or HPV28 when these
types had higher signals than 4,000 or 1,500 MFI, respectively.
In the absence of these types, the assay’s conventional cutoff
of 200 MFI was used. This cutoff value is well above the
background signals and was chosen as a precaution because
cutaneous warts could produce very high concentrations of
viral DNA, possibly challenging the specificity of the genotyp-
ing system. The downside of this precaution is reflected by the
analytical sensitivity of the assay, which ranges from 1 to 10,000
copies per PCR. However, in the panel of 100 swabs of cuta-
neous warts, 96 (96%) of the samples were HPV positive,
indicating a high enough analytical sensitivity of the assay for
this kind of sample.
Current methods for the determination the HPV genotypes
in cutaneous warts are generally based on Southern blot hy-
bridization or on general primer-mediated PCR or type-spe-
cific PCR followed by direct DNA sequencing. Although these
methods can provide accurate results, they are laborious and
not suitable for use in large epidemiological studies. The assay
format of the novel HSL-PCR/MPG method encompasses a
broad-spectrum PCR amplifying all known cutaneous wart-
associated HPV types, followed by a multiplex genotyping as-
say in a high-throughput setting, which allowed genotyping of
a panel of PCR products derived from 96 samples in about 2 h.
The HSL-PCR was designed to amplify all HPV types pre-
viously found in cutaneous warts as well as related types from
the same species (5). Complementing established types with
the HPV types present in the same species is based on the
assumption that these types might also be involved in cutane-
ous wart etiology analogous to the cervical cancer risk associ-
ated with not only HPV16 but also other types included in the
same alpha-PV species 9. In this study swabs from 100 cuta-
neous warts were analyzed from individuals attending their
general practitioners for treatment. Therefore, this panel was
probably representative for warts in the general (Dutch) pop-
ulation. We confirmed the presence of similar HPV types as
reported in the literature, but the other types present in the
same HPV species were not often detected in this panel.
Whether these other types occur less frequently or only in
specific patient groups (e.g., HIV-infected persons) will be the
subject of further investigations.
The common and easily accessible nature of cutaneous warts
led early on to prolific clinical research in PV (17). Currently,
these skin lesions are again the focus of attention as the clinical
relevance of cutaneous warts rises with the increasing number
of chronically immunosuppressed patients (9, 20). Significant
physical and psychological morbidity in these patients may
result from the existence of confluent plaques of warts present
on cosmetically sensitive areas such as the face and hands and
the presence of large warts occurring on pressure-bearing ar-
eas such as the feet. The impact of these problems and the
difficulty in treating them should not be underestimated. In-
deed, in some cases they may prompt the use of lower levels of
immunosuppression, thus potentially endangering graft sur-
vival. In addition, the recently available preventive vaccines for
HPV types causing cervical cancer pave the way for preventive
and possibly therapeutic vaccines against cutaneous warts, par-
ticularly in the case of organ transplant recipients and patients
with HIV. The development of these vaccines will, however,
require a greater understanding of the HPV types that cause
cutaneous warts and their natural history. Easy-to-use, high-
throughput genotyping systems such as that described in this
study will be invaluable for this future research.
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Cutaneous human papillomavirus-related
immune reconstitution-associated disease
in human immunodeficiency virus: an
under-recognized phenomenon
DOI: 10.1111/j.1365-2133.2010.10109.x
MADAM, It is increasingly common in clinical dermatology to
encounter human immunodeficiency virus (HIV)-infected
patients. The advent of highly active antiretroviral therapy
(HAART) in 1996 has been instrumental in improving their
quality of life but new phenomena have emerged. One such is
immune reconstitution-associated disease (IRAD), recently
reviewed by us from a dermatological perspective.1 IRAD is a
term we prefer to ‘immune reconstitution inflammatory syn-
drome ⁄ immune reconstitution disease’ as it encompasses a
wide range of presentations and pathologies, not just those of
strictly inflammatory aetiology.1 Cutaneous warts are very
common in untreated HIV, and remain so despite HAART,
certainly in our experience (servicing around 5000 HIV-
infected patients). Cutaneous (and genital) related HPV IRAD
has previously been reported;2–5 however, it is not widely
acknowledged that cutaneous human papillomavirus (HPV)-
related IRAD exists, even though it may in fact be common-
place.6 We describe two patients who developed an acute in-
flammatory form of IRAD associated with cutaneous HPV. The
progression of HPV disease in response to HAART has not pre-
viously been documented photographically.
Patient 1. A 33-year-old man was seen in the dermatology
department. Screening for generalized pruritus showed HIV
positivity. He had had four persistent warts for more than
6 months on the preauricular area and lateral neck associated
with cryotherapy scarring from treatment in primary care
(Fig. 1a). After initiation of HAART (tenofovir, emtricitabine,
efavirenz) his CD4 T-cell count rose from 12 to 104 cells
per mm3 over 9 months and his viral load fell from 65 506 to
< 50 copies per mL. During this time he re-presented with a
disfiguring and widespread scaling hyperkeratotic inflamma-
tory eruption of multiple viral warts on the lower face and
neck (Fig. 1b). A biopsy showed classical HPV histology, with
a minimal lymphocytic inflammatory infiltrate containing simi-
lar numbers of CD4 and CD8 T cells. He was commenced on
acitretin 10 mg once daily and within 1 week had noticed sig-
nificant improvement.
Patient 2. A 48-year-old man was diagnosed with HIV infec-
tion more than 20 years ago. He had a chronically low CD4
T-cell count (< 50 cells per mm3) for the past 3 years and
numerous skin problems including psoriasis, drug reactions,
tinea corporis and crusted scabies. He also had cryotherapy for
plantar warts. His anti-HIV regimen was altered to improve his
CD4 T-cell count, even though he had an undetectable viral
load, switching from tenofovir, didanosine and lopinavir ⁄
ritonavir to tenofovir ⁄emtricitabine and lopinavir ⁄ritonavir.
His CD4 T-cell count increased from 47 cells per mm3 (CD4
5Æ1%) prior to intensification of his HAART to 72 cells
per mm3 (CD4 8Æ0%) 8 months later. During this time he
developed a florid worsening of the plantar warts, despite
ongoing HAART.
The first case highlights the features of IRAD: the patient
was prescribed a suppressive regimen of antiretroviral therapy
that resulted in a > 1 log10 reduction in his HIV viral load
but then developed a clinical deterioration of an infectious or
inflammatory condition – HPV infection – temporally associ-
ated with antiretroviral exposure.1 The second case illustrates
that a similar phenomenon might also occur with HAART
modification where perhaps a small increment in CD4 T-cell
count is sufficient to facilitate a degree of reconstitution,
although the HIV viral load had previously been undetectable.
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IRAD is ‘protean’: it comprises a diverse range of presenta-
tions of opportunistic infections (such as tuberculosis, crypto-
coccus, herpesviruses) and diseases (such as sarcoid, Graves
disease) that can be precipitated by immune reconstitution fol-
lowing HAART. The aetiology of IRAD may be dependent on
the particular disease and individual host but is surely an effect
of a dysregulated immune system. The pathogenesis may be
due to disease-specific CD4 helper T-cell clone restoration,
regulatory T-cell dysfunction, disordered antigen presentation
of dendritic cells, a switch from a T helper (Th) type 2 (aller-
gic) phenotype to an inflammatory Th1 phenotype or a com-
bination of these.1 The mechanism by which inflammation
might lead to hyperproliferation of HPV-infected keratinocytes
and an explosion of new lesions with immune restoration is
obscure, but the driver may be the cytokine milieu produced
by infiltrating inflammatory cells (Whitfeld M, personal com-
munication). It is known that an increase in CD4 T cells (par-
ticularly) but also CD8 T cells is seen in resolving warts and
also that warts enlarge prior to resolution. In histological sec-
tions from patient 1 an infiltrate of both CD4+ and CD8+ cells
was seen but this was not especially florid.
A chronic form of HPV IRAD might be represented by persis-
tent cutaneous ⁄genital warts and ⁄or HPV carriage despite
apparently effective immune reconstitution on HAART.7,8 This
phenomenon has been previously described, but not mooted
to be IRAD until recently.1 It is likely that this chronic form
of HPV IRAD is different aetiologically from the inflammatory
IRADs, examples of which have been described herein; its
pathogenesis is most likely incomplete reconstitution of the
HIV-decimated immune system.
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Antinuclear antibodies associate with loss of
response to antitumour necrosis factor-a ther-
apy in psoriasis but do not necessarily predict
treatment failure
DOI: 10.1111/j.1365-2133.2010.10101.x
MADAM, we read with interest the paper by Pink et al.,1 docu-
menting a marked increasing positive antinuclear antibody
(ANA) rate in patients on the first antitumour necrosis factor
(a)
(b)
Fig 1. Patient 1. (a) Persistent warts on the neck at diagnosis of HIV
infection. (b) Nine months after HAART initiation the patient
presented with a disfiguring scaling hyperkeratotic inflammatory
eruption of viral warts on the face and neck.
! 2011 The Authors
BJD ! 2011 British Association of Dermatologists 2011 164, pp452–461
Correspondence 459
  
 
 
 
 
 
 
 
ABSTRACTS 
 
ABSTRACTS
1135
HPV associated mucocutaneous disease post HAART/IRD - patient immunophenotype
R Meys,1,2 D Asboe,3 FM Gotch2 and CB Bunker1,2 1 Dermatology, Chelsea and Westminster
Hospital, London, United Kingdom, 2 Immunology, Imperial College, London, United
Kingdom and 3 Genito-urinary Medicine, Chelsea and Westminster Hospital, London, United
Kingdom
HPV (human papillomavirus) related mucocutaneous disease can be persistent and/or emergent
and clinically problematic after HAART (highly active antiretroviral therapy) and may represent part
of the spectrum of IRD (immune restoration disease). IRD is increasingly recognised as a common
complication of HAART in HIV/AIDS. Between 15 and 25% of patients develop some form of IRD
and at least half of these are dermatologic.1 Most IRD appears related to infective agents. However
little is known about host factors in the development of IRD. We identified a cohort (n=24) of HIV
positive patients presenting with persistent cutaneous or genital warts and anogenital carcinoma
in-situ, and HIV+ controls (n=26), from the same clinic population. Utilising routine blood sam-
ples we quantitated haemoglobin (Hb) concentration, percentages of lymphocytes expressing CD4,
CD8, CD56, and CD19 markers, CD4/CD8 T-cell ratios, lipid profiles, and HIV viral loads. Analy-
sis was by parametric statistics (Student’s t test). No significant differences were found for all the
variables examined, although with larger numbers, the trends observed might approach statistical
significance. The mean CD4/CD8 T-cell ratio for patients was 0.53 (SD 0.38) and for controls 0.73
(SD 0.35), p=0.07; and the mean CD4% for patients was 24.2% (SD 11.1) and for controls 29.5%
(SD 8.7), p=0.06. More patients and other immunophenotypic factors are to be studied but pre-
liminary results suggest that post HAART HPV/IRD may be associated with non-immunopheno-
typic variables such as viral or host immunogenetic factors.
1136
Actin filaments and microtubules are required for efficient HIV transfer from dendritic cells
to T cells via infectious synapses
DS Nikolic, E Garcia and V Piguet Dermatology and Venereology, University Hospital and
Medical School, Geneva, Switzerland
Dendritic cells (DC) are the most potent antigen-presenting cells and are widely spread through-
out skin and mucosal tissues. It is now well established that HIV can subvert basic functions of DC
in order to efficiently target CD4+ T cells via infectious synapses. The goal of this study is to ana-
lyze the relative contribution of cytoskeleton actin filaments and microtubules in HIV transfer from
DC to CD4+ T cells via infectious synapses, using confocal microscopy, RNA interference (RNAi)
and infection transfer assays. We first observed that efficient HIV recruitment to the DC-T cell infec-
tious synapse is dependent on actin and microtubules. Treatment with low doses of actin inhibitors
(cytochalasin D, latrunculin A) and microtubule inhibitors (nocodazole, sanguinarine chloride)
abrogated HIV relocation from tetraspanin-rich vesicles to the infectious synapse, without inhibit-
ing DC-T cell contacts, as assessed by confocal microscopy. Treatment of DC with these drugs
induced clear morphological changes of the tetraspanin-rich compartment without other cellular
morphological alterations. We also demonstrated that transfer of infectious particles to target CD4+
T cells is inhibited following treatment of DC with actin and microtubule inhibitors. Next, we inves-
tigated the role of modulators of actin filaments and microtubules such as Larg, Cdc42 and RhoA
in HIV transfer via DC-T cell infectious synapses. Knock-down of these modulators in DC by
RNAi, or inhibition with specific drugs, strongly repressed HIV transfer to CD4+ T cells, thereby
further emphasizing the role of actin and microtubules in DC for efficient transmission of HIV infec-
tion. Our results also support the putative role of filopodia in HIV transfer through infectious synapses
between DC and CD4+ T cells. In summary, this work demonstrates that actin filaments and micro-
tubules are essential for HIV trans-infection of CD4+ T cells via DC. This study opens the way for
potential new therapeutic approaches in order to prevent sexual transmission of HIV.
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IL-1R activation is required for IL-17-dependent neutrophil recruitment against Staphylo-
coccus aureus skin infections
LS Miller,1 EM Pietras,2 N Garcia,1 AL Cheung,3 A Blauvelt,4 G Cheng2 and RL Modlin1,2 1
Division of Dermatology, UCLA, Los Angeles, CA, 2 Department of Microbiology,
Immunology, and Molecular Genetics, UCLA, Los Angeles, CA, 3 Department of
Microbiology and Immunology, Dartmouth Medical School, Hanover, NH and 4 Oregon
Health and Science University, Portland, OR
We previously reported that S. aureus-infected IL-1β- (but not IL-1α) and IL-1R-deficient mice had
a severe defect in neutrophil recruitment and control of the infection as compared with wild type
mice. Recent studies have demonstrated that IL-17 has been shown to regulate neutrophil recruit-
ment to various peripheral tissues by promoting granulopoiesis and by production of neutrophil
chemokines. Since neutrophil recruitment and abscess formation is a key host defense mechanism
against S. aureus skin infections, we hypothesized that IL-1R activation and IL-17 production were
both required for optimal neutrophil recruitment against S. aureus skin infections. To test this hypoth-
esis, we used a mouse model of cutaneous infection with S. aureus in conjunction with biolumi-
nescent bacteria to track bacterial growth. We found that skin lesions of S. aureus-infected IL-17R-
deficient mice were substantially larger (2-3 fold) with higher bacterial counts (up to 9-fold) and
had a 30% defect in neutrophil recruitment (as measured by myeloperoxidase activity) compared
with wildtype control mice (p<0.05). This severe phenotype of skin lesions of S. aureus-infected IL-
17R-deficient mice resembled skin lesions of S. aureus-infected IL-1β- or IL-1R-deficient mice. In
addition, we found that skin specimens from IL-1R-deficient mice had an absence of induction of
IL-17 mRNA at early time points after S. aureus infection, suggesting that IL-1R activation was
required to produce IL-17. Thus, these data provide evidence that IL-1R activation is required to
mediate IL-17-dependent neutrophil recruitment in immunity against S. aureus skin infections.
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Staphylococcus epidermidis protects the skin through mutual symbiosis
AL Cogen,1 K Yamasaki,1 R Dorschner,1 R Gallo1,2,4 and V Nizet2,3 1 Medicine, University of
California, San Diego, CA, 2 Pediatrics, University of California, San Diego, CA, 3 Skaggs
School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, CA
and 4 Medicine, VA San Diego Health Care System, San Diego, CA
Staphylococcus epidermidis (SE), a common skin isolate, lives innocuously on the epithelium. We
hypothesized that the antimicrobial barrier of normal skin includes non-pathogenic resident mutu-
alistic microbes. To investigate if a mutualistic relationship exists between SE and mammalian
skin, SE was inoculated at 104 CFU on freshly excised mouse skin or skin that received a partial-
thickness burn. SE grew on healthy skin (2.2x106CFU) but not on injured skin (4.7x103CFU; p<0.05).
To evaluate if SE protects against pathogens, growth of Group A Streptococcus (GAS) was evalu-
ated on human skin containing SE or washed free of bacteria, with survival observed only in the
latter. Also, GAS did not proliferate on mouse skin explants that were colonized with 106CFU/ml
SE. The capacity of SE to kill GAS was due to a soluble factor since supernatants from SE culture,
but not S. aureus or GAS, inhibited GAS growth at 8h (p<0.01). HPLC purification and MALDI-
TOF MS sequencing of purified active fractions from Se identified two peptides: δ-haemolysin (δh)
and Phenol Soluble Modulin (PSM). Synthetic peptides based on these sequences confirmed activ-
ity against GAS (8μM), E. coli (4-8μM), and S. aureus (4-8μM). The killing mechanism was mem-
brane disruption as vesicles leaked when incubated with δh or PSM, and EM of GAS incubated
with peptide showed disruption. SE also was anti-viral as δh reduced vaccinia PFU by 46% (p<0.05)
and PSM reduced plaque size by ~70%. Targeted deletion of PSM in SE (SEΔPSM) confirmed its
antimicrobial action in vivo. Partially purified supernatants from SEΔPSM showed greatly reduced
inhibition of GAS by radial diffusion assay (11.8mm2 vs 27.5mm2 for WT). These data show that
SE acts as a mutual symbiote by growing on the skin while protecting against pathogens. We con-
clude that the innate immune system of the skin should be redefined to include the cutaneous
microbiota.
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Identification of endemic non-tuberculous mycobacterial infection on the Island of Satowan
associated with swimming in World War II era bomb craters
JV Lillis,1 EL Simpson,1 VE Ansdell,2 S Bremmer,1 A Blauvelt,1 S Kurtz,1 G Tumbaga,2 D Ansdell,2
CR White1 and KL Winthrop1 1 Oregon Health Sciences University, Portland, OR and 2
University of Hawaii, Honolulu, HI
Since World War II, residents of Satowan (n=650), an outer island in Chuuk, FSM, noted a high
prevalence of a chronic, progressive and disfiguring skin disease known locally as “spam disease.”
We evaluated one such patient in Portland, Oregon who developed his plaques while living on
Satowan. A culture from lesional skin demonstrated M. marinum in this index case, prompting us
to travel to Satowan to examine similar patients. A case-control study was performed on the island
of Satowan with cases being defined as patients with chronic, progressive verrucous or keloidal
plaques on the extremities with a duration >3 months. Inquiries into various lifestyle and occupa-
tional exposures were performed with the aid of local health officials. Biopsies were performed for
mycobacterial culture, histopathology and PCR analysis. We examined 45 persons, identified 39
case-patients (point prevalence of 6.0%), and enrolled 98 controls. Most case-patients (75%) had
a single plaque, nearly all (92.3%) reported their lesions occurred at previous skin trauma sites. All
cases were taro farmers (OR 6.3 with P<0.01) and among taro farmers, swimming in water-filled
World War II era bomb craters was associated with infection (OR 8.2 with P<0.01). Histopatho-
logic sections (n=9) showed a pattern typical of mycobacterial and deep fungal infections. All tis-
sue cultures and special stains were negative for mycobacteria and fungi (n=19), whereas PCR
analysis revealed non-tuberculous mycobacterial DNA in 8 of 9 samples analyzed. “Spam disease”
is a chronic, progressive skin disease of high prevalence on Satowan. Taro farming and swimming
in water-filled World War II era bomb craters have been identified as major risk factors for devel-
oping this infection. These risk factors along with tissue culture, histopathology and PCR data reveal
M. marinum as likely the causative agent.
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Adrenergic stimuli mediate suppression of keratinocyte antimicrobial activity, which is
reversible by the neuroendocrine derived antimicrobial peptide, Catestatin
KA Radek,1 SK Mahata,2 L Taupenot,2 DT O’Connor2,3 and RL Gallo1,2 1 Medicine/Dermatology,
VA Healthcare System, University of California, San Diego, San Diego, CA, 2 Medicine,
University of California, San Diego, La Jolla, CA and 3 Center for Molecular Genetics,
University of California, San Diego, La Jolla, CA
Catestatin (Cst) is a neuroendocrine peptide derived from Chromogranin A (encoded by Chga) and
was previously known as a nicotinic cholinergic receptor (nAChR) antagonist in the adrenal medulla.
Recently, we found that Cst acts as an antimicrobial peptide (AMP) and is expressed in keratinocytes.
Here, we sought to further define the function of Cst by examining the ability of mice deficient in
Chga to resist skin infection. Chga-/- mice were more susceptible to Group A Streptococcus, as
lesions were 40% larger (3.5±0.4mm vs. 2.5±0.2 mm,P<0.05) and contained 3X more surviving
bacteria (4x107±1x107 CFU/ml vs. 1x107±5x106,P=0.05)compared to wild-type mice. Chga-/- mice
also had a reduction in the AMP cathelicidin, as measured by qPCR, and a decrease in total AMP
activity extracted from skin, as purified by HPLC and measured by radial diffusion. Since Cst is an
antagonist of nAChR, we hypothesized that a decrease in AMP in Chga-/- mice was due to unop-
posed suppression by acetylcholine(ACh). This hypothesis was supported by the observation that
keratinocytes stimulated by 1,25 vitamin D3 and the TLR2/6 agonist Malp2 increased cathelicidin
mRNA by 212±10 fold, but only 46±6 fold when ACh was present; a ca.4.5-fold suppression. This
effect was dose dependent, also occurred with nicotine, and was inhibited by pretreatment with
Cst. Direct analysis of total extracted AMPs from keratinocytes was also suppressed by ACh and
reversed by Cst. Thus, we have identified two previously unknown mechanisms by which ker-
atinocytes protect against infection. Cst can act as an AMP, but also blocks inhibition of other
AMPs by ACh. These observations further define our understanding of the link between the neural
and immune systems and expand the opportunity for targeted therapy of infection by controlling
the AMP defense system.
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Beta human papillomvirus (beta-HPV) types are common in persistent warts in HAART treated
HIV positive individuals
R Meys,1 KJ Purdie,2 MN de Koning,3 QG Wim,3 C Alison,1 M Atkins,1 FM Gotch,1 CA Harwood2
and CB Bunker1 1 Departments of Dermatology, Virology, Genitourinary Medicine, and
Immunology, Imperial College School of Medicine, London, United Kingdom, 2 Centre for
Cutaneous Research, Barts and the London School of Medicine and Dentistry, Queen Mary
University of London, London, United Kingdom and 3 DDL Diagnostic Laboratory, Voorburg,
Netherlands
To date, the HPV types found in cutaneous warts of HIV positive individuals have not been well
characterised. Beta-HPV types have been implicated as cofactors in the pathogenesis of non-
melanoma skin cancer (NMSC) particularly in immunosuppressed organ transplant recipients, in
whom they are also over-represented in viral warts. Although the incidence of warts and NMSC
are increased in HIV, the contribution of beta-HPV types to either is not known. The purpose of
this study was to establish the prevalence and spectrum of beta-HPV in HIV positive HAART treated
patients with persistent warts. Cutaneous warts from HIV positive HAART treated patients persist-
ent for at least twelve months were excised (39 specimens from 26 patients). Persistent cutaneous
warts from HIV negative patients were also available (12 specimens from 7 patients). DNA from
these warts was analysed with a commercial beta-HPV reverse hybridisation line probe assay (Dias-
say). Beta-HPV types were commonly detected in HIV positive patients; 35/39 (90%) lesions were
beta-HPV positive compared with 8/12 (66%) lesions from HIV negative patients (p=0.08). Onco-
genic beta-HPV types 5 or 8 were detected in 18/35 (51%) of HIV positive individuals but only 2/8
(25%) of HIV negative. Multiple beta-HPV types were significantly more common in HIV positive
individuals (mean 6 types compared with mean of 2 types in HIV negative individuals, p=0.003).
The prevalence and spectrum of beta-HPV types detected in this study are comparable to previ-
ous studies examining NMSCs in which beta-HPV types are a risk factor for NMSC development.
Further work is now required to establish whether these beta-HPV types are involved in HIV-asso-
ciated NMSCs.
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Langerhans cells are necessary for chemical mutagenesis
J Neustadter,1 S Roberts,1 R Filler,1 B Kwong,1 J Lewis,1 A Galan,1 S Reddy,1 R Tigelaar,1 P Fu,2
D Kaplan,3 A Hayday4 and M Girardi1 1 Derm., Yale Univ., New Haven, CT, 2 Toxicol., FDA,
Jefferson, AR, 3 Derm., Univ. of Minn., Minneapolis, MN and 4 Immunobio., King’s Col.,
London, United Kingdom
Polyaromatic hydrocarbons (PAHs) are among the most potent carcinogens in industrial societies,
and DMBA is a model PAH used to study effects on epithelial tissues. We recently demonstrated
that mice genetically deficient in epidermal Langerhans cells (LC-def) are highly resistant to tumor
development invoked by two-stage carcinogenesis with DMBA and TPA. Thus, we sought to gain
insight into this phenomenon and the mechanisms by which LC might promote cancer. Having
previously shown that γδ+ T cells exert a major anti-tumor effect, we assessed whether they are
required for the tumor resistance observed in LC-def mice. While both TCRδ-/- (116.2±11.9 mm2)
and TCRβ-/-δ-/- mice (62.4±12.3 mm2) were highly susceptible to tumor development, corre-
sponding LC-def.TCRδ-/- (2.8±1.7 mm2) and LC-def.TCRβ-/-δ-/- (0.0±0.0 mm2) mice were almost
completely resistant (P<0.000001). To determine whether LC might influence the mutagenic capac-
ity of DMBA, we developed a novel genomic DNA methodology to quantify the H-ras codon 61
DMBA signature mutation with a sensitivity of 1 mutant/>106 normal alleles. Control mouse skin
showed markedly higher levels of H-ras mutations than LC-def mice (>150x; P<0.0001). We next
utilized an LC line to assess the metabolism of DMBA in vitro. HPLC analysis revealed the poten-
tial of LC to internalize and metabolize DMBA, and identified six known DMBA metabolites. DMBA-
containing media cultured overnight with the LC line, but neither DMBA-containing media alone
or cultured with keratinocytes, was capable of inducing H-ras mutations in primary keratinocyte
lines after 24 h (>16x; P<0.01). These data reveal that LC are essential for the emergence of cuta-
neous H-ras mutations induced by DMBA, and provide evidence that this effect occurs inde-
pendently of T lymphocytes and largely as a result of LC conversion of DMBA to more mutagenic
metabolites. Such findings may have implications for tumor development in epithelial tissues
more generally.
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Psph is a protein phosphatase that stimulates UVB-induced apoptosis and is dysregualted in
cutaneous squamous cell carcinoma
MA Bachelor,1 D Ratner,1 EB Desciak,1 YD Eliezri1 and DM Owens1,2 1 Dermatology, Columbia
University, New York, NY and 2 Pathology, Columbia University, New York, NY
L-3-phosphoserine phosphatase (Psph) is a widely expressed member of the haloacid dehaloage-
nase superfamily and primarily thought to function in L-serine biosynthesis. We previously found
Psph expression to be uniquely upregulated in transgenic mouse epidermis exhibiting aberrant inte-
grin expression and predisposed to hyperplasia and squamous cell carcinoma (SCC) formation
implicating a novel function for Psph in epidermal homeostasis. Since ultraviolet radiation (UV) is
a primary etiological agent for SCC development in humans, we evaluated the status and function
of Psph in normal and UV-irradiated keratinocytes. Psph is expressed throughout the proliferative
layer of the epidermis and hair follicles in normal cutaneous epithelium and is found primarily
localized to the endoplasmic reticulum at the subcellular level. Primary mouse keratinocytes sta-
bly expressing Psph exhibited substantially increased sensitivity to UV-induced apoptosis, as indi-
cated by increased PARP cleavage and Annexin V binding, and partial knockdown of Psph dra-
matically reduced the levels of UV-induced apoptosis. Importantly, we have identified a novel
role for Psph as a protein phosphatase and found that mutation of Asp20 to Asn20 in the catalytic
domain of Psph completely abrogated endogenous phosphatase activity and attenuated UV-induced
apoptosis in cells expressing the phosphorylation deficient Psph mutant collectively indicating
that Psph protein phosphatase activity may be an essential component of UV-induced apoptotic
pathway. Interestingly, reduced Psph expression was observed in 70% of human SCC analyzed and
correlated with poor differentiation status in those lesions. Overall, these data suggest that the func-
tion of Psph extends beyond serine metabolism, to regulate the ability of keratinocytes to respond
to apoptotic stimuli such as UV-irradiation, a function that may be critical for the prevention of UV-
induced skin cancer.
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Srcasm inhibits Fyn-induced skin carcinogenesis-a role for Notch 1
L Zhou,1 W Li,1 C Marshall,1 R Hick,1 T Dentchev,1 A Werth,1 E Williams,1 C Miller,1 W Pear2 and
J Seykora1,2 1 Dermatology, Univ. of Penn., Philadelphia, PA and 2 Pathology, Univ. of Penn.,
Philadelphia, PA
Src tyrosine kinases (SFKs) are key regulators of cell proliferation, and are activated in carcinomas.
The goal of this study was to model the elevated SFK activity in human skin squamous cell carci-
nomas (SCCs) using a keratin 14-Fyn Y528F transgenic model and to determine how Srcasm reg-
ulates carcinogenesis. Increased Fyn activity promotes the formation of scaly plaques and tumors
histologically consistent with carcinoma in situ and squamous cell carcinoma (SCCs_ (p < 3.7 x
10-18). This model mimics human cutaneous neoplasia as small precancerous lesions resembling
actinic keratoses were identified, and the SCCs exhibited no evidence of metastasis within 8 months.
Immunohistochemistry and western blotting demonstrated increased levels of activated SFKs, PDK-
1, STAT-3, and Erk1/2 in the murine lesions; similar findings were observed in human SCCs. Increased
Fyn activity decreased Notch 1 transcript and protein levels in precancerous lesions and carcino-
mas, demonstrating that Fyn negatively regulates Notch 1. Double transgenic mice harboring
K14-Fyn Y528F and K14-Srcasm transgenes demonstrated no squamous cell carcinomas (p < 4.9
x 10-5). Double transgenic lines expressing the K14-Fyn Y528F and a non-phosphorylatable Srcasm
mutant demonstrated a phenotype similar to the parental lines (p = 0.77). Molecular analysis demon-
strates that Srcasm normalizes levels of Fyn, activated SFKs, PDK-1, STAT-3, and Erk1/2, and it also
restores Notch 1/NICD levels. These data show that Srcasm is an anti-oncogene that downregu-
lates SFKs. Since Notch 1 and Srcasm are highly expressed in differentiating keratinocytes, a
potential regulatory relationship was evaluated. Human keratinocytes treated with gamma-secre-
tase inhibitors show a robust correlation between lower NICD and Srcasm levels that is dose-
dependent. K14-Fyn Y528F mice represent a skin carcinogenesis model with pre-cancerous and
cancerous lesions. These data reveal a novel regulatory relationship between Fyn, Srcasm, and
Notch 1, including that Srcasm may be a Notch target.
179
Hairless Is repressed by tumor necrosis factor-alpha via activation of NFκB
H Kim,1 A Casta,1,3 MA Bachelor,1 A Englehard,1 DM Owens1 and AM Christiano1,2,3 1
Dermatology, Columbia University, New York, NY, 2 Genetics and Development, Columbia
University, New York, NY and 3 Institute of Human Nutrition, Columbia University, New York,
NY
Hairless (HR) is a key factor in the regulation of the hair cycle of mammals. The phenotype result-
ing from Hr mutations in human and mouse skin manifests at catagen, indicating that HR is criti-
cal for epidermal proliferation and differentiation. However, a specific role for HR and the nature
of HR regulation in epidermal homeostasis are largely unknown. TNFα is an essential regulator of
hair follicle development and cycling, particularly at catagen, the hair follicle cycle phase with pre-
dominant HR expression. TNFα has recently been shown to be required for the transition of ana-
gen to catagen, and TNFα-/- mice show a delayed entry into catagen. Furthermore, exogenously
supplied TNFα can trigger entry into catagen. Here, we asked whether there is a mechanistic link
between the TNFα/NFκB signaling pathway and transcriptional regulation of the HR promoter in
the interfollicullar epidermis. We recently investigated the relationship between HR and TNFα
and found TNFα signaling transcriptionally represses HR gene expression in human keratinocytes.
Furthermore, we determined the TNFα-dependent repression of HR to be mediated through spe-
cific activation of NFκB, which is known to induce tumor progression in initiated or immortalized
keratinocytes. NFκB is recruited to the HR promoter region at a specific NFkB response element,
which mediates the TNFα effect. In addition, TNFα-dependent repression of HR transcription is
enhanced when cells are pre-treated with Trichostatin A, a potent HDAC inhibitor and activator of
NFκB. Finally, HR overexpression blocks the TNFα-induced survival of HaCaT cells in suspension
culture, a hallmark of malignant transformation. Collectively, our data suggests HR repression by
TNFα is required for tumor progression in immortalized human keratinocytes, and that constitu-
tive HR expression is sufficient to attenuate pro-survival signaling via TNFα.
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Increased expression and ectodomain shedding of Dsg2 in skin carcinomas
D Brennan and MG Mahoney Dermatology and Cutaneous Biology, Thomas Jefferson
University, Philadelphia, PA
Invasion and metastasis of malignancies is partially facilitated through the disruption or loss of cel-
lular adhesion as illustrated by the E- to P/N- cadherin switch. Although desmosomal adhesion has
been considered in a similar context, the nature of this deregulation is less defined. Desmoglein 2
(Dsg2) is normally expressed at low levels in the proliferative basal layer of the epidermis and hair
follicles. Here we show a dramatic up-regulation of Dsg2 in human epithelial malignancies, includ-
ing basal cell carcinomas, squamous cell carcinomas, carcinomas of sebaceous and sweat glands,
and adenocarcinomas. Dsg2 expression was absent in malignant fibrosarcomas and melanomas.
We recently demonstrated that Dsg2 overexpression in keratinocytes deregulates multiple signal-
ing pathways associated with increased growth rate, anchorage-independent cell survival, and
tumor development. Here we show that transgenic mice overexpressing Dsg2 developed sponta-
neous skin tumors. Within the tumor mass Dsg2 was expressed in ectopic locations and under-
went extensive proteolytic processing, similar to the processing observed in several metastatic car-
cinoma cell lines. Some of these fragments correspond with expected products of ADAM17 (TACE)
mediated ectodomain shedding. This shedding is enhanced with chemically induced apoptosis
and abrogated with TAPI-2 and GM6001, suggesting that shedding may be the result of metallo-
proteinases, such as ADAM17. We further demonstrate a correlation between Dsg2 shedding,
ADAM17 activation, and EGF receptor phosphorylation. Taken together these results give insights
into the potential mechanisms by which Dsg2 activates cell-signaling pathways and provide evi-
dence that Dsg2 is a multi-functional protein that plays complex roles in cell adhesion, growth
and survival.
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Study by qRT-PCR of the epidermal differentiation of human keratinocytes after evaluation
of candidate housekeeping genes using geNorm algorithm
F Minner, F Herphelin and Y Poumay Cell and Tissue Laboratory, URPHYM, University of
Namur (FUNDP), Namur, Belgium
In serum-free autocrine culture conditions, confluence of cultured human keratinocytes corre-
sponds to a strong commitment towards epidermal differentiation. Quantification of mRNA encod-
ing epidermal markers of differentiation such as keratin14 (KRT14), keratin 10 (KRT10), involucrin,
loricrin, filaggrin or transglutaminase-1 has been usually performed by Northern blotting in order
to characterize the precise phenotype of these cells. The expression of a gene is quantified by cal-
culating a value that is expressed relatively to the measurement performed on the same sample for
the expression of a housekeeping gene (HKG). HKG are genes with stable expression independ-
ently of any particular cell phenotype. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH),
ribosomal protein large P0 (RPLP0), actin or tubulin have been chosen for studies of keratinocytes
by Northern blotting. Today, real-time qRT-PCR is becoming a generalized technique to study the
mRNA expression of markers of differentiation, expressed as a ratio between the gene of interest
and a stably expressed HKG. However, the high sensitivity of qRT-PCR requires particular atten-
tion on data normalization and processing. In this study, we present analysis of multiple markers
of epidermal differentiation by qRT-PCR, with emphasis on the right choice of HKGs. The mRNA
expression of GAPDH, alpha-Tubulin1B (TUBA1B), RPLP0, TATA-binding protein (TBP), ribosomal
protein large 13A (RPL13A) and KRT14, an exclusively epidermal gene presenting a stable expres-
sion in the culture model, was measured to evaluate HKGs. Data were analyzed using geNorm
algorithm. Results obtained support the selection of TBP, RPL13A and RPLP0 as HKGs in order to
study cell density-induced differentiation of keratinocytes by real-time qRT-PCR and highlight that
HKGs used in studies of gene expression in keratinocytes must be evaluated in regard of precise
experimental conditions before their use to normalize expression of regulated genes.
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Identification of five new mutations in ABCA12 gene of three Japanese cases of non-bullous
congenital ichthyosiform erythroderma, suggesting a genotype-phenotype correlation
S Fukuda,1 T Hamada,1 S Sakaguchi,1 K Sakai,2 S Yasumoto,1 M Akiyama,2 H Shimizu2 and
T Hashimoto1 1 Department of Dermatology, Kurume University School of Medicine,
Kurume, Japan and 2 Department of Dermatology, Hokkaido University Graduate School of
Medicine, Sapporo, Japan
Non-bullous congenital ichthyosiform erythroderma (NBCIE; MIM 242100) is a heterogeneous
group of autosomal recessive congenital ichthyoses (ARCI) characterized by generalized superfi-
cial scales and erythroderma without blister formation. NBCIE results from mutations in several
genes, including ABCA12, ALOXE3, ALOXE12B, CYP4F22, ichthyin, and TGM1. ABCA12 is a
member of the ATP-binding cassette transporter, involved in lipid transport from lamellar granules
to the keratinocyte surface of the granular layer. So far, only four ABCA12 mutations in three NBCIE
cases have been reported. In this study, we examined the ABCA12 gene in five unrelated Japan-
ese patients with NBCIE and identified five new mutations and one recurrent mutation in three
patients. All three cases had compound heterozygosity of a truncation mutation (either splice site
or deletion mutation) and a missense mutation: i.e., c.[5940-1G>C]+p.[Arg986Trp],
c.[5128+3A>G]+p.[Asn1380Ser] and c.[6031delG]+p.[Thr1575Pro]. Among these mutations, only
p.Asn1380Ser is a recurrent mutation. Mutations in ABCA12 are also known to result in lamellar
ichthyosis type 2 (LI2; MIM 601277) and harlequin ichthyosis (HI; MIM 242500). In general, a
homozygous or compound heterozygous missense ABCA12 mutation leads to an LI2 phenotype,
and a homozygous or compound heterozygous truncation mutation exhibits an HI phenotype.
Adding to these previous results, our study clearly suggests that NBCIE phenotype is caused by a
combination of truncation and missense mutations. Although the molecular pathology of ABCA12
remains unclear, our study strengthens the genotype-phenotype correlation in ARCI patients with
ABCA12 mutations. The findings also provide clinicopathological evidence for the role of ABCA12
in keratinocyte differentiation.
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Analysis of the HLA-Cw1–B46 psoriasis risk haplotype reveals allelic heterogeneity with HLA-
Cw6
RP Nair,1 PE Stuart,1 R Hiremagalore,1 P Kullavanijaya,2 T Tejasvi,1 JJ Voorhees1 and JT Elder1 1
Dermatology, Univ Michigan, Ann Arbor, MI and 2 Institute of Dermatology, Bangkok,
Thailand
In Caucasians, HLA-Cw6 is the most likely risk allele at the chromosome 6 psoriasis susceptibility
locus PSORS1 (Nair et al, Am J Human Genet 78:827, 2006). In Asians, in addition to HLA-Cw6,
the HLA-B46-Cw1 haplotype is also associated with psoriasis. To examine whether these two risk
haplotypes share a disease allele identical by descent from a common ancestor, we sequenced a
Thai B46–Cw1 homozygote across the ~300 kb PSORS1 risk region. Comparison with previously
sequenced Cw6-B57 and Cw6-B50 risk haplotypes revealed 3 regions of sequence similarity. How-
ever these regions also shared equivalent sequence similarity with one or more haplotypes that
were clearly non-risk, and they contained no polymorphisms unique to Cw1-B46 and Cw6 risk
haplotypes, suggesting allelic heterogeneity at PSORS1. In a sample of 206 Thai cases and 114 con-
trols, we confirmed that Cw1 (p = 0.0011, OR = 2.16) and Cw6 (p = 3.2x10-6, OR = 4.79) are sig-
nificantly associated with psoriasis. The difference in risk between the two alleles, along with greater
nail involvement and later age at onset for Cw1-carrying psoriatics, further support allelic hetero-
geneity. In a sample of 1467 Caucasian cases and 1458 controls, Cw6 was strongly associated (p
= 2.8x10-45, OR = 2.77), but Cw1 was unassociated (p = 0.17, OR=0.83) even though the sample
had >99.9% power to detect association under a multiplicative model (α = 0.05, RR = 2.0). Hap-
lotype analysis in Thais showed strong association for the B46-Cw1 haplotype (p = 0.0019, OR =
2.22), but not for Cw1 haplotypes lacking B46 (p = 0.56, OR = 1.33). There were no B46 carriers
among the 270 Caucasian Cw1 carriers. These results strongly suggest that HLA-Cw1 is not a
direct determinant of psoriasis. Since HLA-B and -C are highly homologous, B46 could possibly
be a psoriasis susceptibility determinant in Asians, a notion supported by a previous report that B46
is the result of a gene conversion event in which a segment of Cw1 was transferred to HLA-B62.
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Immunogenetics of HIV associated HPV disease after HAART
R Meys,1 F Fowles,2 A Little,2 SG Marsh,2 D Asboe,1 DA Hawkins,1 FM Gotch1 and CB Bunker1
1 Departments of Dermatology, Genitourinary Medicine & Immunology, Imperial College
School of Medicine, London, United Kingdom and 2 Anthony Nolan Research Institute &
UCL Cancer Institute, Royal Free Campus, London, United Kingdom
The purpose of this study was to determine the immunogenotypic basis for HPV immune recon-
stitution (IR) associated disease (IRAD) in HIV. Persistent and florid cutaneous and anogenital HPV
infection poses a significant clinical problem in HAART treated HIV patients despite apparently
adequate IR. Such persistent/emergent HPV disease might be viewed as a form of cutaneous IRAD.
Some clinical scenarios in HIV are related to host immunogenotype eg psoriasis (HLA-Cw*0602)
and abacavir hypersensitivity (HLA–B*5701) and others are postulated eg IRAD due to
cytomegalovirus, tuberculosis and herpes simplex virus. HLA associations have been identified for
HPV related disease, including respiratory papillomatosis, non-melanoma skin cancer and cervi-
cal cancer so might characterise HPV IRAD. HIV patients with persistent HPV IRAD were
immunogenotyped. HLA alleles were determined in white (European) HIV positive HAART treated
males with persistent (greater than twelve months) HPV related disease (n=32) and HIV positive
HAART treated controls with no history of persistent HPV disease (n=18). HPV diseases studied
include cutaneous warts, genital warts and anogenital intra-epithelial neoplasia. The HLA types
were compared at eight loci using a Luminex-based system. A significant association was found
for the allele HLA-DQB1*06, which conferred protection against HPV related diseases (12 of 32
cases compared with 14 of 18 controls, p=0.01, Chi Square test). After correction for multiple test-
ing, however, the difference was not significant (p=0.09; Bonferroni correction). The alleles HLA-
DRB1*03 (p=0.07) and HLA-DRB1*11 (p=0.08) were associated with persistent HPV disease,
although the allele frequency differences between cases and controls was not significant (Fishers
exact test). HLA alleles of potential interest have been identified that may be relevant to an
immunogenotypic basis for HPV IRAD in HAART treated individuals.
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Proximal transcription factor binding sites in the loricrin promoter are essential for regulat-
ing its expression in vivo
M Kawase,3 J Chen,1 Y Kawachi,4 D Dai,2 M Longley,2 AJ Huebner,1 K Yamada,4 PJ Koch1 and
DR Roop1 1 Department of Dermatology and Charles C. Gates Regenerative Medicine and
Stem Cell Biology Program, University of Colorado Denver, Aurora, CO, 2 Program in
Developmental Biology, Baylor College of Medicine, Houston, TX, 3 Dermatology, Jikei
University School of Medicine, Tokyo, Japan and 4 Dermatology, University of Tsukuba,
Tsukuba, Japan
Loricrin is the major protein component of the cornified cell envelope (CE), comprising up to 85%
of its mass. It has been demonstrated that the expression of the mouse loricrin gene (Lor) is strictly
regulated at the transcriptional level. The distal promoter region between position –14 kb and –6.5
kb contains differentiation-specific regulatory elements that restrict the expression of Lor to the
upper spinous and granular keratinocytes. A proximal AP-1 site has been shown to be essential for
Lor promoter activity. Here, we identified a putative Sp-1 transcription factor binding site which is
within 20 bp upstream of the AP-1 site. These elements are conserved between mouse and human.
To further characterize the proximal regulatory region of Lor, we generated BAC transgenic mice
in which the coding sequence of Lor was replaced with a LacZ reporter gene (Lor-LacZ-BAC). The
BAC transgene was flanked by 175.8 kb (46.2 kb upstream and 126.6 kb downstream) endoge-
nous Lor sequence. Initially, we confirmed that the retention of the large flanking sequences and
the preservation of the intron in the BAC transgenic vector reproduced the endogenous expression
profile of Lor in transgenic mice. We then introduced mutations into the proximal transcription
factor binding sites in the Lor promoter in the context of the Lor-LacZ-BAC and generated addi-
tional transgenic lines. We report here that the AP-1 site and putative Sp-1 site immediately upstream
of the transcription start site of Lor are essential for the transcriptional activity of Lor both in vitro
and in vivo. Thus, confirming the importance of these proximal regulatory elements for transcrip-
tional control of the Lor gene.
492
Targeted ex vivo gene therapy for epidermolytic hyperkeratosis
J Chen and DR Roop Department of Dermatology and Charles C. Gates Regenerative
Medicine and Stem Cell Biology Program, University of Colorado Denver, Aurora, CO
Epidermolytic hyperkeratosis (EHK), also known as bullous congenital ichthyosiform erythroderma
(BCIE), is an autosomal dominant form of ichthyosis caused by point mutations in the keratin 1 or
keratin 10 genes. These mutations lead to defective suprabasal keratinocytes, resulting in blister-
ing and hyperkeratosis. Gene therapy approaches represent an attractive option for a permanent
corrective therapy for this monogenic disease. Our laboratory has previously developed a condi-
tional “knock-in” mouse model that mimicked EHK at both genetic and phenotypic levels. Obser-
vations based on this mouse model revealed that partial suppression of the mutant allele (Krt10)
might be sufficient to eliminate the clinical phenotypes. We have developed a lentivirus-based
delivery system so that mutant Krt10-specific siRNAs can be delivered to keratinocytes isolated
from the EHK mouse model. We demonstrate that dissociated primary keratinocytes isolated from
the EHK mouse skin were able to regenerate the scaly skin phenotype of EHK when grafted on
immune compromised mice to reconstitute a new skin. Therefore, the ability to genetically mod-
ify EHK keratinocytes ex vivo by lentivirus-mediated delivery of mutant-specific siRNA and sub-
sequently to reconstitute skin with these keratinocytes provides us with an in vivo model to test
the efficacy of these therapeutic strategies for EHK.
S82 Journal of Investigative Dermatology (2009), Volume 129
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Carcinoma in-situ of the penis and β-HPV types
SK Krishna,1 R Meys,1 KJ Purdie,2 MN de Koning,3 A Bardhan,1 FM Gotch,1 WG Quint,3
C Harwood2 and CB Bunker1 1 Dermatology, Genitourinary Medicine and Immunology,
Faculty of Medicine, Imperial College, London, United Kingdom, 2 Centre for Cutaneous
Research, Barts and the London School of Medicine and Dentistry, Queen Mary University,
London, United Kingdom and 3 DDL Diagnostic Laboratory, Voorburg, Netherlands
High risk (HR) genital human papillomavirus (HPV) infection is strongly associated with cervical
and anal cancers but the association with penile cancers is dependent on histological type. Low
risk and HR genital HPV DNA has been found in 70 to 90% of penis in-situ cancer samples, and
predominantly it is HPV-16. β-HPV types (associated classically with epidermodysplasia verruci-
formis) have been detected in 36 to100% of such patients. However, small numbers of cases have
been studied. Almost always β-HPVs are found in low copy numbers as a mixed infection with HR
genital HPV. The purpose of this study was to examine the prevalence of β-HPV in penis in-situ
cancer (and correlate this with HR genital types). We investigated 21 penis biopsies from 21 patients
with invasive cancer (n=5) or in-situ cancer (n=16). Host and viral DNA was extracted from for-
malin-fixed paraffin embedded archival tissue using laser capture microscopy to select cancer-
ous/pre-cancerous zones. DNA derived from lesions was analysed with two HPV reverse hybridi-
sation assays; one for genital types (SPF10-LiPA25, version 1) and one for β-HPV (PM-PCR RHA
method). HPV was detected in 13/16 (82%) of in-situ cancer samples; the relative contributions
were HPV-16 in 12/13 (92%) and HPV-68 /73 in 1/13 (8%). HPV-18 was detected in one of the
five (20%) penis cancer samples. There were no mixed infections (with more than one HPV type).
No β-types were detected. Regarding genital HPV types, this is in line with previous work but is
discrepant with the high prevalence of β-types that have been reported by others (as mixed infec-
tions). This may be accounted for by our use of old archival tissue, the exclusion of surface con-
tamination with microdissection and/or stringent laboratory standards.
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Akt inhibition suppresses the growth of basal cell carcinomas (BCCs) in Ptc1+/-/SKH-1
mice by blocking Akt and sonic hedgehog (Shh)-dependent pathways
Y Zhu,1 JH Back,1 X Tang,1 M Athar,2 AL Kim1 and DR Bickers1 1 Dermatology, Columbia
University Medical Center, New York, NY and 2 Dermatology, University of Alabama at
Birmingham, Birmingham, AL
Dysregulated PI3K/Akt is implicated in the pathogenesis of human sporadic cancers and in hered-
itary cancer syndromes. This pathway is essential for Shh signaling during embryonic develop-
ment and for the growth of Hh-dependent tumors. Inhibition of PTEN or PI3K/Akt activation are
critical for the growth of squamous cell carcinomas (SCCs), but little is known about their role in
BCCs. We show that UVB-induced BCCs, generated in our Ptc1+/-/SKH-1 (PtSKH) mice, as well
as sporadic human BCCs manifest increased Akt1 phosphorylation. Detailed analysis of tissue and
tumor sections from these specimens showed that only a subpopulation of BCC cells manifest
Akt1 phosphorylation, indicating heterogeneous cell populations in these tumors. Treating PtSKH
mice with the smoothened (SMO) inhibitor cyclopamine and the Akt inhibitor LY294002, alone
or in combination, reduced both the number and size of microscopic BCCs, and was associated
with reduced p-Akt1-positive cells. In ASZ001 BCC cells derived from Ptc1+/-/C57Bl/6 mice,
cyclopamine and Akt inhibitors (LY294002 or wortmannin) independently reduced BrdU incor-
poration by 10-20%, but when used in combination resulted in synergistic reduction of 50-60%.
Cyclopamine treatment or SMO knockdown did not substantially alter the level of Akt1 phospho-
rylation in ASZ001 cells, suggesting that Akt1 activation is not a downstream event in the Shh
pathway. However, Akt inhibition decreased Gli-1, and the introduction of constitutively active
myristoylated Akt1 enhanced Shh pathway activation, leading to overexpression of Gli-1 and cyclin
D1. Furthermore, the Akt1-expressing BCC cells had increased levels of cyclin D1, which decreased
substantially following treatment with either cyclopamine or the Akt inhibitors. These results indi-
cate that Akt1 might independently regulate the survival of subpopulations of tumor cells with high
proliferative potential in BCCs.
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Merkel cell polyomavirus impairs repair of UV radiation-induced DNA damage
SK Demetriou,1,2 TK Dong1,2 and DH Oh1,2 1 Department of Dermatology, University of
California, San Francisco, San Francisco, CA and 2 Dermatology Research Unit, VA Medical
Center, San Francisco, CA
Merkel cell carcinomas typically occur on sun-exposed skin and are associated with a high degree
of morbidity and mortality. Recently, these cancers have been strongly associated with a novel
member of the polyomavirus family. The Merkel cell carcinoma polyomavirus (MCV) expresses a
large T antigen (LTAg) that is homologous to that of other polyomaviruses in which it is well-
known to inhibit p53 activity. We hypothesized that expression of MCV suppresses the DNA dam-
age response to ultraviolet radiation (UVR)-induced DNA lesions via LTAg, possibly by inhibition
of p53. In contrast to a Merkel cell carcinoma cell line (UISO) that does not harbor virus, a virus-
infected cell line (MKL-1) exhibited both dose-dependent reductions in survival following UVR,
and drastically impaired global genomic nucleotide excision repair of UVR-induced cyclobutane
pyrimidine dimers and pyrimidine(6-4)pyrimidone photoproducts as measured using an immunoas-
say. In a specific test of the relationship between MCV LTAg and repair, LTAg from a Merkel cell
tumor was ectopically expressed in UISO cells, and resulted in reduced expression of a down-
stream p53 target, p21, as well as deficits in global repair of cyclobutane pyrimidine dimers sim-
ilar to those seen in MKL-1 cells. These results indicate that expression of LTAg by MCV can inhibit
p53’s transactivating functions and lead to loss of global genomic nucleotide excision repair, and
these events may be an important mechanism of genomic instability involved in Merkel cell pho-
tocarcinogenesis.
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p38 MAPK regulates oxidative stress in UVB-induced squamous cell carcinoma by blocking
NADPH NOX2
X Tang,1 Y Zhu,1 JH Back,1 M Athar,2 AL Kim1 and DR Bickers1 1 Dermatology, Columbia
University Medical Center, New York, NY and 2 Dermatology, University of Alabama at
Birmingham, Birmingham, AL
Solar ultraviolet B (UVB) radiation generates reactive oxygen species (ROS), which can drive
development of aggressive malignant phenotypes of cancer cells. p38α mitogen-activated protein
kinase (MAPK), which coordinates cellular responses to many stressful stimuli, can function as an
ROS sensor. p38α MAPK inhibits H-RasV12-induced ROS accumulation by triggering apoptosis in
mouse embryonic fibroblasts, while p38α MAPK deficiency in these cells leads to malignant trans-
formation. In normal keratinocytes, UVB-induced apoptosis entails the ROS-mediated activation
of p38 MAPK, which likely is p53-dependent. However, the importance of p38 MAPK signaling in
the pathogenesis of skin cancer in the absence of wt p53 is currently unknown. We found that the
pharmacological inhibition of p38 MAPK activity with SB203580 markedly accelerated the rate of
UVB-induced skin tumor growth in p53-/-/SKH-1 mice. In human SCC cells harboring mutant
p53, genetic and pharmacological inhibition of p38 MAPK increased intracellular ROS via the
NADPH oxidase NOX2. This was associated with increased levels of cyclin D1, cdc25B/C, and
BrdU incorporation. Furthermore, p38 MAPK inhibition increased the phosphorylation and acti-
vation of the c-Jun N-terminal kinase/stress-activated protein kinase, and resulted in a concomi-
tant increase in c-Jun phosphorylation and the DNA-binding activity of AP-1. ROS levels in UVB-
induced SCCs harvested from p53-/-/SKH-1 mice were higher than those in UVB-irradiated epidermis,
and were undetectable in non-irradiated control skin. NOX2 expression was higher in SCCs har-
vested from SB203580-treated/UVB-irradiated p53-/-/SKH-1 mice as compared to SCCs harvested
from non-treated/UVB-induced SCCs. These data suggest that p38αMAPK regulates oxidative stress
in SCCs by blocking NOX2 in the absence of functional p53, and that the loss of p38α MAPK con-
tributes to an increased capacity for cell proliferation.
158
Epidermal expression of a mutant CYLD promotes skin carcinogenesis and metastasis
P Miliani de Marval, S Lutfeali, JY Jin, B Leshin and JY Zhang Dermatology, Duke University,
Durham, NC
CYLD, a deubiquitinase, has been recognized as a tumor suppressor due to its genetic linkage to
skin appendage tumors. The molecular mechanisms of CYLD action and its role in other types of
skin cancer are not well-understood. Here, we generated a transgenic animal model with K14-
driven expression of a patient relevant and catalytically deficient CYLD mutant (CYLDm). We found
that the transgenic mice displayed increased skin tumor development and malignant transforma-
tion in response to chemically induced carcinogenesis. Most surprisingly, over 50% of the trans-
genic mice developed lymph node metastasis following DMBA/TPA treatment. The tumor tissues
and cells expressing CYLDm displayed increased activation of JNK and its downstream c-Jun and
c-Fos, AP-1 proteins. Consistently, topical JNK inhibition significantly reduced tumor development
and abolished metastasis in the transgenic mice. In addition, a majority of human squamous cell
carcinomas (SCC) samples expressed decreased levels of CYLD and concomitantly increased lev-
els of JNK/AP-1 activation. Moreover, expression of CYLDm or shRNA-mediated gene silencing of
CYLD increased cell growth, migration and subcutaneous tumor growth of human A431 SCC
cells, whereas expression of the wild type CYLD inhibited cell growth and tumorigenesis. These
data indicate that CYLD loss-of-function promotes epidermal malignancy and metastasis in a
JNK/AP1-dependent manner.
162
XPC silencing in normal human keratinocytes induces AKT activation and triggers metabolic
alterations that drive the formation of squamous cell carcinomas
HR Rezvani,1,2,3 F Mazurier,1 AL Kim,2 N Ali,1 M Daly,2 H de Verneuil,1 A Taieb1,3 and DR Bickers2
1 Inserm U876, Bordeaux, France, 2 Columbia University, New York, NY and 3 National
Reference Centre for Rare Skin Disorders, Bordeaux, France
Genomic mutations, the Warburg effect, and alterations in the levels of reactive oxygen species
(ROS) are consistently observed in a variety of cancers. However, the inter-relationships among
these factors and their impact on the neoplastic process remain poorly understood. We took advan-
tage of the intrinsic genomic instability arising in the nucleotide excision repair disease xeroderma
pigmentosum C (XPC) to look at underlying molecular mechanisms. Here we show that shRNA-
mediated knockdown of XPC in normal keratinocytes (KC) leads to the activation of the ser-
ine/threonine kinase Akt1 by DNA-dependent protein kinase (DNA-PK). Akt activation in XPC-defi-
cient KC resulted in 1) increased cell proliferation as determined by BrdU labeling, 2) metabolic
alternation through reduction of mitochondrial function but increases glycolysis, as defined by
decreases in the NADH dehydrogenase subunit 1 and cytochrome c oxidase subunit III; and increases
in proteins involved in glucose uptake and lactate generation. We also detected high levels of
basal cell layer markers Keratin 14, α6 and β1 integrin in epidermis reconstructed with XPC-defi-
cient KC, which manifested epithelial hyperplasia with large and frequent extension of rete pegs,
compared to control epidermis. These effects were also dependent on Akt activation. Furthermore,
XPC-deficient KC formed SCCs in immunodeficient mice, but Akt1 inhibition blocked this effect.
Our results indicate that Akt1 activation in cells lacking XPC contributes to high susceptibility to
carcinogenesis and this may involve Akt1-mediated alteration of mitochondrial function.
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The HPV profile of cutaneous warts in HIV infected patients
R Meys,1 KJ Purdie,2 MN de Koning,3 SK Krishna,1 M Kamp,3 M Nelson,1 D Asboe,1
DA Hawkins,1 WG Quint,3 FM Gotch,1 C Harwood2 and CB Bunker1 1 Departments of
Dermatology, Genitourinary Medicine and Immunology, Faculty of Medicine, Imperial
College, London, United Kingdom, 2 Centre for Cutaneous Research, Queen Mary
University, Barts and the London School of Medicine and Dentistry, London, United Kingdom
and 3 DDL Diagnostic Laboratory, Voorburg, Netherlands
Cutaneous warts in HIV infected individuals are very common, despite anti-retroviral treatment.
The problem is stigmatising for patients and consumes dermatology resources. Little is known about
the human papillomavirus (HPV) types found in these cutaneous warts. We have profiled them
using newly developed Luminex technology (HSL-PCR/MPG). A sensitive reverse hybridisation line
probe assay (SPF10-LiPA25, version 1) was also used to identify the presence of genital HPV types.
DNA was extracted from 64 cutaneous warts from 42 HIV infected patients and 45 warts from 24
healthy individuals. Warts were clinically and/or histologically confirmed. HPV-7 was found in
22% (14/64) of warts from ten HIV infected patients but none (of 45 lesions) from healthy indi-
viduals (p=0.002). The commonest types in lesions from HIV infected patients were HPV-57 (38%;
24/64) and HPV-27 (34%; 22/64). HPV-2 was less common in warts from HIV infected patients
(3% or 2/64 compared with 29% or 13/45 in healthy individuals; p=0.004). Mixed infections with
cutaneous HPV types were seen in 19% (12/64) of lesions from HIV infected patients compared
with 7% (3/45) from healthy cases (p>0.05). Genital HPV types were also frequently found in
cutaneous warts from both groups; 19/64 (30%) in HIV infected lesions and 10/45 (22%) in lesions
from healthy individuals (p>0.05). High and low risk types were equally represented. HPV-7 causes
common warts but is also associated with butchers warts in meat and fish handlers. To date, case
reports and smaller studies have implied that HPV-7 may be more prevalent in HIV and our data
are in accord. Genital types seem common in cutaneous lesions; this phenomenon may be partly
explained by the high sensitivity of modern assays.
747
Langerhans cell dendrites penetrate through epidermal tight junction barrier during foreign
antigen uptake
A Kubo,1,2 K Nagao,1,2 M Yokouchi,1 K Yoshida,1 H Sasaki3,4 and M Amagai1 1 Department of
Dermatology, Keio University School of Medicine, Tokyo, Japan, 2 Center for Integrated
Medical Research, Keio University School of Medicine, Tokyo, Japan, 3 Department of
Molecular Cell Biology, Institute of DNA Medicine, The Jikei University School of Medicine,
Tokyo, Japan and 4 The Center for Advanced Medical Engineering and Informatics, Osaka
University, Osaka, Japan
The mammalian skin consists of two sets of epidermal barriers: stratum corneum (SC) and tight
junctions (TJs). It has been long believed that epidermal Langerans cells (LCs) acquire foreign anti-
gens encountered in skin, but how such antigens penetrate the epidermal barriers is completely
unknown. Using 3D visualization method of epidermal TJs in mouse ear skin, we investigated the
behavior of LC dendrites in relation to TJs. In resting state, LCs projected their dendrites upward to
the skin surface but stopped short of TJs. Surprisingly, once activated by tape stripping or intra-der-
mal injection of IL-1β or TNFα, elongated LC dendrites docked with TJs, and sometimes penetrated
through, to reach to the SC. Next, we investigated whether LC dendrites that penetrated TJ could
engage in endocytic activity. To this end, we topically applied a protein biotinylation reagent on
the skin. Remarkably, membrane biotinylation revealed endocytic activity that took place at the
dendrite tip. Birbeck granule formation was observed at the tip of TJ-penetrated dendrite in elec-
tron microscopy, suggesting that Birbeck granules were involved in this process. Of note, TJ for-
mation was observed between LC dendrites and surrounding keratinocytes, and lanthanum pen-
etration assay indicated that the TJ barrier integrity was maintained during this dynamic process.
Finally, we successfully visualized human epidermal TJs in 3D and demonstrated the existence of
functional TJ barrier in human skin. TJ-docking of LC dendrites was also observed in human, sug-
gesting that this ability of LCs to gain access to extra-TJ environment is conserved among mam-
mals. These findings will provide a new fundamental framework for the immunological behavior
of dendritic cells at the body surface.
749
TRIF-mediated IgE isotype class switch which are inhibited by TLR9 and MyD88 activation
E Lee, K Na, I Cheon, M Jeon and T Kim Laboratory of Dermatology-Immunology, Catholic
Research Institute of Medical Science, The Catholic University of Korea, Seoul, Republic of
Korea
The commitment of a B cell to isotype class switch to an IgE-producing cell is tightly regulated
process. Lipopolysaccharide (LPS), a ligand for toll like receptor 4 (TLR4) can strongly induce IgE
in B cells together with interleukin 4 (IL-4). This induction is inhibited by CpG oligodesoxynu-
cleotides (CpG-ODNs) which are TLR9 ligands. TLR4 signaling is activated by TRIF and MyD88
adaptors whereas TLR9 is mainly activated by MyD88. However, the exact molecular mecha-
nisms how CpG inhibit IgE production are not fully understood. Here, we first showed that CpG
inhibit the TRIF-mediated TLR4 signals such as phosphorylation of IRF3 and processing of NF-kB
p100 to p52. Consistently, we found that Trif-/- B cells could not produce IgE under LPS and IL-4
stimulation whereas Myd88-/- B cells produced the IgE similar level to wild type B cells. Also,
LPS-induced NIK stabilization and p52 expression are impaired in Trif-/- B cells but not in Myd88-
/- B cells. These findings may explain why CpG effectively inhibit allergy diseases such as atopic
dermatitis and asthma in mouse model system.
748
Development of a Staphylococcus aureus superficial skin infection model in mice that uses
advanced in vivo imaging to evaluate topical antimicrobial therapy and immune responses
in real-time
J Zussman, JS Cho, RI Ramos, NC Garcia, RL Modlin, J Kim and LS Miller Division of
Dermatology, of California Los Angeles (UCLA), Los Angeles, CA
S. aureus skin infections represent a rapidly growing epidemic that has been further complicated
by the widespread emergence of MRSA and multi-drug resistant strains. To evaluate potential new
topical antimicrobial therapies and cutaneous immune responses, a superficial S. aureus infection
model in mice was developed. A bioluminescent S. aureus strain (2x105-2x107 CFUs/10 μl) was
inoculated into three superficial scalpel cuts on the upper backs of mice and bacterial burden was
measured in real-time by using in vivo bioluminescence imaging. To determine whether this model
could be used to evaluate the efficacy of topical antibiotic therapy, mupirocin versus vehicle oint-
ment was applied at 4 h then twice daily for 7 days. Mupirocin treatment resulted in up to 34-fold
lower bacterial counts than vehicle treatment. To determine whether this model could be used to
evaluate cutaneous immune responses, bacterial counts were compared between IL-1R-deficient
mice and wt mice. IL-1R-deficient mice developed up to 20-fold higher bacterial counts than wt
mice, consistent with the known role of IL-1 in immunity against S. aureus skin infection. Lastly,
this model was used to evaluate the host neutrophilic response in real-time by using lysEGFP
mice. The lysEGFP mouse strain is a genetically engineered mouse line that possesses green-fluo-
rescent neutrophils due to a knockin of EGFP into the lysozyme M gene. We found that S. aureus
burden as well as neutrophil infiltration could be measured in real-time by sequential in vivo bio-
luminescence and fluorescence imaging. Taken together, this superficial S. aureus skin infection
model in mice may be a valuable tool to evaluate novel antimicrobial topical treatments and cuta-
neous immune responses.
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The HPV profile of genital warts in HIV infected patients.
R Meys,1 KJ Purdie,2 MN de Koning,3 SK Krishna,1 M Kamp,3 M Nelson,1 D Asboe,1 DA Hawkins,1
WG Quint,3 FM Gotch,1 C Harwood2 and CB Bunker1 1 Departments of Dermatology,
Genitourinary Medicine and Immunology, Faculty of Medicine, Imperial College School,
London, United Kingdom, 2 Centre for Cutaneous Research, Barts and the London School of
Medicine and Dentistry, Queen Mary University, London, United Kingdom and 3 DDL
Diagnostic Laboratory, Voorburg, Netherlands
HIV infected individuals are more likely to harbour genital human papillomaviruses (HPVs) and
have mixed HPV infections with high risk (oncogenic) HPV types. In contrast to cervical and anal
lesions, HPV types in external genital warts from this group have been poorly characterised. The
purpose of this study was to investigate the genital HPV profile found in external genital warts affect-
ing patients with HIV. Twenty-one histologically confirmed genital warts from 16 patients were stud-
ied. Warts from healthy patients were also investigated (28 specimens from 21 patients). DNA
derived from warts was analysed with a genital HPV reverse hybridisation assay (SPF10-LiPA25, ver-
sion 1). The commonest HPV types detected in HIV infected patients were HPV-11 (48%; 10/21),
HPV-6 (33%; 7/21), and HPV-40 (10%; 2/21). In warts from healthy patients HPV-6 (82%; 23/28)
and HPV-11 (11%; 3/28) were detected most frequently. HPV-6 was significantly less prevalent in
HIV infected patients (p=0.002). Oncogenic genital HPV types were detected in one lesion from
HIV infected patients and two lesions from healthy individuals. Multiple genital HPV types were
found in similar numbers of lesions from both groups (3/21 in HIV infected patients and 2/28 in
healthy individuals). Contrary to the detection ratio of HPV-6 : HPV-11 of 2-3:1 in the general pop-
ulation, we found that HPV-6 was much less prevalent in HIV infected persons (ratio 0.7:1). Deter-
mination of viral loads using real time PCR may be useful in ascertaining the significance of this.
750
An antimicrobial protein, lactoferrin is expressed in eccrine glands of the human skin and
exists in the sweat
J Park, I Cho, G Park, J Yang and D Lee Dermatology, Samsung Medical Center, Seoul, Republic
of Korea
The eccrine gland is one of the major cutaneous appendages and secretes sweat. In addition to
thermoregulatory function, antimicrobial peptides such as dermcidin and cathelicidin are secreted
in human sweat. Lactoferrin is expressed and secreted by glandular epithelial cells such as mam-
mary glands. It has demonstrated potent antibacterial, antiviral and antifungal activity. In this
study, to investigate the hypothesis that sweat glands produce lactoferrin and sweat can play an
important part in establishing a skin defense barrier against microbes, we evaluated the expression
of lactoferrin in eccrine glands and sweat. By immunohistochemistry lactoferrin was detected in
eccrine glands of normal human skin. In addition, lactoferrin was found in sweat obtained from
healthy volunteers based on Western blot and ELISA. Interestingly, the specimen obtained from the
normal skin surface showed lactoferrin. In the proteomic analyses of sweat, several antimicrobial
peptides and proteins including lactoferrin were detected. These findings suggest that lactoferrin
may contribute to skin defense against infection through its secretion in sweat.
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Subcutaneous phaeohyphomycosis (mycotic cysts)
Carlos Garcia, MD, Dermatology at the Oklahoma University Health Science
Center, Oklahoma City, OK, United States; Roberto Arenas, MD, Departamento
de Dermatologia, Mexico, Mexico
Phaeohyphomycosis is a term coined in the 1970s to group diseases casued by
dematiaceous (pigmented)moulds other than chromoblastomycosis andmycetoma.
Their clinical spectrum of disease includes superficial, cutaneous and nail, subcu-
taneous, sinusitis, and systemic/disseminated. The most frequent etiologic agents
are Exophiala jeanselmei,Wangiella dermatitidis, Exophiala spp, and Phialospora
spp. Herein, we present our experience with subcutaneous phaeohyphomycosis
including the epidemiology, clinical presentation, mycologic study, histopathology,
and treatment of cases. In addition, we present a brief summary of current literature
to update the clinical dermatologists on these interesting and increasingly frequent
infections.FEBRUARYcial support: None identified.CommerP2418
Chromoblastomycosis: A good treatment response to itraconazole com-
bined with terbinafine
Santuzza Kelmer, MD, Hospital Mario Kroeff, Rio de Janeiro, Brazil; Jeferson
Oliveira, MD, Hospital Mario Kroeff, Rio de Janeiro, Brazil; Marcelo Lyra, MD,
Hospital Mario Kroeff, Rio de Janeiro, Brazil; Roberta Bizerra, MD, Hospital Mario
Kroeff, Rio de Janeiro, Brazil
Chromoblastomycosis (CbM) is a subcutaneous mycosis with a chronic and
progressive course. It is caused by dematiaceous fungi; Fonsecaea pedrosoi is the
most common agent in Brazil, and other agents include Phialophora verrucosa,
Cladophialophora carrionii, and Rinocladiella aquaspersa. Fungi are found in soil
or on plants and are inoculated by trauma or injury. It mainly affects the lower limbs
of men who are rural and have a low socioeconomic level. Our patient, a 65-year-old
healthyman living in Rio de Janeiro had a verrucous plaque, surmounted bymultiple
papular nodular lesions extending from the knee to the root of the left thigh, with 10
years’ evolution. He reported gradual increase in size and appearance of new
satellite lesions. Skin biopsy and mycologic examination were performed and the
diagnosis of CbM caused by F pedrosoi was confirmed. We decided to combine
itraconazole 400 mg and terbinafine 250 mg in a daily basis with excellent
preliminary results. It showed significant reduction of injuries with only two
months of treatment. The patient is tolerating the treatment well and continues to
have his hepatic enzymes monitored monthly as an outpatient. CbM is a ringworm
difficult to treat, and its first-line treatment option is surgery and oral antifungal
therapy. However, the delay in seeking medical care and the extent of injuries can
derail this alternative. Treatment with one oral antifungal in most cases does not
produce good results and there are very few publications showing good response,
usually only isolated cases or small series have shown satisfactory results. Another
factor that hinders the adherence is the high cost of medication and the need for
prolonged treatment. Up to date there is no universally accepted oral antifungal
combination scheme for the treatment of CbM, but the results of the combination of
itraconazole with terbinafine has been quite promising.cial support: None identified.Commer2011INFECTION—VIRAL
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Clinical analysis of solid organ transplant recipients with herpetic infec-
tion reveals favorable, intermediate and poor prognosis clusters based
organ systems involvement
Ivan Litvinov, MD, PhD, McGill University, Montreal, Canada; Manisha Patel, MD,
The Johns Hopkins School of Medicine, Baltimore, MD, United States; Michael
Marchetti, MD, The Johns hopkins School of Medicine, Baltimore, MD, United
States
Solid organ transplant recipients (OTRs) are at increased risk of infection because of
chronic immunosuppression. The incidence of herpetic infections (herpes simplex
and varicella) was documented to be increased in these patients in comparison to
the immunocompetent population. Individual case reports and small case series
suggest that these patients are likely to experience a morbid disease course. Under
current standards of care most OTRs with herpetic infections are hospitalized to
receive intravenous (IV) antiviral medications. In order to evaluate the severity of
HSV/VZV disease course in OTRs and to develop a new protocol on how to properly
manage herpetic infections in these patients, we performed a retrospective analysis
of 70 herpes-related hospitalizations in OTRs. Obtained results document that the
majority ([85%) of patients experience a mild disease course and only a minority
(\15%) of patients is at risk of developing severe complications. Stratification of
patients based on organ system involvement reveals three distinct clusters (ie, poor,
intermediate, and favorable prognosis) based on clinical disease outcome. In the
favorable prognosis cluster, patients with # 2 organ systems affected had a mild
disease course and a short hospital stay. In contrast, in the poor prognosis cluster,
where patients had $ 4 organ systems affected, individuals had a morbid disease
course that was associated with significant systemic symptoms, ICU admission, and
death, while patients in the intermediate cluster with three organ systems affected
had moderate severity of the disease. Based on these findings, OTRs who on
presentation with HSV/VZV have # 2 organ system involvement can be treated on
outpatient basis, individuals with $ 4 organ system involvement are likely to benefit
from admission to the hospital, while individuals with three organ systems affected
can be treated in hospital or on outpatient basis depending on other factors.cial support: None identified.CommerP2501
Cutaneous HPV-related immune reconstitution associated disease (IRAD)
in HIV: An underrecognized phenomenon
Rhonda Meys, MBBS, Department of Dermatology, Chelsea and Westminster
Hospital, Faculty of Medicine, Imperial College, London, London, United
Kingdom; Christopher Bunker, MBBS, Department of Dermatology, Chelsea and
Westminster Hospital, Imperial College, London, London, United Kingdom;
Francis M Gotch, PhD, Department of Immunology, Chelsea and Westminster
Hospital, Faculty ofMedicine, Imperial College, London, London, UnitedKingdom;
Justin Weir, MBBS, Department of Histopathology, Charing Cross Hospital, Faculty
of Medicine, Imperial College, London, London, United Kingdom
It is not widely acknowledged that cutaneous human papillomavirus (HPV)-related
immune reconstitution associated disease (IRAD) exists. We describe two patients
who developed an acute inflammatory form of IRAD associated with cutaneous HPV.
The florid progression of HPV disease in response to antiretroviral treatment (ART)
has not previously been documented photographically. Patient 1 was a newly
diagnosed 33-year-old HIV-infected male seen in dermatology. Fully suppressive ART
(tenofovir, emtricitabine, and efavirenz) was admitted with an ensuing rise in his
CD4 T cell count (from 12 to 104 cells/L) over a 9-month period. During this time,
four persistent warts on the preauricular area and lateral neck transformed into a
disfiguring, widespread, scaly, hyperkeratotic, inflammatory eruption of multiple,
coalescing viral warts on the lower face and neck. A biopsy specimen revealed
changes associated with HPV infection and a minimal lymphocytic inflammatory
infiltrate containing similar numbers of CD4 and CD8 T cells. He was commenced
on acitretin 10 mg once daily and within 1 week had noticed significant improve-
ment. Patient 2 was a 48-year-old man who was diagnosed with HIV more than 20
years earlier. He had had a chronically low CD4 T cell count and numerous skin
problems, including extensive plantar warts treated with cryotherapy. His ART
regimen was changed to improve his CD4 T cell count, switching from tenofovir,
didanosine, and lopinavir/ritonavir to tenofovir/emtricitabine and lopinavir/ritona-
vir. His CD4 T cell count increased from 47 cells/uL before intensification of his
HAART to 72 cells/uL 8 months later. During this time, he developed a florid
worsening of the plantar warts. The first case highlights the features of IRAD; the
patient, prescribed a suppressive regimen of ART that resulted in a [1 log10
reduction in his HIV viral load, then developed a clinical deterioration of an
infectious or inflammatory condition (HPV infection), temporally associated with
ART exposure. The second case illustrates that this phenomenon can also occur
with ARTalteration, resulting in an elevation of the CD4 T cell count, and, therefore
(perhaps), a degree of immune reconstitution, although his HIV viral load was
previously undetectable. The mechanism by which inflammation might lead to
hyperproliferation of HPV infected keratinocytes and an explosion of new lesions
with immune restoration is elusive, but may be driven by the cytokine milieu
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